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Abstract 
 
This thesis investigates the governance of biobanks in Mexico, exploring 
elements of legislative reform for the improvement of current legal and 
ethical guidance. It argues that the great benefits to be obtained from 
research using biobanks (e.g. personalised or stratified medicine) are at 
risk of being undermined by the absence of clear legal pathways. 
A number of legal and ethical issues have emerged from the different 
aspects of biobanks. Diverse theoretical approaches are reflected in 
academic literature and heterogeneous legislation of biobanks around the 
world. Specific binding rules have worked for some, whereas self-
regulation has proven suitable for others. Social solidarity has played a 
key role in innovative biobanking law and decision making, in which 
traditional governance approaches have become more reflexive, 
involving not only law and policymakers, but also the public.  
A detailed legal analysis revealed significant gaps within the 
complex Mexican laws governing biobanks; this has caused confusion. 
Areas of concern were identified in relation to the ethical management of 
research samples and the protection of donors’ rights. This is concerning 
in Mexico where economic interests influence legal reform, giving way to 
opportunistic actions by the international pharmaceutical industry and 
leaving vulnerable populations unprotected. The greatest challenges for 
Mexican legislators are finding ways to respond to legal gaps with new 
laws and improving the effectiveness of existing rules.  
Due to the scarcity of literature on the topic, interviews were 
conducted with representative actors in strategic areas. Participation in 
the European Union research network BTCure enabled the inclusion of a 
study investigating how European experiences can be valuable examples 
for Mexico to follow. The results of this research indicate ways forward for 
Mexican governance, which are expected to influence further legislative 
reforms of biobanks. 
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I. INTRODUCTION AND METHODOLOGY 
 
1. Introduction 
This thesis investigates the governance of biobanks in Mexico, focusing 
mainly on clinical and research biobanks. It will explore elements of 
legislative reform for the improvement of current legal and ethical 
guidance and protective frameworks for research subjects within different 
biobanking areas. This research will cover public and private tissue banks 
for research purposes. Other biomaterial storages, e.g. cord blood banks 
will therefore be excluded, as their implications would constitute a 
completely independent research object. 
 
In Mexico, where the proliferation of biobanks is significant, the 
current laws and ethics cannot remain indifferent to potential cases of 
abuse. Vulnerable populations include minority groups, such as 
indigenous populations, and any other group with a higher susceptibility 
than average to be exploited are susceptible to abuse or having their 
rights undermined. As we will see, this is due to the potential predictive 
power of genetic data. Similar unfortunate situations may occur if the 
alleged absence of specific ethical and legal rules is unresolved. 
 
At the present time, the collection and storage of human tissue for 
the use of molecular or genetic information from specific groups sharing 
particular characteristics has proven to be of great potential for medical 
science and population studies. This is due to the biological capability of 
cells to replicate unique molecular and genetic information, no matter 
which body part they come from. Genetic and molecular elements can be 
studied in isolation from each other. Collections of patient samples –
biobanks– play a central role in this work by revealing genetic, molecular 
and environmental factors of importance for the development of disease, 
14 
 
as well as for personality or longevity traits.1 This potential has become 
crucial for the development of new therapies and significant knowledge 
on genetic history of populations. “The successful application of large-
scale biological analyses to determine total genome sequences inspires 
similar grand attempts to understand the function of the encoded 
molecules in health and disease.”2 As a consequence, the unknown 
ancestry elements of populations can now be traced and therapies 
developed or improved, sometimes as a result of increased drug 
effectiveness in a specific genetic profile.  
 
This chapter establishes a statement of the problem to be addressed 
by this research. Biobanking practices have been the object of bioethical 
debates, the outcome of which directly impact on governance. The first 
section of this chapter will consist of the conceptualisation of biobanks 
and its boundaries. This will also include a review of the main 
classification criteria, supported by academic literature. 
 
1.1 Conceptualising biobanks 
It is necessary to begin by discussing the implications of the term 
biobank and the degrees of variation it presents. The conceptual 
spectrum is very broad, for example, “many scientists believe that 
effective biobanking amounts to no more than a freezer and a fraction of 
technician’s time to fill the freezer,”3 while Watson and Barnes understand 
the concept of biobanking is formed by two elements: a collection of 
human research biological samples (tissues, blood, and body fluids and 
their derivatives) and the associated data for research purposes.4 Taking 
                                                          
1 L Jonsson and U Landegreb, Storing and using biobanks for research (Report I from 
the Research Project The Use of Human Biobanks Ethical, Social, Economical and 
Legal Aspects, Uppsala University, 2003) 1 
2 Ibid 
3 Directorate-General for Research and Innovation European Commission, Biobanks 
for Europe, A challenge for governance (2012) 328 
4 PH Watson and RO Barnes, ‘A Proposed Schema for Classifying Human Research 
Biobanks’ (2011) 9 Biopreservation and Biobanking 327 
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rheumatology as an example, body fluid could be synovial fluid, synovial 
fluid cell pellets or urine. Solid tissue may consist of synovium, lymph 
node, bone marrow, cartilage or bone. A derived product could be DNA 
(from whole blood or swab) or RNA (from whole blood, peripheral blood 
mononuclear cell or primary cell culture). Blood and blood-derived 
products are an easy source of biomaterial to collect, whilst collection of 
body fluids and solid tissues require more invasive procedures. Genetic 
data may be obtained from body fluids, solid tissue and derived products.  
 
Barnes explains that the perception of biobanks has also evolved 
from merely “comprised formal entities within hospitals and research 
institutions” to “a variety of different biobank types spanning a broad 
spectrum.” Hence, today individual biobanks can include very small 
collections aimed to support specific research (mono-user biobanks), 
collections associated with several research groups or clinical trials (oligo-
user biobanks), or larger collection programmes, commonly known as 
repositories (poly-user biobanks from national efforts).”5 
 
1.1.1 The characteristics of biobanks 
In the absence of consensus on the definition of a biobank, a set 
of characteristics can be used to identify a biobank. In the opinion of 
Kaye6, these are the most common characteristics:  
(a) Biological materials are collected for research purposes with either  
medical or epidemiological data associated (e.g. environmental 
exposures, lifestyle, occupational information);  
(b) Biological materials and data are collected on a continuous or long-term 
basis; 
(c) Research projects using samples can either be defined or not specified 
(e.g. not planned  at the time of biospecimen collection); 
(d) Data protection mechanisms are likely to be established in order to 
assure donor privacy; coding or anonymisation with or without the 
possibility to be identifiable.  
(e)  Use minimal structures of control (ethics review committees and 
informed consent) in order to balance stakeholders’ interests. 
 
                                                          
5 Ibid 327 
6 European Commission 13 
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1.1.2 Historical background 
  The definition of biobanks has been commonly associated with 
their history and purpose. Approximately two decades ago, early 
collections would be organised, used for independent research and 
known as biobanks, but they have expanded in the past 20 years.7 
However, this has happened “in a rapid, uncoordinated and unregulated 
proliferation,”8 which has led to the hasty, sometimes uncontrolled, 
establishment of biobanking activities.9 Even nowadays the purpose of 
these collections is not always clear. The commonly attributed diagnostic 
purposes tend to be frequently overtaken by further research, “when 
residual material exists after diagnostic procedures have been 
completed.”10 
 
So much of science today revolves around using human biological 
tissue of some kind.11 Any small, short-term, or project-specific collection 
generally involves research; all biobank formats are interlinked and, to a 
certain degree, represent a continuum within the infrastructure supporting 
all gradual steps of the biomedical research “pipeline.”12  Biobanks are 
thought to have emerged from clinical pathological tissue samples 
collected for medical purposes. The formal organisation of specimens 
allegedly started in the United States, when biological materials were 
collected during the Civil War for pathological research purposes. A 
characteristic of those old collections is that they were not planned but 
residual. Since then, the collection of specimens has evolved in response 
to the changing landscape.13 In contrast, a biological sample is any 
                                                          
7 Watson and Barnes 327 
8 Ibid 328 
9 PHJ Riegman and others, ‘Biobanking for better healthcare’ (2008) 2 Molecular 
Oncology 327-333 
10 Watson and Barnes 327 
11 S Zielinski, ‘Henrietta Lacks’ ‘Immortal’ Cells’ SMITHSONIANCOM 
<http://www.smithsonianmag.com/science-nature/henrietta-lacks-immortal-cells-
6421299/> accessed 20 January 2012 
12 European Commission 15 
13 E Eiseman and SB Haga, Handbook of Human Tissue Sources A National Resource 
of Human Tissue Samples (RAND Monograph Report, 1999) iii 
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biological material, which originates from human tissues, susceptible to 
preservation and capable of containing genetic information,14 a 
characteristic that makes this material difficult to be seen as simply 
biological leftovers.  
 
1.1.3 Legal consequences of conceptualising biobanks 
For legal purposes, it is crucial to clarify the main conceptual 
understanding in the practical biobanking areas. However, this is not a 
simple task. The concept of biobanks is highly debated in the literature 
and has caused great differences in practice. A great variety of academic 
terminology has been used to describe sample and tissue collections. It 
is necessary to make distinctions between them in order to clarify the 
scope of the concept; particularly in respect to associated key issues. 
These involve access and consent, and apply to the different categories 
in practice. The differences between tissue banks, biobanks, 
biorepositories and other bio collections cannot always be easily, or 
precisely, indicated. The terms ‘research biorepository’ and ‘biobank’ may 
be used indiscriminately to refer to a collection of biological human 
samples with preservation, sharing and scientific research purposes.  
 
The differences are related to whether bio specimen collections 
were created specifically for health and medical research purposes, or 
created for other purposes but secondarily used also for research. This is 
further complicated when a variety of regulations differ in both literature 
and practical situations. The adoption of a concept for legal purposes is 
key in legislation in order to ascertain the relevant legal consequences, 
such as authorisations to use tissue for research. Kaye has highlighted 
the current inconsistency to denote, “organised collections in medicine.”15 
Although the terms biobank and biorepository have been used 
                                                          
14 Ley reguladora de la base de datos geneticos para el estado de Chihuahua (Rules for 
genetic databases for the state of Chihuahua) (Mex) 
15 European Commission 13 
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interchangeably,16 others have defined the latter independently, as “an 
actual or virtual entity that may receive, process, store or distribute 
specimens in support of a study or multiple studies and their associated 
data as appropriate.”17 According to this definition, a specimen resource 
generally refers to the specimens collected for a particular study;18 human 
tissue repositories “collect, store, and distribute human tissue materials 
for research purposes.”19 Repository activities involve three components:  
(i) the collectors of tissue samples; 
(ii) the repository storage and data management center; and 
(iii) the recipient investigators”20 
 
The dissention on what biobanks are has an effect on regulatory 
issues. Evidently, “diversity in legal requirements has an effect on the 
development of a common infrastructure for biobanks and the sharing of 
data and samples from biobanks across the borders for scientific 
purposes.”21 
 
1.1.4 The concept of biobanks from the international 
perspective 
In the absence of specific legislation for biobanks, international 
guidelines must be revised, and these could constitute immediate 
emergent instruments to set and define the boundaries of biobanks. For 
example, the United Nations Educational, Scientific and Cultural 
Organisation (UNESCO) has used the term ‘database’ to denote the 
physical samples as well as the derived information, a tendency followed 
by the World Health Organisation (WHO). The WHO, regarding both 
                                                          
16 G Marodin and others, ‘Biobanking for health research in Brazil: present challenges 
and future directions’ (2012) 31 Rev Panam Salud Publica 523 
17 International Society for Biological and Environment Repositories (ISBER), ‘Best 
practices for repositories: collection, storage, rerieval and distribution of biological 
materials for research’ (2012) 10 Biopreservation and biobanking 1 
18 Ibid 88 
19 HHS.gov U.S. Department of Health & Human Services, ‘Issues to Consider in the 
Research Use of Stored Data or Tissues’ (1997)  
<http://www.hhs.gov/ohrp/policy/reposit.html>  
20 Ibid 
21 European Commission 77 
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samples and data, states “no regulatory framework for genetic databases 
has been developed to date that is global in scope yet developed with 
regional input, while being specific enough to provide practical 
guidance.”22  
 
The conceptual divergence “with regard to the infrastructure and 
practices regarding the collection of human biological material for 
research,” is a major challenge in countries where biobanking governance 
is to be or was recently implemented. Most Latin American countries are 
in this situation, such as Brazil, where international sources inspired the 
national legal framework. International instruments are helpful sources of 
reference for standard biobanking definitions. 
 
The Organization for Economic Cooperation and Development (OECD) 
uses the term “biological resource center” (BRC) to refer to, not only 
repositories, but also suppliers of health research services. The 
International Agency for Research on Cancer (IARC) uses the term 
“biological resource center” for collections of human cancer samples. In 
the United States of America, the National Cancer Institute defines the 
term “biorepository” as an “organization, place, room, or container where 
biospecimens are stored,” and the term “biospecimen resource” as the “. 
. . formal organization as well as informal collections of biological material 
stored in a freezer by an individual researcher.”  Likewise, the term 
“biobank” has been used in this context by other U.S. and European 
institutions.23 
 
1.2 Different types of biobanks 
Biobanks can be defined as structures containing biomaterials, 
and by the type of research they carry out, e.g. a breast cancer tissue 
bank.24 Surgical leftovers, biopsies and other donated samples have been 
classified and tidied up for studying and drawing conclusions about the 
role(s) of genes in the presentation of diseases. As Watson and Barnes 
have pointed out, “biospecimens are critical for discovery and clinical 
                                                          
22 World Health Organization, ‘Human genetic databases: towards a global ethical 
framework ’ ( Experts' Consultation Meeting, Geneva, 8 and 9 May 2006) 
23 Marodin and others 523 
24 RC Elston RC, JM Olson and L Palmer, Biostatistical Genetics and Genetic 
Epidemiology. (John Wiley &Sons 2002) 17 
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research.”25 Biobanks belong to several general classes, but within these, 
they have specialised aspects relating to the range of research questions 
these intend to support.26  
 
A central point is classification. It is important to determine whether 
guidelines’ enforceability and design should be affected by the particular 
characteristics of collections. Population biobanks, for instance, is a 
category which deserves special attention. The main research objective 
of this category is the study of the genetic characteristics of particular 
groups. Population studies consist of analysing particular biomarkers of 
population groups, and how the environment (lifestyle and other factors) 
influences these. The Council of Europe’s Recommendation on Research 
on Biological Materials of Human Origin in March 2006 stated that 
biological materials are defined and are distinguished from ‘collections of 
biological materials’, and has listed the main characteristics of a 
population biobank:27 
 
1. A population biobank is a collection of biological materials that has 
the following characteristics: 
i. The collection has a population basis; 
ii. It is established, or has been converted, to supply biological 
materials or data derived therefrom or multiple future research 
projects; 
iii. It contains biological materials and associated personal data, 
which may include or be linked to genealogical, medical and 
lifestyle data and which may be regularly updated; 
iv. It receives and supplies materials in an organised manner 
 
Population studies also include genomic studies on ancestry. 
Population studies “are becoming increasingly common as a means of 
identifying genetic predispositions to complex diseases in a particular 
                                                          
25 Watson and Barnes 327 
26 Ibid 329 
27 Recommendation of the Committee of Ministers to member states on research on 
biological materials of human origin Art 17 
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population, as a result from an interaction of environmental, lifestyle and 
genetic factors.”28  
The main research objective of population-based biobanks is generally 
to discover biomarkers for disease susceptibility within a specific 
population through prospective molecular epidemiology research 
strategies. These types of biobanks typically recruit health donors who 
are representative of a region, country or specific ethnic group. One of 
the most commonly stored biospecimen is germ-line DNA isolated from 
venous blood. Associated data comprise not only medical history but 
also physical measures and epidemiological information (e.g. life habits, 
socioeconomic status). The specifics of population biobanks are 
compiled and analyzed by the Public Population Project in Genomics in 
its internet resources.29  
This may create a conflict between individual and societal interests 
towards the research study. In terms of public health, clashes of interests 
can also be present. Population biobanks address key issues at the time 
of recruitment and result interpretation.  
 
1.2.1 Categorisation 
Watson and Barnes refer to classification as “the process whereby 
ideas and entities, in this case biobanks, are recognized, differentiated, 
and understood”30  but they also highlight that “there currently exists no 
accepted classification system for human research biobanks.”31 
Biobanking terminology is inconsistent, reinforced by the application of 
the “preferred generic label.”32 Criteria based on the size of a collection 
and other parameters have been common. Barnes and Watson33 
proposed a schema based on the type of research they intend to support, 
which consists of the following categories: 
 population study biobank 
 basic research biobank 
 translational study biobank 
 clinical trial biobank and pathology archive biobank. 
                                                          
28 R Andorno, ‘Population bio-banks: a juridical analysis based on Icelandic and 
Estonian experience’ (2006) 25 Rev Derecho Genoma Hum 55 
29 The Public Population Project in Genomics P3G, ‘P3G’   
<http://www.p3gobservatory.org/> accessed 16 March 2011 
30 Watson and Barnes 329 
31 Ibid 328 
32 S Gibbons, ‘Regulating biobanks: A twelve point typological tool’ (2009) 17 MLR 6 
33 Watson and Barnes 331 
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Biobanking categorisation can be standardised according to the 
purpose of their creation. The classification scheme suggested by Watson 
and Barnes is based on four functional biobank “elements” 
donor/participant, design, biospecimens and brand.”34 It is still debatable 
if factors such as the size of a collection could determine whether a 
collection should be regarded as a biobank and therefore subject to legal 
consequences. “The absence of a classification system may also soon 
impact research users by hampering the ability to interpret and reproduce 
research results.”35 A Mexican academic biobanking classification36 
includes: 
Usage 
The classic biobanks and databases in a minor scale 
for clinic and 
Academic 
research. 
Medical 
research. 
Forensic biobanks integrated by samples and genetic data in order 
to solve legal cases. 
 
Financial 
gain 
purposes 
Pharmaceutical 
Biotechnological industry 
 
Operation 
level  
 
Local Biobanks for research 
National 
Population biobanks 
Genetic databased biobanks with forensic ends 
Transnational 
Genetic assessment 
Genetic advice 
.   
General 
purposes 
Clinic 
Academic 
 
Trading 
purposes 
Sample commercialisation Through 
catalogues Data commercialisation 
 
                                                          
34 Ibid 328 
35 Ibid 329 
36 Ingrid Brena, ‘Biobanks, a subject pending upon legislation’ (2010) 129 Boletín 
Mexicano de Derecho Comparado 1055 
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However, Gibbons suggests that categorising biobanks based on 
their initial location or ownership is a trap to be avoided, due to potential 
future changes in terms of purposes, uses, and users, location and 
ownership.37 According to Gibbons, regulatory exhaustiveness should 
never be attempted.38 Biobanking definitions should not aim to be 
exhaustive. Rather general and inclusive rules would be more favourable. 
“In the end, trying to draw sharp or hard-and-fast dividing lines between 
different kinds of biobanks based on size may prove to be impossibly 
problematic, unworkable, and arbitrary.”39 A more flexible, discretionary 
framework (with clearly stated assessment criteria and provision for 
reviews or appeals) may be preferable.40 Gibbons41 has provided 
guidance for conceptual matters and criteria helpful to identify current 
biobanking issues.  In her opinion, the field of biobanking is so 
heterogeneous that exhaustively listing all distinguishing characteristics 
of biobanks is difficult. However, simple criteria can be used for this 
purpose: 
a) Size 
b) Research design 
c) Disease/research focus.  
 
The extent of 
biobanks           
a)    The recruitment of donors 
b)    The consent procedures 
c)    The scale of informatics support 
needed 
d)    The governance structures  
e)    The potential for commercial 
exploitation. 
 
 Age 
 Timing 
 Duration 
 Nature of Participants 
 Uses and users 
 Other stakeholders 
 
                                                          
37 Gibbons 323 
38 Ibid 316 
39 Ibid 318 
40 Ibid 317 
41 Ibid 314 
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Biobanks 
Research 
purpose 
Scientific Public/governmental 
Academic Private 
Clinic Altruistic 
Private pharmaceutical 
Stem cells 
Public forensic 
Population (analysis of the interaction 
genes/environment) 
 
According to the conceptual views by Gibbons, it would not be 
necessary to regulate separately every type of biomaterial (blood, serum 
and plasma), but to include all types in a single regulation which also 
takes into account key exceptions, such as forensic biobanks (an area 
under criminal law). 
 
For an accurate biobank categorisation, terminology may not be so 
important. Shickle42 has expressed a concern that general information on 
terminological grounds is only a standard. Evidently, some terminological 
variations do not necessarily reflect substantive distinctions; excessively 
technical or descriptive definitions may work for specific areas, such as 
sample management, but a suitable definition for the resolution of ethical 
and legal dilemmas in practice should follow criteria able to deal with the 
diversity of terms used in practice. The following has worked for works 
done within the European Commission: 
 
“Sample size is a characteristic that can be used to distinguish different 
kinds of biobanking activities. Biobanks comprise comparatively small 
collections of up to several thousand samples. Within the context of medical 
research there are multiple biobank formats which can be differentiated 
based on their design and scientific target.”43 
 Disease-oriented 
 Case-control 
 Tissue banks 
 Biobanking with the context of clinical trials 
 Other specific biobanking formats: Guthrie cards, cord blood, stem cells.  
                                                          
42 D Shickle, M Griffin and K El-Arifi, ‘Inter- and Intra-Biobank Networks: 
Classification of Biobanks’ 77 Pathobiology 181 
43 European Commission 14, 15 
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This is particularly relevant for recently generated genomic 
technologies, since acquisition involves significant costs in taxes covered 
by research budgets. In addition, other challenges arise in relation to 
equipment and chemical substances imported from other countries. The 
excess of rules and long procedures harm equipment and cause delays 
in the course of research projects.  
 
Biobank classifications cannot aspire to incorporate the totality of 
diverse biobanking functions, this is an exhaustive, not to say impossible 
task to conduct. Some work is required to place particular importance on 
certain aspects of clarity, balance, inclusiveness, fitness for purpose, non-
exhaustiveness and protection.  
 
The choice is “whether differentiation, leniency, or even parallel 
governance frameworks may be justified”44 or whether the general 
concept of biobanks should cover any biological collection and 
categorisation. The latter choice would imply that all biobanks would be 
covered by a single framework, scrutinised at the same level. Each choice 
would have a different impact on the governance of biobanks.  
  
Therefore, a brief categorisation is necessary to fulfil legal gaps 
and avoid ambiguity. It will eventually be necessary to classify current 
Mexican biobanks (for regulatory purposes) while avoiding the pitfalls 
associated with attempts at exhaustive descriptions. General parameters 
can be very helpful, and generic categorisation, such as access and types 
of use can work as an emergent means for standardisation. 
 
1.3 The importance of personalised medicine 
Biobanking operates to improve the knowledge of health and 
illness processes, the identification of the causes of disease, the 
development of diagnoses and the application of preventive methods and 
                                                          
44 Ibid 
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therapies. Human research biobanks are critical to the current drive for 
personalised medicine as they provide the necessary biospecimens to 
fuel the majority of research platforms. The Genome-Wide Association 
Study (GWAS), for example, attempts to establish associations between 
diseases and particular genomic variants, which is a significant area of 
great analysis potential.45 A comparison is generally made between the 
mapped common genomic variants i.e. single nucleotide polymorphisms 
(SNPs) and unaffected controls.  
 
Diagnostic purposes are one of the main priorities. In fact, many 
governments are seeking to improve the translation of medical research 
innovation by developing mechanisms to aid the flow of information 
between the laboratory and the clinic.46 Another type of research is also 
associated with the use of genomic techniques; in this case, both array-
based genotyping and whole-exomes, which are cost-effective 
alternatives to whole-genome sequencing. The exome represents a very 
small fraction of the human genome, but represents 85% of known 
disease-causing variants. Therefore, encoding protein regions can be 
used (instead of the whole sequence) to investigate how particular parts 
of the human genome are related to the occurrence of specific diseases.47 
This type of genomic study needs samples and clinical data, not only from 
the patient, but also from his relatives.48 
 
1.3.1 Personalised/stratified medicine 
To paraphrase Gotweis and Lauss, personalised medicine, one of 
the promises of the so-called genomic revolution, would require different 
types of data associated with lifestyle information that could be used for 
                                                          
45 J Kaye and others, Governing Biobanks, Understanding the Interplay between Law 
and Practice  (Hart Publishing 2012) 283 
46 J Kaye, ‘Embedding biobanks as tools for personalised medicine’ (2012) 21 Norsk 
Epidemiologi 169 
47 S Banerji and others, ‘Sequence analysis of mutations and translocations across 
breast cancer subtypes’ (2012) 486 Nature 409 
48 Kaye and others 284 
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biomedical research purposes.49 The potential of personalised medicine 
involves the ability to predict the risk of certain diseases based on 
‘personal genome’ information in combination with lifestyle data, age, sex, 
occupation, etc.; and ‘preventativeness’, that is based on individualized 
risk prediction. This requires an active ‘participation’ of the individual 
concerned in proactively maintaining their health.50  
 
Some types of patient matching to a medicine include therapies in 
which a marker is available, indicating that a patient is likely to show a 
response to the therapy. Although this type of matching could be applied 
to an individual patient in principle, this is mostly prescribed in selected 
groups. A population group can be compared to a cohort that has 
previously shown a specific therapeutic response through genetic 
characteristics (biomarkers). Hence some have considered the term 
‘stratified’ more suitable rather than ‘personalised’ for this area of 
biomedicine. “Stratified medicine involves therapies matched with specific 
patient population characteristics using clinical biomarkers.”51 And once 
population-identified genetic information can be easily accessed, even 
through online databases, the treatment of genetic categories becomes a 
matter of social responsibility.52  
 
1.4 The main challenges of biobanking 
Biobanking has the potential to impact on countries’ economic 
development, offering them valuable opportunities; “with the rise of 
biomedical technosciences and the completion of the Human Genome 
                                                          
49 H Gotweis and G Lauss, ‘Biobank governance: heterogeneous modes of ordering and 
democratization’ (2012) 3 J Community Genet 61 
50 European Commission 17 
51 MR Trusheim, ER Berndt and FL Douglas, ‘Stratified medicine: strategic and 
economic implications of combining drugs and clinical biomarkers’ (2007) 6 Nature 
Reviews Drug Discovery 1 
52 J Kahn, ‘Human Genes and Human Rights’ (2006) 96 American Journal of Public 
Health 1967 
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Project, tissue collections worldwide have become increasingly important 
to scientific and economic interests.”53  
 
For example, in 2004 the Federal government of Mexico officially 
unveiled a public health programme to analyse and utilise DNA 
information obtained from the Mexican population. Initial efforts led to the 
modification of existing regulations to enable the creation of the National 
Institute of Genomic Medicine (INMEGEN). This government agency on 
public genomics, created through parliamentary action, led the Mexican 
HapMap project. It aimed to “develop a national platform in genomic 
medicine that is focused on national health problems, based on the 
genomic structure of Mexican populations.”54 The government initially 
invested US$120 million from public funds. The purpose of the 
programme was to provide medication which would react optimally to the 
DNA profile of Mexican citizens.55 The institutions responsible for these 
activities are the National Ministry of Health (Secretaría de Salud), the 
National Autonomous University of Mexico (Universidad Nacional 
Autónoma de México) (UNAM), the National Council for Science and 
Technology (Consejo Nacional de Ciencia y Tecnología) (CONACYT) 
and The Mexican Health Foundation (Fundación Mexicana para la Salud) 
(Funsalud). These institutions intend to enhance genomics training and 
research, and develop public education in the subject, and scientific 
divulgation. However, these efforts have expanded in a way that has 
allowed profound legal gaps in relevant regulatory aspects. More detail 
and further discussions on Mexican legal gaps will be forthcoming in 
chapter 5. 
                                                          
53 M Bister, ‘Discovering informed consent: a case study on the practices of informed 
consent to tissue donation in Austria’ in C Lenk and others (eds), Human tissue 
research, a European perspective on the ethical and legal challenges (Oxford 
University Press 2011) 169 
54 B Séguin and others, ‘Genomic medicine and developing countries: creating a room 
of their own’ (2008) 9 Nat Rev Genet 
55 G Jimenez-Sanchez, ‘Developing a Platform for Genomic Medicine in Mexico’ (2003) 
300 Science 295-6. 
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 Nevertheless, biobanking presents significant governance 
challenges, which tend to be more specific to developing countries.56 This 
is especially evident in Mexico, where the legal framework has not kept 
up with considerable biobanking expansion.57 Mexico is in the process of 
developing genomics initiatives focused on challenges and opportunities 
of genomic medicine, which should gradually lead to a stronger regulation 
of biobanks.  Some have commented that “as genomic medicine develops 
in Mexico, the need for modern legislation related to its ethical and social 
implications will also increase.”58 However, the complex background of 
Mexican legal and socioeconomic problems has obstructed the 
government’s aims to produce effective biomedical public health research 
through the use of biobanks.59 
 
At the beginning of this research, the following relevant 
pronouncements by Mexican academics were identified: Alberto Arellano, 
researcher at INMEGEN, considered in 2005 in a study on genetic data 
protection that the Mexican legal guarantees regarding genetic privacy 
did exist but were insufficient.60 Similarly, in 2008, medical law 
researcher, Ingrid Brena, expressed an interest in unifying Mexican 
biobank legislation. She organised a conference ‘Coloquio Internacional 
Muestras Biológicas y Biobancos para Investigación Biomédica’ Estado 
actual y retos de futuro (International Colloquium on Biological Samples 
and Biobanks for Biomedical Investigation, current status and future 
                                                          
56 B Hardy and others (eds), The Next Steps for Genomic Medicine: Challenges and 
Opportunities for the Developing World, vol 9 (Nature Reviews Genetics 2012) S25 
57 Notimex, ‘Promueven entre empresarios aplicar la genómica a economía’ SDP 
Noticias (Mexico City, 17 August 2011) 
<http://www.sdpnoticias.com/notas/2011/08/17/promueven-entre-empresarios-aplicar-
la-genomica-a-economia> accessed 12 March 2013 
58 G Jimenez-Sanchez and others, ‘Genomic medicine in Mexico: Initial steps and the 
road ahead’ (2008) 18 Genome Research 1196 
59 Séguin and others 486 
60 A Arellano-Mendez, ‘La regulacion juridica de la informacion genetica (the legal 
regulation of genetic information)’ Derecho comparado de la informacion 
<http://www.juridicas.unam.mx/publica/rev/decoin/cont/6/art/art2.htm> accessed 12 
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challenges)’61 with other scientists and researchers to discuss how this 
might be achieved. During the course of the conference, Brena became 
increasingly aware of the inadequacy and inconsistency of Mexican 
legislation regarding biobanks. Brena highlighted three main areas for 
improvement: 
i) The consolidation of public rights. 
ii) Increasing public participation. 
iii) The establishment of a legal framework among stakeholders, i.e. the 
public, biobanks and researchers.  
 
At the conference called by Dr. Brena, the medical researcher 
Clara Godorezky62 agreed with Dr. Brena’s recommendations. Moreover, 
she highlighted that over the previous fifteen years no progress had been 
made in personalised medicine63 in Mexico. She attributed this to the poor 
standard of biobanking legislation. These initial pronouncements 
constituted enough reason for scepticism on the adequacy of Mexican 
biobanking rules.  
 
1.5 Towards a Sound Legal and Ethical Policy to Enhance 
Biomedical Research in Mexico Using Biobanks: Research 
Questions 
The following research questions cover the current main ethical 
and legal concerns within Mexican biobanking, the main one being:  What 
are the best ways forward to alleviate legal weaknesses in Mexican 
biobanking governance? The spectrum of responses to this question can 
                                                          
61 I Brena, ‘Biobanks in Mexico, legal aspects (Biobancos en Mexico, Aspectos 
Juridicos)’ Coloquio Internacional Muestras Biologicas y Biobancos para la 
Investigacion Biomedica (International Colloquium Biological Samples and Biobanks 
for Biomedical Research), Mexico City, 4 July 2008 
<http://juridicas.unam.mx/vjv/activ.htm?e=122&t=14&m=884&p=384&mx=1>  
62 C Gorodesky, ‘Biobanks and Umbilical Cord Banks: Common and Specific Aspects 
Related to Research. Social, Ethical and Legal Implications. Biobancos y bancos de 
celulas de cordon umbilical: aspectos comunes y especificos relativos a la 
investigacion en las implicaciones sociales, eticas y de regulacion.’ (International 
Colloquium Biological Samples and Biobanks for Biomedical Research Current State 
and Future Challenges (Coloquio Internacional Muestras Biologicas y Biobancos para 
Investigacion Biomedica Estado actual y retos de futuro), Mexico City, 4 July 2008) 
63 A Nyika, ‘Ethical and practical challenges surrounding genetic and genomic research 
in developing countries’ (2009) 112 Acta Tropica s21 
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lead to numerous options. Hence, it is necessary to subdivide this 
question into the following research sub-questions:  
 
 Are biobanks effectively regulated in Mexico? 
 This question leads to the investigation of the applicable legal 
biobanking frameworks which have been enforced. The legal assessment 
resulting from this question should provide criteria to recommend the form 
and classification which the guidelines ought to take. 
 
 What risks, harms and values are involved? 
After the legal analysis, the second sub-question looks at the 
ethical side of the thesis, aiming to investigate what risks and harms 
would be present if biobanking was not properly regulated. This question 
also investigates the criteria for a sound ethical policy, in other words, 
what guidelines would be effective at protecting participants’ rights.  
 
 What can we learn from the international experience? 
In addition to questions on legal and ethical issues, this question 
aims to investigate how past experiences can help future implementation, 
using problems encountered by other countries and emphasising the 
importance of taking into account other countries’ experiences within 
different contexts.  
 
 What changes need to be implemented in Mexico? 
Following the legal analysis, possible changes in governance need 
to be discussed, searching for suitable implementation measures and 
determining legal action to improve effectiveness on legislation for public 
and private biobanking. The role of self-regulation should also be 
discussed. It should be decided whether ethics needs to be split from law, 
e.g. through codes of ethics, or whether ethics should be part of the 
biobanking binding legislation in Mexico. The latter question aims to find 
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answers on elements of soft law, including international instruments that 
would best ensure effectiveness and transparency.  
 
 What are the main challenges when implementing change in 
Mexico? 
In terms of legal structure, it needs to be decided what options are 
the most viable for suitable proposals of reform, whether new legal 
frameworks or amendments are necessary, and whether biobanking rules 
should be compressed into a single framework or distributed across the 
various related laws.  
 
 What is the role of social involvement in Mexican biobanking 
regulation? 
Finally, proposing ways to improve the regulation of biobanking 
implies analysis beyond legal perspectives. In order to support the 
recommended criteria to be followed as a regulatory basis for biobanks, 
the last question leads to the investigation of the role of social justice 
within the regulation of biobanking. For this reason, the role of public 
engagement, and how it impacts the law, will also be discussed. 
 
1.6 Synopsis of each chapter  
As a brief synopsis of this thesis, each chapter is described here, 
including the main points to be covered.   
 
In chapter one, the current legal and ethical position is considered 
through relevant literature based on the main concepts of biobanks. This 
primary examination of the situation highlights some of the background 
issues within the proposed research topic, such as the absence of 
biobanking definitions in Mexico.   
 
Chapter two explains the methodology selected for this thesis. It 
describes how the theory was initially approached and how the scarcity 
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of research caused significant changes. These resulted in the 
incorporation of fieldwork, which impacted on the information considered, 
from theoretical expertise to analysis of fieldwork and primary evidence. 
Finally, it defines the questions addressed by this research project.  
 
 Chapter three investigates risks, harms and values of Mexican 
biobanks. It analyses potential harms from an ethical perspective, 
including a brief historical background. This chapter is supported by the 
analysis of two relevant case studies in order to illustrate how the potential 
identified harms have affected the development of biobanking projects. 
The Cohort Profile Study, population specific project and the Mexican 
HapMap have been selected as they clearly showed promissory benefits 
and uncertain dilemmas associated with biological material. Progress on 
human rights’ protection has favoured suitable biobanking backgrounds. 
For this reason, the Mexican situation on human rights is also evaluated, 
since future biobanking governance could significantly depend on this 
factor. 
 
Chapter four covers an extensive legal review in order to determine 
the competence of enacted regulations on the Mexican legal treatment of 
biobanks. It provides the legal rationale of the Mexican legal system and 
detects specific legal instruments affecting biobanking. Hence, health, 
administration, management, genomics, data protection and even some 
international perspectives are evaluated. The development of this chapter 
identifies formally enforced biobanking rules, allowing their analysis. 
 
Chapter five aims to identify gaps in the regulation of biobanking in 
Mexico, recognising the absence of specific legal frameworks. Biobanking 
management rules, if they involve partial legal controls, are led in 
accordance to various parameters concerning issues such as sample 
preservation. It is apparent that a great number of Mexican governmental 
institutions follow self-defined guidelines; other institutions are based on 
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international standards through Internet governance tools.64 This chapter 
also focuses on ethics research guidelines which may be indirectly 
applicable to biobanks. It demonstrates the existence of significant legal 
gaps and inconsistencies and identifies a set of guidelines for ethical 
biobanking based on ‘soft law’. 
 
Chapter six was inspired by my involvement in the Error! 
eference source not found. (an EU funded research network, whose 
details are provided in the introductory section of the chapter). It develops 
an illustrative legal study through European examples. European national 
biobanking frameworks vary significantly, depending on each country’s 
situation. However, this chapter argues that the common European legal 
instruments on data protection and data sharing can be relevant 
examples to follow, especially where biobanking international 
collaborations take place. For this reason, a range of European 
frameworks is considered, in order to assess which are best suited to 
tackle issues prevalent in Mexican biobanking.  
 
Chapter seven evaluates implementing change in Mexico. This 
chapter demonstrates how the governance of biobanks is still a relatively 
unexplored area in Mexico. Each implementation area requiring attention 
has been analysed independently, contrasting the different perceptions of 
involved actors. This chapter also reviews the governance principles 
under which implementation should be supported. Major issues in current 
practices, such as institutional project monitoring and oversight, are also 
included. 
 
Chapter eight investigates the impact of public attitudes towards 
biobanking through the evaluation of social solidarity. The biobanking 
problem in Mexico is associated not only with governance issues but also 
with social attitudes, which influence the governance of biobanks 
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internationally. The lack of public trust towards Mexican governance 
institutions is partly due to the poor communication of realistic biobanking 
promises to Mexican society and could be alleviated if they were 
strengthened. The grounds for legal regulation of standard bioethical 
guidelines could be determined, rather than being imposed, using 
particular social and cultural norms.  
 
The construction of recommended criteria for biobanking in Mexico 
will be provided in a concluding section after chapter seven. This section 
presents possible solutions for the Mexican biobanking issues raised, and 
more specifically, a brief statement of what legal challenges Mexico 
should implement. 
 
 This section also includes a reflection on the value and relevancy 
of fieldwork, and the difference it makes to the research. Specific findings 
of each chapter are independently presented, followed by a brief 
explanation on the originality of the research and how it is expected to be 
helpful in practice. 
 
1.7 Concluding remarks 
The basis of any type of implementation for new policies should 
consist of inclusive concepts. It would also be relevant to include 
stakeholders, note the particular exceptions, and ascertain what should 
be the treatment of existing collections. This introductory panorama has 
helped to gain an insight into the current state and justification of the 
research by presenting the existing nature of ethical facts, which will 
support further views on Mexican biobanking regulation.  
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2. Methodology 
 
2.1 Research methodology  
This section describes the methods that were followed through the 
development of this research, how both desk-based research and 
fieldwork methods were combined, the reasons for their selection and 
their role within the research process. The research questions are 
included.  
 
2.1.1 Research methodology insights 
This research project was motivated by indicators of concern 
regarding the biobanks in Mexico. The verification of such indicators were 
based (in principle) on articles by INMEGEN; these reported the recent 
targeted governmental efforts, covering technical aspects, highlighting 
perceived population benefits and the economic potential of personalised 
medicine. The previous insights were obtained from academic literature 
up to September 2010, when this research project commenced. By that 
year, most research issues for Mexican biobanking were undocumented 
in published academic literature. 
 
2.1.2 Research methods 
The scarce academic literature identified supported the hypothesis 
that biobanking legislation was problematic. However, the topic presented 
some difficulties, such as the absence of written legal reports or opinions 
on the biobanking situation in Mexico. On the one hand, this proved 
insufficient to investigate the current position; on the other hand, this 
significant challenge contributed to the originality of this research, 
(leading to the design of empirical work). The determination of the 
following research questions is based on the biobanking concerns and 
will be complemented by those of biobanking actors in subsequent 
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chapters; e.g. Chapter 3 evaluates stakeholders’ perceptions on biobanks 
and their regulation. 
2.1.3 Desk based research 
The ethical and the legal perspectives were combined using 
theoretical and practical approaches. The literature review began by 
searching for biobanking concepts and associated issues, the analysis of 
the critics, and up-to-date legislation. The initial search for biobanking 
literature was filtered by conceptual issues, regulatory issues and case 
studies, focused on Mexican and legal sources such as journals, reports, 
institutional reports and recent news from serious-minded newspapers. 
Emerging academic research and fresh government activity in this field 
were obtained and filed. Additionally, international sources were used, 
such as online broadcasting from news sources with international 
recognition; i.e. the BBC web page. This required constant review and 
updating. The state of documental Mexican and international literature 
has been under consultation and review for the length of this stage of the 
project. 
 
Mexican academic articles on biobanks, from a legal perspective, 
were scarce and the methodology changed from desk-based research to 
include fieldwork on the topic. Progress up to chapter three demonstrated 
that no consistent legal study proposals had been presented for the 
regulation of biobanks in Mexico. Apart from being inconsistent, past 
studies were characterised by being purely based on theory. This 
motivated the organisation of a serious and detailed fieldwork plan, which 
finally made a substantial difference in the analysis of biobanking, by 
confirming ways forward and considering feasibility. 
 
Further progress allowed the identification of potential 
representative actors, associated to governance, policy making, 
governmental ethical advice and academia. Their accounts were valuable 
for a full understanding of the issues so far identified. At least one actor 
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of each area was to be identified among accessible public institutions. 
This contributed to the originality of the research, as no previous integral 
studies were detected combining theoretical with practical works. 
Consequently, it also increased the reliability of the proposal. 
 
The evaluation of the legal status of Mexican biobanking made it 
necessary to identify existing binding and soft law national guidelines, 
supported by the literature review. The criteria for the legal and 
governance analyses primarily focus on binding regulatory frameworks 
and their competence and secondly, on alternatives to improve 
effectiveness. 
 
There seems to be valuable lessons to learn from countries that 
have already achieved a fit for purpose framework for biobanking. Hence, 
the analysis of relevant examples has been included. For this purpose the 
case of Europe was selected. It allowed the identification of viable sources 
of expertise that may be applicable to the Mexican framework.  
 
This research also involved the investigation of sociologically 
focused resources. These were mainly obtained from recent innovative 
documental sources analysing issues on biobanks from a sociological 
perspective. Introduction and familiarisation of new concepts such as that 
of ‘social justice’ were necessary for this purpose. This approach was 
analysed in order to produce the development of the last stage of the 
thesis.  
 
2.1.4 Fieldwork 
Initially, the main research focus was intended to be desk based, 
with documented and reliable sources providing the main pillar of 
research. The National Institute of Legal Research of the National 
Autonomous University of Mexico was one of the first to report concerns 
from the legal academic perspective through conferences, whose results 
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were published in 2011 (one year after this research commenced). 
Nevertheless, the legal basis of biobanks was only starting to emerge, as 
shown in the initial related publications by Alberto Arellano (INMEGEN) 
based on genomic privacy and more specifically Ingrid Brena (National 
Institute for Legal Research). By 2011, the book “LatinBanks: study on 
the legal and social implications of creating banks of biological material 
for biomedical research,”65 was published as a result of an academic 
collaboration of various countries. The book consisted of purely 
descriptive reports on the situation of biobanks in Germany, Portugal, 
France, Colombia, and Mexico, by the Institute for Legal Research as a 
result of the previously mentioned 2008 International Colloquium. The 
topic had also been observed from the anthropological point of view by 
Ernesto Schwartz66 (INMEGEN-University of Exeter).  
 
The variations in approach (biological, medical, economical and 
ethical) from a legal perspective caused significant challenges. As 
biobanking is a very wide topic, the initial research seemed exhaustive, in 
which any subtopic could justify an independent work. In principle, the 
determination of the research topic was meant to establish what 
constituted a biobank in the absence of a Mexican legal concept. These 
theoretical challenges were helped by a standard delimitation of legal and 
ethical analysis. The initial research approach was expanded to include 
governance, and international and sociological analyses.  
 
2.1.4.1 Fieldwork development 
Fieldwork was directed to participants who were selected from an 
online search for representative biobanking related institutions. Those 
who verbally agreed to be interviewed were given a chance to ask 
                                                          
65 CM Romeo Casabona and JW Simons (eds), Latin banks, study on the legal and 
social implications of creating banks of biological material for biomedical research, 
vol 3 (Bruylant 2011) 277 
66 Ernesto Schwartz, ‘Genomic Sovereignty and the “Mexican Genome” an 
ethnography of postcolonial biopolitics’ (DPhil thesis, University of Exeter 2011) 
40 
 
questions beforehand, and then signed the consent form on the day of 
the interview if they were still happy to continue.  
The questions were focused on biobanking research in Mexico. 
These were phrased in layman’s terms with some technical language 
familiar to the respondents. This essential part of the research sought 
diverse opinions regarding biobanks through a semi structured plan. 
Participants were given freedom to talk about central points of each 
question, opinions, examples and experiences. I listened to them and 
often asked for clarification or further explanation. In some cases, the 
initial question led to relevant sub-questions during the course of the 
interview. If time allowed, up to 3 questions were added in relation to very 
particular activities associated with the role of each participant. 
 
Interviews were recorded using a recording memory stick, which 
automatically created WAV files. Fifteen WAV files were stored on a hard 
drive. Interviews lasted no more than an hour and some notes were taken. 
Translations from Spanish to English are complete, data recorded, notes, 
transcriptions and translations are available for potential University audits 
at any point. Translations and notes are still available for participants if 
this were to be requested by them.  
 
The representatives’ opinions were collected in the participants’ 
original language. After transcribing the interviews in the Spanish 
language, the information was selected, summarised and translated. 
Qualitative analyses have been necessary to fully examine the 
responses. To a lesser extent, quantitative analysis was also used. This 
was done with questions such as, “how many stakeholders considered 
that biobanking regulations were not effective?” in order to provide some 
comparative statistics. 
 
The following table shows the profile of each participant, their 
identities are not disclosed for ethical reasons: 
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Participants Area of expertise 
A Research manager INMEGEN 
B Researcher in medical science INMEGEN 
C Legal researcher in bioethics and human rights IIJ 
D Manager at the social, legal and ethics department INMEGEN 
E Researcher at the social, legal and ethics department INMEGEN 
F Legal researcher and manager in bioethics and medical law IIJ 
G Manager at the legal department INMEGEN 
H Ethics advisor at the CNB 
I 
Manager at the Ethics and law department of the Human Genome 
CNB 
J Legal researcher in data protection IIJ 
K 
Manager legislator in science and technology, Mexico City 
Assembly  
L Ethics advisor on informed consent at the CNB 
M 
Researcher at the Ethics and law department of the Human 
Genome CNB 
N Legal advisor at a health ethics committee 
O Philosophy and Law professor  at UNAM 
 
Fieldwork stages 
Stage 1: Planning the fieldwork  
Interviews with different stakeholders were planned shortly after 
completing chapter 4 of this thesis. Key Mexican biobanking stakeholders 
were interviewed to enable a fuller understanding of the issues involved. 
The main purpose was to evidence “the insufficient biobanking regulatory 
frameworks in Mexico67” in practice. The initial fieldwork plan aimed to 
include direct views from those affected by the state of the biobanking 
regulations, i.e. stakeholders from the different biobanking areas. This 
focus would make a substantial difference. It would provide an 
examination of practical challenges and recent theoretical frameworks, 
with an empirical basis as a firm rationale of evidence. Consequently, 
interviews were planned with several biobanking stakeholders, mainly 
                                                          
67 Arellano-Mendez 29 
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representatives of each area involved and those engaged in practical 
disciplines. 
 
Stage 2: Ethical approval of fieldwork 
The fieldwork plan necessitated careful consideration of ethical 
issues and required the ethical approval from the University of Leeds. The 
main points covered by the ethics application included responsibility to 
explain to participants as fully as possible what the research was about, 
the purpose of the interview, what was involved,68 what was done with the 
information obtained and  the forms in which interviewees have been 
protected, e.g. consent and confidentiality. The corresponding 
assessment was completed before the interviews (November 2012). 
Participants were informed that no economic benefit would be obtained 
from their participation. 
 
Stage 3: Fieldwork to reveal further issues and problems 
A series of semi-structured interviews were planned in order to 
measure any discrepancies shown by some stakeholders’ opinions, how 
these differed from legal requirements, to the deepest disagreements and 
their attitudes towards the oversight law of formal regulations. Hence, the 
sample of participants aimed to be representative and balanced.  
 
Interviews: The following questions were asked: 
 
a) For academics and law-makers involved in the design of 
biobanking guidance design. This set of questions focused on 
indirect biobanking treatment, e.g. it focuses on policy/law making, 
oversight and academic involvement. 
 
1. What is a biobank in your own words?  
                                                          
68 Bell J, Doing your research project. A guide for first time researchers in education, 
health and social science (Open University Press 2009) 156 
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2. What is the content of a biobank?(samples and/or data) 
3. Does Mexico require a specific biobanking legal act? 
4. Regarding the improvement of current frameworks, what 
would be more suitable: clear ethical guidance or stringent 
enforced rules? 
5. How are biobanks regulated in Mexico? 
6. How could the current framework be improved in legal/policy 
terms? 
7. What is the main legal basis of biobanking procedures in 
Mexico? 
8. What should an ethical informed consent form contain? 
9. Is sensible information from biobanks suitably protected in 
Mexico? 
10. Do genetic rules apply to any other types of biobanking? 
 
b) For researchers and stakeholders involved directly in biobanking 
practices. The objective was to obtain opinions from biobanking 
operators about their work in practice, the effectiveness of the 
current guidance, and governance on biobanking. These answers 
were used to compare points of view and identify priority areas of 
debate. 
 
1. In your opinion, is biobanking governed effectively?  
2. Does Mexico require a specific biobanking legal act? 
3. What is the main authority for biobanking procedures in Mexico? 
4. What are the processes followed to conduct a clinical trial in 
Mexico? 
5. What are the most serious sanctions for a researcher responsible 
for unethical actions within a clinical trial relating to the 
mistreatment of samples? 
6. Have the recent changes in Mexican legislation been effective? 
(within your area) 
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7. Regarding the improvement of current frameworks, what would 
be more suitable: clear ethical guidance or stringent enforced 
rules? 
8. Are there any restrictions for the processing of personal data from 
research samples?  
9. Are you subject to periodical inspections?  
10. If so, by whom? 
 
For the purpose of the interviewer the two sets of questions were printed 
in cards. 
 
Stage 4 Selection and recruitment of participants 
 A governmental biobank 
Legal department (1 participant) 
Ethics department (1 participant) 
Academic research department (1 participant) 
Scientific department (2 participants) 
 
 Bioethics advisory governmental institution 
Legal and ethical advice (2 participants) 
Public policies (1 participant)  
Social policies (1 participant) 
 
 Legal research institution at a public university  
Law, health and bioethics section (2 participants) 
Human rights (1 participant) 
Data protection (1 participant) 
 
 Philosophy department at a public law school  
Bioethics analysis (1 participant) 
 
a) Negative responses to recruitment  
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Data protection authority (1 participant) 
b) No response to recruitment 
The Mexican Parliament, science and technology law making (1 
participant) 
Biobanking national authority (2 participants) 
c) Impossibility to arrange an appointment 
Biomedical research at a public university (1 participant) 
 
Ethical approval was acquired from the Faculty Research Ethics 
Committee of the University of Leeds.69 
 
Fieldwork principles 
The following principles constituted the ethical basis of the fieldwork plan 
and development: 
 
a) Informed consent 
The autonomy of participants was the main principle to be protected for 
this type of research study. It was protected by providing the full 
information before formal consent was obtained. This involved the use of 
two documents; an information sheet and the actual informed consent 
form.  Initially, participants were invited to participate by e-mail with the 
Information Sheet attached. Once they accepted this initial invitation, the 
documents were explained and signed in person. An appointment was 
organised in Mexico at their place of work. Information sheets and 
informed consent forms were provided in Spanish. 
 
b) Withdrawal 
It was agreed that information would be sent beforehand so that 
respondents had an opportunity to query the meaning and implications of 
any statements, and to withdraw at that stage. It was established that 
                                                          
69 Ethics application formally approved by the ESSL, Environment and LUBS (AREA) 
Faculty Research Ethics Committee (16 of July 2012) 
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participants could opt out of the project at the following times: after 
reading the information sheet, at any point during the interview or at the 
end of the interview. Participants knew that in the case of voluntary or 
involuntary termination of the interviewer/interviewee relationship, they 
could leave with full dignity. They had the choice to withdraw from the 
research at any point, up until the point in which data was impossible to 
be removed, e.g. once it has been published.  
 
c) Data protection and confidentiality 
Due to the sensitivity which criticism about Mexican Biobanking 
regulation might cause, anonymisation was used at all times. Identity and 
other individual characteristics were changed for this purpose. Once 
participants agreed to be interviewed, they had the opportunity to ask 
questions. At this point, I asked them to sign a consent form. The 
information that was kept about them – including taped interviews, 
transcripts, notes etc. – have been stored on a secure university hard 
drive. The minor limitations to confidentiality and disclosure of information 
were also identified. The issue of access to data was covered by informing 
participants that their answers would be shared only for academic 
purposes in relation to my work. This meant that any further use of data 
for non-academic purposes (e.g. publication) or any action involving data 
sharing would be a reason for re-consent. The same would happen if for 
some reason data was shared outside of Mexico or the UK. This would 
be possible only if that country had the same levels of protection. 
 
d) Transparency 
Accurate identification of qualifications, both verbally and in writing 
were covered before the interviews. In this case, my position as a 
research student at the University of Leeds was presented in the 
information sheet for participants. They knew my identity and were free to 
contact me or my supervisors at any point through our university e-mails. 
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e) Respect for Diversity 
Questions were deliberately presented in an objective way. 
Awareness of the diverse opinions of individuals, when dealing with the 
issues of biobanking in Mexico, ensured that the interview and research 
was objective. It was essential to recognise the need to work co-
operatively in a multi-disciplinary background respecting the unique 
contribution of each member. The selection criteria were based on 
targeted areas, preferably decision makers in public biobanking 
management and academic analysts involved in the storage of samples 
for population/specific studies, ethical advisers, legal advisers, policy/law 
makers, data protection analysts, academics and human rights 
advocates. 
 
f) Contact 
The first step in making contact was to investigate the roles and particular 
functions from five main representative institutions associated with the 
targeted areas. Initially, twenty participants were identified. Each selected 
participant was contacted individually, two to four weeks before visiting 
Mexico, through publicly disclosed institutional e-mail addresses. I 
enclosed an information sheet, explaining the purpose of the visit and 
asking for an interview, between the 5th of December 2012 and the 10th 
of January 2013, and informing them that they could agree to participate 
at any time up until the end of my visit. All interviewees chose office hours 
at their workplaces. The tone of the invitation was informal. Out of twenty 
participants, fifteen were interviewed. One negative response was 
received, three participants did not reply to the invitation e-mail and one 
more participant accepted but was not available on the proposed dates. 
 
2.1.4.2 Fieldwork: main challenges 
Some difficulties had to be faced in order to achieve a 
representative sample of biobanking opinions. The early development of 
self-funded fieldwork allowed contact with only a few stakeholders, who 
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replied briefly after receiving the e-mail. About 50% of the participants 
replied once the dates were close (on the days before the interviews) and 
the rest were contacted by telephone. It was agreed that detailed 
information would be sent to their e-mail. The most obvious restrictions 
were time limits to carry out the interviews and adjusting visiting 
schedules for each of the participants without clashes. Time was limited 
and government members of staff tend to be very busy people. I 
appreciated the fact that most of them accepted to take part in the 
interviews. The necessary trips to Mexico were funded from the 
CONACYT (National Council for Science and Technology) grant for this 
project. 
 
2.2 The Mexican situation 
The United States of Mexico, commonly referred to as Mexico, is 
a Latin-American country divided into 31 states. Mexican society is 
diverse, consisting of mixed racial and genetic profiles with large regional 
variation. The World Health Organisation (WHO) has stated “the 
importing of medicines and other drugs may not be as effective to 
Mexico's population.”70 Mexico needs medicines that respond to the 
particular characteristics of Mexicans. The characterisation of the genetic 
variation of the Mexican people and determination of drug response is 
undoubtedly a significant aim, which could be achieved through 
personalised medicine. 
 
2.2.1 Main biobanking concerns in Mexico 
These concerns will be explained in more detail in chapter 2. 
Biobanks emerged in Mexico as a result of jointly funded efforts by the 
Federal government and private enterprise. The first Mexican biobank 
was created as a result of a collaboration between the National 
                                                          
70 World Health Organization, ‘Global applications of genomics in healthcare: Mexico’ 
(WHO Genomic resource centre)  
<http://www.who.int/genomics/professionals/applications/mexico/en/> accessed 30 
November 2012 
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Autonomous University of Mexico and the public hospital ‘Highly 
Specialised South Central Hospital PEMEX’ (Hospital Central del Sur de 
alta especialidad de PEMEX) in 1994.71 This first biobank stored radio-
sterilised amniotic membranes for patients who suffered from serious 
burns. By 2000, Mexico had 53 tissue banks.72 In addition, the amount of 
both public and private biobanks have significantly increased.73  
 
The first brain bank in Mexico was opened in September 2012 “with 
the objective of a better understanding of neuro-degenerative diseases.74” 
Jose Luna Muñoz, neurology researcher, emphasised the open access 
that researchers will have to the new biobank centre, so that “all interested 
researchers can request the biological material and this will be facilitated 
under due ethical requirements.”75 However, no further clarification has 
been provided in terms of preservation periods and secondary uses of 
biological samples within biobanks. It is also unclear whether the initial 
consent covers the specific research project on which the sample 
collection is based, or whether it can be extended to additional research 
projects. Researchers at INMEGEN (Mexican National Institute of 
Genomic Medicine) are not sure whether the destruction of valuable 
‘leftover’ samples, after the collection purpose has been met, is the most 
ethical thing to do. In the experience of participant A, in some 
circumstances there is not enough information to make a suitable 
decision in the management and administration of the samples. There is 
nothing that can provide parameters, guidelines or policies in this 
respect.76  
                                                          
71 M Montes Guadarrama and others, ‘Bancos de tumores (tummour banks)’ (2011) 49 
Patologia 251 
72 Daniel Luna-Zaragoza and Ma. Lourdes Reyes-Frías, ‘Donation transplants and tissue 
banking in Mexico’ (2001) 2 Kluwer Academic Publishers 255 
73 Gorodesky 
74 ‘Crean Banco Nacional de Cerebros’ El Universal (Mexico City, 21 September 
2012) <http://www.eluniversal.com.mx/articulos/73647.html> accessed 20 October 
2012 
75 Ibid 
76 Responsible-for-the-research-department-at-a-public-biobank-Participant:A, PhD 
thesis fieldwork (2012) 
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The most common samples taken in Mexico are blood, followed by 
tissue, (brain tissue, heart tissue, skin cells, plasma, cerebrospinal fluid, 
DNA, RNA, immortal lymphocytes, cellular lines and bone marrow fluid).77 
 
2.2.1.1 Conceptualisation issues: what is a 
biobank in Mexico? 
This section will introduce the main problems when dealing with 
biobanks and the conceptualisation issues in Mexico. In the absence of a 
Mexican definition of biobanking, different measures have been taken. On 
the experience of INMEGEN’s researchers,78 everything is based on 
informed consent. This is based on the rules of the General Health Law 
on health research. It is explained to the research subject what will be 
done with his samples, where it will be kept, by whom and how the data 
will be protected. Research subjects are always told that the sample will 
be kept in a repository, not a proper biobank, just the storage freezer.  
 
Legal challenges on biobanks in Mexico are related to 
conceptualisation and classification, sample-age, uses and users, 
duration of the study, types of participants, stakeholders and governance 
oversight and enforcement. The term “biobank” is now the over-arching 
term that is most commonly used. For governance purposes, at least in 
Mexico, the use of term “biobank” should be preferred due to the 
inclusiveness of the term and since it is widely used in practice.  
 
The understanding of what a biobank means varies significantly in 
Mexico. Participant M believes that “biobanks are both the samples and 
the data contained in them.”79 However, in participant A’s opinion, 
                                                          
77 Casabona and Simons 277 
78 Responsible-of-the-ethics-department-and-researcher-at-a-public-biobank-
Participants:DandE, PhD thesis fieldwork (2012) 
79 Responsible-of-the-Human-Genome-Department-at-a-public-ethics-advisory-
institution-Participant:M, PhD Thesis fieldwork (2012) 
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“biobanks, as such, do not exist yet, just bio-libraries;”80 For this 
participant, proper biobanks are like those in Nordic countries.   
 
“Those are immense, have great amounts of data and are super 
regulated, something Mexico is far from. Those in Europe are different in 
many aspects, in their laws, how they work and their health systems. 
They have centralised databases on health data from thousands of 
samples. We cannot compare them both. We have envisaged having a 
structured biobank in the future, not just a sample repository.” 81  
 
 
Participant A expressed that a biobank is really a structured and 
particular collection.  
“We have collections from somebody who is doing a research project; 
we aim for a biobank, that each institution has rules allowing access to 
those collections and database, justified by a good research project. The 
collection preserved by INMEGEN could potentially encourage the 
creation of a national biobank, a resourceful database to support 
Mexican and overseas researchers. The project exists but has not been 
yet approved. We are working on that.”82  
 
Participant A’s opinion resembles the description by Kaye; “the key 
factor that distinguishes a biobank from a research collection is that a 
biobank has established governance mechanisms in place to allow 
access to the resource in a systematic way to outsiders.”83 However, this 
might involve a causality circular dilemma, at least if it was applied to 
Mexico. A great number of research collections in Mexico have no 
established governance mechanisms. Under Kaye’s approach, therefore, 
they could not be considered biobanks. If biobanks do not exist, a 
biobanking regulation for Mexico would not be so necessary. Participant 
A explained that she does not know whether the pathological collection at 
the National Institute of Cancerology, is a biobank; “there is a type of 
biobank of pathology samples.”84 
 
                                                          
80 Responsible-for-the-research-department-at-a-public-biobank-Participant:A 
81 Interview with participant A  
82 Interview with participant A  
83 European Commission 14 
84 Interview with participant A  
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2.2.1.2 What does a biobank contain? 
Participant C believes that “a biobank is formed by biological 
samples and the information derived from them. A biobank may contain 
even bones, it is very broad. One of the problems is precisely that the 
content of biobanks can include tissues, organs, for different uses. Yet 
there is no suitable classification based on biobank types.”85 For 
participant F, a biobank is a collection of samples. “There are different 
types of biobanks. Some are for research purposes, others preserve 
gametes, cord blood. Biobanking is the preservation of samples and 
organs with different purposes.”86 It is difficult to provide a definition on the 
utility of the biobank and the material they contain as the latter varies 
significantly. It is the storage of biological material but differs from a simple 
storage because it is classified and organised, otherwise it would just be 
a repository. It is possible to exchange samples with other biobanks of the 
same type.87  
 
Participant C agreed on the fact that first, “we need a law defining 
what a biobank is, what the extent of a biobank is, who will control them, 
how will the data be regulated, the purpose, the content and each 
possibility. There might be biobanks in universities and we don’t even 
know they exist. They may be working with pathological samples and 
operating with no controls.”88 In effect, defining what a biobank is would 
be a very good beginning. 
 
Self-guidance is common where no biobanking definitions have 
been adopted. In the words of Participant B, a Mexican scientist, “a 
reference point would be good, it would seem arbitrary to me to determine 
a threshold, a limit in the quantity to define a biobank; I am not very 
                                                          
85 Interview with participant C Legal researcher at a Public research institution. 
(Mexico City, December 2012) 
86 Interview with participant F 
87 Interview with participant F 
88 Interview with participant C 
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familiar with international law and I do not know if there are instruments 
that give these criteria.”89 Participant B said that quantitative biobanking 
criteria was not a concern, “I do not think there are criteria to determine 
how many samples constitute a biobank. We could start by that.”90 Large-
scale biobanks are generally used for prospective and longitudinal 
molecular epidemiology research projects, while smaller scale biobanks 
are established for specific research projects, such as case-control 
studies. The latter “have been more the norm…while large scale biobanks 
are relatively recent.”91 These smaller scale projects represent an 
indispensable scientific resource complementary to large-scale biobanks. 
However, that still leaves the “remainder of the biobank spectrum that 
encompasses increasing levels of operational complexity and associated 
cost.”92  
 
2.2.2 The particular commercial pressures  
Medina-Arellano observed that “lately, Mexico has seen increasing 
interest from private foreign companies in nurturing this area of research, 
creating international transnational alliances between countries and 
research institutes.”93 Examples of such strategic alliances are those at 
INMEGEN, where they have been developed. 85% of them were formed 
in the first 3 years of the Institute.12 state universities, including the main 
national university UNAM, and research institutes: the Mexican national 
institute for health NIH, and public health provider ISSSTE. Participating 
institutions abroad are: Vanderbilt University, the University of Toronto, 
Translational Genomics Research Institute (TGen), the New York State 
Centre of Excellence in Bioinformatics and Life Sciences and Nestlé.  
 
                                                          
89 Interview with participant B 
90 Interview with participant B Researcher at a public biobank. (Mexico City, 
December 2012) 
91 European Commission14 
92 Watson and Barnes 328 
93 MJ Medina-Arellano, ‘Stem cell regulation in Mexico: current debates and future 
challenges ’ (2011) 5 Studies in Ethics, Law, and Technology   1941 
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Another area of interest is the activity of the pharmaceutical 
industry; it involves more focused clinical research by laboratories aiming 
to develop diagnostic and predictive tests from specific areas of the 
human genome. Increasing pharmaceutical activities have caused 
Mexico to attract the attention of industrial activity in this area. 
Additionally, the low cost of research and density of diverse population94 
has created interest in terms of patient recruitment for clinical trials. 
 
Other reasons why Mexico has also become a popular location for 
clinical trials are the free trading facilities with the USA and Canada, which 
make the country an attractive place for the development of clinical trials. 
30% of the total cost of the trials can be saved in comparison with the cost 
of trials performed in the USA. Besides, Mexico has been targeted by the 
pharmaceutical industry because of the diverse ethnicity among the 
population and the availability of “virgin patients” (those who have never 
participated in a clinical trial). Fernando Santiago considers current 
guidelines are rather general, weaker compared to current industry 
standard practices; and somehow inadequate to tackle challenges 
resulting from an expanding market.95 
 
A factor that makes Mexico a place of interest for the development 
of new drugs is the prevalence of diseases associated with genetic 
components, e.g., diabetes. In Mexico, the mortality caused by diabetes 
mellitus is 64% and has increased 5.2% in women between 1999 and 
2009.96 For example, the Slim Initiative for Genomic Medicine is a project 
funded by the Carlos Slim Health Institute. The foundation aims to 
                                                          
94 KP Virk, ‘Trials in Mexico: Addressing the challenges. Clinical trials outsourcing 
Mexico’ (2009) 21 Biotech and pharmaceutical researvh language connections 21 
95 F Santiago-Rodriguez, Facing the Trial of Internationalizing Clinical Trials to 
Developing Countries: With Some Evidence from Mexico (UNU-MERIT, Maastricht, 
The Netherlands, 2008) 16 
96 Mexican Population National Council CONAPO, ‘Consejo Nacional de Poblacion 
CONAPO’ (SEGOB (Mexican Ministry of Governance), 2009)  
<http://www.conapo.gob.mx/> accessed 28 May 2011 
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develop steps in genetic knowledge leading towards the cure of diabetes 
type 2 and many types of cancer which have a significant public health 
impact in Mexico. Hence, it has sponsored studies such as “the sequence 
analysis of mutations and translocations across breast cancer 
subtypes,”97 (a collaboration of the Broad Institute in Cambridge, USA, in 
which the INMEGEN also participated). The results of the study have 
been surprising in terms of the genetic alterations that had not formerly 
been associated with breast cancer. Genes unexpectedly participating in 
the breast cancer process have been discovered. The study represented 
a preliminary opportunity to evaluate the genetic first step toward breast 
cancer research in Mexico. 
 
In Mexico, these types of studies are becoming more common. The 
Mexican government has centred on strategies to use evidence-based 
population studies to inform public health decision-making and target 
health interventions accordingly.98 The intention is that medical advances 
would bring social and economic benefit to the population and encourage 
pharmaceutical research.  
 
The import and export of human tissue is commonly used in 
research activities in Mexico. The UNAM study revealed that nine 
biobanks do not import or export, whereas four biobanks have import and 
export agreements with academic institutions (mainly in the USA and the 
UK). One biobank imports samples from a North American Company. 
“Samples are often sent to countries counting on a more solid structure in 
order to join efforts and accelerate research.”99 International schemes for 
sharing samples will be analysed in chapter 6. 
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2.2.2.1 Ethical conduct of the pharmaceutical 
industry 
Biobanks also involve the participation of the private sector, which, 
far from being limitless, should be controlled. There is an important gap 
between the development of the first clinical trials, in 1983 and the 
establishment of official minimum regulatory controls in 2008. COFEPRIS 
the Federal Commission for the Protection against Sanitary Risk 
(Comisión Federal para la Protección de Riesgos Sanitarios) has 
recognised that the authorisation protocols started when the Commission 
became an authority for the approval of clinical trials. COFEPRIS began 
to conduct elaborate statistical studies in relation to clinical trials in 2011. 
The latter creates great concern on the numerous past and present ethical 
issues. Biological samples can be preserved for years. The longer they 
are preserved, the greater the ethical risks become. The present situation 
of Mexican biobanking is problematic and it is possible that old biological 
collections are still being used. It is not determined whether retrospective 
actions should apply for those cases. Participant K, a policy maker, said 
he was not aware of any regulation of benefits obtained by industry from 
biobanking in the country.100  
 
According to an investigation made by the Mexican magazine 
“Contralínea,”101 5025 clinical trials involving human beings have taken 
place from 1983 to 2011 with national and international participation. 
More than 3476 have been performed by national public health 
institutions and international health institutes. The National Institutes of 
Health (NIH) from the USA have also developed self-sponsored and 
collaborative biomedical research; at least 20 transnational firms have 
collaborated in half of the total research performed by Mexican health 
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institutes.102 The investigation highlights the fact that the international 
private pharmaceutical industry has sponsored most of the clinical trials 
in the country (46%) through 20 laboratories established in Mexico.103 
 
Regarding international participation, the US NIH has developed 
1549 clinical trials, 929 (60%) in collaboration with transnational 
pharmaceutical companies. Out of those 1549, 1472 (95%) have been 
invasive. More than 14187 people have participated. COFEPRIS has 
reported that most of the research protocols which have applied for 
approval were national and international private institutions, some of them 
were collaboration studies between national and international private 
institutions,104 e.g. a private health centre from Mexico City and an 
international pharmaceutical company.   
 
The main identified problem is the insufficient supervision by the 
Mexican authority to verify the compliance with minimum ethical 
requirements. According to information provided by COFEPRIS, between 
2003 and 2011, 690 committees were authorised by the Commission (169 
research committees, 516 ethics committees and 5 biosafety 
committees).  From January to April 2012, 33 applications have been 
approved (15 research committees, 14 ethics committees and 4 bio-
safety committees.105 However, these numbers are not proportional with 
those disclosed by the Contralinea investigation on the number of 
research trials developed in the country. In addition, biobanking 
evaluation should theoretically be done by a bio-safety committee and 
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only a small number of bio-safety committees have been approved. This 
means that biobanking is being evaluated by non-specialised ethics 
committees, a situation which could be advantageous for the 
pharmaceutical industry but not for research participants. Currently, 90% 
of experimental trials, which are related to biobanking, are advanced 
(phase 3)106 and they need evaluation by people who are research or 
biobanking experts on ethics topics.   
 
Problems associated with research protocols have also been 
detected. Research protocols of international pharmaceutical companies 
tend to follow their own formats, but these do not always comply with the 
specific regulations of each country and if the national authority has weak 
controls, transnational companies avoid updating their standards.107 
 
The CNB has provided a list of elements for the Mexican 
government to consider in order to increase the controls on the activities 
by the pharmaceutical industry. The institution has detected unethical 
conduct; laboratories have offered money to health staff instead of 
recruiting “virgin” patients.108 This is a serious problem which could have 
numerous implications. One of them is the high probability that such 
recruitment also include the collection of biological samples. 
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2.2.2.2 The relevance of the specific populations 
inside the country’s boundaries 
The practice of personalised medicine involves not only a 
biological challenge but also one with significant cultural and social 
implications. In the opinion of Cavalli-Sforza and Feldman,109 cultural 
influences in human behaviour are greater than those of biology. 
However, the authors support the idea that still “some release from 
genetic determinism” must not be underestimated. Following this idea, the 
particular cultural characteristics of indigenous populations in Mexico, 
including religious convictions and established legal or political claims, 
can be challenged by genetic studies at collective and individual levels. 
 
Approximately 90% of the Mexican population is racially mixed. 
The remaining 10% corresponds to 56 indigenous groups, whose 
integration into modern Mexican society has been a long process related 
to national identity and recognition. This process is still taking place after 
centuries of discrimination, domination, exploitation and cultural 
submission. In contrast, great efforts are being undertaken to preserve 
this cultural, social and linguistic legacy.110 Participant D believes that in 
the case of indigenous groups, “no time has been dedicated to reflect 
whether indigenous populations need different protection, I believe that it 
is important to request their informed consent in their own language.”111   
 
It is well known within Mexican society that indigenous peoples are 
considered vulnerable for many reasons, including historical 
discrimination against indigenous ethnic groups, which is still within 
people’s living memory. Indigenous groups are associated with ignorance 
and poverty by many. The word “indio,” i.e. Indian, a term associated with 
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indigenous ancestry before Mexico was a Spanish colony, may be used 
in a pejorative sense. This could signify high risks of stigmatisation, since 
population studies also involve “reification of race, a mostly social 
construct as a highly meaningful biological construct.”112 
 
There are good reasons for the emergence of different types of 
biobanking in Mexico. One of them is undoubtedly the diversity among 
the Mexican population. “Mexico serves as an important focal point for 
medical genetic analyses, because it harbours one of the largest sources 
of pre-Columbian diversity and has a long history of complex civilizations 
with varying contributions to the present-day population.”113 Genomic 
diversity studies represent the initial reasons for the creation of 
INMEGEN; the analyses of genomic variation in, and between, particular 
populations for various purposes. Such examples include ‘investigations 
on the Mexican human genome for population study purposes’ and ‘the 
consequent further development of genomic benefits.’114 The studies 
conducted by INMEGEN involve sample collection and, therefore, 
potential research ethical concerns.  The genotyping results achieved in 
the HapMap study (the Map of the Mexicans’ Genome on national 
genomics identity) are planned to be used in future epidemiological 
research. 115 
 
2.2.2.3. Ethical dilemmas on biobanking 
To encourage the participation of vulnerable groups requires 
funded projects with integral views, not simply disclosing scientific 
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research results, but demonstrating their utility towards the communities’ 
welfare. Therefore, the topic of indigenous communities participating 
involves more than issues relating to data protection or a later return of 
scientists to disclose meaningless research results for the real needs of 
these communities. In practice, the ethics committee is the one 
responsible for looking at the needs and best interests of vulnerable 
people participating in research protocols.116 The CNB does not provide 
special training for the cases of vulnerable populations, a CNB 
representative admitted that “it has not happened.”117  
 
Hence, recruitment procedures, informed consent and 
confidentiality protections must include protective measures. The General 
Health Rules on Research anticipates protection for vulnerable people 
through specific chapters on research on underage persons, pregnant 
women or incapable persons. Protection for communities, students and 
workers is also anticipated.118 
 
2.2.2.3.1 The ‘unique’ Mexican genome and the 
claims of genomic sovereignty  
Population genetics is closely related to biobanking. Regulation 
has been introduced governing the research on human beings in relation 
to genomic studies. Genome resources that use samples from identified 
populations raise scientific, social and ethical issues that are, in many 
ways, inextricably linked.”119 Eugene Thacker120 has explained how the 
concept of genomic sovereignty has been understood from two different 
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views. The first is a progressive one from genetic identification and 
differentiation, in which individuals and populations can be analysed 
according to their unique characteristics. When the Spanish conquistador 
Cortés married his indigenous translator ‘La Malinche’, their union and 
many others like them depicted how two divergent genomes merged.121 
This has led to the sometimes exaggerated measures to defend this 
allegedly unique genome. The second from bio-politics, combines the 
potential of population genomics with the risk of neo-colonialist practices, 
caused by potentially unfair appropriation of biological material from 
groups with specific genetic profiles (e.g. from transnational 
pharmaceutical companies).  In Mexico this latter view has been the 
motive for protecting the allegedly ‘Mexican unique heritage’. The 
increasing popularity of this new concept contributed to the proposal of 
unusable legislative measures; in order to protect, not precisely Mexican 
indigenous groups, but the economic value of their samples. Additionally, 
group stigmatisation is inherent in any study of samples from identified 
individuals or populations, especially indigenous groups. This also 
constitutes a risk for the general population, who potentially can be 
affected on the grounds of genetic variation. This topic will be further 
discussed on chapter 4, as it involves a brief legal analysis of the current 
related Mexican rules. 
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II. THE MEXICAN CONTEXT 
3. Risks, harms and values 
 
3.1 Introduction 
This chapter argues that the present guidelines do not favour the 
ethical treatment of biological samples in Mexican biobanks by 
researchers. The allegedly inconsistent legal framework, with ambiguous 
oversight and procedures, does not cover all biobanking practical areas. 
This involves a negative impact on the development of valuable research 
which, in many cases, is done at the risk of participants being exploited. 
Hence, this chapter aims to investigate the current risks and harms 
potentially posed by the current state of Mexican biobanking, covering 
their history. Troubling historical cases have often precipitated significant 
changes regular to reform all over the world. A few relevant examples are 
presented. 
 
The first section briefly reviews traditional bioethical principles 
based on academic literature. The understanding of ethical values is 
elemental to understand the main legal weaknesses within biobanking. 
Hansson states that many ethical concerns ‘…test our traditional legal 
concepts, governance provisions and bioethical principles.122’ A number 
of risks and harms tend to emerge without a firm ethical consideration 
within legislation.  
 
The second part of this chapter analyses the main Mexican 
research ethics guidelines for biobanking, as far as they exist; this 
includes inconsistent and weak guidelines, ethics committees, institutions 
and operational factors. Areas requiring more attention will be identified.  
A case study analysis on obstacles related to the effectiveness of 
research ethics will follow. A comparison will be done between two cases, 
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illustrating the main practical biobanking dilemmas in Mexico. The chapter 
will finish with a brief proposal on ways to improve the current framework 
for research ethics in Mexican biobanking. 
 
The protection of human rights has also been a key element in 
alleviating potential risks and harms. Hence, the final section of this 
chapter will evaluate whether this could be the case in Mexico. How the 
state of human rights impacts on identified potential risks and harms will 
be analysed. Knowledge on the strengths and weaknesses of the 
Mexican human rights’ system may be fundamental for suitable Mexican 
biobanking legislation.  
 
3.1.1 Historical cases 
The undetermined uses of biobanks have led to cases of alleged 
abuse through the history of biobanking. Lawsuits related to the 
inappropriate use of specimens and the absence of consent have been 
exposed by the U.S. press123 The majority of these cases did not involve 
technical misuse but touched on ethical issues.  
 
This was the case of Henrietta Lacks (1920–1951), whose cells 
were the first immortal human cells ever grown in culture. (Her cells, due 
to induced mutation, kept undergoing division through prolonged growing 
in vitro). During radiation treatments for a tumour, two samples of 
Henrietta's cervix were removed by the Johns Hopkins Hospital in the 
USA - a healthy part and a cancerous part - without her permission.124 
These were essential to developing the polio vaccine in 1954. Many 
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scientific landmarks since then have used her cells, including cloning, 
gene mapping and in vitro fertilization. Twenty years after Henrietta’s 
death, scientists using her cells also began using her husband and 
children in research without informed consent. And though research using 
her cells had launched a multimillion-dollar industry that sells human 
biological materials, her family never saw any of the profits.125 In the 90s, 
a cell line donor claimed the legal property of his sample used in 
unauthorized research (the Moore case in California)126, leading to an 
intense ethical debate centred around the concept that “inadequate 
unclear laws generate distrust and anger.”127 For scientists, this has 
reinforced the lesson that there are human beings behind every biological 
sample used in the laboratory.128  
 
Post mortem tissue has been an object of controversy linked to 
gaps in legislation at national levels, such as that which led to national 
bioethics scandals in the UK, which would later be known internationally. 
What became one of the most controversial points was the absence of 
authorisation to use such sensitive biological materials for the 
development of potentially valuable medical research. Alder Hey 
Children's hospital scandal was centred on the retention of hearts and 
organs from hundreds of children, who died at the hospital between 1988 
and 1996, without the parents’ consent.129 Decades after, and even when 
legislation was set in place, controversial cases keep emerging. Recently, 
in 2012, relatives of British soldiers killed in Afghanistan received a public 
                                                          
125 D Keiger, ‘Immortal Cells, Enduring Issues’ Johns Hopkins Magazine 
<http://archive.magazine.jhu.edu/2010/06/immortal-cells-enduring-issues/> accessed 2 
June 2012 1 
126 Moore v. Regents of the University of California John Moore, Plaintiff and 
Appellant, v The Regents of the University of California et al, Defendants and 
Respondents (Supreme Court of California) 
127 JB Prowda, ‘Moore v. The Regents of the University of California: An Ethical 
Debate on Informed Consent and Property Rightsin a Patient’s Cells’ (1995) 77 JPat 
&Trademark Off Soc 611 
128 Zielinski 2 
129 BBC News, Organ scandal background (BBC 2001) 
66 
 
apology over the revelation that body parts had been stored without 
permission. Approximately six organs and more than 50 tissue samples 
were reportedly discovered in Oxford,130 raising suspicion that the 
biological material was being used for research. This and other 
international experiences highlight the importance of contemporary 
research ethics and the diverse perspectives of its regulation. 
 
As previously reviewed, historical experiences have highlighted the 
significance of informed consent, as most cases of abuse are a result of 
its absence. The legal coverage of informed consent in Mexican 
regulation is controversial; even when it exists no single law covers its 
wide scope related to biobanking. No specific consent type has been 
determined; or what should be best, an open or generic informed 
consent.131 The latter would expand informed consent by allowing sample 
use in unforeseen future studies, whereas a consent type referring to a 
particular research “study,” would restrict any further studies.132  
 
3.2 The concept of risk  
Risk has been traditionally approached by policy makers before 
situations of uncertainty arise, in the best ways they can. Sunstein has 
made a connection between society types, legal systems, and societies’ 
common methods tackling certain risks. Under the European 
Precautionary Principle, a margin of safety is meant to be taken into 
account in all decision making.133 In Britain, it was not so much science, 
as expert judgement that formed the basis for assertions of safety; and in 
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Germany, to begin with, bureaucratic procedures and public consultation 
were the instruments of choice for allaying the fears of a nervous 
citizenry.134  
 
Sunstein has proposed that the best attitude before precaution is 
that reflected by the public, and not precisely a fearful but an informed 
one. Following this proposal, policy makers are still responsible for the 
best implementation of precautionary laws. However, this responsibility 
would be shared with a participative public and the values justified by 
them. Instances of actual discrimination, based on a participant’s 
involvement in a biobank genetic research studies, are extremely rare, 
whereas population studies involve a higher risk of discrimination or 
stigmatisation, not only at the individual level but particularly the collective 
level. The change in focus from investigating risk factors with relatively 
large effects exploring networks of risk factors with weak effects requires 
a radically different approach. Thus, careful thought needs to be given to 
the level of evidence that justifies clinical use of genomic profiling,135 
taking into account the strength of the observational data, the clinical 
benefit and the potential to harm.136 Risks are present with the 
introduction of a sole promissory discourse with ambiguous expectations.  
 
3.2.1 Potential risks 
There are numerous examples of medical advances that have 
relied upon human research biospecimens. Undoubtedly, even when 
discoveries are extremely important for national and international health 
science, ethical aspects must not be disregarded through the processes 
used to achieve such discoveries. There has been very strong public 
support for breakthroughs promising better medical diagnosis and 
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treatments but there are anxieties about “increased loss of privacy and 
the potential for genetic discrimination, as well as the capacity to regulate 
genetic science in the public interest.”137  
 
Biobanking risks are not the same for each type of research. For 
example, statistical analysis of samples within biomedical research has 
proven to be very low risk in comparison with genetic studies, which can 
be highly risky in the case of population studies where vulnerable 
populations take part. Genomic research should have a lower public 
health priority, because a population approach to prevention will achieve 
a greater public health benefit than interventions targeted at high-risk 
groups on the basis of genotypes.138 There must be a balance between 
taking the necessary measures to reduce potential risks, where found, 
and avoiding biobanking policies because of social fears. In this case, the 
precautionary principle can be applied; better safe than sorry, “even 
though they face a statistical risk, they might well be seeking to avoid the 
anxiety that comes from an understanding of the inevitability of risk.”139 
Ulrich Beck portrayed risk as a systematic way of dealing with hazards 
and insecurities induced and introduced by modernisation itself.140 As 
such, it would be capable of reshaping social relations throughout the 
industrial world. He suggested that people everywhere were at risk from 
their own creative powers, materially transformed into hazardous 
technologies, and the risks could strike one down regardless of one’s 
social or economic standing.141  
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3.2.1.1 Non-specific governance and 
consequent risks 
The necessity for effective decision making, because of the 
struggle to find uniform and consistent guidance, has resulted in self-
regulation for the protection of those who participate actively in 
biobanking activities. However, protection of vulnerable populations 
against high stigmatisation risks should not be solely governed by general 
guidance and the goodwill of population projects organisers, even if “only” 
biological samples are involved. If scientists are unable to follow existing 
rules in a simplified way, research subjects will not be fully aware of their 
rights. 
 
Ruth Macklin, regarding the legal situation in the United States of 
America, describes how risky the absence of legal guidelines at a national 
level can be. “The researchers might be faulted for not waiting until such 
guidelines were established. On the other hand, they surely could not fail 
to conform to national guidelines when such guidelines do not exist.”142 In 
the USA there have been cases in which ethics committees are so vague 
in their wording that the researchers cannot be condemned for violation 
of unofficial, unclear ethical research guidelines; e.g. on preembryos. This 
was reported by the American Fertility Society (AFS). Something similar 
would happen in Mexico, where it is illegal to impose any penalty on the 
basis of interpretation, analogy or even by majority opinion. The sanction 
needs to be explicitly and accurately enforced to be applicable.143 
 
The fragmentation of legal rules can impact negatively on the 
practice of ethics in biobanking. Guidance can be accessed from 
international sources. In the opinion of Manson and O’Neill, when basic 
consent requirements are given in a purely ethical way (not legal), they 
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become at risk of being considered optional. Hence, other more basic 
legal standards are necessary to make it compulsory.144  
 
3.3 Ethical values which should underpin regulation 
Mayrhofer and Prainsack suggested that “the creation of ethical 
standards, as well as adherence to them (in the context of networks of 
biobanks) is neither imposed on the scientific communities, nor is it 
separable from the very core of scientific research; instead, ethics and 
science are literally co-produced.”145 Governance tends to be based on 
the notion of a participatory arrangement relying on traditional ethical 
practices that impact on the reliability of scientific research and potential 
social benefit; such as autonomy, respect and privacy rights.  
 
Ethical principles should provide the foundation for human 
research governance. Beauchamp and Childress146 established four 
fundamental principles applicable to biomedicine: 1) autonomy or respect 
to persons, their opinions and decisions based on personal values and 
beliefs; 2) non-maleficence, which avoids harm to other persons; 3) 
beneficence, which forces the prevention or elimination of damage and to 
promote righteousness; and 4) justice in the equal treatment of persons 
unless there is a relevant difference between them.  
 
Biobanking has been the subject of international concerns 
emerging from the need to protect universally recognised values and 
fundamental rights, such as: autonomy, liberty, equality, security, and 
self-determination of participants and donors of samples. It presents a 
number of significant legal challenges, the most important of which is the 
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incorporation of universally recognised ethical principles. Morality and 
public order principles are being surpassed by the legal interpretation of 
positive contemporary systems. Such an interpretation is subject to the 
common rules of each positive legal system, which may contain ethical 
barriers.147 According to Alexy, there is always a component of morality 
within legal issues; individual legal norms and decisions as well as whole 
legal systems necessarily make a claim to correctness. The ideal 
dimension of law connects it with a procedural, universalistic morality.148 
Ultimately, “the governance of biobanks demands complex analyses of 
both the legal and ethical framework.”149 Legal incorporation should also 
be based on legitimising principles of fairness and justice; more 
specifically, the statutory ‘five principles of good regulation’: transparency, 
proportionality, accountability, consistency and targeting.150 
 
3.3.1 Human dignity 
Kantian literature regards dignity as an absolute inner value of 
human beings.151 The view that human body parts (as samples could be 
regarded) cannot be considered commodities or property objects was 
discussed extensively by Kant.152 He rejected the prevalence of economic 
interests over priceless values such as human dignity. The ethical aspects 
of research are relevant not only in relation to property issues of the 
samples, but also recruitment, future use, privacy, benefit sharing and the 
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subject’s consenting matters. A selection of ethical values will be 
described in the following section. 
 
3.3.2 Informed consent 
 General concerns from the public take the form of “making an 
active and informed initial decision about biobank participation but that 
they have concerns about the need for and potential adverse impact on 
future-use consent mechanisms such as categorical and study-specific 
consent.”153 Gibbons has emphasised the absence of certainty when 
collections “may simply happen to be held together, perhaps for reasons 
of convenience or necessity.”154 It may be the case that the initial purpose 
of some collections change over time, or that the purpose was not clear 
or inexistent since the outset. “The material taken originally for diagnostic 
purposes may well have been kept simply as a matter of routine or 
professional culture or retained ‘on spec.’”155 
 
Typical informed consent means that clear information is provided 
through simple terminology, and must include a description of any 
research/medical related procedures and the use of technical terms. 
Consent is divided into two parts: information rights and election freedom. 
Election freedom, or expressive freedom, means every citizen’s ability to 
make choices in an uncoerced manner. Several types of consent 
definitions have been proposed by the literature. Hansson156 has 
proposed the following types of consent: 
 
 Blanket or broad consent is open and generic, expands informed consent 
by allowing sample use in unforeseen future studies 
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 Consent to biomedical research allows samples to be used for multiple 
purposes (even unspecified future purposes) in future biobank-based 
research 
 
 Consent to a specific type of research is referred to a “type” of research, 
as precisely specified as possible, and conducted in the centre holding 
the sample. This ensures the consent is valid and the sample preserved 
beyond a particular study so that further similar studies on the same topic 
are possible later 
 
 Multi-layered consent requires several options to be explained to the 
research subject in a detailed form 
 
 Waived consent condition. If it is not possible to re-contact participants 
for re-consent, some guidelines allow for waived consent for the use of 
biological material, if certain conditions are met.157 However, these 
conditions are not harmonized among international guidelines 
 
 Broad consent models are becoming increasingly popular in recent 
literature by “the bioethics developed for epidemiological research aimed 
for social benefit.”158 The unexpected changes which tend to appear from 
time to time constitute a reason to prefer flexible rules in order to ease 
required modifications. “Decisions will be needed about whether or not 
[one is] seeking fresh consent, or employing some alternative 
safeguard.”159 A consent model sensitive towards public needs would 
consist of an agreement that includes even re-consent possibilities. 
Consent models have been designed to appropriately regulate tissue 
based research. It has been characterised by a maze of laws, policies 
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and ethical recommendations that range from strict (specific informed 
consent) to unrestricted use (broad consent).160 
 
In the case of broad consent, “participants are asked to consent to 
the use of samples and data within a biobank at the time of collection 
rather than to a specific project or type of research.”161 This choice has 
been heavily criticised from various perspectives, to the point of being 
considered not meaningful enough to be informed consent. “A blanket 
approach to consent requirements, that seeks to standardise procedures 
for consent for all treatment or all research, shows a lack of understanding 
of the reasons why consent matters.”162 
 
3.3.2.1 Consent Withdrawal 
The most widely acceptable trend is that “participants should be 
able to exercise their right to have their sample withdrawn at all times.”163 
However, other views suggest that withdrawal of consent is unrealistic or 
limits practical implementation.164 It has also been proposed that tissue 
donors may determine “how far they will be informed and that (when it is 
technically possible) they remain free to rescind their initial choice.”165 It 
is preferable to have all the necessary arrangements for withdrawal 
choices set out in advance in order to avoid working retrospectively. Some 
biobank models offer the following set of graded options for withdrawal of 
samples and data, which may vary according to different situations: 
irreversible anonymization, in which no code key and no re-identification 
are possible; reversible anonymization, in which a link exists, but the 
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researcher does not have access; and coding, in which the researcher 
has access to the code trough a code key.166 
 
For instance, a UK-based, self-regulated public biobank, offers the 
following withdrawal choices: 
 
Option 1 – Withdraw  
Samples and identifiable data would be destroyed. Any links to medical records 
would be broken.  
 
Option 2 - Discontinue participation  
No more information would be collected. Any links between the participant and 
samples or data, including the link with the health record, would be destroyed. 
This would allow the samples and data already contained in the UK Biobank to 
be used, but no further contact with the participant would be made. 167 
 
The preference of a specific model rather than a broad one favours 
the inclusion of withdrawal choices. “Efforts to consent individuals are 
needed to satisfy public and other stakeholder expectations for being 
informed and given the opportunity to refrain from research 
participation.”168 A specific consent model would be committed to explain 
the cases in which withdrawal, at a point, would be impossible. However, 
in Mexico, discarding existing samples could stop future research projects 
which involve collaboration among the main national health institutions. 
Sample destruction, when consent was not obtained for further specific 
purposes, is an ethical measure to protect participants’ autonomy. It does 
not mean that this is the only way forward, but possibly that new contact 
with patient/donor needs to be established in order to ask for re-consent.  
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Normally, it requires an ethics committee to decide on the fate of 
those samples. This would be ethically controversial if it is weighed 
against the concerns involving privacy and data protection of participants 
who are still alive. From the position of the International Ethical 
Guidelines for Biomedical Research Involving Human Subjects (WHO 
AND CIOMS169 2003), “access will always require prior approval of the 
project by a properly constituted ethics committee, and verification that 
the proposed research is within the scope of the initial consent.”170  
 
The participant’s autonomy and privacy could be put at stake on 
the grounds of respecting the initial granted consent. Currently, there are 
no means of controlling potentially unethical biobanking behaviours that 
are not overt. The donor’s informed consent is required since it is 
prohibited to commercialise germ cells (reproductive cells).  If samples 
are anonymised and no privacy risks are involved, the ethics committee 
could determine that no further re-consent is necessary.171 The most 
important ethical aspect is the maintenance of “a strong link between the 
use of biological samples and donor’s informed consent.”172 It could be 
interpreted that if samples are collected for the study of diabetes, more 
than one national institution can access the samples (as long as they do 
research related to diabetes). The meaning of the word “incompatible” is 
subjective; it could mean that compatibility involves further research 
purposes on the disease that motivated the collection or even other 
‘compatible’ diseases. If that is the case, secondary purposes could be 
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carried out legally without asking the donors for authorisation or re-
consent. Although legal, this would not be ethical.  
 
3.3.3 Data protection  
Research results involve potential medical results or findings of 
interest for research participants. The participant should be consulted on 
the uses of the samples as this could compromise privacy or 
confidentiality. In terms of privacy and confidentiality, questions of 
insurance, employment, discrimination and loss of privacy are negative 
developments to be guarded against. Margaret Otlowski has pointed out 
that “concerns about genetic screening are magnified once account is 
taken of future gene chip analysis and the potential for testing for a range 
of non-medical traits, such as aggression, alcoholism or criminality; traits 
that an employer would undoubtedly be keen to screen for.173 Mark Taylor 
has pointed out that “in circumstances where data does not relate to an 
identifiable individual, data protection law will not cover the processing of 
the data at all”174 and in Van Veen’s opinion, “under certain conditions 
two-way coded data can be considered as anonymous data under the 
European data protection directive.”175  
 
Coding is sufficient to avoid an individual patient being traced back, 
unless many variables are included. Ensuring that a bio-collection entry 
is completely anonymous is technically impossible, particularly as DNA 
data will be linked with biographical data and medical records. 
Furthermore, biographical data will need to be more than a ‘one-off 
snapshot’ to be of real use. This means that follow-up checks will need to 
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be undertaken with individuals and this will necessitate researchers 
knowing their identity. 
 
3.3.3.1 Data protection mechanisms 
There is a need to be precise in the use of concepts and to 
distinguish between data sets being anomymous, encoded or encrypted. 
The conceptual confusion here is such, that this may in itself form a topic 
for research and investigation. However, even if the social arrangements 
for protecting confidentiality are clear, given the nature of genetic 
information, it may prove impossible to ensure that biological samples can 
be truly anonymous.176 
 
Anonymisation has not proven to be the best choice for some areas 
of tissue bank research on specific diseases, such as rheumatology, due 
to its limited scientific value177 and the impossibility to truly anonymise 
data. Penelope Manasco argues that “due to the increasing amounts of 
clinical and genomic data, the ability to truly anonymise data and samples 
is impossible.”178 The best option for any research type should be decided 
on these grounds. Extrapolating this question to large-scale rheumatology 
studies involves the treatment of huge volumes of DNA sequence and 
expression data from large numbers of people.179 Anonymity will be 
further jeopardised by the need to gain repeat consent for each new 
study. Therefore, the priority is the implementation of safeguards to 
prevent theft or error and the access of data for purposes that may have 
discriminatory consequences.180 
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Diverse data protection mechanisms are described in the 
literature.181 The main ones, with some overlap, are presented as follows: 
 Identified. The information that allows identification (e.g. name) is 
associated directly with the tissue or data, (i.e. the participant’s nametag 
is attached to the sample.)182    
 Identifiable.  All information related to identification (such as patient 
name, D.O.B) is stored separately from the samples/data but available. 
183   
 Unidentifiable. Sample/Data which cannot be linked to specific 
individuals by the investigator(s) either directly or indirectly through 
coding systems.”184  
 Anonymous.  Association between samples/data and a particular 
individual is impossible; no code key and no re-identification possible. 
Samples are collected without identifiers.185  
 Anonymised. Sample/data has been de-identified in such a way as to 
remove the link between them and an identifiable individual.186 In 
European documents, the term anonymised could mean either unlinked 
or linked anonymised.187      
 
 Biological hazards have captured the public imagination and 
fostered a kind of ‘genetic anxiety’ in several countries, as remarked by 
Jasanoff.188 The tensions generated by the promise of personalised 
medicine have worked as a test for the politics and policy capacity of 
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mature liberal democracies which have dealt with this differently. For 
example, in Britain “the regulatory and political upheavals of the early 
1990s undermined the social role of the expert, forcing the creation of 
new advisory institutions that were both more diverse and more 
transparent.”189 It was part of a process where traditional standards were 
challenged. The German example “is in many ways the most interesting, 
because here an experimental democratic settlement was revoked in 
favour of a return to a more technocratic approach.”190 
  
The idea of a universally acceptable process to create an open 
deliberative space for science and technology did not work for Germany, 
in the same way that facticity of science and the reliability of expertise had 
done in countries like Britain.191 The situation of Britain during the 1990s 
revealed new fault lines between those demanding empirical evidence of 
risk to justify more stringent regulation and those urging greater 
precaution, in the presence of the unknowns.192 Similarly, it needs to be 
determined what will best work for Mexico. 
 
3.4 Mexican risks 
Risk analysis is an area of interest, since it reflects the relationship 
between the laws of democratic societies and their most common fears, 
which can be very variable. Following Jasanoff, biotechnology politics and 
policies have been influential in generating cognitive and political views. 
This, in turn, has caused biotechnology to serve as a comparative 
instrument to measure technological development in capitalistic 
democracies.193 Some of the current biobanking ethical guidelines are too 
broad. As a result, these general principles can be interpreted in more 
than one way leading to mistreatment and exploitation. An active 
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participation and a systematic clarification of guidelines are necessary to 
achieve this at the regional level.194 In Mexico’s case, this leads to 
reflection in terms of responsibility, for instance how the challenges posed 
by biobanking will be tackled. 
 
3.4.1 Historical background 
A historical analysis is useful and relevant to help understand the 
current ethical problems because of inoperable guidelines, which have 
proven weak when confronted with the issues and dilemmas posed by the 
practice of research. Mexican ethics frameworks have traditionally been 
understood as moral mandates; e.g. medical ethics had been linked to 
respect for moral values. Although governance is closely linked to ethics, 
both areas have been treated differently by Mexican governance and 
ethics has not been necessarily binding. This may be due to cultural 
reasons.  In the past, it was not considered necessary to have stringent 
laws as there were few violations. In the opinion of Aluja and Birke, 
“violations of codes of ethics were not as common as in developed 
countries.”195 However, situations and circumstances have changed and 
become more complex due to historical factors. Tamayo196, a Mexican 
biomedical researcher, has pointed out that historically, health research 
has been regarded in numerous laws and regulations rather than just one. 
However, the most basic questions on the regulation of health research, 
such as who is responsible and what for, have still not been answered.   
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Biomedical research in Mexico started in the 1940s, when the role 
of professor-researcher was recognised.197 This happened as part of the 
creation of merged labs in existing health care facilities. Other events 
which caused Mexican research to emerge were the creation of 
international foundations supporting research (Rockefeller, Kellogg and 
Carnegie, Kaiser and Pasteur institutes), the formal inclusion of new 
medicine subjects (such as biochemistry and molecular biology), the use 
of antibiotics, the microscope, the X-ray and other new diagnostic 
techniques.198 
 
No evidence of ethical guidelines for research was identified before 
1966. The creation of the The Mexican Institute of Social Security (IMSS) 
(Instituto Mexicano del Seguro Social), led to the simultaneous 
establishment of healthcare units for research. However, health research 
was officially institutionalised when the activities of the department of 
scientific research within the National Medical Centre started in 1966.199  
 
The first health committees were created to protect the rights of 
research subjects’.200 Seven years later (1973), the Code for Sanitary 
Care201 (Código sanitario) was enacted as the main federal health 
regulator. Thus, protective measures for the rights of Mexican research 
subjects were also implemented. These measures were the first to 
crossover between law and ethics on health research. This Code was the 
first regulation which specifically covered health law in Mexico, and the 
social right to physical and psychological health was implemented 
through it. Additionally, this regulation reflected the first ethical 
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considerations as a source for some criteria. However, this was left to the 
discretion of ethics committees.  
 
Ethical guidelines have formally existed since 1982, but have 
changed in nature due to the evolution of Mexican research and have had 
differing levels of enforceability due to the diverse legal and institutional 
attempts to effectively regulate it. The Code for Sanitary Care was 
amended in 1982.202 The amendments included the obligation to create 
research and ethics commissions (which would later become committees) 
wherever biomedical research was performed (one in each research 
institution, potentially including universities); these commissions were 
responsible for the evaluation and approval of research protocols. In 1984 
the Sanitary Code was derogated and The General Health Law 
enacted,203 which covered health research in a more specific way. 
However, it took three more years for the requirements to be extended to 
cover the approval of research protocols within health research.204   
 
In 1989 the General Health Council CSG (Consejo de Salubridad 
General), the second health authority after the General Health Law, 
founded a group for the study of bioethics, which three years later would 
be established as the National Commission of Bioethics (CNB). This was 
done in response to the need for a bioethics culture and also, the need 
for worldwide instruments. Not many of the public understood what 
bioethics meant when it emerged in 1970.205 Therefore, even when the 
remit of ethics committees was defined in 1982, it was necessary to 
                                                          
202 Acuerdo mediante el cual se comunica que es obligación de los directores de los 
establecimientos en donde se efectúen investigaciones biomédicas construir una 
comisión de investigación  (Agreement which communicates it is compulsory for 
managers, where biomedical research is carried out, to organise a research 
commission)  
203 Ley General de Salud (The General Health Law) (Mex) 
204 Reglamento de la Ley general de Salud en Materia de Investigacion para la Salud 
(The Ministry of Health Rules of the General Health Law on Health Research) 
205 P Van Rensselaer, ‘Bioethics, the Science of Survival  ’ (1970) 14 Perspectives in 
Biology and Medicine 127-53 
84 
 
encourage responsible attitudes towards the consequences of biomedical 
research. Moreover, the international bioethics boom caused the Mexican 
government to show an interest in developing guidelines concerning 
research, health and environment.206  In 1992, the CNB was founded for 
the promotion of hospital bioethics committees in private and public 
institutions as an advisory institution focused on human rights. By 2000, 
the CNB was officially declared a permanent institution by presidential 
agreement207 and its purpose was re-established as an institution for 
promoting ethical principles in health care and health research208. In 2004 
the General Health Law was amended once more. This time article 41 bis 
recommended the creation of hospital ethics committees.  Consequently, 
the IMSS established an institutional programme on ethics, promoting the 
creation of hospital ethics committees. In 2001, COFEPRIS, the national 
health authority, was created.  
 
According to Ingrid Brena, “the expectations on biobanks overpass 
the scarce Latin American legislation.”209 This seems to be the case with 
Mexican biobanking, in which a too general framework is partially 
applicable to biobanks in the absence of specific legally enforced 
guidelines. For this reason, the following section will demonstrate that 
currently, the ethical frameworks are not fit for purpose. In order to 
guarantee effectiveness, the increasing number of research activities in 
the country demand guidance and an effective ethical regulation, 
culturally sensitive yet binding. 
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3.5 Case studies 
This section will provide a legal insight across aspects of practical 
biobanking in Mexico under two case studies: The Mexico City Cohort 
Profile Study and The HapMap Study. The Mexico City Cohort Profile 
Study and The HapMap Study210 have been selected as they clearly show 
the dual aspects of biobanking; “these studies will in turn facilitate 
research that will focus on relating genomic information, of the Mexican 
population to significant causes of morbidity and mortality in Mexico, such 
as macular degeneration, diabetes mellitus, hypertension and obesity, 
cancer, infectious diseases, and cardiovascular diseases;”211 in 
contraposition with the apparent; the absence of guidelines causing 
delays, inconsistencies and problems. Apparent conflicting areas will be 
identified and explored on a general basis. The similarities found between 
these two examples allow a detailed comparative case study. A summary 
of the central issues is presented in tabular form to aid comparison (See 
table 8 in annex p. 10). The issues will be elaborated upon in the following 
sections to demonstrate the inconsistencies and regulatory issues 
referred to in the present chapter. 
 
The HapMap study followed a comparative methodology to 
analyse Mexican ancestry; “by including one Mexican Amerindian group 
and data from the HapMap: northern Europeans (CEU), Africans (YRI), 
and East Asians (EA), including Chinese (CHB) and Japanese (JPT)”. 
The first analysis of genomic diversity in Mexican populations from 
INMEGEN was published bearing in mind that most of the global burden from 
chronic diseases, and especially vascular diseases, at the time,was borne by 
low and middle-income countries, few large-scale epidemiological studies of 
chronic diseases in such countries had been performed.212  
                                                          
210 P Kuri-Morales and others, ‘The prevalence of chronic diseases and major disease 
risk factors at different ages among 150 000 men and women living in Mexico City: 
cross-sectional analyses of a prospective study’ (2009) 9 BMC Public Health 1-9 
211 Jimenez-Sanchez and others 1191 
212 I Silva-Zolezzi and others, ‘Analysis of genomic diversity in Mexican Mestizo 
populations to develop genomic medicine in Mexico’ (2009) 106 PNAS 1 
86 
 
The researchers aimed to explain the origin of genetic differences 
among Mexican Mestizos from different regions in Mexico. “Mexican 
Mestizos, as other Latino populations, are a recently admixed population 
composed of Amerindian, European, and, to a lesser extent, African 
ancestries. Although the diversity of Latino populations poses several 
challenges for genetic studies, it makes them a powerful resource for 
analysing the genetic bases of complex diseases.”213  
 
INMEGEN’s first step focused on generating the Mexican HapMap 
in order to facilitate the next phase of the research, which concentrated 
on examining genomic information of the Mexican population to identify 
significant causes of morbidity and mortality in Mexico. All data analyses 
were performed at INMEGEN in Mexico City.  
 
The Mexico City Prospective Study,214 a genetic association study 
or ‘Cohort Profile,’ investigated the relationship among chronic diseases 
and lifestyle among Mexican people. It was conducted by ‘The Mexican 
Ministry of Health’ (SSA) and the Clinical Trial Service Unit (CTSU), 
Oxford, England.  This independent, joint project by the Ministry of Health 
and CTSU Oxford relied on support from the National Council of Science 
and Technology. Apparently the goals of incorporating genomics into 
economical methods of prevention, diagnosis, and treatment of disease 
have not been continued since. On the other hand, the intervention from 
an overseas institution causes unresolved issues in areas such as the 
acquisition of informed consent and sample exchange and management.  
 
3.5.1 Background: available guidance 
The main element to be discussed within the case studies is the 
control on this type of participation, which is tantamount to being optional. 
This can be translated into potential risks, which could be mitigated by 
                                                          
213 Ibid 
214 Kuri-Morales and others 1-9 
87 
 
further guidance. Mexican population biobanks involve the participation 
of ethnic groups whose genetic data may need special protection. 
INMEGEN is affiliated to P3G,215 a not-for-profit international consortium 
that provides the international population-genomics community with easy 
access to the expertise, resources, innovative tools and most up-to-date 
information from all areas of public population genomics expertise. 
 
 P3G is an Internet repository of scientific information and tools to 
aid in developing, realising and harmonising research projects on health 
and social science, including biobanks. P³G works with researchers from 
around the world providing best practice guidelines. Margaret Otlowski 
from the Australian National Health and Medical Research Council 
(NHMRC) considers “these harmonisation initiatives cover a broad 
spectrum, from highly-technical scientific matters, through to governance 
and access principles and procedures.”216 This situation can be 
problematic as Mexico may not be prepared, in terms of legal guidelines, 
for international exchange of biobanking data.  
 
It includes a series of catalogues documenting large population 
based biobanks worldwide, and it allows a rapid overview of the 
similarities, differences and potential for harmonisation between 
participant biobanks. Moreover, the facility could be used for more than 
guidance in research. This type of electronic resource has been used in 
Mexico. A member of INMEGEN217 stated that the P3G Observatory218 
worked as helpful guidance for the Mexican HapMap project. The member 
also pointed out that The International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (2002) were being followed by 
INMEGEN in the HapMap Study. However, this type of resources tend to 
be limited. Participant A claimed that the website was no longer being 
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consulted by 2010 “because the subscription was no longer 
affordable.”219  
 
3.5.2 Identified problems 
These projects were intended to contribute to emerging globalised 
scientific information, in which samples are a key issue. Both projects 
have in common an attempt to develop proper genomic and personalised 
medicine research projects. However, the particular conduct and 
regulation involved constitute reasons for criticism. This is an example of 
“the rapid advances of scientific research and the need for a suitable legal 
framework.”220 Both pieces of research present risks, though each of them 
followed different measures to prevent them.  
 
3.5.2.1 Inconsistent self-regulation  
 In the absence of codified ethical standards, Mexico-based 
biobanks have resorted to self-regulation and internal decision-making. 
Self-regulation is most likely due to the inconsistent rules mentioned in 
various partially applicable regulations. This issue was identified within 
both studies; while the study conducted by the CTSU and Ministry of 
Health actually reports that it was self-authorised. The two case studies 
also illustrated the different forms of Mexican biobanking guidelines 
(general legal rules, self-regulation, and soft law) used by scientists and 
academics. Experience has demonstrated that self-regulation has not 
been effective in related topics. “Historically, physician self-regulation has 
not been particularly successful in controlling the behaviour of individual 
physicians.”221 
                                                          
219 Responsible-for-the-research-department-at-a-public-biobank-Participant:A 
220 E Godoy, ‘El negocio de los genes. Ante la proliferación de biobancos, surge el 
interrogante de cómo se maneja la información de los donantes (The bussiness of 
genes. Towards biobanks' proliferation, the question of how donors' data is managed 
has emerged)’ Poder 360° Electronic magazine  <http://www.degerencia.com/> 
accessed 30 March 2010 
221 PD Jacobson PD, ‘Regulating health care: from self regulation to self regulation? ’ 
(2001) 26 J Health Polit Policy Law 1175 
89 
 
Recapitulating one of the case studies described above, 
INMEGEN led the participation of Mexico in the International HapMap 
project. The project was carefully organised to focus on ethical aspects 
associated with participants’ protection, paying special attention to the 
participation of vulnerable populations. The project was approved by the 
committee of ethical, legal and social aspects of the International HapMap 
project, one of the main sources of ethical guidance for the project. The 
participant from INMEGEN mentioned the diverse resources for guidance 
followed by the project; a great number of which were international and 
were put into practice by the internal committee of the institution. The 
INMEGEN representative explained that the institution has created its 
own guidance, which is very strict. 
 
In this case, self-regulation was prevalent within the HapMap 
study; the application of rules to deal with data from 3000 sample donors 
was internal. The consent process, in the presence of two witnesses, was 
decided following international standards, in the absence of specific 
national rules. Similarly, the Mexican HapMap was organised in 
independent collaboration with the International Genomics 
Consortium;222 although no benefit sharing rules have been defined.  
INMEGEN seems to follow general self-regulatory guidelines. The 
HapMap study was nevertheless widely approved by the internal 
commissions of INMEGEN. Self-regulatory practices are not always 
something negative. As will be analysed in chapter 7, it has been a viable 
choice in other countries. However, this type of practice has not been 
suitable for Mexico, mostly due to cultural reasons, which will be 
discussed in chapter 8. 
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INMEGEN followed the guidelines encouraged by the international 
HapMap organisation223 as the main source for ethical guidance. The 
HapMap international standards are very detailed in specific topics for 
population studies, which provide sufficient ethical parameters on 
biobanking (even when they are not specifically directed at biobanking). 
Relevant standards consisted of specific criteria for participants of 
different ages, competence to provide informed consent, re-consent from 
living donors, non-inclusion of medical information, non-inclusion of small 
isolated populations, justification for targeting that part of the population, 
clarification that no intellectual property rights would result from the study, 
and clarification that there would be no immediate benefit for the 
population participating.224 
 
The standards provided by the international HapMap project are 
general; it was not complicated for the INMEGEN to apply independent 
standards directly. The rest of the applicable standards were adapted into 
the national rules of the country. In this case, a national ethics committee 
had to provide a clear opinion on the ethical aspects of research and 
evaluate the research protocol in terms of risks, benefits and informed 
consent. Another standard provided by the HapMap organisation was 
non-inclusion of names or other identifying information; “anonymous 
blood samples from 300 nonrelated and self-defined Mestizos and 30 
Amerindian Zapotecos were collected in 7 states in Mexico.”225 The 
interviewed members from INMEGEN confirmed that every collected 
sample from the Mexican HapMap study was anonymised. “All data was 
anonymised and it is only known whether the donor is a man or a woman 
and from what ethnic group.”226 It was also a recommendation to provide 
“opportunity for consideration of the specific ethical and cultural factors 
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relevant to the decision how to identify each population.”227 INMEGEN 
complied with the recommendation, and several forums were organised 
as a means of communication with participating members to resolve any 
concerns raised by the Mexican HapMap project, including cultural 
questions. 
 
INMEGEN has intended to show “a transparent and responsible 
performance that respects life and human dignity within human research 
and medical applications.”228 INMEGEN claims to be following CIOMS 
regulations in this respect, guidance which should become binding under 
minors’ best interest. Minimum requirements by CIOMS are still not 
covered by the Mexican civil rules. These include cases in which children 
will be accepted to participate (or deny to participate) in research trials.229 
Another example can be taken from the UNAM study in which at least 
fourteen participants providing samples across two biobanks were under 
18.  
 
Exceptionally, it is possible that INMEGEN followed a strict self-
regulation. However, this, being self-reported by the institute, cannot be 
totally proven. Self-regulatory efforts have been made to date to ensure 
capability, but lack of coordination and disparity on measures taken by 
different stakeholders are important signs that biobanks need specific 
attention. 
 
3.5.2.2 Accessibility of the results 
Due to the findings of the above analysed cases, both studies 
should be widely distributed among concerned bodies. The HapMap 
study provided “evidence of genetic differences between Mexican 
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subpopulations that should be considered in the design and analysis of 
association studies of complex diseases.”230 However, the findings from 
the CTSU study seem to be not easily accessible, e.g. they are not 
available in Spanish. It was stated that the researchers in charge would 
be open to questions.  
 
The unavailability of results has several ethical implications at both 
individual and general levels. The subject whose sample will be used 
needs to decide whether to know or not to know231 the purpose and 
findings of the research project. At the collective level, the nature of some 
research findings can be of extreme importance for public knowledge or 
a specific group, e.g. a scientific community may have a particular interest 
in data collection for research purposes.  
 
In some instances, it can be clarified from the beginning that no 
results will be available, for example, when data becomes anonymised or 
it is established that it will be used for statistical purposes for data 
protection purposes.  
 
3.5.2.3 Consent 
HapMap 
INMEGEN, in the absence of available clear guidelines, attempted 
to follow guidelines from different sources within the Legal Mexican 
framework including: the Mexican Constitution, the General Health Law, 
expertise from the National Bioethics Commission, the CIOMS guidelines 
and advice from the President of the World Human Genome Organisation. 
This intervention may operate to increase protection, thereby putting the 
vulnerable in a better position. Informed consent was obtained in the 
presence of two witnesses (members of the community). Participants 
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would have access to the informed consent documents. 3,000 informed 
consent forms were printed for the mestizo population and 500 for 
indigenous populations, as well as 25,000 information leaflets. Comics 
were used to explain in an illustrative way what genomic medicine is. 
Some of the documents presented a finger print instead of a signature. 
Some samples were taken from family groups of three. There were open 
forums in the communities and the participants were formally approached 
three weeks before the study started in order to explain the purpose. 
Communities (including children) showed interest and participated. The 
informed consent form was translated from Spanish to the required 
language and translators came from the community itself. No 
compensation was offered to the participants and no withdrawal rules 
were established. Participant A expressed “the anonymised samples that 
were used for the HapMap study are still being kept,”232 even when the 
purpose of the research was satisfied.  
 
However, despite the use of meaningful sources such as laws, 
regulations, guidance materials, codes of practice, reports, regional and 
international instruments of various kinds, academic literature, policy 
documents, scientific papers, professional guidance and good practice 
materials were used to endorse elements as important as informed 
consent for the HapMap study, something else is required. In this 
instance, it was not established whether, once consent was provided, the 
donor could revoke it at any time with no consequences. “La Jornada” 
Newspaper investigated the forms for informed consent, within the 
INMEGEN HapMap Study. The forms stated that “it is not always possible 
to predict the research results. This involves unpredictable future risks.” 
The statement has been seen by the press as a way to evade risk 
responsibility.233   
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ICTSU 
Consent acquisition of ICTSU followed a brief procedure. The 
CTSU study was affordable through maximisation of economic resources, 
in which sample taking and the corresponding recording of IC was 
performed using electronic methods. The possibility of “open consent” 
has been considered when either multiple research or total anonymisation 
takes place. However, in this case, it is risky to consider electronic 
consent as genuine informed consent.  
 
It would be impractical to attempt to discuss only issues of informed 
consent deeply in this chapter, it is just relevant at this stage to point out 
that electronic informed consent was apparently not the best choice for 
the type of research conducted. Even disregarding the fears of 
discrimination, there are good reasons for rejecting electronic informed 
consent, such as the fact that it cannot be formally applied in legal terms. 
It can be argued that participants were significantly unprotected due to 
inconsistencies to determine the type of informed required; a 
consequence of insufficient, clear, legal and institutional guidelines. 
Participant B described the informed consent form within the HapMap 
project as presented as questions and answers. Participant B pointed out 
that:  
“This made it easy for the participants to understand. However, there are 
people that design it as a long complicate narrative with little meaning for 
the participant, who may find it difficult to understand. It can be valid as 
well. I think a pre-established basic proforma would work; then, we could 
adapt it to our project. This should be more accessible for those who are 
interested in these areas.”234 
 
 The idea suggested by participant B is of a pre-established 
consent form that could become effective in terms of clarity, as long as 
general pre-established consent parameters could be orientated towards 
the specific nature of the project. The means to achieve effectiveness 
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involve ethical and legal perceptions within the national context. “We 
cannot understand informed consent, the standards that it must meet, or 
the limits to its use, without taking that background picture seriously.”235  
 
3.5.2.4 Data protection  
 The topic of data protection within the INMEGEN was established 
by the ethics committee of the institute and they are responsible for 
establishing the best way to protect the privacy and confidentiality of 
genetic data contained in samples.236  
 
 The HapMap was an assessment of the potential benefit of 
generating a haplotype map to optimize the design and analysis of genetic 
association studies in Mexicans and to improve the identification of genes 
related to common diseases within the Mexican population. Access to 
samples and medical files was possible. The specific purposes were 
related to Mexican diversity. This was evaluated through “linkage 
disequilibrium patterns, and extent of haplotype sharing using genome 
wide data from Mexican Mestizos. They are from regions with different 
histories of admixture and particular population dynamics (300 nonrelated 
self-identified Mestizo individuals from 6 states located in geographically 
distant regions).”237 In participant A’s opinion, “the value of the samples 
is contextual. Security is needed as the value of the samples involves 
participants’ data independently of the samples’ conditions, location or 
context.”238  
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3.5.2.4.1 Data protection mechanisms 
Following data protection mechanisms at INMEGEN, the samples 
are completely anonymised and unlinked239  and participants are told 
whether their data will be codified.”240 Hence, in the HapMap project, all 
the samples were anonymised and it is assumed they “belong” to 
INMEGEN. In this case, data protection mechanisms are being used 
partially. Regarding data sharing, participants D and E pointed out that 
because of the absence of rules, subjects are not informed of further 
potential sample sharing with other projects or the protection mechanisms 
that that would involve. They are simply told that their samples may be 
used for other projects.241   
 
3.5.2.4.2 Re-contact 
Similarly, as with informed consent issues, only a few brief 
comments are presented regarding re-contact. Possibilities for re-contact 
are shown differently in each of the studies, although they deal with similar 
ethical issues such as the destination of the samples in the future. Due to 
the absence of specific re-contact rules, it is not clear whether the 
participating institutions should should not recontact participants, and if 
so, under what terms. Within the HapMap study, the samples were coded 
with no intentions of further re-contact. However, the possibility of a future 
exceptional re-contact, under special reasons, was not discarded. It is not 
clear what would be done in case the samples were required overseas. 
Probably INMEGEN would decide internally. The nature of the Oxford 
profile study, where samples have been made identifiable, may require 
future re-contact. 
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3.5.2.4.2 Lack of coordination  
The overview of the current biobanking issues shows insufficient 
national communication between academics, scientists and policy 
makers. This has caused these stakeholders to follow different processes 
when dealing with biobanks. The ideal would be if public health institutes 
collaborated together in order to develop projects. In such cases, the 
research manager would be responsible for making decisions on 
collaboration, due to the specific guidelines establishing the terms under 
which collaborations should be done. Participants D and E pointed out 
that INMEGEN projects rarely have collaborations with other institutions 
and that researchers often store what they consider “their” samples.242 
The two analysed studies were carried out with no collaboration, even 
though they targeted common national problems such as genetic illness 
studies. Researchers, citizens and policy makers all have an important 
role to play.243 
 
Ideally, “a dedicated, independent statutory authority could reduce 
this risk.”244 A great issue with biobanking is that fundamental human 
rights would be threatened by the further use of biological samples in 
relation to biobanking topics. The envisioning of future governance calls 
for accessible guidelines where ethical issues such as informed consent, 
data protection and data protection mechanisms will be given a clearer 
definition. In the case of Mexico, it would be unnecessary to concentrate 
on placating unrealistic fears which biobanking could create. On the 
contrary, the main discourse needs to be centred on the control of 
biological samples, associated genetic information and the cultural impact 
around them, especially when vulnerable populations have become 
involved in biobanking activities. 
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3.6 Human rights 
Every sample has a history going back to the original human donor. 
Blood samples have the potential to threaten fundamental human rights; 
stored collections of genetic samples in the form of blood or tissue can be 
linked to medical, genealogical or lifestyle information from a specific 
population.245  
 
A great part of the current Mexican self-regulatory guidelines 
depends on adherence by national institutions to international documents. 
The implementation of international documents regarding human rights 
and fundamental freedom (e.g. autonomy, privacy, non-discrimination 
and non-stigmatisation) has been diverse. The regulation for the use and 
procurement of biological samples and data has appeared, both at the 
national and international levels, sometimes through specific legally 
binding instruments or by general regulatory texts.246 Consequently the 
topic is highly variable. 
 
“In Europe the laws that have been applied to biobanks have 
largely been drawn from the legal traditions and jurisprudence that have 
been developing around the protection of human rights and the 
advancement of public health.”247 A number of biobanking human rights 
related instruments have been established as a result. 
 
 The initial discussions within the ‘Convention for the Protection of 
Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine’ included principles and topics of 
interest for developing countries. The term ‘human rights’ was mentioned 
in the title of the declaration and the principles of social responsibility, 
health, shared benefits and international cooperation were included. The 
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latter implied the introduction of bioethics from a social perspective. The 
first draft of the declaration (2004) highlighted the reinforcement of 
cooperation, taking into account the needs of the least developed 
countries.248 The concept of health as an individual right has not been 
effective in terms of global international cooperation. Social bioethics is 
concerned with the right for citizens to obtain minimum health conditions, 
a concern shared by many Latin American countries. In the final draft, 
vulnerable populations were also recognised as possible benefactors of 
international cooperation. 
 
The Universal Declaration on Bioethics and Human Rights 
(October 2005)249 was designed to encourage international cooperation 
to remove inequalities, caused by different development stages, among 
countries like those in Latin-America. Those most entitled to the benefits, 
according to the declaration, are those who take part in research 
activities. The Latin American perspective was crucial for the 
development of this inclusive instrument. There have been various 
attempts at international cooperation among countries with different 
development stages. The Declaration stated the need for bilateral 
agreements allowing developing countries to create the necessary basis 
for exchanging scientific and technical knowledge for benefit sharing, and 
involving the protection of those who participate. The resulting benefits 
from the use of this genetic data, proteomics or human samples for health 
or scientific research are to be shared with society and the international 
community: 
1. Article 15: Benefits resulting from any scientific research and its 
applications should be shared with society as a whole and within 
the international community, in particular with developing countries. 
In giving effect to this principle, benefits may take any of the 
following forms:  
(a) special and sustainable assistance to, and acknowledgement of, 
the persons and groups that have taken part in the research;  
(b) access to quality health care;  
(c) provision of new diagnostic and therapeutic modalities or 
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products stemming from research;  
(d) support for health services;  
(e) access to scientific and technological knowledge;  
(f) capacity-building facilities for research purposes;  
(g) other forms of benefit consistent with the principles set out in 
this Declaration.  
 
2. Benefits should not constitute improper inducements to participate in 
research.250  
 
3.6.1 The human rights perspective in Mexico 
All human rights rules in Mexico will be interpreted under the 
constitution and international treaties in favour of a persons’ protection. 
The rights of vulnerable groups will take priority over any other rights. In 
this case, the role of international law is complementary, never 
contradictory.251 The latter, known as ‘conformed interpretation’, is also 
covered by article 1 of the Mexican constitution. 
 
Fundamental reforms on human rights and incorporation of human 
rights international treaties took place in 2011. They have been enacted 
to alleviate “the profound deficiency in human rights protection”252. The 
concept of human rights had not been previously recognised by the 
Mexican Constitution CPEUM (1917). The denomination was changed 
from “individual guarantees” (garantías individuales) to “human rights and 
their guarantees” (derechos humanos y sus garantías). The latter “is 
much more modern than that of individual guarantees and it is commonly 
used in international law.”253 In the opinion of Miguel Carbonell, 
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constitutional law expert, it would have been more pertinent to use the 
denomination “fundamental rights” (derechos fundamentales), as a 
stronger denomination which could impact biobanking related rules; 
“scientific research, innovation, technological development and human 
genome applications are orientated to the protection of health, in which 
respect for human rights, freedom and dignity of the subject prevail. They 
are subject to the corresponding legal framework.”254  
 
According to the last constitutional reform (2011), specifically 
article 1,255 the constitution does not grant rights, but recognises them. 
Since this reform the Constitution is believed to be more open to 
international law on human rights. The second paragraph is the inclusion 
of the interpretative principle ‘pro personae’. This principle consists of the 
legal duty to select, among all normative choices, that which favours a 
subject of human rights at all times. If two norms are applicable in a 
concrete case, the judge must select the most protective regarding 
human rights. 
 
The third paragraph is the governmental duties; human rights must 
be protected, promoted and respected at all governmental levels. This 
includes human rights recognised by the constitution and international 
treaties. Government employees who do not accept the 
recommendations from the National Human Rights Commission 
(Comisión Nacional de Derechos Humanos) (CNDH) will have to publicly 
provide the reasons.  The CNDH has the following attributions for the 
application of human rights duties derived from international law:256 
 Receive complaints (including those from citizens) on presumed human 
rights violations. 
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 Formulate non-binding public recommendations before authorities. 
 Formulate actions to support compliance with adopted international human 
rights treaties, conventions and agreements; i.e. governmental coordination 
programmes. 
 Proposing to the president the legal subscription of international agreements 
on the subject. 
 
The topic of human rights is also related to recommendations; both 
biobanks and human rights would need to be given more legal power.257 
 
3.6.2 Obstacles for the application of human rights 
international treaties  
 Ariel Dulitsky has stated that “before thinking of new laws, it is 
necessary to think of ways to guarantee enforcement,” implying that well 
written laws, by themselves, will not be effective enough for the protection 
of human rights if the three governmental powers do not commit to such 
a goal and it is necessary for some of them to be adapted through 
secondary legislation.258   
 
The Mexican non-jurisdictional human rights protection system is 
believed to be “one of the most complete”259. However, several 
inconsistencies have prevented the consolidation and implementation of 
international treaties regarding human rights. This is due to the “absence 
of systematic organisation in the constitutional framework;”260  i.e. only a 
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few precepts expressly mention international instruments and there are 
no special rules to comply with the decisions from international human 
rights bodies. In the opinion of Carmona, a constitutional law researcher, 
the Mexican constitution is “neither detailed nor tidy regarding rules on 
international treaties.” 261 
 
Another practical issue is the general belief by authorities that 
international rules do not apply if they are not integrated into federal 
legislation.262  Judges may refuse to apply international treaties, partly 
because of a lack of knowledge and partly because they do not consider 
them a part of Mexican law: this is worthy of criticism, especially if law 
makers based on the same grounds do not enforce secondary legislation. 
If indeed transition is occurring now, following the reforms on human 
rights, it is likely that this situation will gradually improve. The knowledge 
of the limits of international rules needs to be improved by training and 
professionalism at local and federal levels.263 The content of treaties and 
CNDH recommendations must be followed by the government and 
disclosed to the public. 
 
Another important obstacle is the absence of effective interaction 
between governmental and non-governmental organisations. The 
National Development Programme (2007-2012)264 (PNDH) has stated “it 
is necessary to encourage training for NGOs on international human 
rights standards;” since their role is relevant for the defence and 
promotion of human rights. The obstacles to Mexican adoption of human 
rights treaties can be summarised in three issues, 
1. Absent or insufficient legislation, allowing the incorporation of 
international law; 
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2. The absence of adherence to the hierarchy of international treaties; 
3. Reservations or interpretative declarations of international treaties. 
 
Awareness on prevailing limitations for human rights rules is 
determinant since biobanking is not an isolated topic. It is fundamental for 
Mexico to encourage a responsible regulatory body that can deal with the 
oversight challenges as soon as possible.  
 
3.7 Concluding remarks 
The acceptance of scientific principles can be extremely broad. 
Specific biobanking ethical rules legally implemented could be of great 
benefit for Mexican research. The legal inclusion of research ethics in 
Mexico is fragmented. It does not provide sufficient guidelines. When 
legal incorporation is nonexistent, incomplete or unsuitable, ethical 
principles become subject to disorganised interpretation. As pointed out 
by Kaye, “as with ‘governance’, so too with ethics: the development of 
these complicated and shifting forms of research collaboration and their 
associated biological samples and data is leading to the parallel 
emergence of ethical considerations not previously encountered in 
combination... It is important to pay attention to these features of 
biobanks, which have ethical as well as sociological significance.”265 
 
Attention must be paid to the consequences of conducting high 
level research; ethics need to become more stringent to benefit both 
researchers and research subjects. Ethical management guidelines, 
mainly for researchers, could govern biobanks from their creation. 
Gibbons suggests that “this could prevent controllable issues from 
becoming complex.”266 Mexican biobanking practices are becoming more 
complex as a result of the irregular and too general legal coverage of 
different ethical aspects, e.g. biobanking for the analysis of genomic 
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medicine, population studies, clinical trials and pharmaceutical studies. 
“Genetic research on Amerindians — who are much sought after for their 
distinctive genetic lineages — is even more sensitive.”267 These practices 
raise different ethical concerns. If there were violations to human subjects 
as part of biomedical research, it would be difficult to constitute a legal 
offence. 
 
Public academic biobanking follows self-regulatory guidance 
resulting from minimum legal requirements and self-regulatory principles, 
such as respect for the participants’ human dignity, honesty, prevalence 
of the individual interest over the interest of science and society, and 
predominance of the potential benefits over the possible risks. The 
guidelines state that “research involving humans must follow scientific 
principles generally accepted, including a solid theoretical basis and a 
suitable methodology”268 and “it is considered unacceptable that a patient 
accepts to participate in a research study as the only choice to receive 
treatment.”269 These phrases are subjective and ambiguous on the direct 
application of general principles to biobanking.   
 
 A number of cases, from population genetics to academic 
biobanks, depend on urgent harmonisation of guidelines in practice. 
These should be motivated from a more humanistic and moral 
perspective, based on human rights protection. Institutional efforts adhere 
to alternative guidelines that generate self-regulation. Both cases studies 
were approached differently by stakeholders due to the inconsistency of 
current laws.  
                                                          
267 R Dalton, ‘Tribe blasts 'exploitation' of blood samples’ (2002) 420 Nature 1 
268 Reglamento de la Ley general de Salud en Materia de Investigacion para la Salud 
(The Ministry of Health Rules of the General Health Law on Health Research) 
269 UNAM, ‘Código Ético para el personal académico del Instituto de Investigaciones 
Biomédicas (Code of Ethics for the academic staff of the Institute of biomedical 
research)’ (2005)  
<https://www.biomedicas.unam.mx/_administracion/reglamentos_formatos/archivos_p
df/CodigoIIBO.pdf>   
106 
 
4. Current Mexican Regulation 
 
4.1 Introduction  
This chapter reviews the Mexican legal system, providing 
familiarisation with basic concepts, such as the regulation of the human 
genome. According to Kaye, the main advances in this area signalled a 
change in research focus, an evolution starting with genetics.270 
Therefore, this chapter also explores relevant frameworks that would 
apply directly to biobanks, including the human genome, an area partially 
regulated by Mexican Law, and population biobanks.  
 
This chapter is the basis for further analysis of the current 
legislation to identify legal holes and weaknesses. Formally binding rules 
will be emphasised, which consist of primary laws (federal statutes) and 
secondary laws (local statutes). This thesis will recommend changes 
affecting the current regulation, and understanding the legal competence 
of the actors involved is essential for these purposes.  
 
4.2 Mexican internal law system 
4.2.1 Basic familiarisation concepts 
Before analysing the legal situation of biobanks in Mexico, it will be 
necessary to understand how the law is formed. There are different legal 
categories of laws, guidelines and recommendations within the Mexican 
legal system applicable to biobanks. The established primary legislation 
in the following paragraphs cannot be ignored as it constitutes a basis for 
further extensive legal analysis. In the words of Jane Kaye,271  the term 
‘law’ can be understood in both a broad and a narrow sense. The first 
refers the national legal system, whereas the latter refers to the structure 
of systematic rules contained in a regulatory framework governing a 
specific area. 
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4.2.1.1 Sources of law 
The hierarchy of laws and other legislative instruments (acts, 
statutes and regulations) will depend, primarily, “on the legal source 
where they emerged from with formal governance bodies at three high-
level players: legislators, judiciary and government.”272 In the case of 
Mexico, formal governance emerges from parliamentary action. Law 
making generally belongs to the Mexican Congress, which is subject to a 
formal process, as described in the following paragraphs. 
 
4.2.1.1.1 Formal sources of law 
Any formal law in Mexico, to be given such a character, requires to 
go through a formal legislative process,273 which consists of the following 
stages:  
A. Initiative 
Deputies and senators of the Congress of the Union and the 
legislatures of the states have authority to initiate this process. The 
initiatives submitted will go follow the legal procedures established in the 
Ordinance of Debates (article 56 of the Constitution). The initiatives 
submitted by members of the chambers will go through the Commissions.     
 
 B. Discussion and approval or rejection 
The initiatives could be submitted to either of the Chambers 
(Deputies or senators). The chamber where the proposal came from is 
called the ‘Chamber of Origin’ and the other is called ‘Chamber of 
Revision (or report)’. The members of one Chamber cannot present 
initiatives to the other Chamber. Hence, the initiatives from deputies shall 
be discussed in the Deputies’ Chamber. The discussion of legislative 
initiatives or proposals will remain in the chamber of origin for at least one 
month. If after one month it is reported or revised with no submission, the 
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proposal will be transferred and discussed in the other Chamber 
(senators).  Three situations may occur: 
a) The legislative proposal is approved by both the Chamber of Origin 
and the Chamber of Revision. In case of approval it will be sent to 
the Executive (the President of Mexico), if no observations are 
given, for immediate publishing. 
b) If the legislative project is rejected by the Chamber of Origin it 
cannot be sent again until the following session period (which 
takes place twice a year, from the 1st of September to the 15th of 
December and from the 1st of February to the 30th of April).  
c) If a legislative proposal is approved by the Chamber of Origin but 
partially rejected by the Chamber of Revision, the project will be 
returned to the Chamber of Origin with observations to be 
discussed. If it is approved by the majority of the present members, 
the proposal will be sent to the Chamber of Revision for a second 
review. 
  
C. Sanction 
Once a proposal has been approved by the Chambers, it will be 
sent to the National Presidency for sanction. However, the Presidency 
can exercise a veto right. If the Executive rejects a proposal, this will be 
sent back to the Chamber of Origin to be discussed again. If the 
observations from the Executive are rejected by two thirds of the Chamber 
of Origin, the project will be sent to the Chamber of Revision. If two thirds 
of this Chamber’s members approve the proposal, the project will be sent 
to the Executive for publishing with no rejection possibilities. The 
discussions are made in plenary sessions. 
 
D.  Promulgation and publication   
Once a law is approved and sanctioned, the Executive is obliged 
to order publication. The publication of the law is done in the Federal 
Official Diary (DOF). The president is exceptionally authorised to enact 
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legislation in some situations274 and it has been specified in which cases 
this will happen,275 for instance, “to issue regulations for the purpose of 
interpreting the language of legislative enactments.” It is also within 
presidential powers and duties to promulgate and execute the laws 
enacted by Congress.  
 
4.2.1.1.2 Informal sources of law: custom, practice and 
doctrine 
In addition to formal sources of law, custom and practice is also 
relevant in some circumstances. The custom in Mexico formed gradually 
by custom or habitual practice. These will be recognized as a source of 
law when an explicit provision of the applicable law formally allows such 
recognition. The general principles of law are also helpful when a legal 
rule is obscure. Jorge A. Vargas has stated that “a principle is a general 
proposition of law of some importance from which concrete rules 
derive.”276 A European Union framework decision has stated that these 
principles can be “unwritten and derived from the courts.”277 This is the 
case for Mexico. For example, within the legal system278 is a ruling 
dictating that the general principles of law are not applicable when there 
is an explicit legal text governing a specific legal situation. Following this 
precedent, the role of general principles of law is for guidance or 
clarification. The basis for these principles as a source of law is included 
in the Mexican Constitution, according to which legal academic opinion is 
a source of law formed by the written ideas, interpretations and comments 
from legal experts. These generally occur when the law is not clear, 
although these scholarly contributions are not legally binding.  
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Regarding how informal sources of law can be applied to biobanks, 
their role should be seen as influential but not determinant. Normally, 
states adopt external regulation models through formal processes based 
on their own specific needs. For example, the complexity of biobanks 
implies the formal adoption of suitable safeguards, in which the 
international custom can be inspirational, but not sufficient. Participant F 
explained, “when we have these gaps in legislation, international law is 
very important. Many countries have adapted their national legislations 
from international instruments and the custom.”279  
 
4.2.2 Main legal instruments 
4.2.2.1 The Federal Constitution 
Mexico has a written constitution. The constitution forms the 
written rules in which the Mexican legal system is founded. It contains 
fundamental basic legal principles. As Carroll states: 
 
“A constitution consists of the laws, rules (e.g. conventions) and other 
practices which identify and explain the institutions of government, the 
nature, extent and distribution of powers within those institutions, the 
forms and procedures through which such powers should be exercised, 
the relationship between the institutions of government and the individual 
citizen, often expressed in terms of a ‘Bill of rights’.”280  
 
The Mexican Constitution (Constitución Política de los Estados 
Unidos Mexicanos) (1917) (CPEUM) came with essential reforms, as a 
result of the Mexican Revolution’s achievements (1910), which embodied 
a move towards “the inclusion of social rights, for the first time in the 
history of constitutional law.”281 
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The Constitution incorporates basic guarantees which apply to all 
of its citizens.  
According to Carroll; 
“Within the nation-state to which it applies, the constitution will usually be 
regarded as both the ultimate source of legitimacy and authority for the 
practice of government and as a framework for the application of that 
society’s political beliefs concerning how the process of government 
should be conducted and by whom.”282  
 
No secondary regulations can contradict the dispositions stated by 
the constitutional document, which is the main founding instrument of the 
legal system. Constitutionally, Mexican law is founded in several sources 
in accordance with this hierarchy: The Federal Constitution, international 
treaties and conventions (to which Mexico is a party), federal statutes, 
codes, doctrine, custom and the general principles of law. 
 
4.2.2.2 Codes 
In current Mexican law, a code is “the written formulation of a 
specific branch (i.e., civil, commercial, criminal, etc.) of positive law (i.e., 
the law which is in force today) presented and organized under a certain 
subject, plan, system and method.”283 The Mexican Constitution284 
provides a list of the Congress’ faculties. The enactment (and change) of 
a “Federal Civil Code” is not the Congress’ attribution as it is not explicitly 
mentioned. Vargas has pointed out that “out of a lengthy list of areas 
where Congress is explicitly empowered to legislate, enunciated in great 
detail in thirty paragraphs, there is no reference whatsoever to civil law 
matters.”285  
 
The Mexican codification originated from the European tradition. 
By definition, countries within the civil law tradition have codes, which 
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form an important part of their legal system and sustain it. Having codes 
as part of the definition of countries within a civil law tradition comes from 
ancient Roman law ‘for the people’ (family, property, offences etc.) 
“corpus iuris civilis.” After the fall of the Roman Empire, this obsolete law 
compilation was codified, later expanded and finally put into use by 
European countries, including Spain, in the 19th century. Codification in 
Europe started as “the work of a special commission, appointed by the 
federal or local executive, for the enactment of the corresponding 
codes.”286 In Jorge Vargas’ point of view, one of the main sources in the 
Mexican codification efforts was “the powerful influence exercised by 
leading European countries, in particular Spain and France, followed by 
Italy and Germany.”287 Mexico became independent from Spain in 1810, 
with the Spanish colonial law remaining in place. Most of the modern 
codes relate to a common and universal ancestor, the French Civil Code 
(1804) known as Code Napoleon, designed and formulated by Napoleon 
Bonaparte. It has been said that “this Code initiated the contemporary 
system of civil law as we know it today with codifications.”288 The first 
Mexican “codification efforts were initiated at the state level.”289 As a 
result, Mexico has the five basic codes in any civil law country; the Civil 
Code (1928), the Code of Civil Procedures (1943), the Penal Code 
(1931), the Code of Penal Procedure (1934) and the Code of Commerce 
(1889), originally dating back to 1822. 
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4.2.2.3 Administrative standards 
The administrative standards have been enacted in order to 
protect non-specialised consumers. These binding “Official 
recommendations” (Normas Oficiales), (also known as “NOMs”), help to 
secure quality requirements in activities, such as design and the 
production of goods and services. These technical standards are covered 
by the Mexican Regulation of Metrology and Standardisation. (Ley 
Federal de Metrología y Normalización) (1992). In most cases the NOMs 
include applicable requirements, generally on technical management, 
that must be complied with by both individuals and companies. For 
example, the Federal commission for protection hazard analysis in health 
products and services grants licenses for health control. The Official 
administrative recommendation NOM-087-ECOL-SSA1-2002 Norma 
Oficial Mexicana NOM against sanitary risks 087-ECOL-SSA1-2002) 
provides the classification and management of dangerous biological 
infectious residues, regarding how remaining samples from hospitals 
must be disposed. NOM Standard methodologies for collection, 
processing, storage, transport and preservation period need to be 
established across Mexico. 
 
4.2.3 The Mexican Federal System 
The Constitution establishes in article 50 that the legislative power, 
one of the Federal Government’s three powers, aside the executive and 
judiciary, will consist of a Federal Congress. The Federal Congress will 
be divided into the Chamber of Deputies (Cámara de Diputados) and the 
Chamber of Senators (Cámara de Senadores). Each chamber is divided 
into commissions: specialised workgroups for legislation among diverse 
areas, i.e. agriculture, science and technology, national defence, culture, 
human rights, health, public education and educational services, etc. 
Apart from the Federal Congress, the 32 autonomous entities that form 
Mexico count on the three powers at a local level. Therefore, each entity 
has the ability to legislate through 32 local legislatures.  
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The Federal Congress creates regulations, that is, laws and 
decrees (Art. 70). Federal regulations (statues) are divided into two 
categories by relevance: a) Laws (Regulatory acts) and b) Ordinary laws. 
Laws or regulatory acts (Leyes reglamentarias) are those that detail the 
provisions of the Federal Constitution, establishing the legal bases for 
effective implementation. Ordinary laws (Leyes ordinarias) are the 
statutes enacted by the Federal Congress that do not derive from a 
specific constitutional provision. They legislate on a specific subject.  
 
4.2.3.1 Relevant Federal legislation  
This section describes relevant federal legislation. The binding 
level and competence of any biobanking instruments will depend on their 
status in the legal hierarchy (i.e. whether they are local or federal, 
administrative rules ‘reglamento,’ or a statute ‘ley’).   
 
At the time of writing, there is no specific federal legislation dealing 
with biobanking. However, there is a range of federal laws which impact 
on it. Currently, The Parliamentary Science and Technology Commission, 
which is responsible for biobanking, “does not count with specialised 
experts in bioethics.”290 According to participant K, “in science and 
technology we have someone in charge called the technical secretary.” 
This participant, who has a scientific profile, pointed out that “if the 
commission legislated on bioethics, it would contact academia, institutes, 
labs and experts who could provide an opinion on the topic. We need to 
be coordinated. The budget cannot cover experts for each area, instead 
we organise opinion forums.”291 In principle, the lack of biobanking 
regulations could be due to this structural fact. 
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4.2.3.1.1 The regulation of public health: federal 
statutes  
The Mexican health care system is governed by the General 
Health Law (Ley General de Salud) (1984), which is a federal law. The 
right to health is provided by article 4 of CPEUM; “All persons have a right 
to the protection of their health. Laws will state the ways in which the 
federation, and the federative entities, will concur to provide health 
services.” Moreover, this article establishes that every person has the 
right to an environment for development and wellbeing. This further 
alludes to the human rights perspective.  
 
It has been stated that “during the past few years, Mexico has 
proven to be one of the most important advocates with regards to the 
notion of the right to health.”292 This has been achieved through legal 
reforms and the implementation of public programmes. By the year 2000, 
the WHO reported that Mexico had great issues with financial distribution 
of public funds in regards to healthcare. This affected people since their 
access to the health system had significantly reduced.293  
 
The Ministry of Health is responsible for the direction of the national 
medical policy, medical legislation is meant to be covered at the federal 
level by the Ministry of Health regulations. The main regulation is the 
General Health Law (1984),294 which also deals with scientific research. 
However, it is not clear whether biobanks are adequately covered. The 
General Health Law establishes the guidelines and principles for scientific 
and technological regulation in relation to health. The secondary rules of 
this act (ley) aim to comply with the primary legislation in the public and 
private sectors. Secondary laws are: The Regulation on Sanitary Disposal 
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of Human Organs, Tissues and Cadavers (1985),295 the Regulation on 
Scientific Health Research (1987)296 and the regulations put forth by the 
National Institutes of Health Law (2000). The Regulation on Scientific 
Health Research in health research (Reglamento de la Ley general de 
Salud en materia de Investigación para la Salud) (1986) establishes 
specific allowances for research in specific matters e.g. infertility. All those 
integrate the regulation of health related law in Mexico.  
 
4.2.3.1.2 Regulation of human tissue 
The General Health Law covers human tissue, and the transport 
of human tissue (blood, blood components, hematopoietic stem cells and 
derivates) that can be used as a source of genetic material for population 
studies. Genomic research, under these amendments, must be part of a 
research project. The only reference identified in terms of biobanking for 
genetic studies is the rule mandating that “genetic material obtained for 
population studies cannot be used for different or incompatible purposes 
from those that motivated the collection.”297 Although the legal 
amendment signified progress, little ethical guidance can be derived. 
 
In 2008, The Mexican Senate unanimously approved the reforms 
to the General Health Law which was meant to make “the sampling of 
genetic material and its transport outside of Mexico without prior approval 
illegal,298” although this currently does not happen in practice due to poor 
enforcement. The amendment states that Mexican-derived human 
genome data is the property of the Mexican government. It prohibits the 
collection and utilization of human genome data without prior approval, 
and stipulates that the Ministry of Health will reserve the right to consult 
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INMEGEN for opinions pertaining to requests for the transporting of any 
human genetic material outside of Mexico.299  
 
4.2.3.1.3 Regulation of the human genome 
 Peterson points out that strong criticism of the political-regulatory 
handling of genomics is not surprising. The high expectation is that "the 
science of genomics should materialize in the near future.”300 In this 
context, the former Ministry of Health initiatives provided the grounds for 
further law making discussions. As a result, the human genome would be 
a matter of health. Many of the policy decisions, therefore, have to do with 
resource allocation and where to invest for maximum possible health 
gain.  
 
Background 
In 1990, The Human Genome Project started, funded by 
governments and charities under the leadership of James Watson. The 
project aimed to reveal the entire genetic code of our species, which 
would be crucial for the continuing progress of medicine and other health 
sciences,301 and also to underlie “the fundamental unity of all members of 
the human family, as well as the recognition of their inherent dignity and 
diversity. In a symbolic sense, it would be the heritage of humanity.”302  
 
Mexico has not been indifferent towards the use of the human 
genome and the consequences. By the year 2000, genomic research was 
starting to develop, for example genomic mapping and searching on 
diabetes and arthrosclerosis were starting to be a reality in the country. 
However, the country lacked the capacity to participate in the Human 
Genome Project due to the poor human and material national 
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infrastructure303 to develop genomic research. Such an absence had a 
negative effect on the development of high profile scientific research in 
academic areas and the means to interact with social demands. 304 It was 
clear that for Mexico to catch up with cutting edge genomic advances, it 
would be necessary to prepare the national health system and physical 
infrastructure, create more research groups and update the legal 
framework. Otherwise, the social cost would be too high; the country 
would depend on the import of required genomic resources, which would 
be difficult to afford. 
 
Despite no Mexican scientists officially participating in the Human 
Genome Project, the Mexican scientific community (and government) 
followed its progress. The National University of Mexico (UNAM), through 
the Centre for Studies in Health and Law (Núcleo de Estudios 
Interdisciplinarios en Salud y Derecho) was one of the first national 
academic institutions to evaluate the human genome from a legal 
perspective.305 As the Human Genome Project released findings, this 
produced new expectations and concerns within parts of the Mexican 
government.  Hence, the Mexican State began concentrating on the 
bioethical debate with a view to developing new bioethical laws.306 
  
Mexican National Bioethics Commission307 has adopted the 
following UNESCO308 documents: The Universal Declaration on 
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the Human Genome and Human Rights,309 The UNESCO International 
Declaration on Human Genetic Data and The Universal Declaration 
on Bioethics and Human Rights.310 However the binding character of 
these sources of international law is relative. The merely declaratory 
focuses of these documents were taken on the need to protect data 
derived from the genome, which worked as a partial rationale for the 
former Mexican legislative project on the human genome.311  
 
1990-2000 
 In 2001, legislators from the Democratic Revolution Party started 
to draw up the project for the “Law on investigation, encouragement, 
development, control and regulation of human genome.”312  
 In addition, in 2000, an alliance of four key institutions (the Ministry 
of Health, the UNAM, CONACYT and the Mexican Foundation for Health 
(FUNSALUD) analysed genomic medicine opportunities. This alliance 
resulted in the foundation of the National Commission of the Human 
Genome (Comisión Nacional del Genoma Humano). The Human 
Genome Commission called for legislation on the regulation of research 
on the human genome for the first time. The main focus of this legislation 
attempt was to inclusively cover the regulation of human genomics, “the 
design and development of suitable governmental policies regarding 
research on human genetics which had become necessary.”313 
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 The results of the analysis identified possible areas of benefit, 
including the contribution of a more individualised, predictive, preventive 
medical practice, the development of pharmacogenomics, and the 
development of an ethical and legal framework for genomic medicine in 
Mexico.  
 
 Biobanking was identified as a key area for the discovery and 
development of new drugs.314 Illnesses could be identified and treated 
before the manifestation of symptoms. If genomic medicine is not 
developed in Mexico, this could prove to be expensive in the long term as 
preventative treatment might be delayed.315 Hence, the development of 
genomic medicine would save public funds and the cost associated with 
treatments for common diseases would be significantly reduced. 
 
2001 
Two legislative initiatives on the human genome development 
were identified: 
 25th September 2001 Deputy Francisco Patiño Cardona, from the 
Democratic Revolution Party (PRD), announced a legislative proposal 
entitled “The human genome in terms of investigation encouragement, 
development, control and regulation.”316 This was sent to the Congress, 
more specifically to the Commissions of Health, Science and Technology, 
for analysis and report.  
 14th December 2001 Deputy Manuel Wistano Orozco Garza, from National 
Action Party (PAN), announced a proposal in order to amend the General 
Health Law, including the addition of title XVIII: “The human genome.”317 This 
was sent to the Commissions of Health, Science and Technology for analysis 
and report.  
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Both proposals focussed on the prevention of the misuse of 
genetic data by private companies and governmental agencies. The 
potential diminishment of confidentiality when individual genetic data is 
exposed to third parties was also considered. Additions to the General 
Health Law (‘Title XVIII: The human genome’) were designed to establish 
a regulatory framework for the treatment of the knowledge on the human 
genome. This potential loss of confidentiality limits people’s expectations 
and affects their personal decisions. One of the main purposes was to 
find the balance between the individual right of genetic privacy and the 
social duty of avoiding harm to third parties. The Congress saw in these 
proposals “an advantage to guarantee health rights and a better quality 
of life.”318 Illness diagnosis, therapeutic techniques and drug use could be 
more effective within medical practice and problems, such as the body’s 
rejection of specific medicines and side effects, could be avoided.  
 
Opinions from relevant groups, such as INMEGEN, researchers 
from health institutes, the UNAM and the Mexican Academy of Science 
were taken into account. The 2001 proposals for the General Health Law 
were later condensed into one319 It was evident by 2001 that new primary 
legislation was necessary. Since the Congress had considered the 
human genome as a health topic, conceptualisation, research orientation, 
knowledge and applications for health protection, data protection and 
confidentiality, and prohibition of discrimination, were central to the 
proposal.  It should be noted that the current controls for biobanking in 
Mexico resulted from these legislative efforts to regulate the human 
genome. The following table, obtained from the official website for 
                                                          
318 Comision Parlamentaria para la Salud (Parliamentary-Health-Commission) and 
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legislative information system, shows the details of the proposed addition 
of Title XVIII.320  
 
DENOMINATION 
(TITLE) 
Proposal for decree in order to add Title 
XVIII to the General Health Law.  
SUB- CATEGORY Secondary Law 
CHAMBER OF 
ORIGIN  Deputy’s chamber 
PRESENTATION 
DATE  14/12/2001 
PRESENTED BY  Deputy Manuel Wistano Orozco Garza  
POLITICAL PARTY National Action Party PAN 
LEGISLATURE  LVIII 
TRANSFERRED TO 
 1.-
Deputies -
Science 
and 
Technology 
For report   
2.-
Deputies 
-Health.-
For report 
 
STATUS 
 
Published 
in D.O.F. 
on 16-
NOV-2011   
 
TOPIC 
 1.-
Education 
and 
Culture   2.-Health   
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Source: Legislative data System321  
 
2002-2003 
In 2002, another proposal was introduced by the Green Ecologist 
Party (Partido Verde Ecologista de México PVEM):  
 27th  November 2002 The Congress’ Commissions of Health, Science 
and Technology approved the human genome focused proposals; 
hence, the legislative process began. 
 
This proposal intended to modify the Constitution as follows: 
 Article 1 originally expressly prohibits discrimination. Examples of 
discrimination are defined by the constitution. “All discrimination 
motivated by ethnic or national origin, genetic characteristics, gender, 
age, different abilities, social condition, health condition, religion, 
opinions, preferences, civil status or is prohibited.”  
 
The Congress members of PVEM planned on adding “Genetic 
characteristics” as one of the reasons for discrimination, among others, 
“against human dignity, undermining the rights and freedoms of people.” 
 
 PVEM had planned on defining the human genome within  article 4 
(regulating the health system) and stating that “The law will protect the 
investigation, control and regulation of the human genome.”  
 Article 28 prohibits monopolies in Mexico, but exempts various 
activities. To counteract this exemption, PVEM suggested that an 
inclusion should be made; “Under no circumstances will the human 
genome be able to be patented in its natural state.”  
 Article 89 grants inventors or developers of particular industry areas 
exclusive privileges for a limited time. PVEM also proposed that these 
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privileges “will never be granted in terms of human genome in its 
natural state.”322 
 
On 2 December 2003, a report made by the Congress’ 
Commissions of Health, Science and Technology, was presented to the 
Congress in a plenary session. It was approved and remitted to the 
Senate. 323 
 
On 4 December 2003, the Mexican Senate received the report 
from the Congress in a plenary session. The proposal for a decree 
included: the addition of section fracción IX bis to article 3; title V bis and 
its unique chapter; and article 421 bis of the General Health Law. It was 
exposed for analysis and report to the Senate Commissions of Health, 
Social Security and Legislative Studies. An extension was requested to 
the Health and Science Commission of the Congress and the extension 
was accepted. 324 
 
2008-2011 
In 2008 regulation was introduced governing research in human 
beings, apparently targeting genomic studies.325 
 On 3 April 2008, the report by the Senate’s Commissions was 
approved. On the 8 of April 2008, the report was sent back to the 
Congress’ Commissions, which officially encouraged the 
amendments, following the requirements of Article 72 of the Mexican 
                                                          
322 Proyecto de Decreto que reforma los artículos 1, 4, 28 y  89 de la CPEUM (Proposal 
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Constitution. The report was finally presented to the Congress’ 
Commissions. 326 
 
4.2.3.1.3.1 The human genome enactment 
In 2011, ten years after the first attempt at human genome 
regulation, the proposal was finally approved. The decree was enacted 
with the main intention to avoid undermining fundamental rights by bio-
scientific research. As a general health policy, public interest, ethical 
research and development began to be preserved, but the policy only 
covered the human genome. Individual registration by authorities was 
required, establishing the object and specific applications of research 
projects.327 In the new decree328 added to the General Health Law, key 
issues are covered, such as the recognition of the human genome as a 
world heritage, recognition of the human genome as belonging to the 
individual, confidentiality on genetic data, prohibition of discrimination 
based on genetic characteristics and the establishment of penalties for 
breaching these rules. Even when the new amendments established that 
the human genome would belong to each individual, it was not made clear 
what implications this could have. Under the recently modified General 
Health Law,329 the request for expressed consent is compulsory: “every 
study in this area (human genome) must count on the expressed 
acceptance of the subject.” This is the only rule in terms of informed 
consent. This reform was meant to be “the foundation for scientific 
research, innovation, technological development and medical 
applications in terms of human genome; and to have an impact on the 
regulation of genetic screening, biobanks and gene therapy.”330  
                                                          
326 SCJN 
327 LGS 
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Legislative delay was attributed not only to a lack of resources and 
infrastructure to achieve scientific progress, but societal, political and 
historical elements have also influenced the late emergence and 
development of genetic research in the country.331 Additionally, the 
complexity of the topic made the legislative examining commissions 
amend the proposal several times, for example, it was reported that “it did 
not have the necessary elements for protection.”332 
 
When the preliminary report on the proposal333 was ready, 
Congress members, who were deputies from the National Action Party 
(PAN), conditionally approved the proposal on the basis that “any type of 
cloning activities” were rejected by Congress. José Galán attributes this 
to the pressure made by civil and religious groups when they were 
consulted by the legislators.334 Silvia Alvarez Bruneliere and María 
Eugenia Galván Antillón, PAN deputies responsible for the Commission 
of Science and Technology, and the Commission of Health, denied 
approval for the report of the decree proposal because “enforcement 
would cost nearly 250 million dollars” although this is somewhat 
contradictory since it was initially believed that not developing guidelines 
for the human genome would be more expensive in the long term.335 
 
The above chronology highlights the overall steps, within the 
former law making process, towards the approval of a regulated human 
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genome project. This successful legislative attempt, passed into law in 
2011, could provide the rationale for future biobanking governance. In 
general, normative and practical frameworks have evolved logically 
through the derivation and adaptation of existing biomedical regulatory 
frameworks applicable to research on humans.336 Before these 2011 
regulations, human tissue was regulated with the exception of the human 
genome. The regulation of the human genome is now included, however 
it will be necessary to clarify the most effective mechanisms for the 
enforcement of the reforms, e.g. granting authorisation. Some statements 
are similar or the same as those in previous legislative proposals, such 
as considering “the only reasonable way of dealing with the human 
genome sequence is to say that it belongs to us all -it is the common 
heritage of humankind.”337  
 
Similarly, as with other areas of biobanking, different 
interpretations may be applied within population biobanking. Juan Carlos 
Elizarrarás, academic researcher in law and bioethics, recognised that 
some rules within the Mexican legal system indirectly protect aspects 
such as informed consent, right to health and right to privacy. This can 
seriously affect human rights. Hence, “immediate action mst be procured 
to avoid Mexico converting into a ‘genetic and bioethical paradise.”338 
Participant O’s critical opinion of the human genome regulation expressed 
that “laws such as the human genome rules become “dead documents” 
(laws that are enforced but not applied).”339 The enforcement and 
clarification of the laws implemented in 2011 is a key issue for Mexico to 
avoid being a country where controls cannot be effectively applied to 
biobanking activities.  
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The improvement of medical practice, through more effective 
methods of the diagnosis, therapeutic techniques and drug use was 
included amendments to article 103 Bis of the general Health Law.340 
Despite the current regulation for genomic studies it does not cover the 
ethical aspects of biobanking satisfactorily. Some aspects of the human 
genome remain unregulated and the associated bioethics confusing, for 
example, only human tissue that could be a source of genetic material is 
covered. This was enacted “in order to protect the national sovereignty on 
the genomic data of Mexican citizens.”341  
 
4.2.3.1.3.2 Genomic sovereignty 
The concept of genomic sovereignty has been at the centre of an 
intensifying debate in Mexico, which led to amendments to General 
Health laws. These aim to protect the national genomic sovereignty of 
Mexican citizens. With respect to the transfer of tissue to foreign 
countries, the Mexican General Health Law342 establishes that organs, 
tissues and cells may not be taken outside national territory without 
authorization. Requirements to obtain an authorisation to transfer genetic 
information are confusing. Human research is only allowed at medical 
facilities under the supervision of competent health authorities and with 
the approval of the INMEGEN (National Institute of Genomic Medicine). 
It would be desirable to clarify which government agencies are authorized 
to grant approval. The abovementioned approval of the INMEGEN 
reportedly does not happen in practice.  
 
The proposals provoked high criticism from members of the 
Mexican scientific community, who considered the proposals as too 
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extreme.  Extracting ‘a little tube of DNA’343 could mean imprisonment or 
a fine. It was also claimed that the final objective was the creation of a 
governmental monopoly on genomic research. The only institution legally 
entitled to perform research on population genomics would be the 
INMEGEN, whose greatest achievement (the genomic map of the 
Mexican population) generated economic interest in the “uniqueness of 
the Mexican genomic profile.”344 Schwartz has pointed out that the reforms 
of 2008 were “initiated in response to reports of ‘safari research’, in which 
foreign researchers attempted to obtain blood samples from Mexican 
subjects, including indigenous groups, without the approval of the Ministry 
of Health and local ethics committees.”345  
 
The requirements set forth in Article 317 for transferring tissue 
outside national territory are still unclear; e.g. cases requiring urgency are 
mentioned but not defined. Regulations enacted to protect Mexico’s 
genomic sovereignty, an attempt to control international tissue transfers, 
have been criticized for being ineffective rules, where the bioethical 
approach is incipient.346 Progress was achieved, although with the 
amendments on genomic sovereignty, greater improvement had been 
expected. According to Schwartz, the amendment is an incipient 
bioethical framework.347 Similarly, participant E has stated that “the 
production of the Mexican HapMap was too relevant to health issues to 
end up with a simple modification to the General Health Law;” and “the 
term genomic sovereignty is not helpful.”348 It has been made to sound 
like a discourse, i.e. the “key to understanding the socio-legal design of 
population genomics and the political framing of this new technology in 
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the public sphere.”349  However it consists of something simple: samples 
will not leave the country if they do not have approval in order to protect 
the Mexican DNA. If samples have approval, they will leave the country, 
but in words of participant J, this is “just a rule,” not genomic sovereignty. 
The participant wonders, “whose genomic sovereignty? What does it 
mean?” 
 
The provision contained in article 317 bis 1 is not clear in ethical 
terms. The opinions of Mexican indigenous populations have never been 
taken into account and, in the end, the debate resulted in “an inoperable 
regulation which was somehow forced under assumptions far from the 
practice of population genomics.”350 Hence, the attempt to protect 
national sovereignty351 caused a confusing regulation. The only human 
tissue covered for research is DNA, which left other type of tissues 
unprotected. Similarly, the only other point covered regarding DNA was 
in terms of genomic sovereignty; all other aspects remain unregulated.  
 
In principle, economic interests have clearly prevailed over 
humanistic and ethical ones. In the opinion of Ruha Benjamin, “protection 
should be provided against foreign companies producing therapeutics, 
targeting the population without the population’s involvement.”352 The 
emerging proposals, being purely based on nationalistic populism, 
signified the total exclusion of the Mexican population from international 
genomic projects. The concept of genomic sovereignty should signify the 
ethical treatment of samples containing Mexican genetic data and the 
translation of principles into policies. If it happened, the so called neo-
colonialist action or safari research would become a legal offence.  
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4.2.3.1.4 Protection for vulnerable participants 
within scientific research 
The General Health Rules on Research anticipate protection for 
vulnerable people through specific chapters on underage persons, 
pregnant women or incapable persons. Protection for communities, 
students and workers is also anticipated.353 Relevant articles are as 
follows: 
Research in communities 
Article 28 Research referring to human health in communities will be 
admissible when the expected benefit is reasonably assured. 
Article 29 Within research in communities, the main researcher must 
obtain approval from health authorities and other civil authorities of the 
community under study and the letter of informed consent of individuals 
included in the study. 
Article 30 When the individuals from a community have no capacity to 
understand the implications of participating in research, the ethics 
commission (that which the main researcher belongs to) will authorise 
that the informed consent of the research subjects be obtained through 
a reliable person, with moral authority over the community. If the 
authorisation is denied, the research cannot be done. Individuals must 
participate under a free decision and each of them can withdraw from the 
study at any moment of the study. 
Article 31 Experimental research in communities can be done only by 
establishments that count with the previous authorisation of the Ministry. 
These must comply with toxicity tests.   
Article 32 In all communities’ research, the experimental design must 
offer practical measures for individuals and assurance that valid results 
will be obtained, making participation minimal and representative. 
In any community research, ethical considerations for individuals must 
be extrapolated to the communal context in pertinent aspects.  
Regarding research of minors or incapable people:  
Article 36 For research of minors or incapable people, informed consent 
must be obtained, at anytime, from the parents or legal guardian. Any of 
the parents can consent if it is impossible to obtain both parents’ consent 
or in the case that the life or health of the minor is at imminent risk.  
Article 37 If mental capacity and psychological state of the minor allow it, 
his/her acceptance must be obtained to be a research subject, after an 
explanation of what will happen. The ethics commission is authorised to 
allow justified exemptions. 
Article 38 Research classified as risky, and with direct probabilities of 
benefit for the minor or incapable person, will be acceptable when: 
I. Risk is justified for the importance of the health benefit. 
II. The benefit is equal or greater than current diagnostic and 
treatment options.  
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No specific rules for the protection of samples have been identified. 
As emphasised by Participant D, “The rules on health research are too 
scarce regarding vulnerable people.”354 "Ciencia y desarrollo" (Science 
and development) magazine,355 concerning sample uses, reported that at 
least one of the investigated biobanks obtained samples from specific 
targeted communities, e.g. Chiapas and Oaxaca. The article also 
reflected that the sample collection was promoted through a national 
campaign, in which most participants were mestizo students.  
 
Regarding article 28, it is not explained what ‘benefit is reasonably 
assured’ means. Participant F has posed some of the problems that this 
type of research implies in practice: 
“In genomic population studies it is not clear how the community is 
benefited, how the individual and the group are protected. Sometimes 
the individual is protected through anonymisation. However, the group 
remains unprotected. I have heard someone saying ‘here it is, the DNA 
from the tepehuanes,’ an indigenous people. That is unacceptable 
because the group can be discriminated against.”356 
 
 In this case, no data protection measures are mentioned for the 
group. In participant E’s opinion: 
“The feedback from results is somewhat peculiar because it is uncertain 
whether the publication of research results will benefit participants. 
Researchers do not come back to the sample source to inform them of 
the publication. If they received that information, it would also be 
necessary to explain to them what the publication is about. I do not know 
anyone who has done that. The ethical commitment becomes interesting 
as well as deciding if such a commitment should be more stringent. It is 
difficult since the information of research publications tends to be very 
technical, rather than individually beneficial.”357  
 
Regarding withdrawal, the conditions under which it can happen is 
not specified and what would happen if the samples were already 
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collected. In general, withdrawal from a research study would imply the 
automatic destruction of the samples collected however research 
withdrawal can happen at different stages. Sometimes, withdrawal is no 
longer possible at a particular research stage; the participant can 
withdraw from the research project but his data may still be used.  
 
4.2.3.1.4.1 Participation of persons with legal 
incapacity 
Participant D remarked that “there are no guidelines on biobanking 
to protect children or other members of the vulnerable population.”358 
There have been cases in which under 18s and vulnerable people have 
participated in genomic research studies, such as the Mexican HapMap 
project. Another case showed the following: 
 
The Faculty of Medicine at UNAM follows a specific consent model 
for those under the age of 16.359 The consent letter covers a significant 
number of aspects, such as consent withdrawal, economic aspects of 
participation, confidentiality protection, clarification that refusing 
participation will not lead to negative consequences and compensation in 
case of harmful consequences. The presence of two witnesses has been 
made compulsory for the institution. No consent documents within UNAM 
mention biological samples from minors. 
 
The provision by the General Health Law prevents under 18s from 
being (living or dead) organ donors. This provision is not extended to 
biobanking, and ethics committees allow the participation of children 
through the use of written consent and forms signed by parents, relatives 
or guardians “for all severely ill patients whose decision making difficulties 
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are compromised by their illness and for all research involving children up 
to 18 years old.”360 Although the General Health Law has not determined 
whether it is lawful to obtain samples from children, the Rules of the 
General Health Law on Health Research establish that “when the minor’s 
mental capacity and psychological state allow it, acceptance must be 
obtained to become a research subject, after explaining to him what is 
intended.”361 Children commonly participate and according to participant 
L: 
“Children are normally asked for their acceptance as well but the parents 
have the final decision. I know that the parents are responsible until their 
children are 18. In medical practice, mature children are asked for 
acceptance if their parents agree.”362 
CIOMS guidelines are unofficially followed by Mexican research 
institutes like INMEGEN. However, Mexican regulations do not 
guarantee, for example, psychological assistance for the child and his 
family if it were necessary as the result of participation in research, as 
recommended by CIOMS guidelines. CIOMS guidelines recognise the 
decision of a 9 year old child refusing participation in research trials, which 
could consist of sample donations from children, though this parameter 
remains unresolved under the current Mexican regulations. Regulations 
for sample donations to biobanks by persons with legal incapacity 
depends on the decisions of ethics committees.  
 
The legal implications of samples are different to those covered by 
the General Health Law Rules on Health Research. Therefore, 
biobanking institutions are presumably bound by legal regulations, 
supplemented with additional, non-legal regulations, namely: integration 
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and operative rules of the administration and organisation council,363 
operative internal rules of the information committee,364 operative internal 
rules of the biosecurity commission365 and internal rules of the ethics 
commission.366   Participant F367 confirms this position:  
“It is a general principle that no specific research ethics measures for the 
protection of children have been provided in relation to samples.”368 
 
For underage participants, special attention must be paid beyond 
the present consent of minors regarding their samples. For example, if 
data repositories are created for long term use, children’s re-consent 
when reaching adulthood would be highly recommended. In this respect, 
participant D is certain that: 
 “Within the National Health Institutes (INS), no differentiation is made 
between paediatric samples and adult samples. Similarly, the National 
Paediatric Institute (INP) does not give different treatment to children’s samples, 
from the treatment INMEGEN gives to adults’ samples.”369  
 
Significant limitations can still be found, and further legislation is 
required to determine whose consent should prevail, confidentiality, risk 
benefit ratios, storage periods and children’s objection to participate. 
 
4.2.3.1.5 Administrative regulation on biobanks 
The Federal government has accepted the challenge of 
elaborating upon a Norma Oficial Mexicana (NOM) in terms of 
pharmacogenomics, through the Suplement of the National Programme 
of administrative norms’ standardisation 2013, published on the 23 
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September 2013 in the Official Journal of the Federation (DOF). 
Pharmacogenomic studies are related to personalised medicine, as these 
aim to identify genomic variations, which allow therapeutic targets to be 
selected and identifying more precisely individuals at risk of adverse 
reactions to particular medicines. This new obligatory rule has established 
general requirements for the use of genetic data protection, in terms of 
efficacy and risk of some medicines. However, this new administrative 
norm does not cover biobanks.  
 
Lara and Arellano, in an article published by FORBES Mexico370, 
propose changes to the regulation of biological samples through 
administrative norms. They have suggested that this administrative 
change could be the basis of further legal reforms for biomedical 
research,371 although this is questionable since the nature of NOMs is 
focused towards technical management parameters. Importantly, 
Arellano and Lara have recognised that the development of areas such 
as pharmacogenomic studies will signify “an exponential increase of 
biobanks, since biomedical research relies on opportune access to quality 
biological samples and their suitable management.” 372 
 
4.2.3.2 Relevant local legislation 
Federal law gives each state its own legislature in accordance with 
the following general principles. Legislation consists of rules of law made 
by the Federal Congress (Mexican Parliament), either directly in the form 
of statute (sometimes referred to as ‘primary legislation’) or indirectly by 
those other authorities on which the congress has conferred the power to 
legislate (delegated, subordinate or ‘secondary’ legislation).373 It is 
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therefore assumed that according to the constitution, “the powers not 
expressly conferred by this Constitution upon federal officials, are 
understood to be reserved to the [local Mexican] States.”374 
 
Biobanking guidelines are available at the Mexican Federal level, 
and therefore work as the foundation for local regulations. In Mexican law, 
it is expected that each Mexican state administers local regulation 
reflecting federal regulation. This has not always been achieved. In the 
light of Mexican Law, no local regulations would be expected without a 
federal background. However, related rules were identified in the Code 
for criminal procedures from Mexico City and the local rules for genetic 
data bases for the State of Chihuahua: Ley Reguladora de la Base de 
Datos Genéticos para el Estado de Chihuahua. These came into effect in 
2009, signifying progress but also confusion due to the inconsistency that 
such regulation does not have a federal basis, as would be expected, 
taking into account the Mexican legal system’s rules.  
 
Regarding this situation, Participant J has inferred that the 
aforementioned law was provisionally implemented due to the creation of 
a criminal data base with forensic purposes in the state of Chihuahua. 
This law, however, is too generic, for instance, it is not established who 
will provide the information for such a database. The currently emerging 
local databases could end up feeding a national security database called 
‘Plataforma México.’ This should not happen in the absence of clearly 
defined national authorities to resolve this. In addition, it appears that 
even children are participating and it is not clear at what point the data 
should be destroyed.375 
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These are two examples in which no correspondence is identified 
between a federal and a local rule. Both are independent.  
 
1. The code for Criminal Procedures from Mexico City (1931) (Código de 
Procedimientos Penales para el Distrito Federal) Art. 149 protects 
genetic data. The disposition of germ cells is considered to be illicit when 
it is performed against the purposes for which the donor has granted 
authorisation. 
2. The local legislation from Chihuahua defines the term ‘biological sample’ 
as any biological material, originated from human tissues, susceptible 
to preservation and capable of containing information regarding a 
person’s genetics. 
 
Therefore, it would be expected that the corresponding sanctions were 
initially implemented at the federal level, but this has not happened. Only 
the local Code of Penal Procedure for Mexico City protects genetic data. 
In Ingrid Brena’s point of view, this creates “an obscure law.”376  
 
4.3 International law 
The incorporation procedure of international legal rules in Mexico 
consists of a procedure described in the constitution.  
“This Constitution, the laws of the congress and all the treaties in 
accordance with the Constitution, signed by the President, approved by 
the senate will be supreme law of the Union. Hence, the judges of each 
state will follow the Constitution, laws and treaties. International treaties 
are binding for local entities, despite possible contradictions that the 
Constitution or state (local) laws may have.”377 
 
Firstly, international treaties need to be signed by the President to 
become part of the Mexican legal system. Secondly, they need to be 
approved by the Senate; thirdly they are returned to the President for 
confirmation and finally, the incorporation becomes official through 
publication in the Official Journal of the Federation, Diario Oficial de la 
Federación (DOF). Completion this process makes international rules 
part of the national legal system and consequently binding. Therefore, 
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international treaties have a higher status in the legal hierarchy than 
federal laws but not higher than that of the Constitution. 
 
According to the Supreme Court's current interpretation of Article 
133 of the Mexican Constitution, international treaties rank second. 
Addressing the question of the hierarchy of the Mexican legal norms, in 
‘International treaties are hierarchically above the laws and under the 
federal constitution’,378 it was held that “only the Constitution is the 
Supreme Law,” adding: “This Supreme Court of Justice considers that 
international treaties are placed on a second plane immediately below the 
Fundamental Law and above the federal and local law.”379 In the court's 
opinion, placing treaties in second rank is justified because they reveal 
“international commitments [which] are assumed by the Mexican State as 
a whole, and [which] commit all of its authorities with respect to the 
international community.”380 Potential application of international 
biobanking instruments for Mexico would first require an investigation of 
the instrument. A treaty is not the same as a convention, a protocol or a 
UNESCO declaration. Participant F explains: 
 
“We have to see the hierarchy of those instruments, whether it is 
an agreement or treaty and whether it has been signed. If it was 
ratified by the senate, it is mandatory in Mexico. The situations 
with no ratification tend to be more problematic. Other instruments 
could be considered, such as declarations and the international 
custom. This is not automatic, needs interpretation. The Ministry 
of Health or the National Bioethics Commission could do it.”381 
 
It has been noted that Mexico has looked for guidance in 
international documents. In addition, Mexico has signed documents 
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regarding scientific goals and participants’ rights, including the 
International Covenant on Economic, Social and Cultural Rights (1976)382 
and the Universal Declaration on Bioethics and Human Rights (2005).383  
Both are international standards that Mexico, as a signatory, is bound to 
support.384 
 
In the year 2001, the Congress recognised that international 
collaborations in research were highly desirable in the Proposal for the 
Decree that modifies the General Health Law referring to the human 
genome (Iniciativa de Decreto que adiciona la Ley General de Salud, 
referente al genoma humano).385 This participation would be founded on 
documents, such as the Universal Declaration on the Human Genome 
and Human Rights (1997), the Council of Europe for the Protection of 
Human Rights and Human Dignity, and the agreements on Human Rights 
and Biomedicine (1997).  
 
The Organisation for Economic Cooperation and Development 
(OECD)386 has stated that “the advanced knowledge of genes and 
complex cell processes is one of the main elements involved in the 2030 
bioeconomy;”387 and Mexico, as an OECD signatory, must take part. The 
international norms specific to biobanks of human biological materials, 
associated data and corresponding genetic testing are relevant as they 
provide specific guidance. However, the main motivator for the country to 
adhere to the OECD was more economic rather than scientific.  
 
                                                          
382 The International Covenant on Economic. Social and Cultural Rights 
383 The Universal Declaration on Bioethics and Human Rights 
384 Mexico joined the ICESR on the 23 of March 1981 
385 Cardona 
386 Barahona and Ayala 
387 The Organisation for Economic Cooperation and Development OECD, ‘The 
Bioeconomy to 2030: designing a policy agenda ’ International Futures Programme 
<http://www.oecd.org/futures/long-
termtechnologicalsocietalchallenges/thebioeconomyto2030designingapolicyagenda.ht
m> accessed 11 March 2012 
141 
 
One of the main challenges in Mexico is “to strike an appropriate 
balance between freedom of researchers and the interests of participants 
and the public,” a matter included in the OECD report.388 First, it is vital to 
establish regulations for the main interests in research, the participants’ 
interests (welfare, respect for human dignity and justice) and for the 
researchers’ interests (freedom and justice). The main benefits of 
genomic medicine in Mexico are health-care benefits. However, these are 
still seen as long term goals in Mexico. According to the OECD, it would 
be worth fostering public participation by community consultation. The 
operators of the Guidelines for Human Biobanks and Genetic Research 
Databases HBGRD (2009)389 require that access requests include a 
scientifically and ethically appropriate research plan, and provide further 
details in this respect. The formulation of guidelines should be clear, 
flexible, amenable and general enough to be applied to different 
biospecimen resources, as it has been established by the NCI best 
practices in the USA. 
 
Privacy is recognised in several international conventions signed 
by Mexico. The Universal Declaration on Human Rights (1948) and the 
International Covenant on Civil and Political Rights (1996) state that: “No-
one shall be subjected to arbitrary interference with his privacy, family, 
home or correspondence.” These instruments are legally binding, under 
the Mexican Constitution.390  The Mexican panorama requires further 
analysis towards a basic regulatory model and legal effectiveness.  
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4.3.1 International treaties and conventions to which 
Mexico is a party  
The role of international law is essential within new governance. 
International law documents are “extremely important either to affirm 
common principles (UNESCO) or to standardize practices (OECD).”391 
However, international law adherence is more ethically oriented and 
works “as a reference for scientists and regulatory bodies, and although 
their violation cannot, in any circumstances, lead to direct sanctions, they 
can influence the adoption of more binding texts.”392 International rules 
are the result of an increasing amount of work from the international 
community. Their incorporation into national rules can be achieved in 
various ways; some have challenged the traditional methods of solving 
conflicts between international and internal rules. In most Latin-American 
countries, the incorporation (adoption) into internal law is facilitated by 
constitutional law.393 Direct or automatic incorporation of international 
treaties is common in Latin America.394 Mexico also follows this 
procedure. The category of a law or statute depends on recognition by a 
formal authority. In Mexico, any international frameworks will become 
compulsory once they are adopted through a specific ratification process.  
 
4.3.1.1 Statutory recognition of international 
sources 
Broadly speaking, statutory recognition comes from a 
documentary source (generally written) encouraged or adopted by 
parliamentary action. Additionally, the compliance of the law needs 
enforcement actors, with oversight power from a direct formal legal 
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authority. This can be delegated. The senate is responsible for the 
approval of treaties and diplomatic conventions. The adopted 
International Law in Mexico is considered to be internally legally binding. 
 
In the opinion of Elizarrarás,395 the discretional criteria of 
international conventions impact on the ineffectiveness of such 
instruments at the internal level. International treaties have the same 
binding level as the constitution in Mexico, but Elizarrarás believes that 
declarations are the future of multilateral agreements. Nevertheless, it is 
the responsibility of each country to be prepared to adopt international 
guidelines. International documents, such as those from UNESCO, have 
been partially followed by Mexico, however, other factors (politics, social 
and economic issues) have also been influential. The delay in the human 
genome regulation is an example of a bioethics topic that is influenced by 
a range of factors. 
 
4.4 Concluding remarks 
The Mexican context presents a difficult social and political 
situation that affects the regulation of diverse topics, especially those 
unexplored in relation to science and technology. In the middle of difficult 
times that affect the health system, the only way to obtain knowledge 
involves institutional communication. Institutional coordination between 
academia and policymakers could provide the guidance needed for the 
scrutiny of legislative proposals, commissioned research, consultations, 
and spearheading public engagement and educational initiatives.396 With 
coordinated interaction, the government can obtain precise knowledge on 
the differentiation among bioethical issues, like that of biobanks. Once 
clear knowledge is available, it would be possible to develop specific 
regulation. This does not mean that the regulation of biobanks needs to 
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be exhaustive; “the diversity of practices could produce greater result than 
the attempts to control them exhaustively.” 397 
 
Although there is a relationship between human cloning and 
human genome research, both topics are completely different. 
Elizarrarás398 explains this confusion was caused by the lack of 
knowledge of the legislators; something regretful that “must be corrected 
now.” The approval of the reforms of 2011 was related to issues taken out 
of context, i.e. human cloning and the manipulation of stem cells from 
embryos,399 which should have been material for the elaboration of 
different proposals. Participant F suggested that deciding whether articles 
on genetics apply to biobanks is a matter of interpretation, whereas some 
articles are specific.400 The provision of procedural guidance in Mexico 
will only be achieved if it is determined who will take enforcement 
responsibilities. However, the creation of any procedures has to be made 
carefully, since bureaucratisation processes could end up hampering the 
scarce research.401 
 
The rationale of a fit-for-purpose proposal should be led by both 
expertise and realism regarding the particular barriers of the legal system. 
By tradition, Mexico has intended to regulate every single area. There are 
plenty of related biobanking rules. Nevertheless the law is not 
applicable.402 Furthermore, there are categories, such as the human 
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genome and population biobanks, which may require further attention. 
The analysed reports fuel concerns that neither the research participants 
nor the general Mexican population would benefit from such research.  
 
Although important principles have been established for a more 
modern regulatory framework, in order to ensure that genomic medicine 
will successfully contribute to improve healthcare in the population of 
Mexico, biobanking guidelines are still inconsistent. The evidence of 
regulatory inconsistencies in biobanking has now established the grounds 
for an extensive ethical analysis, which should work as the basis for future 
legal frameworks. Looking at the choice of encouraging an integral and 
inclusive biobanking law, rather than partial reforms, would be of help.  
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5. Legal holes and weaknesses: fieldwork analysis 
 
5.1 Introduction 
This chapter discusses how far the current Mexican legislation 
governs biobanking, identifying any inconsistent areas and the main 
failures that have prevented Mexico from optimising the benefits of 
biobanking. It will describe partial controls, followed by a discussion of 
their limitations, initially through a detailed legal analysis in the search for 
functional biobanking rules. The most significant expert opinions will be 
analysed. This chapter also identifies specific elements to help integrate 
the perspectives from both biobanks and governance, which according to 
Hawkins and O’Doherty, determine the legal effectiveness.403 
 
The first section will identify elements of governance which can be 
considered as indicators of consistency. How these areas are perceived 
by stakeholders will provide insights on the state of different areas of 
governance requiring attention. The complexity of biobanking is 
associated with the diversity of practical areas involved. According to 
Kaye et.al, “different types of research will tend to use different kinds of 
biobank, both with respect to data and samples, in relation to the nature 
of research collaborations they call into existence.”404 This is quite 
common: “There is a huge variety of laws and regulations which have 
relevance for biobank research.”405 In this context, relevant regulatory 
areas to be analysed in the subsequent sections are: human tissue, 
informed consent, data protection, health research, and finally, potential 
sanctions.  
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5.1.1 Statements on the effectiveness of Mexican 
biobanking governance 
This section presents the responses from several stakeholders on 
whether biobanks are effectively regulated in Mexico. In order to identify 
weaknesses on the current biobanking rules, 15 participants were asked 
whether biobanking rules were effective. (See Table 1 in annex p. 1) The 
following data was obtained: 
 
 Two participants (K and L) said they did not know. Participant K 
(law maker) said he would need to study the topic more deeply to provide 
an answer. Participant L (Bioethics adviser) said he was not a law expert, 
and did not have knowledge of biobanks from a legal perspective. Out of 
the remaining thirteen participant responses to the question, seven 
responded that biobanks are not regulated effectively. Out of the seven 
negative responses, one said that regulation in biobanks is non-existent. 
From the remaining seven, six said that they are regulated, not effectively 
but partially. These six participants described the regulation as: partial, 
unclear, spread, ambiguous, covered by other laws and ineffective. No 
positive answers were obtained. Participant D “witnessed a discussion at 
the National Institute of Respiratory Illnesses (INER) to decide the fate of 
seventy year old samples. Obviously, there was no informed consent or 
the possibility to obtain it. The samples could be used for scientific 
research or disposed of, kept by a single institution or shared. This 
situation reminded me a case from Iceland, where samples dating from 
1916, were allowed to be used.”406 Participant B407 recognised that the 
collection currently preserved at INMEGEN was created specifically for 
the HapMap study, the first genome wide genotyping effort of a recently 
admixed population in Latin America. However, since the study was 
concluded, the fate of the samples is no longer clear. Should the samples 
be discarded?  
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According to Gibbons, samples with no clear purpose “can predate 
contemporary biobanking norms or principles.”408 This is concerning in 
Mexico, where fieldwork shows that no laws have been enacted 
specifically in relation to biobanking. Ambiguous guidance regarding 
sample treatment is expected to cause clashes where there is a contra-
position of rights among researchers and participants. These responses 
reveal great concerns pointing to an apparent lack of regulation and public 
information, with the potential for further consequences. If laws are weak, 
institutions are confused due to the absence of guidance as to how to 
proceed. 
 
5.2 Tissue regulation 
The legal status of human tissue has been an issue for 
consideration over the last decade, making it essential to determine who 
has rights over tissue samples, how they can be used and under what 
circumstances.409 The law has traditionally regarded human tissue 
samples as having no legal status. However, the development of new 
technologies and the increasing importance of biological samples in 
medical research has given human tissues a new value and importance. 
Ingrid Brena’s results on surveying biobanks pertaining to sample 
ownership revealed that 8 out of 14 biobanks considered the sample as 
their property, 3 biobanks regarded the donor as unique proprietor and 3 
biobanks affirmed that the samples do not have an owner.410 It is 
concerning that 50% of the surveyed biobanks consider they are entitled 
to property rights which could lead to illegal commercialisation. The 
commercialisation of human tissue is prohibited is under article 22 of the 
Regulation on Sanitary Disposal of Human Organs, Tissues and 
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Cadavers (1985). The use of eggs and sperm are covered independently. 
The content of biobanks can be extremely varied, as shown in the 
diagram below.411 Fundamental rights can be involved in more ways than 
just genetic practices.  
 
 
Tissues and cells are typically the object of biobanks. The currently 
enforced Mexican norms dealing with the donation of cells, organs and 
tissues were initially based around organ transplantation412 and were not 
concerned with samples for research. They were not originally designed 
to provide a regulatory regime for research using human tissue. Hence, 
organ donations could only be used for transplantation purposes. 
However, in 1997, the term ‘cell’ was included in the regulation regarding 
the disposition of organs, tissues and their compounds. The definition of 
concepts, such as cells, tissues, and what is understood to comprise 
                                                          
411 IBMT, ‘ Innovative Technologien für die Biomedizin  ’ (Fraunhofer-Institut für 
Biomedizinische  Technik, , 2006)  <http://www.ibmt.fraunhofer.de/ > accessed 13 
March 201213 March 2012 
412  'Federal Regulations for the Control of Organs, Tissues and Cadavers of Human 
Beings' (’Reglamento Federal para la Disposición de Órganos, Tejidos y Cadáveres de 
Seres Humanos') 
150 
 
artificial reproduction, is included in the General Health Law Rules on 
Health Research.413  
 
Marcia Medrano highlighted that such reform came because of the 
boom in genetic experimentation at that time. Genetic experimentation 
would be covered by the section entitled “Disposition of organs, tissues 
and their compounds.” Additionally, it was stipulated that improper use of 
organs, tissues, cells and cadavers from human beings, would be against 
the law and public order.”414 In the opinion of Medrano,415 by 1997, the 
reform was a very superficial framework.  
 
The current minimum guidelines on transplantation, however, 
cannot be directly applied to biobanking. The General Health Law needs 
to differentiate between organs and tissues. Each of them requires 
specific rules since each of them lead to different legal consequences. 
For example, storage periods are not the same for population biobanks, 
clinical biobanks or cord blood biobanks;416 tissues commonly used for 
research (such as bone marrow, blood, skin and synovial fluids) involve 
different ethical issues depending on the potential to reveal sensitive 
genetic data. Ethical decisions should recognise such differences. 
Inconsistencies of rules for collecting DNA samples between different 
national regulatory agencies and also between ethics committees may 
further hamper prospective studies in this area.417 
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The minimum legal requirements cover extreme situations, such 
as selling tissue and the commerce of organs, which are prohibited. In 
order to benefit a larger number of Mexicans, it has been stipulated that 
organs and tissues must not be taken outside the country. Recently, 
informed consent became compulsory for donations and the 
management of biological samples, tissues and cells.418 According to a 
preliminary report by University Central Hospital from Asturias, 
“Encephalic death in Ibero-America, preliminary inform” (Muerte 
Encefálica en Iberoamérica),419 Mexico is one of the 7 Ibero-American 
countries with no guidelines or recommendations by scientific societies 
regarding organ donation.   
 
One Mexican legal stakeholder (Participant G) made the point that 
differentiating between biological samples can be relevant. “There have 
been arguments between supervisory and research public institutions. 
Researchers support the position that DNA is not blood, but something 
purified from blood.”420 This situation emerged when the supervisory 
institution requested the research institution ‘to bag’ DNA for transport 
purposes, as they considered it was blood. “First it is necessary to 
investigate how blood is defined by the law. It has been required that 
blood is “bagged” when transported. But DNA cannot be bagged.”421 
Participant G hinted at the legal consequences originating from this, 
“hence, technically, DNA would not require an authorisation to be 
transported outside the country because blood does not require 
authorisation for this.”422  
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5.2.1 Post mortem tissue 
Another relevant topic is tissue from the deceased. The General 
Health Law has stated that cadavers must be treated with respect and 
dignity. However, no specific ethical guidance has been provided on the 
fate of samples from deceased donors in biobanking. The main principle 
for Mexican organ transplantation is altruism; in this case the families of 
diseased donors are intended to apply the mechanisms for voluntary 
donation or the denial of donations at the moment of death. Biobanking 
implies a different treatment for samples from deceased donors which 
generally depends on informed consent from the donor when he/she was 
alive.  
 
5.3 Informed consent  
There are also inadequacies in the regulation of consent 
requirements for research projects in Mexico. Protection for research 
participants’ autonomy is essential. Informed consent is mentioned in the 
General Health Law, Rules of the General Health Law, local rules on 
health, rules for health services at the National Institute for Social Security 
(IMSS), official administrative rules (NOMS), National Commission for the 
Certification of Health Centres (CNCES) and rights of patients guidelines 
(CONAMED). Apart from legal guidelines, the administrative guidelines 
and the NOMs423 establish ethical requirements for informed consent. As 
a whole, the specific cases which require signed and written informed 
consent include hospitalisation of psychiatric patients, surgical 
intervention, fertility treatment, participation in research projects, any 
diagnostic procedures implying physical, emotional or moral risk, invasive 
procedures, procedures which produce physical or emotional pain, and 
socially invasive procedures which can provoke exclusion or 
stigmatisation. In applicable cases, the document will be filed as part of 
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the subject’s medical records. The General Health Law Rules on Health 
Research cover informed consent as follows; 
Article 20 Informed consent is the written agreement in which the 
research subject or his/her representative agrees to participate in 
the research, with full knowledge on the procedures, their nature 
and the risks; with capacity of freedom of choice and with no 
coercion.  
 
Article 21 For informed consent to exist, the research subject (or 
his legal representative) must receive a clear and complete 
explanation, so he/she can understand, at least, the following: 
 Justification and research objectives; 
 Procedures to be used and their purpose, including the 
identification of experimental procedures; 
 Discomfort and expected risks; 
 The benefits that can be observed; 
 The alternative procedures which could be of benefit to the 
subject; 
 The guarantee of receiving an answer to any question and 
clarification on any doubt about the procedures, risks, benefits 
and other aspects related to the research and the treatment of 
the subject; 
 The freedom to withdraw his/her consent at any point and stop 
participating in the study, with no risk of prejudice to continue 
his/her treatment; 
 The security that the subject will not be identified, and 
confidentiality of the data related to privacy will be maintained; 
 The commitment to provide the subject with updated 
information during the study, even when this could affect the 
subject’s will to continue his/her participation; 
 The availability of medical treatment and compensation to 
which the subject could have the right, by the health institution, 
in case of damage directly caused by the research; 
 If there are additional expenses, these will be covered by the 
research funding. 
 
Article 22 Informed consent will be written and must meet the 
following requirements: 
 It will be explained by the main researcher, containing the 
above mentioned information and following the administrative 
rule made by the Ministry; 
 It will be revised and, if this is the case, approved by the Ethics 
Commission of the health institution; 
 It will indicate the names and addresses of two witnesses and 
the relation that they have with the research subject; 
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 It must be signed by two witnesses and by the research subject 
or his/her legal representative (if this is the case). If the 
research subject does not know how to sign, his/her finger print 
will be printed, and another person designated by him will sign; 
and 
 The informed consent will be duplicated. One will be for the 
research subject and the other for his/her legal representative.  
 
Article 23 In case of research with minimal risk, the Ethics 
Commission, with justified reasons, will be able to authorise that 
the informed consent can be obtained in a non-written way. In case 
of research with no risk, it will be able to allow the researcher to be 
exempt from the requirement to obtain informed consent.  
 
Article 24 If there was a relationship of dependence, ascendance 
or subordination between the researcher and the research subject 
that affect him/her granting his/her consent, the informed consent 
will be obtained by another member of the research team, 
independent of the relationship of researcher-research subject. 
 
Article 25 When it is necessary to determine the mental capacity 
of an individual to grant his consent, the main researcher must 
evaluate his understanding capacity, reasoning and logic capacity, 
according to the parameters approved by the Ethics Commission.  
 
Article 26 When it is alleged that the mental capacity of a subject 
had varied through time, his/her informed consent (or that from 
his/her legal representative) must be certified by a professional 
group with recognised scientific capacity and moral standing in the 
specific areas of research, and an observer independent from the 
research, in order to secure the suitability of the mechanism to 
obtain consent and validity through the research.  
 
Article 27 When a psychiatry patient is in an institution for being an 
‘interdiction subject’ (the UK equivalent would refer to ‘someone 
who has been sectioned, or detained, under the Mental Health 
Act’), apart from complying with the previous articles, it will be 
necessary to obtain the approval of the corresponding authority.  
 
Clearly in the case of the normal informed consent, it is only 
intended that specific information be provided making it clear that the 
study is voluntary. The different types of informed consent constitute a 
wide topic, in which types can be summarised in the requirement for 
“either broader, initial consent procedures or multiple requests for consent 
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over time.”424 “How that consent process should be carried out and using 
what information will vary from study to study and consent seeking in 
biomedical practice is known to be variable and selective.”425 In terms of 
standardisation, Manson and O’Neill have stated that consent forms and 
procedures do not need to be treated as a trivial matter, rather the 
contrary.426 A standardisation of consent types is at risk of being over-
simplified and far from being effective, it would be inadequate to cover the 
variable and selective nature of biomedical consent. 
 
In terms of the provision of consent, despite the 2011 amendments 
to the General Health Law, the regulation of informed consent does not 
provide further details on biobanks.  Hence, either blanket or single 
purpose consent for this situation would be admitted.  It has been written 
in the law that individuals need to be able to understand their right to 
withdrawal. For this reason, the participant’s right to withdraw 
participation can be assumed. Nothing has been said of the sample’s fate 
if withdrawal occurs, which suggests that further guidance on the terms 
and conditions for withdrawal are required. It is necessary to clarify the 
traditional consent mechanisms for complete protection of participants. 
Anonymised samples are the main source of biomedical research.  
 
If a participant from the Mexican research project on ancestry 
HapMap decided to exercise his newly guaranteed right, it would be too 
late; the samples are anonymised before the research starts.427 Under the 
new additions, anonymisation is a non-regulated activity that would 
prevent participants from exercising their ‘right to know.’ The regulation of 
consent should cover essential matters, such as secondary uses of data, 
identification mechanisms, e.g. anonymity and coding, re-contacting 
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participants, participants’ withdrawal, the return of results to participants, 
accessibility and implications. Clear informed consent guidance would 
benefit not only participants, but researchers, for instance, it has been 
shown that information provided to participants to avoid accusations of 
discrimination positively impacts on participation rates.428  
 
5.3.1 Governance perceptions on informed consent 
Basic consent requirements “far from being ethically fundamental, 
presuppose other more basic ethical and legal standards.”429 The 
following are examples of how stakeholders perceive the governance of 
informed consent, not necessarily in terms of biobanks, but based on how 
these could indirectly be covered by existing guidelines. (See Table 7 in 
annex p.8) 
 
For most participants, informed consent is currently not covered or 
too generally governed in terms of biobanking. The approach taken by the 
CNB institution (currently responsible for the governance of informed 
consent) is too general and is unfit for biobanking purposes. A typical 
misunderstanding of consent happens when it is seen as “a stamp of 
approval for medical practice.”430 The current goals of the Mexican CNB’s 
are centred on encouraging informed consent to be seen as a process, 
not a document.431  Informed consent must reflect patients and their 
families’ motivations for participation since the proliferation of genetic 
testing involves knowledge on the genetic component of their risk for 
disease, as well as risk perceptions, preferences and level of involvement. 
The availability of these choices must be established in the original 
informed consent. 
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 Even when the creation of the CNB was focused on health care 
and research, it seems that more attention has been focused on health 
areas rather than research. According to the Commission’s guidelines,432 
informed consent is an instrument for respecting a person’s autonomy in 
research and health areas, consisting of a continuous process which 
involves health staff and patients. However, some aspects have been left 
behind, especially in research. In the words of Participant I, “there is 
nothing on biobanks but in clinical areas, it is necessary to differentiate 
between medical and research consent which would be applicable to 
biobanking.”433 
 
Guidelines by the CNB present an imbalanced focus; they are 
mostly directed to patients, leaving research subjects unprotected. 
“Consent will be used by health staff in order to inform a competent patient 
on illnesses, therapeutic procedures, diagnostic procedures, risks, 
benefits and feasible options,”434 and “the informed consent document is 
the evidence that a doctor has provided information to a patient, who has 
understood such information.”435 The legal qualification of the person in 
charge might not be the same when samples are obtained within the 
healthcare context or within the research context.”436 Another observation 
is that the Commission’s role is purely advisory, and even under this 
governance hierarchy it cannot invigilate or ethically advise the numerous 
ethics committees in the country.  
 
                                                          
432 Comisión Nacional de Bioética (National Bioethics Commission) CNB, 
‘Consentimiento informado ’ http://wwwconbioetica-mexicosaludgobmx/ 
<http://www.conbioetica-
mexico.salud.gob.mx/interior/temasgeneral/consentimiento_informado.html> accessed 
2 October 2012 
433 Responsible-of-the-Genetics-department-at-a-public-ethical-advisory-institution-
Participant:I 
434 CNB 
435 Ibid 
436 Cambon-Thomsen, Rial-Sebbag and Knoppers 1118 
158 
 
Informed consent is not seen as a protective element for research 
subjects but as a protective measure for patients. Ethical guidelines by 
the CNB for biobanks should cover both health services and research 
areas, since both of them deal with biological samples. There may be 
types of research that do not represent any hazard to patients, but these 
must be regarded as exceptions and only official guidelines should decide 
on exemptions to informed consent. 
 
5.4 Federal legislation on data protection 
In terms of National Law, the Mexican Constitution guarantees 
data protection through a ‘right to information’, which is to be enforced by 
the Mexican State. Hence, private information and personal data will be 
protected according to the law: “all persons will have free access to public 
information without the need for justification or proving interest;”437 and all 
persons will have free access to their personal information and will be 
able to correct misinformation.  
 
Personal data is regulated by the Mexican Federal Law on 
Transparency and Access to Public Government Information (Ley Federal 
de Transparencia y Acceso a la Información Pública Gubernamental) 
(2003) (LFTAIPG) which sets forth general principles of public information 
laws. It should be noted that this legislation applies exclusively to 
governmental institutions.  The Federal Law on Protection of Personal 
Data Held by Individuals (Ley Federal de Protección de Datos Personales 
en Posesión de los Particulares) (2010) includes a definition of personal 
data, the regulation of personal genetic data as a sensitive matter, and 
the protection of personal data and responsible subjects. The Statutes for 
the Protection of Personal Data (Lineamientos de Protección de Datos 
Personales) (2009) were enacted by the Federal Institute of Access to 
Public Data (Instituto Federal de Acceso a la Información) (IFAI) in order 
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to protect the personal data stored in electronic databases and related 
networks.  
 
In 2010, the Federal Law on Protection of Personal Data Held by 
Individuals was enacted with no clear constitutional basis. It should be 
noted that genetic data is sensitive data, and the latter is covered by the 
Statutes for the Protection of Personal Data. “Sensitive data is any 
information that affects the most intimate sphere, or whose misuse can 
cause discrimination or involves related risks for the individual.” According 
to article 3-IV, the information contained in Mexican biobanks is a 
sensitive matter. Biobanks’ typical uses, consisting of storing samples 
and associated data, range in scope from small hospitals and research 
centres to large national organisations. Inconsistencies with respect to 
data protection in Mexican law reflects an absence of integrated policy. 
 
Both scientific and academic communities in Mexico are aware 
that the genetic research boom and have questioned how data from 
sample donors is managed.438 However, there are no rules that respond 
to the specific needs of sharing samples, citizens’ participation, sample 
donation and research in general.   
 
One suddenly has the dilemma of whether to rescue the existing 
framework, just amend it, or ‘wipe the slate clean’ and encourage a new 
instrument. The 1987 modifications to the General Health Law came as 
a necessity to regulate blood banks. Diseases such as AIDS were 
proliferating and more controls on blood transfusion were required to 
avoid HIV infection spreading. Then the rules on disposition of organs, 
tissues, transplants and so on, emerged from demands to control blood 
and organ donation.”439 
 
It is fair to say that a framework that comes from 1987 cannot deal 
with the present situation.”440 Participant D agreed that “it seems 
contradictory that after 10 years of public and private biobank 
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proliferation, no concrete answers have yet been found”. Federal 
regulations provide no specific biobanking guidelines, only one related 
local regulation has been identified.441 Evidently, biobanking legislation is 
applied in an inconsistent manner with no uniformity. The current health 
legislation, including the latest reforms, constitutes partial controls for 
biobanking, which is in some cases, a reference for potential legal 
interpretation.  
 
5.4.1 Data protection perceptions applicable to 
biobanks 
In the opinion of Participant J, the currently enforced data 
protection regulations’ confusing effects are partly due to “the inclusion of 
genetic data in the coverage by LFTAIPG on personal data; and to this 
framework’s failure to cover data preserved by private institutions.”442 The 
Statutes for the Protection of Personal Data regulate data held by private 
institutions, but “it is not clearly specified whether this includes genetic 
data in any of the 9 articles on personal data.”443 This is subject to 
interpretation and if we interpret that personal data includes genetic data, 
the consent for the use of such data is assumed by opposition, in other 
words, if no-one makes clear their disagreement on further uses, it may 
be used; it is open. However, in the case of public institutions, consent for 
further uses must be stated. In the opinion of the data protection expert 
(participant J), the information preserved by public institutions seems to 
be better supervised, through periodical inspections of the institutions.444 
Hence, biobanking should be covered by both public and private data 
protection regulations. 
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Participant A also believes that it has not been specified whether 
personal data includes genetic data.445 Similarly, participant G 
understands that “IFAI rules do not apply. IFAI protects personal data, in 
which genetic data is not included. As far as I know, this has not been 
defined.”446 However, participant C believes that IFAI rules may apply to 
biobanks. “We have general rules. At the moment, individuals dealing with 
personal data are requested to declare it. However, there is much to do 
on genetic data, operation, defence mechanisms, inspection 
mechanisms, data access and rectification.”447 This is participant I’s 
clarifying opinion:  
 
“The current legislation on personal data has not been explicit enough to 
clarify what samples contain health data. These are sensitive due to the 
genetic data contained and need different protection. That should be 
emphasised; we have to go deeply and be more protective with samples 
containing genetic data, rather than just health data. The data protection 
systems, both public and private, involve some obligations but not 
policies on biobanks.”448  
 
For participant O, the problem is not simply regulation; “data 
protection is starting to be carried out. However, people doubt that the 
government can keep their data safely. Databases were the subject of 
illegal trading in Mexico City markets not long ago.449 Participant J added 
that nearly one year after the Law on Data Protection for Private 
Individuals was enacted, it is not clear whether the law has been effective. 
“It is too little time to know if the law is complying with initial 
expectations.”450 In participant J’s opinion, an expert authority for 
protecting personal data (clinical data, biometric data) and regulation for 
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biobanks are absent at the moment. Participants D and E agree with the 
idea that biobank transparency has not been included by the IFAI.451   
 
Ingrid Brena has stated that the Statutes for the Protection of 
Personal Data, which regulate data sharing and the management of 
personal data, are applicable to genetic data “because of its content.”452 
This argument could be challenged from a constitutional basis; it is 
sustained by the Mexican Constitution that the purpose of LFTAIPG 
(2003) applies exclusively to governmental institutions. Therefore, data 
protection of biobanks in Mexico, a challenging topic that requires integral 
governance, is not governed as such by the current Mexican data 
protection laws.  
 
5.4.1.1 Data protection mechanisms 
Dr. Brena conducted a survey as part of the 2008 International 
Colloquium ‘Biological samples and biobanks for biomedical research’;453 
in which 14 questionnaires were completed by various biobanks in 
Mexico. The findings showed that it was not clear how the confidentiality 
of genetic data for research purposes would be achieved without 
established procedures. According to the study, all 14 biobanks store 
biological samples and protect the confidentiality of their participants 
following various procedures. For example, samples are anonymised and 
only the codes remain available for the samples. These codes can reveal 
the place where the sample comes from, the participants’ gender, even 
the specific population of origin, but never the name of the person. Two 
biobanks reported that they dissociate all personal data by the end of the 
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project.454 There are access restrictions to the freezers where the 
samples are kept and not all of the staff have access to the samples. All 
the surveyed biobanks asked for informed consent from participants. 
However, in two biobanks, where research is centred on purposes other 
than those stated in the initial informed consent, no re-consent was 
requested. By 2008, it was practically optional for biobanks to follow data 
protection guidelines. Of the fourteen biobanks, only one was found to 
use systematic controls to protect data; another biobank complied with 
the ‘existing data protection national law’. This single biobank reported to 
be following general data protection guidelines, which in principle are 
binding only for governmental institutions. 
 
5.4.1.2 Data and sample sharing 
The problem of inconsistency extends to the protection of 
participants’ privacy and confidentiality. Sample and data sharing is not 
regulated and it is not clear how this would happen. For instance, 
Participant B commonly faces dilemmas on sample treatment in various 
circumstances:  
“I don’t know what happens with the samples if the researcher that 
started a project leaves the institute and goes abroad. What happens if 
the funds were from the government? How to establish a protocol, benefit 
sharing between participants and researchers, publications? It would be 
good to have some standards at the national level. Each institute has 
rules but in the end everybody is free to do what they want to do.”455  
 
 Participant A, for example, emphasises that currently, each 
institute holds the “ownership” of samples stored.  
“Regarding the Cancerology biobank, even if I had a good research 
project, I will not be able to access their tissues or their patients, it is just 
cancerology. They may have patients’ consent to prevent sharing the 
samples with institutions which have nothing to do with cancerology. 
There are particular concerns of particular institutions and the samples 
of their own patients…For the release of previously collected samples, 
INMEGEN requires a detailed research project.”456  
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The main principles regarding procedural standards for data 
sharing policy “should be transparent, equitable, practicable and give 
clear and consistent decisions.”457 This is one of the main principles 
followed by the UK Medical Research Council (MRC). 
 
5.4.1.3 The impact on governing data protection 
on the national economy 
Lina Ornelas, General Director of Classification and Personal Data 
at IFAI reported in 2012 that one of the advantages of the Federal Law on 
Protection of Personal Data Held by Individuals has been attracting 
foreign investment into the country.458 The recent law has unified data 
protection criteria at the national level. Clinical trials are reportedly an area 
in expansion. The IFAI representative highlighted that “medical expenses 
are cheaper in Mexican currency than in Euros, for example, and the trials 
would be more protected by the aforementioned data protection law for 
individuals.” Additionally, these measures should avoid foreign investors 
being able to process data in jurisdictions where the law is more relaxed 
or the taxes lower. This makes Mexico reliable for international 
investment, since data protection is a great concern among democratic 
nations these days.  
 
New sanctions have been implemented and, as a result, the IFAI 
will be able to impose fines of up to $3 million dollars (if offences are 
repeated with sensitive data) and establish self-regulation for private 
companies, including corporative rules. The impact this would have on 
the Mexican economy has created great expectations: 
“If there is an independent regulatory framework and authority, such as 
IFAI, European countries could invest in Mexico. Current trading 
agreements request us to provide a suitable level of data protection. 
When Argentina was regarded by Europe as a safe destination for data 
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protection, this country received more than $1 billion dollars through 
direct investment per year, mainly on clinical data. This is what Mexico 
is after.”459  
 
To a lesser extent, the IFAI representative stated that the law was 
also designed to protect individuals. “In 2011, we received complaints by 
individuals that several companies were not protecting their data well 
enough. Anomalies were detected and people did not want their data be 
disclosed with no controls.”460 
 
5.4.1.4 Data protection on health research 
Current legal regulations regard genetic data as sensitive. 
However, no ethical guidance is provided on how sensitive data 
protection should be achieved within biobanking research. In Mexico, 
both public and private research deals with sensitive data, which may 
need more protection mechanisms and guidance than just the general 
rules from the Federal Law on Protection of Personal Data Held by 
Individuals (2010).461 This is highly problematic since clinical data 
management needs to be safely stored under appropriate conditions, due 
to the potential for identification of individuals from databases linked to 
recruitment. Not only is research subjects and patients’ data at risk of 
being unlawfully disclosed, but also those associated with their family 
members. Specific guidance is required as research is designed to 
generate knowledge rather than individual data, and “research 
laboratories are not necessarily held to the same standards as clinical 
laboratories.”462 The original consent for the study needs to establish what 
approaches will be taken regarding the disclosure (or non-disclosure) of 
individual genetic research results, for example, the return of results, re-
contact processes, and the conduct and dissemination phases of the 
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follow-up study. The required guidance on health research data protection 
could be introduced by institutional codes of ethics. 
 
Research ethics for privacy is governed by article 16 of the General 
Health Law rules for health research.463 Individual privacy of research 
subjects will be protected within research involving humans, by identifying 
such individual subjects only if they authorise it and only if it is required 
by the research results. LRECs (Local Research Ethics Committees) 
have the authority to decide on privacy matters related to biological 
samples. The definition of health data encompasses genetic data too. It 
has also been suggested by Kosseim et.al464 that data should be 
protected within research areas and regarded as sensitive data because 
they can reveal racial and ethnic origins.   
 
Currently anonymisation approaches have been used to protect 
the participant beyond initial consent from unintended identification and 
to enable the broader use of data. However, anonymisation involves 
significant disadvantages, which include the impossibility to fully 
anonymise large amounts of clinical data. Menasco465 has concluded that 
a great number of anonymisation attempts have resulted in limited use 
and an imbalanced cost of the clinical study. Of particular relevance are 
concerns related to the use of data by third-party researchers who have 
potential access to sensitive data. The criteria followed by Mexican 
regulations cover general aspects of privacy and consider that the risk of 
privacy violations for individual sample donors or genetic discrimination 
does exist but is insignificant. IFAI could be responsible for biobanking 
data protection but it has limited competence, due to the unclear coverage 
of its public transparency rules. 
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5.5 Current guidance and institutions on health research 
 This section will identify the most relevant ethical guidelines, 
consisting of research ethics principles. These are gathered from the 
procedural rules as well as the General Health Law, outlining their reform 
towards more specific principles. The current involved institutions will be 
introduced.  
 
Relevant rules for research involving humans are provided by 
article 14 of the secondary legislation ‘General Health Law Rules for 
Health Research.’466 The ethical rationale of research relies on ethics 
committees rather than on enforced rules. The main rules for research 
involving humans are provided by primary legislation overseen by the 
National Ministry of Health, through the General Health Law article 98. 
The scientific and ethical justification for the research include the following 
criteria: previous experimental basis on animals, the impossibility to 
obtain scientific results by other means, high probabilities of benefit over 
predicted risks, request for the written informed consent of the research 
subject or his representative, participation of experienced health 
professionals, the committee’s approval, and approval by the manager of 
the health institution.  
 
The General Health Law Rules for Health Research, which are 
secondary legislation, state that protection for research subjects is based 
on principles of “human dignity, human rights and welfare.”467 Mexican 
regulation normally establishes principles in primary Acts, for example, 
the General Health Law and its procedural rules on health research. The 
fact that a secondary legislation establishes principles and not procedures 
is unexpected. If the principles are included in a regulation for procedures, 
there is no ‘place’ to include the expected procedures to comply with the 
                                                          
466 Rules of the General Health Law on Scientific Research (Reglamento de la Ley 
General de Salud en Investigación Científica)  
467 Ibid Article 13  
168 
 
protection of human dignity. This disproportional responsibility is normally 
expected to be established by rules. Instead, this fundamental prerogative 
has been delegated to ethics committees. Therefore, all institutions which 
depend on the public health sector have ethics committees for 
supervision purposes such as for the authorisation of research projects. 
“Some biobanks require approval of their protocol and their informed 
consent documents from the research ethics committees. Nevertheless, 
once the research is underway, the committees, in most cases, do not 
carry out any supervision of the biobank or the research.”468 According to 
the General Health Law Rules, health research through clinical trials can 
only be authorised by the Mexican health authority, that is, COFEPRIS. 
 
Although the approved reforms show significant progress, 
specifically in the human genome area, it seems that the rest of the 
related areas still present legal gaps (e.g. the regulation of data protection 
within scientific research). In Mexico, this framework, the Regulation on 
Scientific Research, intends to avoid undermining human rights in 
scientific research:469 
 
a) Respect to human dignity, protection of human welfare and other rights 
are the criteria that must prevail in any research that involves humans 
(article 13).  
b) The Ministry of Health will be in charge of the evaluation of research 
activities in the national territory (article 5-IV). 
c) Research in humans must be based on previous research in animal labs 
or in other facts whenever it is not possible to obtain that knowledge by 
other means (article 14-I, III).  
d) Research in humans requires approval from the Commissions of Ethics, 
Bio-security and Research (article 14-VII). 
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e) For human research, the informed consent from the research subject, 
legal representative or the Ministry of Health, is indispensable (articles 
14-V, 20, 21, 36 and 43) (with the exceptions of articles 17-III and 23). 
f) For human research within communities, the responsible researcher will 
have to obtain, apart from the individuals’ consent forms, the approval 
from health and civil authorities within the community (article 29). 
g) In research where under 18s participate, it must be secured that similar 
studies have previously been performed with adults and with animals, 
except when the aim is to study particular conditions in new-borns or 
other particular ages (article 35). 
h) Research in pregnant women must be preceded by previously performed 
studies in non-pregnant women that prove safety, except from those 
specific studies that require such a condition (article 44). 
i) For research in subordinate groups, one of the members of the 
population who will participate in the study must take part in the Ethics 
Commission (article 58). 
j) Research in clinic pharmacology must be preceded by previous finished 
clinic studies (article 67). 
k) Authorisation from the Ministry will be required for experimental research 
in individuals and communities and in that which implies construction and 
management of recombinant nucleic acids (articles 31, 62, 65, 69, 71-
73, 88 and 102). 
l) Ethics, Bio-security and Research Commissions will be constituted in all 
those institutions where health research is performed (articles 99, 104, 
109, 105,110, 106 y 111). 
 
The General Health Rules for Health Research classifies research 
risks into minimal, medium and high.470 The potential risk of discrimination 
tends to depend on the type of research being carried out. Participant F 
remarks that this classification  
“refers to physical questions, not emotional. For example, I have seen 
research protocols on obesity, they are ‘just questions,’ but questioning 
someone on overweight issues is conflicting; this may result in negative 
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consequences.  It must be determined who will respond in such cases; 
the biobank or the researcher? Who will respond for the data?”471  
 
With respect to professional operation requirements, the UNAM 
study reported that ten biobanks were asked for their research protocols. 
It was found that out of these ten biobanks asked by the Ministry of Health 
assistance regarding governance, two of them follow the “NOM for the 
management of biological materials and international guidelines” (2005). 
Only one biobank follows the guidelines of the University of Cambridge to 
store brain tissue. In the opinion of Ingrid Brena, frameworks like NOM 
are not sufficient for the operation of biobanks. The 2011 reforms472 could 
definitely make a difference if they presented concrete procedures. 
 
The role of access to health care has a great impact on biobanking. 
Patients may not evaluate their participation objectively if they feel they 
have no choice but to participate in a trial, which can be through sample 
donation, or to obtain a medicine or a treatment they need. Participation 
in a research project might be the only choice for a patient to receive 
treatment, a situation aggravated by illiteracy. 8% of the Mexican 
population are illiterate and it has been calculated that 19% of patients of 
the General Hospital (Mexico City) reflect these statistics. The General 
Hospital provides health care for poor people who do not have a job 
(employed people are assisted by ISSSTE or IMSS) or people who cannot 
afford private medical treatment. Some people in Mexico are illiterate in 
Spanish since they speak other indigenous native languages.473 Poverty 
and illiteracy are important factors to consider when enrolling subjects for 
clinical trials, particularly in a developing country like Mexico.474 
 
                                                          
471 Legal-researcher-at-a-public-research-institution-Participant:F 
472 , Decreto por el que se adiciona la fracción IX Bis al artículo 3o.; se adiciona un 
Título Quinto Bis y su Capítulo Unico; y el artículo 421 Ter de la Ley General de 
Salud. (DECREE which adds section IX Bis to article 3, the title "V bis" and its unique 
chapter and article "421 Ter" of the General Health Law) 
473 Comisión Nacional de Bioética (The National Commission of Bioethics) 75 
474 Virk 22 
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5.5.1 Reforms 
The parliamentary reform, which encouraged these new 
committees, was enforced in December 2011.475 Some biobanking issues 
should hypothetically be solved by a bio-safety committee; the biosafety 
committee was responsible for the regulation of the use of ionic radiation 
or genetic engineering techniques. Since these committees are covered 
by the General Health Law, the committees’ remit can’t be extended to 
other areas involving biobanking, for example clinical trials by the 
pharmaceutical industry.  
“The national health care centres (public, social or private) will 
have the following committees;  
 A hospital bioethics committee for the solution of problems regarding 
medical attention (for the analysis, discussion and support of decision 
making of bioethical problems within clinical practice and health 
teaching). These committees will permanently promote institutional 
ethical guidance for members of staff.  
 If health centres perform research on humans, a committee of ethical 
research will be responsible for the evaluation of research protocols. It 
will provide ethical recommendations and institutional guidelines for 
health research. Recommendations will be reviewed.  
 
Hospital and research committees must follow the enforced 
legislation and the criteria established by the National Bioethics 
Commission. The committees will be multi-disciplinary, and these must 
be formed by medical staff with different areas of expertise: psychology, 
nursing, social work, sociology, anthropology, philosophy or legal 
professionals. Members of staff should have bioethics training. Each 
committee must have representatives from the population groups 
involved in research, covering a gender quota.”476 
 
                                                          
475 , Decreto que incluye el artículo 41 bis y reforma el artículo 98 de la Ley General 
de Salud (Decree which includes article 41 bis and amends article 98 of the General 
health law) 
476 LGS 
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This is evidence of the “patchy” methodology regarding health 
research. The amendments to the General Health Law from 2011477 led 
to a great number of research ‘commissions’ having their original registry 
invalidated. Research Commissions for Research, Ethics and Bio-
security before this are not valid since they were not established under 
the current legislation. Many Committees have formed with diverse titles 
according to their established function i.e. ethics committees, hospital 
bioethics committees, ethical clinics committees, bioethics sub-
committees and research ethics sub-committees.478  
 
Hospital committees must follow the parameters given by article 
41 bis of the General Health Law,479 while health research is covered by 
article 96 of the same regulation.480 Accordingly, health research involving 
humans requires the creation of a research committee, an ethics 
committee or a bio-safety committee, depending on the activities 
performed by the institution. The committees must be formed by a 
minimum of three scientists with broad experience in health research; no 
detailed description of the professional background of the members is 
provided. This applies only to health institutions.  
 
                       5.5.2 Involved key governing institutions   
According to Lipset, legitimisation is “the capacity of the system to 
engender and maintain the belief that the existing political institutions are 
the most appropriate ones for the society.”481 When legitimacy cannot be 
sustained, the only way to inspire a sense of reliance among citizens is 
suitable implementation of policies. Nevertheless, the current 
                                                          
477 Decreto por el que se reforman y adicionan diversas disposiciones de la Ley 
General de Salud (Decree amending various dispositions of the General Health Law) 
478 MJ Khoury and others, ‘Challenges in communicating genetics: a public health 
approach ’ (2000) 2 Genet Med 87 
479 LGS 
480 Ibid 
481 SM Lipset, Political man, the social basis of politics (New York: Doubleday ed, 
1960) 77 
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implementation of biobanks in Mexico has led to confusion regarding 
alternatives for biobanking practices, starting by directly involved 
institutions. Involved key governing institutions are as follows: 
 
5.5.2.1 The National Council for Science and 
Technology (CONACYT) 
 The National Council for Science and Technology (Consejo 
Nacional de Ciencia y Tecnología) (Conacyt) was created by Congress 
as a public and decentralised organism of the Public Federal 
Administration, responsible for the elaboration of science and technology 
policies in Mexico.  
 
5.5.2.2 The National Institute of Genomic 
Medicine (INMEGEN) 
 The emerging discipline of public health genetics in Mexico aimed 
to maximise the benefits of genomic medical advances.482 Based on this 
principle, General Health Law and the regulations concerning the national 
health institutes were modified in order to create INMEGEN in 2004. The 
creation of The National Institute of Genomic Medicine was based on the 
conception of genomic sovereignty in Mexico.483 INMEGEN, as the official 
centre for genomic medicine, is intended to interact with the Mexican 
Parliamentary Congress.  
 
However, the operation of INMEGEN in Mexico has been 
associated with politics to an excessive extent, a fact that has delayed the 
social legitimation on the institution, which will depend on rules reconciling 
the interests of the public and industry fairly. The pharmaceutical industry 
is involved and towards this, the protection of human dignity is an 
essential principle of political ideology. 
                                                          
482 Khoury and others 199 
483 E Schwartz and A Mendez, ‘The law of Genomic Sovereignty and the protection of 
“Mexican genetic patrimony”’ (2012) 2 Medicine and law 284 
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5.5.2.3 The Federal Commission for the 
Protection against Sanitary Risk (COFEPRIS) 
COFEPRIS was not specifically created for biobanking purposes; 
however, it is fundamental for the current operation of biobanks at legal 
and ethical levels. It is part of the National Ministry of Health, and is a 
decentralised organisation with technical, administrative and operational 
autonomy. Its purpose is to protect the population against sanitary risks 
through sanitary regulation, control, and promotion under a unified 
leadership, with a view to providing unity and homogeneity to the policies 
determined. The initial objective of the Commission was extended to a 
public policy, with the intention of preserving the population’s health more 
efficiently.  
 
5.5.2.4 The UNAM (National Autonomous 
University of Mexico) and other academic institutions 
Another significant governance area within the Mexican public 
sector are the academic research institutions. A representative example 
is the UNAM, which develops most of the academic research in the 
country. Most academic institutions have had no choice but to found 
research committees for general evaluation on procedural compliance 
regarding the management of biological samples. Diverse ethical 
guidelines, including international, integrated self-regulatory frameworks, 
followed in the absence of specific official ethical guidelines for research. 
 
UNAM ethics guidelines recommend “the reading of the Universal 
Declaration of the Human Genome and Human Rights UNESCO,484 
genetic data protection UNESCO485 and published documents by the 
committee of the Human Genome Project HUGO”486 with no analyses on 
                                                          
484 The Universal Declaration on the Human Genome and Human Rights 
485 UNESCO International Declaration on Human Genetic Data 
486 Human Genome Organisation, ‘HUGO’ (2016)  <http://www.hugo-
international.org/>  
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how these international guidelines could be applicable to the different 
operation of institutes related to biobanking activities.  
 
An example of principles followed by the Biomedical Research 
Institute at UNAM follows that: “research must be led by qualified 
researchers in the area, with the participation of clinical researchers 
familiarised with the pathological purpose of the study”487 and “all 
protocols must be previously evaluated by the committee specialising in 
research with humans, which involves the participation of biomedical 
staff, in order to carry out research involving humans.”488 The participation 
of researchers as members of the committee is recommended only if it is 
complemented with ethics expertise in biomedical research.  
 
An example of a sanction framework can be taken from one of the 
biobanks within the UNAM Institute of Biomedical Sciences, which has a 
Committee of Scientific Integrity, responsible for dealing with accusations 
of unethical activities regarding research. Presumably, this includes 
biological samples. The committee is responsible for initiating 
investigations on ethical misconduct and deciding what cases should 
proceed. If it does not proceed, the allegation has no effects. If it 
proceeds, the committee produces a report which is taken to a university 
council for a final resolution.  
 
5.5.2.5 The National Bioethics Commission 
(Comisión Nacional de Bioética CNB) 
The National Commission of Bioethics was established in 1992 by 
a group of academics in order to discuss issues related to Bioethics. It 
was created in order to establish public health policies in relation to 
bioethics. One of the main responsibilities of the commission is to 
encourage public and private medical institutions to use bioethics 
                                                          
487 UNAM 
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committees and the registration of such ethics committees,489  not for 
official monitoring purposes but for consultation and study 
purposes. Since 2005, it has been recognised by a presidential decree as 
a more independent body in operation, although its budget still comes 
from the Ministry of Health. The institution was intended to encourage a 
bioethical culture in Mexico, and its mandate is directed to activities in 
public policy, infrastructure and public awareness. It is the official body 
responsible for defining national policies on bioethics and consultation. 
Nevertheless, the Mexican Commission of Bioethics does not provide 
biobanking guidelines. (See Table 3 on annex p. 4)  
 
5.5.2.6 Ethics committees 
The first institutions entitled to deal with biobanking risks in Mexico 
are ethics committees; “the ethical review board bears the primary 
responsibility for setting up requirements for the coding and secure 
handling of information.”490 Hence attention to ethics committees is 
fundamental.  
 
As a result of current Mexican health regulations being primarily 
based on medical grounds, the 2011 reform focused on health 
institutions, rather than those for research. By the end of 2012, a year 
after the reform, committees were still in the process of regularisation and 
their role was seen as one of ethical advice, rather than oversight. Hence, 
biobanks are still far from being a priority subject of ethical attention from 
an independent research focus. (See supporting fieldwork statements on 
Table 4 annex p. 5) 
 
                                                          
489 Comisión Nacional de Bioética, ‘Comités Hospitalarios de Bioética (Bioethics 
Hospital Committees)’ (Comisión Nacional de Bioética (National Bioethics 
Commission), 2 August 2013)  <http://www.conbioetica-
mexico.salud.gob.mx/interior/registrocomites/chb.html> accessed 3 September 2013 
490 M Hansson, ‘Building on relationships of trust in biobank research ’ (2005) 31 J 
Med Ethics  417 
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For example, Participant L recognised it is now compulsory that 
health (not research) institutions must have ethics committees, which are 
generally multi-disciplinary.491 However it is not yet clear if this will apply 
to research institutions. Participant N said there was no certainty if this 
was the case with research committees.492 Participant C493 recognised 
that the recently enforced guidelines were only published for committees 
created and operating within hospitals. Only Participants H and M show 
more optimistic views on the committees. (See supporting fieldwork 
statements on Table 4 annex p. 5) 
 
One of the largest health institutions, IMSS, the health care and 
social security provider for 50 million Mexicans,494 was founded in 
1943.495 IMSS has a system of 335 Local Research Ethics Committees 
(LRECs),496 whose regulation is covered by the IMSS Medical Research 
Handbook.497 IMSS has a National Health Research Council (CIS) which 
is the governing body that coordinates all activities in the Institute related 
to research on health at the national level. CIS has 54 health research 
centres and units located strategically in different states across Mexico, 
namely: 13 epidemiology and health services research units, 16 clinical 
epidemiology research units, 20 clinical research units, and five 
biomedical research centres.498  
 
                                                          
491 Ethical-adviser-at-an-ethics-public-advisory-institution-Participant:L 
492 Bioethics-expert-at-a-public-legal-research-institution-Participant:N, PhD Thesis 
fieldwork (2012) 
493 Legal-researcher-at-a-public-research-institution-Participant:C 
494E Valdez-Martinez and others, ‘Descriptive ethics: A qualitative study of local 
research ethics committees in Mexico’ (2006) 6 Developing World Bioethics 96 
495 Garduño-Espinosa and others 333 
496 Valdez-Martinez and others 96 
497 Mexican Institute of Social Security IMSS, Manual de Investigación Médica en el 
IMSS (IMSS Medical Research Handbook) (IMSS Internal handbook, 1999) 
498 Mexican Institute of Social Security IMSS, ‘Coordinación de investigación en salud 
(National Council for Health Research)’ (IMSS)  
<http://www.imss.gob.mx/profesionales-salud/investigacion/etica> accessed 10 
October 2013 
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Other public health institutions have established their own ethics 
codes, such as the Institute of Security and Social Services for the State’s 
Workers (ISSSTE): ISSSTE’s ethics code for research in family medicine. 
ISSSTE is the health care institution for government workers in Mexico, 
and performs substantial biomedical research which involves biobanking 
at a national level. For example, it is leading several current national 
projects on Alzheimer and Parkinson diseases.499  
 
LRECs, according to the IMSS handbook, must be formed by at 
least three executive directors; the term for this position is 3 years and 
can be extended for a second period500. Apart from LRECs, the IMSS 
depends on the National Commission for Scientific Research to evaluate 
the ethics of scientific research proposals. The composition of IMSS 
committees is normally expected to be cross-cutting, that is, to include 
lawyers, ethicists and laypersons as active members. LRECs were 
designed to make the necessary changes for the benefit of science and 
participants’ protection in a balanced way. According to this regulation, 
the purpose of LRECs is to evaluate each research project performed 
within the IMSS, scrutinise research proposals (in terms of scientific 
validity and methodology), report irregularities (due every six months), 
and protect research subjects’ rights and welfare.  
 
Every research project must follow an established procedure, 
beginning with a project submission to the committee secretary’s office. 
The secretary’s office designates Executive Directors to the committee as 
internal scrutinisers for each project. The result of each individual 
evaluation is passed on to the rest of the committee before plenary 
meetings, which are led by a Chair Executive Director. Following the 
                                                          
499 S Casillas Mendoza, ‘Erogación de más recursos a investigación, entre los retos de 
la siguiente administración federal (More resources for research: amongst the 
challenges of the following federal administration)’ Cambio de Michoacán 
(Michoacán, 24 July 2012) 
<http://www.cambiodemichoacan.com.mx/vernota.php?id=178974>  
500 Garduño-Espinosa and others 333 
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plenary meeting, the secretary sends the main researcher an integral 
assessment, including outstanding issues within the research protocol. 
The main issues regarding public institutions will be analysed in chapter 
7 (7.3). 
 
5.5.3 Rules for private companies 
In Mexico, the pharmaceutical industry is not governed by specific 
rules. However, there are controls for the development of pharmaceutical 
research. These are authorised from the corresponding authorities (in this 
case COFEPRIS) and the informed consent of the research participants. 
The rest of the regulatory framework consists of self-regulatory powers to 
the pharmaceutical companies’ own committees. Research proposals are 
evaluated by the pharmaceutical industry committees which have been 
authorised by COFEPRIS. The principal investigator for the project is 
proposed by the company, and the company is also responsible for 
verification “that the research project complies with the requirements 
established by the General Health Law and applicable regulations.”501 
However compulsory ethical controls seem to be insufficient, and it is not 
clear who is responsible for many issues. 
 
In 2005, the National Chamber of the Pharmaceutical Industry 
(CANIFARMA) approved the creation of the Council of Ethics and 
Transparency for the Pharmaceutical Industry (CETIFARMA). The latter 
institution is intended to “strengthen the development of a socially 
responsible and transparent pharmaceutical industry.”502 CETIFARMA 
                                                          
501 Acuerdo que establece los lineamientos que deberán observarse en los 
establecimientos públicos que presten servicios de atención médica para regular su 
relación con los fabricantes y distribuidores de medicamentos y otros insumos para la 
salud, derivada de la promoción de productos o la realización de actividades 
académicas, de investigación o científicas. (Agreement which establishes the 
guidelines for public health establishments to regulate relationships with 
pharmaceutical distributors and makers, derived from product promotion, academic or 
research activities)   
502 CETIFARMA, ‘Consejo de ética y transparencia de la industria farmacéutica 
(CETIFARMA)’ (CETIFARMA, 2013)  <http://www.cetifarma.org.mx/> accessed 12 
May 2013   
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has two ethics codes: the Code of Ethics and Transparency of the 
Pharmaceutical Industry,503 which provides the ethical framework for the 
members of CETIFARMA, and the Code of Good Practice for the 
Promotion of the Pharmaceutical Industry,504 which aims to promote the 
compliance with ethical conduct in research activities, development, 
production, promotion and distribution of medicines. Section 4.9505 
provides the ethical criteria which members must follow within clinical 
research, however, the adherence to these instruments is voluntary.   
 
CETIFARMA codes are non-binding self-regulatory instruments, 
whose sanctions may be warnings, membership withdrawal and fines. 
Only some serious cases will be reported before the sanitary authorities. 
Self-regulatory agreements are common instruments signed between the 
national representative of the pharmaceutical industry in Mexico: 
CETIFARMA and COFEPRIS. For instance, both parties have signed an 
“agreement on the actions to be followed regarding self-regulation on 
health production inputs and advertising ethics.”506 These ethics topics 
tend to be agreed for regulatory purposes. 
 
According to the CNB, one of the greatest concerns with 
pharmaceutical clinical trials is sponsorship, since “unacceptable 
misconduct has already occurred.”507 This could be related to the fact that 
it is optional for pharmaceutical companies to establish their own rules in 
sponsorship. Frequently, public projects have limited funding to develop 
their own research. Hence, there should be supervision to ensure that no 
pressure is involved when public institutions accept external collaboration 
                                                          
503 National Chamber of the Pharmaceutical Industry (Cámara Nacional de la Industria 
Farmacéutica) CANIFARMA, Códigos de la industria farmacéutica establecida en 
México (Codes of the Pharmaceutical Industry Established in Mexico) (Consejo de 
Ética y Transparencia de la Industria Farmacéutica 2009) 
504 Ibid 
505 Ibid 
506 CETIFARMA, ‘XXV Sesión Grupo Compliance CANIFARMA ’ (XXV Sesión 
Grupo Compliance, Mexico City, July 23 2012) 
507 Comisión Nacional de Bioética (The National Commission of Bioethics) 75 
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because it is the only way to develop research. In relation to funding 
research trials, it has been established that public institutions, which 
develop research projects, must follow applicable regulation which has 
not yet been determined. The fact that health institutes sign agreements 
on research collaborations with industry (including international industry) 
is ethically risky but partly justifiable.  
 
5.5.3.1 Private institutions 
A great issue, which may not be obvious within biobanking, is the 
ethical practice of pharmaceutical industry activities in Mexico. The OECD 
has recognised that “regulations still hold back the interaction between 
scientific researchers and business.508” Biobanks are established for 
research purposes mostly in connection with clinical drug trials. 
Pharmacogenomics,509 nowadays a common pharmaceutical activity, 
consists of studying how genetic factors influence different responses to 
drugs. There can be a great range of responses which depend on 
elements, such as the toxicity level of the drug, human metabolism, age, 
alcohol intake, interaction with other drugs, smoking, infections and other 
factors.  
 
The public sector of research involving biobanking presents 
various risks, which could be significantly increased within the private 
sector where economic interests become involved. The ability to 
sequence the whole of the human genome facilitated the study of new 
genetic factors determining the response to drugs, which can be 
disclosed through biological samples. Hence, a great number of the 
responses of the human body to a new drug can be investigated through 
biological samples, including those with genetic and non-genetic content. 
                                                          
508 OECD, Getting it Right OECD Perspectives on Policy Challenges in Mexico 
(OECD, 2007) 
509 AK Dubey and others, ‘Understanding the Essentials of Pharmacogenomics- The 
Potential Implications for the Future Pharmacotherapy’ (2008) 2 Journal of Clinical 
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Generally those with genetic content are the main objects of ethical 
interest, due to the sensitive information which may be potentially 
disclosed. 
 
5.5.4 Federal Sanctions 
The rationale for Federal sanctions is in Article 101 of the General 
Health Law, which provides the basis to sanction: “those who perform 
research involving humans against this law and applicable regulations will 
be subject to the corresponding sanctions.” One would expect to find the 
definition of applicable rules in the General Health Law and its procedural 
rules on health research. However, this is not the case. Article 130 of the 
General Health Law’s procedural rules is repetitive in terms of the primary 
regulation of the General Health Law and this makes the sanction rules 
more complicated. 
  
“The corresponding sanctions will be for those who perform 
research involving humans and use pathological microorganisms (or the 
biological material in which such microorganisms are present), 
construction and management of recombinant nucleic acids.”510 Sic 
 
Article 130 then confusingly continues with a list of nuclear material 
commonly used in hospitals which can be hazardous, and pointing out 
that misuse will be subject to sanctions. The article does not mention the 
corresponding sanctions other than those related to misuse of radioactive 
material. No references relevant to biobanking are explicitly stated. It can 
be assumed that the corresponding sanctions would be imposed by the 
national health authority COFEPRIS. This commission is an 
administratively independent institute, which belongs to the National 
Ministry of Health. As an authority, it is currently responsible for 
administrative sanctions in the case of “non-compliance with legal 
dispositions, rules and additional applicable regulations” and for 
                                                          
510 LGS 
183 
 
“determining safety, preventive and corrective measures for which it is 
competent.”511 Different assumptions could be made on biobanking, and 
it’s not clear what type of committee will have the competence to decide 
on sanctions in these cases. Hypothetically, if a collection of samples 
involved genetic information, a bio-safety committee should be 
responsible for deciding on cases in which rules allegedly have been 
breached, something nearly impossible to prove because of the absence 
of specific rules. Even if the allegation on unethical biobanking was 
considered, it is not clear what sanctions would be applied and by whom.     
 
There are no clear sanction frameworks which go beyond general 
sanctions. It would be extremely complicated to prove misuse of biological 
samples under the statement, “the commercialisation of organs and 
tissues is a legal offence.”512 This general statement was initially enacted 
for transplantation purposes; it is too broad to include the 
commercialisation of tissue samples for research purposes. It is not 
known how violations of human dignity are constituted, and it would be 
necessary to emphasise the topic, i.e. specific biological donations, and 
the area of law responsible for the establishment of the so called 
“corresponding sanctions.” Participant I does not believe that the current 
articles on the human genome are applicable to biological samples, as 
these have a particular genetic focus.513 Other questions on the 
effectiveness of the Mexican health law provisions could emerge, for 
example, nothing has been said regarding the practicalities of 
accessibility. So far, the proposals, modifying the General Health Law, 
have been implemented in regard to accessibility and knowledge of an 
individual’s genome. The regulation for this right was included in 2011. 
However, legal mechanisms, such as those for an individual to exercise 
                                                          
511 Reglamento de la Comisión Federal para la Protección contra Riesgos Sanitarios 
COFEPRIS (Rules of the Federal Commission for the Protection against Sanitary Risk 
rules) 
512 LGS Article 327 
513 Responsible-of-the-Genetics-department-at-a-public-ethical-advisory-institution-
Participant:I 
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the right to know or not to know, have not been established, for example, 
participants should be able to decide if they do not want to know about a 
predisposition to an illness, or when they do not want to know the results 
of a genetic test, so they can request that that information is withheld. 
 
Initial regulation on general issues is normally the basis for later, 
specific regulation. Therefore, the human genome regulation should have 
been derived from a more general regulation, i.e. biobanks.  
 
5.6 Summary on identified problems in the current Mexican 
regulation of databases and/or biobanks 
 Identification of the problem (what the main problem is) 
 The main problem can be seen under two important perspectives: 
lack of specific regulation and partial regulation. 
 
o  Lack of specific regulation 
Biobanks, as a legal subject, are not regulated in Mexico. Analysis 
of the current legislation has revealed that this is a problem for 
stakeholders that work in the major fields of tissue samples514 or data 
protection or both.515 
 
The main instrument in which biobanks are currently believed to 
depend on is the General Health Law.516 It was created in 1984, intending 
to cover the emerging aspects of health research at that time. The major 
fields of tissue and associated data, are weakly covered by the following 
derived rules: The Regulation on Sanitary Disposal of Human Organs, 
Tissues and Cadavers (1985),517 the Regulation on Scientific Health 
                                                          
514 See page 151 
515 See page 161 
516 LGS 
517  'Federal Regulations for the Control of Organs, Tissues and Cadavers of Human 
Beings' (’Reglamento Federal para la Disposición de Órganos, Tejidos y Cadáveres de 
Seres Humanos') 
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Research (1987),518 the regulations put forth by the National Institutes of 
Health Law (2000) and the Regulation on Scientific Health Research 
(Reglamento de la Ley general de Salud en materia de Investigación para 
la Salud) (1986). 
 
o Partial regulation  
The problem is that the available rules are not only unclear, but 
incomplete and enforcement instruments are absent. Insufficient 
regulation has led to the opening of legal interpretation, making it difficult 
for stake holders to resolve the constant problems in the operation of 
biobanking. This creates a situation in which it is impossible to determine 
the legality of an activity.  
 
 The regulation of genetic information: a relevant example 
The regulatory situation on genetic information, an essential aspect of 
biobanking, clearly illustrates how difficult it can be to find legal guidance 
on the subject. None of the above mentioned derived rules cover genetic 
data specifically. Interestingly, some aspects of genetic information are 
specifically regulated by the Federal Law on Protection of Personal Data 
Held by Individuals (2010).519 This is unexpected, as the main legal body 
on which biobanks currently depend, as mentioned above, is the General 
Health Law. Hence, genetic information is partially covered by a law 
intended to regulate transparency on private data and was not designed 
to cover health research.  
 
o So, does the problem relate to biobank or databases 
or both? 
Both areas are seriously affected. The regulation of genetic data is 
incomplete. Data protection within scientific research has not been 
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General de Salud en Investigación Científica)  
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considered and most important aspects are not covered as a result. For 
example, the terms "health data" or "genetic data" have not been 
differentiated from other types of data.  
 
Current laws on personal data have not explicitly set forth what 
types of samples (blood, saliva, tissue) contain health data, even when 
“in biobank research it is not the tangible features of biological samples 
that are at issue but informational content.”520 Mexican data protection 
laws refer to personal data processing in general, failing to specify 
biological samples used in research.  
 
The regulation of associated samples should belong to the General 
Health Law, which covers some aspects but not the essential ones. The 
General Health Law covers some types of human tissue, (blood, blood 
components, hematopoietic stem cells and derivates) but only for 
population studies.521 Other types of research are not mentioned. Health 
regulations have not determined whether it is lawful to obtain samples 
from children. The Law on Health Research establishes that:  “When the 
minor’s mental capacity and psychological state allow it, acceptance must 
be obtained to become a research subject, after explaining to him what is 
intended.”522 This will be open to interpretation as the statement is 
ambiguous.  
 
Nothing has been enacted regarding binding research controls on 
biobanks e.g. authorising bodies or mechanisms for authorisation 
requests. The law also fails to specify data protection operations, 
inspection, data access, rectification or sanction mechanisms. Presently, 
health research authorisation is under the Mexican health authority 
                                                          
520 European Commission 38  
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(The Ministry of Health Rules of the General Health Law on Health Research) Chapter 
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COFEPRIS, specifically created for dealing with sanitary risks. 
Committees, being covered by the General Health Law, lack competence 
for dealing with clinical trials by the pharmaceutical industry which is 
currently self-regulated.  
 
o What is the effect of the problem for biobanking or 
research use of health databases? 
Current rules were enforced on accessibility and knowledge of an 
individual’s genome, without legal mechanisms, to exercise individual 
rights such as the right to know or not to know. Anonymisation, for 
example, is a non-regulated activity that would prevent participants from 
exercising their ‘right to know.’523 Secondary uses of data, identification 
mechanisms, e.g. anonymity and coding, re-contacting participants, 
participants’ withdrawal, the return of results to participants, accessibility 
and implications are important aspects on tissue and associated data, 
which remain completely open to interpretation. 
 
There are significant risks within biobanking for research subjects. 
These require specific standards which cannot depend on variable 
interpretation e.g. conservation periods and secondary uses of samples. 
Sanctions are non-existent. These are sensitive due to the genetic data 
contained and need different protection.   
 
Sensitive data, understood as that which can reveal racial and ethnic 
origins, should be protected within research areas, since both public and 
private research use it. Stronger protection mechanisms relying on 
general ethics committees with limited legal power are required.524  
 
These matters are important for the individual as well. For example, a 
person could be discriminated against, regarding work, if their ethnic 
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group was found to have certain health traits. It could also increase their 
health insurance costs, or remove the option of obtaining health insurance 
altogether. If a person does not have a right to know or not to know about 
their genetic data, they may be informed of an impending chronic illness 
in the future and that knowledge could cause that person’s mental health 
to decline. 
 
 Situation of the problem within the legal system: at what 
level in the Mexican structure does the problem occur? 
Due to the structure of the Mexican legal system, the absence of 
biobanking regulation occurs at both federal and local levels. This is 
because the regulation of a topic at the federal level impacts on the state 
level, which has an implicit obligation to regulate on the topic accordingly. 
The states can follow federal regulations while local legislatures work on 
specific state rules. For this reason, the role of federal regulations is 
substantial. Hence it is not acceptable that current primary (federal) 
regulations show failures such as regulated principles with absent 
procedures. These constitute the rationale for the states to legislate.  
 
Currently, the only rationale for any federal sanctions derived from 
biobanking is article 101 in the General Health Law, which very broadly 
states that research involving humans against the law will be sanctioned. 
If primary rules are not specific, sanctions cannot be specific either. Their 
application can remain open, once again, to interpretation. Some specific 
sanctions have been stated for the use of pathological microorganisms.525 
However, no context has been described and no enforcing mechanisms 
for such sanctions have been mentioned. If this happens at the federal 
level, no more can be expected at the state level. 
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Presently, even federal guidance is not sufficient as a basis to regulate 
biobanks. For example, it is currently compulsory that health institutions 
must have ethics committees. However it is not yet clear if this will apply 
to research institutions. This results in confusion for states attempting to 
regulate according to the federal law. 
 
5.7 Concluding remarks 
This chapter, based on both desk based and field research, 
comprised the analysis of relevant ethical guidelines. These were 
contrasted with practical issues in biobanking. Planned interviews with 
members of relevant institutions complemented the current research and 
identified areas that need urgent legal improvement. 
 
The governance of biobanking has not entirely been solved in 
Mexico. The additions planned in the 2001 initial proposals526 reflected 
the constitutional principle but with no further guidance. Nothing has been 
enacted on research controls, e.g. authorising bodies or mechanisms for 
authorisation requests. The issue on the “prohibition of discrimination” 
included in the Mexican constitution was raised in 2001. Not even the 
2011 reforms on the human genome have resolved elemental concerns. 
Practice shows with such a great range of situations, that only well 
motivated legislation will cover it, for example, the main drive for the legal 
work is currently focused on national development and economic goals. 
Tissue rules are relevant for the regulation of biobanks, however, the 
current coverage in Mexico is not based around human tissue for 
research and hence is not sufficient. 
 
Most of the rules for research involving humans are not fit for 
purpose. New rules have been included through amendments rather than 
new regulations, such as Acts. This has resulted in an extremely 
complicated patchy framework, where the rules applicable to a particular 
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area are not covered by a single body, but by different regulations that do 
not distinguish between principles and the ways to achieve them, a 
differentiation that would normally be expected within the Mexican legal 
system.  This is the case with biobanks, they are not specifically 
regulated.  It is very difficult to say whether biobanking legal guidance is 
available. Determining the availability of biobanking guidance currently 
depends on variable interpretation criteria. The “Overview of the 
Legislation on the Human Genome in Latin America and the 
Caribbean”,527 which focused on the human genome, concluded that 
“after analysing the current Mexican laws (constitutional, health and 
criminal law) which could be applicable to the human genome, we 
conclude that Mexican rules have been surpassed by science. 
Deficiencies are huge and the absence of specialised laws is creating 
confusion.”528  
 
A great number of potential risks could breach the founding 
principles of research bioethics in areas which are not obvious and go 
beyond physical damage; the implications of biobanking belong to this 
category. There are significant risks within biobanking for research 
subjects. These require specific standards which cannot depend on 
variable interpretation e.g. conservation periods and secondary uses of 
samples. It is not defined how long samples can be preserved and what 
secondary uses are allowed. Sanctions are perceived in Mexico by 
biobanking stakeholders as non-existent: “To the best of my knowledge 
there are no sanctions.”529 Sanctions are not defined. This has to be 
developed in accordance with other legal codes. It needs to be defined 
                                                          
527 Alya Saada and Diego Valadés (ed), Panorama sobre la legislación en materia de 
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genome in Latin America and the Caribbean) (National Autonomous University of  
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whether this will consist of a fine or will be included in the penal code; 
sanctions are necessary too.530 
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III. IMPLEMENTING CHANGE 
 
6. European examples: What can be gained from the European 
experience? 
 
6.1 Introduction 
This chapter highlights the importance of international experiences 
as a source of help in the design of effective legal biobanking guidelines 
in Mexico. More specifically, it analyses the legal situation of Mexico in 
the light of the European experience. This analysis also aims to identify 
the weaknesses that could affect future legislation. Recently, a number of 
European countries have developed a comprehensive framework for 
addressing biobank expansion within ever-growing scientific and 
biomedical research communities. The analysis will be achieved by 
reviewing the flaws of current biobanking regulations in Mexico, 
comparing them with experiences from Europe, which was in a similar 
position approximately twenty years ago.  
 
6.1.1 The BTCure project 
From September 2011, I started an academic collaboration with 
the project BTCure, an extensive European consortium which 
investigates new therapies for the treatment of Rheumathoid arthritis. 
One of the main challenges of this academic-industry funded consortium 
has been the exchange of data and samples across Europe. Participating 
institutions, whose samples are intended for sharing as part of the 
project’s scientific activities, manage tissue banks under the different 
legislations of each country involved. My participation in ‘work package 
five’ consisted of the development of guidelines for Rheumatology 
biobanks in Europe. 
 
Under the BTCure project, the legal frameworks of the 27 member 
countries of the European Union (2012) and Switzerland were analysed 
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in depth evaluating the state of each country regarding legal rules on 
tissue banks. Different aspects, such as informed consent, data 
protection, data protection mechanisms and data sharing were evaluated. 
The data obtained, under previous authorisation by Dr. Frederique 
Ponchel (responsible for the BTCure work package), was used for the 
development of this chapter. 
 
The first section of this chapter justifies the analysis of relevant 
pieces of European legislation, explaining how they would help resolving 
specific issues within the Mexican context. Mexican biobanking 
provisions, which fail to satisfy consistency requirements, will be 
compared with several European countries’ frameworks in order to 
identify which may be best suited for Mexico. National frameworks vary 
widely from country to country. This chapter argues that several European 
provisions regarding data protection and sharing, such as Directive 
45/46/EC,531 can serve as guidelines for international research 
collaboration currently taking place between Mexico and Europe. 
 
The second section of this chapter will pay special attention to 
specific issues, including legal competence and subjects of regulation, 
informed consent models, exclusions and exceptions, consent from 
minors, the legal effects of tissue biobanking in practice, such as the 
regulation of post-mortem tissue and the regulation of data protection, 
including sensitive data, data protection mechanisms and data sharing. 
Oversight will also be emphasised, which is a major concern to strengthen 
regulatory bodies and procedures. 
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6.1.2 Background on international cooperation 
There are reasons and incentives encouraging governments to 
keep up to date with international harmonisation. Robin Bunton532 has 
pointed out, in respect to the related issue of ‘genetic governance’, that 
regulation is not merely a local and national issue, but also a transnational 
issue. International cooperation consists of the transfer of resources, 
knowledge and experiences among governments, public entities and the 
private sector. These bodies aim to achieve of common objectives in 
order to share common benefits, i.e. economic development and social 
welfare. Global and political dynamics are constantly creating pressure on 
harmonisation schemes.533  In some cases, this is the result of international 
organisations’ decisions at various levels (regional, governmental or non-
governmental). Ethical norms from international codes are widely 
accepted; an operative programme on health research has stated that 
“there is no research activity which does not find an answer in 
international documents.”534 
 
The European Council Recommendation on Human Biobanks and 
Genetic Research Databases  (2009) highlights “the importance of 
issues, such as access.”535 Various international guidelines have 
provided further parameters for the management of biobanks. These 
guidelines have different binding levels. The International Covenant on 
Economic, Social and Cultural Rights has been fostered in terms of 
economic cooperation and scientific research, based on the principle of 
reciprocal benefit. The first paragraph of article 24 of the Universal 
Declaration on the Human Genome and Human Rights points out that 
countries mostly promote information sharing and the free circulation of 
scientific and technological knowledge.536  
                                                          
532 Bunton and Peterson 190 
533 J Maschke and TH Murray, ‘Ethical Issues in Tissue Banking for Research: The 
Prospects and Pitfalls of Setting International’ (2004) 25 Theor Med Bioeth 144 
534 (The-Mexican-Ministry-of-Health) 
535 Council Recommendation on Human Biobanks and Genetic Research Databases  
536 The Universal Declaration on the Human Genome and Human Rights 
195 
 
Other European directives have also been encouraged, providing 
ethical guidance at a regional level. Despite the existence of basic 
principles in a general European framework, each Member State is 
responsible for implementing specific laws on the ethics of biological 
material for research. The European law is intended to be respectful of 
the national laws of Member States and “such an approach also allows 
Member States to adopt more stringent measures, which reflect differing 
national socio-cultural, economic and political priorities.”537 The European 
directive 2001/20/EC on good clinical practice in the conduct of clinical 
trials,538 and the directive 2005/28/EC on human tissue and cells,539 are 
relevant examples. The former directive on good clinical practice in the 
conduct of clinical trials has stated that clinical trials on medicinal products 
for human use must be based on an "informed and free decision." The 
directive also provides guidance on the protection of minors and 
individuals who are incapable of giving their informed consent. The 
European directive 2005/28/EC on human tissue and cells, has 
established basic principles regarding the donation of cells and tissues, 
which must be free and based on minimum information provided to 
donors.540  
 
Internationally, biobankers are developing voluntary standards to 
address concerns about inconsistencies in the collection, storage and 
retrieval, and distribution policies of biobanks.541 Currently, in terms of 
                                                          
6 J Hunt and CJ Wallace, ‘Governing the body: Examining EU regulatory 
developments in Relation to substances of human origin ’ (2005) 27 Journal of social 
welfare and family law 434 
538 Directive 2001/20/EC of the European Parliament and of the Council on the 
approximation of the laws, regulations and administrative provisions of the Member 
States relating to the implementation of good clinical practice in the conduct of clinical 
trials on medicinal products for human use 
539 Directive 2005/28/EC laying down principles and detailed guidelines for good 
clinical practice as regards investigational medicinal products for human use, as well as 
the requirements for authorisation of the manufacturing or importation of such products 
540 Ibid 
541G Laurie and T Caulfield, Biobanks Information Paper ( National Health and Medical 
Research Council, 2010) 12 
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science and technology, it is not sustainable for developed countries to 
develop knowledge, skills and products, and then to make this available 
to poorer countries. This is why so many developing countries, especially 
the emerging economies, are focusing more on local innovation, invention 
and commercialisation, to break the cycle of dependency.542 
 
International studies present advantages if implementation is 
developed to take into account the unique characteristics of each country. 
Past mistakes should assist future improvement. Most interviewed 
participants agree that the impact of implementing frameworks, based on 
the international experience, would be positive if adequately done. (See 
Table 6 in annex p. 7) At the European level, the provision of common 
explanatory biobanking guidelines, in addition to general directives, would 
be essential. In principle, there are quite a few features that are shared 
by the regulatory instruments enacted so far. These could therefore 
represent a starting point of common and coherent principles for 
biobanks.543   
 
National coordination of Mexican biobanking is more complex from 
the international perspective. As reviewed in chapter 4, in Mexico, 
international declarations are not strictly compulsory. Nevertheless, there 
are challenges to be overcome. In this case, a significant problem is the 
inconsistency of Mexican institutions’ interpretation. 
 
6.2 Why Europe? 
The European experience has been chosen for examination for 
several reasons. It resembles the Mexican experience in the sense that, 
similarly to Mexico, the European Union has general instruments which 
can be applicable to biobanks. The current challenges at the European 
Union level are centred on the recognition of international diversity to be 
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discussed across national hubs, “in order to develop good solutions, avoid 
duplication of effort, and facilitate international collaborations.”544 The 
case of Europe was chosen due to the diversity of biobanking legislations, 
which are currently the object of joint efforts to reach standards to facilitate 
international collaborations involving biobanking. Mexico can learn many 
lessons, including those involving the implementation of laws, procedures 
and stakeholders’ consensus to ethically maximise the potential of 
samples.  
 
6.2.1 Guidelines based on human rights  
Several European countries have effectively implemented 
international guidelines into their national laws. Some of them evolved 
from situations similar to the current Mexican biobanking framework or 
followed similar routes resulting from more general perspectives, e.g. 
human rights. The regulation of human rights in Europe is related to the 
emergence of biobanking regulations. Salter and Jones maintain that “the 
rights-based discourse of biobanks is part of a predominantly international 
bioethical debate of policy statements, interest and legitimation, which 
impact to produce common agendas at the national levels.”545 This can 
help as a reference that improving human rights in Mexico can have a 
favourable impact on better ways to regulate biobanks in Mexico. This 
has been the case with data protection rules; “when drafting the Directive, 
the European Union legislators clearly envisaged a rather more robust 
human rights based system of personal data protection.”546  
 
The Council of Europe Convention for the Protection of Human 
Rights and Dignity of the Human Being with regard to the Application of 
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Biology and Medicine547 is the basis for safeguarding the rights of human 
subjects in relation to scientific progress within Europe. This convention 
stipulates general principles that are supplemented by additional 
protocols. In the run up to the adoption of the 1998 Data Protection Act, 
the Data Protection Registrar praised the Government White Paper for 
recognising in its proposals the concept that individuals were entitled to a 
right of privacy with respect to personal data deriving from the right of 
respect for their private life contained in Article 8 of the European 
Convention on Human Rights. 
 
6.2.2 The European Union background on biobanks 
The use of biological samples in research has been addressed by 
some European countries as part of their healthcare national agendas, 
such as research for healthcare and diagnosis. This fact presupposes 
adequate health systems and conditions. However, every country 
prioritises health needs differently. “It is necessary to recognise that the 
developing world presents greater challenges from those of the 
developed world in terms of substance and structure.”548  
 
The evolution of biobanking regulations in Europe has been largely 
spurred by the expansion of research activity and the priority given to 
biobank regulation. Emerging economies, following a delayed but similar 
expansion in research, are just now confronting the often precarious 
balance between their home-grown legal framework and related legal and 
ethical issues.  
 
European consensus was required for effective proposals, initially 
at the local level. Inconsistent policies may result in unfair treatment and 
contribute to risks of regulatory capture, in other words, the unfair 
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preferential treatment of a public institution towards particular groups of 
interest.  
 
Both Mexico and the European Union are still in the process of 
adopting a fit-for-purpose legislation for biobanking research. On the 
other hand, the European Union can be a specific illustrative example for 
Mexico, and in particular, the situation of each member state. The 
effectiveness of biobanking in some countries has proven to be 
dependent on the urgency to regulate practical situations effectively. Not 
all European countries have responded with similar solutions, or at the 
same pace. For example, in contrast to from the rest of Europe, “it can be 
stated without exaggeration that the legal framework in France has been 
continuously evolving ever since legislators became aware of the 
importance of biobanks.”549 The European Commission550 recognises the 
variety of regulations resulting from biobanking activities in Europe. Two 
main positions are explained: “either specific legislative acts are adopted 
focusing on biobanks’ activities (Iceland551, Estonia552, Hungary553, 
Sweden554, Spain555 and Belgium),556 or provisions about biobanks or bio-
collections are integrated into broader administrative and legislative 
instruments (France557 and the United Kingdom).”558 
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6.2.3 Pioneering biobanking legislation in Europe 
Europe is a world leader in the development of biobanking 
infrastructure to support research, it makes huge investments each year 
to support such initiatives,559 and in individual aspects of health by specific 
regulation on topics like confidentiality of genetic data.560 Europe involves 
great commonalities in the nature of challenges that it is facing 
internationally.561 This resembles the Mexican overview in various topics. 
However, as Favale and Plomer have stated, “these issues are often not 
straight forward to address. Even when the same moral principles tend to 
be the ethical basis of biobanking guidelines universally, such principles 
are differently interpreted, enforced and implemented in each country.”562 
 
Several European countries, such as Spain, are pioneers of 
specific legislation for human biological samples. Additionally, some 
countries follow similar legal systems to that of Mexico (Civil Law), 
including Spain and France. In many cases, however, the rules on the 
use of biological samples for research purposes have to be pieced 
together taking into account a number of different regulatory 
instruments.”563 The Mexican biobanking framework did not emerge 
uniformly but in fragments, a situation comparable with that of France, 
where the regulation of biobanks does not fall under the purview of a 
specific law but rather is scattered in several pieces of legislation.564 The 
number of specific authorisations required from the Ministry of Research 
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of various biobank activities, including exporting and importing samples, 
proved generally disadvantageous. The French legislator recently 
provided biobanks with a relatively interconnected legal framework,565 
which manages to regulate the administrative status of a biobank from the 
moment that it is created until the moment that it stops functioning.566 
“Although Europe and Latin America appear to be similar with regard to 
normative elements, the level of involvement of competent authorities in 
ethics reviews and the enforcement of regulations differs among 
countries.”567 
 
6.2.3.1 The role of population biobanks in 
European regulation 
Several European countries, similar to Mexico, encouraged 
legislation based on population biobanks. The Mexican biobanking 
framework emerged from a source similar to that described in Europe. 
The first biobanking related rules were an attempt to establish a legislative 
framework for the emerging population studies by the HapMap Project, a 
comparable situation with Estonia’s first attempts “to establish a 
legislative framework and codify law in the genetic era.”568 In the case of 
Estonia, legislation has been motivated by the sudden creation of large 
biobanks, which promptly motivated rules fit-for-purpose on this matter. 
With the aim of establishing the necessary institutional and organisational 
framework for the Estonian Genome Foundation, the Estonian 
government adopted the Human Genes Research Act569 in December 
2000 which came into force at the beginning of 2001. The Estonian 
Human Genes Research Act “is an example of those frameworks created 
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for practical reasons, and it has already served as a model for other 
countries intending to launch their own genome projects.”570   
 
Mexican regulation of the human genome presents essential and 
structural issues. The HapMap project was a practical reason for the 
creation of a framework, which was also inspired by political reasons. The 
enforcement of the initial human genome law project was delayed almost 
fourteen years due to political arguments. In the words of a legal ethics 
expert who worked on the project, General Health Law articles “did not 
make any difference in the regulation of practical areas.” 571 The 2011 
reforms572 “were the result of copying and pasting parts of the Universal 
Human Genome Declaration.”573 The law makers felt pressure to avoid 
‘falling behind’ in comparison with other countries implementing the 
declaration.  
 
6.3 Specific regulation subjects 
6.3.1 Informed consent models and their implications 
Based on current research ethics within the European framework, 
each Member State has adopted consent models based on its own 
specific needs.  How this is achieved varies from country to country. 
Currently, no common standard has been established for informed 
consent at the regional level. The diverse standards applied by each 
nation are subject to debate. A clear example of such variation consists 
of the different procedures following the adopted informed consent model 
in each country.   
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Based on the current basic research ethics principles provided by 
the European framework, all European countries have rules on informed 
consent. The European consent criteria vary significantly and some 
national rules are more open than others. “Some biobanks require 
approval of their protocol and their informed consent documents from the 
research ethics committees. Nevertheless, once the research is 
underway, the committees, in most cases, do not carry out any 
supervision of the biobank or the research.”574 This is not the case in 
countries such as Lithuania, where a double scrutiny of biomedical 
research is necessary. First, as biobanking typically involves biomedical 
research, approval has to be received from the Lithuanian Bioethics 
Committee or the Regional Biomedical Research Ethics Committee, as 
laid down in Article 12 of the Law on Ethics of Biomedical Research. 
Secondly, according to Article 10 of the Data Protection Law for collecting 
and storing medical data, it is necessary to obtain a notification from the 
State Data Protection Inspectorate. As to the former procedure, Article 15 
lays down further rules on the receipt and examination of applications.575  
 
The sponsor or the principal investigator of the biomedical 
research has to submit an application to the Lithuanian Bioethics 
Committee or the Regional Biomedical Research Ethics Committee. The 
documents must be examined and a reasoned approval or a refusal must 
be issued within 45 calendar days from the registration of the application, 
and after payment of all the fees for biomedical research expert 
examination. According to Article 16 the Lithuanian Bioethics Committee 
and the Regional Biomedical Research Ethics Committee not only issue 
approvals, but also have the right to invalidate them in cases where there 
is evidence of non-compliance with the requirements of ethics of 
biomedical research. In such cases the sponsor, the principal investigator 
of biomedical research and the heads of health care institutions where the 
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biomedical research is being conducted must ensure that biomedical 
research is immediately terminated. An appeal is possible. 
 
According to German law, a patient–doctor relationship only exists 
between a biobank and a sample donor if the sample was taken in order 
to treat or diagnose a disease. Outside of a therapeutic or diagnostic 
context, that is, if the sample was taken purely for research purposes, 
only the process of physical extraction of the sample itself represents an 
intervention that falls under medical professional regulations. General 
consent is established as the rule for further use of uncoded non-genetic 
health related personal data. However, if the requirements for consent 
and information cannot be met, biological material or health related 
personal data may exceptionally be used for further research, inter alia, if 
it is impossible or extremely difficult to obtain consent.576 
 
The aspiration to offer a distinctive answer and to resolve Mexican 
normative questions thus poses a number of challenges: Informed 
consent is one of them. In Mexico, it is not clear whether the consent 
obtained initially covers only the research project which motivated the 
sample donation, or whether it can be extended to further research 
projects. The rules governing this topic are not condensed into a single 
section but are distributed amongst various sections which do not make 
reference to the others. There is no interconnection. Three main consent 
issues, where no single law covers the wide scope of consent related to 
biobanking, can be identified as follows: 
 
1. The general aspects of Mexican consent are vague on which 
aspects could be improved through defining appropriate rules for 
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the diverse issues associated with informed consent for example, 
genetic material cannot be used for aims different to those which 
motivated their acquisition.577 However, this article only applies to 
genetic material, which is not expressly defined by the law. Genetic 
material is understood as any source of DNA.578 It can be inferred 
that the informed consent for non-genetic material can be used for 
any type of research, even if this was not initially consented to.  
 
2. The Federal Commission for the Protection against Sanitary Risk 
(COFEPRIS) needs to review and scrutinise the informed consent, 
but no scrutiny parameters have been provided. The section 
mentioning that “the health institution will do this” is ambiguous.579 
The ambiguity caused by too wide interpretation margins could 
deprive research subjects of autonomy rights over the sample 
donated. These rights go beyond basic physical safety rules and 
discrimination risk by insurance companies. Of particular 
relevance are concerns related to the potential use of data by third-
party researchers who access the data, including concern that the 
data might be put to inappropriate uses, for example, that attempts 
might be made to identify individuals or that data might be used for 
research incompatible with the scope of the original consent. 
 
3. Even when the creation of the CNB was focused on health care 
and research, it seems that more attention has been focused on 
informed consent for health areas. Guidelines by the CNB present 
an imbalanced focus, and are mostly directed to patients, leaving 
the interests of research subjects unprotected. 
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The Mexican position is theoretically that of a specific consent, but 
unlimited interpretation causes a greater risk for participants. A suitable 
informed consent form for biobanking research needs to be designed, 
reflecting all the variables associated with the research type, rather than 
just the requirements of any consent form.580 If a particular type had to be 
chosen for Mexican biobanking research, blanket consent is not 
recommended. “Ambiguous consents for future research are not ideal.”581 
Hence, the inclusion of the main aspects related to the fate of samples 
and data is always preferable. A concise, interconnected framework is 
believed to work; information does not need to be excessive since “more 
information will not always support better-informed choices.”582  
 
The most important issue in the Mexican context is to define 
whether informed consent is specific or broad. It could be of help to review 
other frameworks, such as those from Switzerland and France. In 
Switzerland, consent is given in a general form, allowing further use of 
samples and data for future research projects as a rule,583 whereas in 
France, consent to sample storage is for a single specific research 
purpose through a narrow consent, as it is set down by 2004 Bioethics 
Law.584 Data can only be retained for a minimum period of time necessary 
to serve the purpose for which they were initially obtained, and should be 
destroyed immediately afterwards. This stipulation also refers to all 
medical and personal data associated with the biomaterials so that, once 
a biobank has ceased to exist, there would be no legal basis for further 
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use of its database.585 However, an exemption to this rule may be 
possible, which permits transfer of the data in anonymised form to another 
research institution.586   
 
6.3.1.1 Consent of vulnerable population 
This section examines the ways in which persons considered as 
vulnerable can participate in research under specific protective measures. 
Regarding international instruments, even when inferences can be made, 
their binding power is relative and protection of vulnerable people must 
not depend on relative rules.  
 
The provision in law of consent by proxy, in the case of children or 
other vulnerable individuals involved in a research, is a regional European 
rule.587 At the national level, Spain provides detailed rules, as far as 
minors and disabled persons are concerned (BMRA 2007, art. 58.5),588 
and Article L. 672-5 of the French public health code589 prohibits the 
extraction of tissue, cells and other human body products in under aged 
people without a therapeutic purpose. According to the recommendations 
of the Austrian bioethics commission, in the case of a minor, consent must 
be sought from his or her legal representative until he or she has attained 
the capacity to consent (as a general rule at the age of 14). Storage and 
utilisation of samples donated by minors who have reached legal maturity 
is only permissible if the test person gives his/her consent. 
 
At the present time, most genetic studies around the world require 
parents to voluntarily provide a cell sample from a child. It is likely that 
parents will increasingly be asked to involve their newborn children in 
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gene therapy programmes, or for drug testing in pharmacogenetic 
studies. The former might go beyond minimal risk, but the latter is less 
likely to do so.590 Criteria are different according to the situation and 
degree of risk. In the opinion of Knoppers, research into carrier status 
should be delayed until a minor is competent to consent to the test.591 As 
discussed in chapter 5, the consent of underage Mexican persons is 
included in the Federal Civil Code and, specifically, conventions on the 
rights of children. There are ethical rules for medical research in humans 
with incapacity conditions under Mexican civil law. However, the provided 
rules are not protective enough as many aspects are not covered. 
 
6.3.1.2 Withdrawal of consent 
Withdrawal of consent with no negative consequences for the 
research subject is covered by Mexican legislation. However, it is 
worthwhile to explore further the implications of this subject. A general 
provision by the European Commission consists of the possibility of free 
withdrawal, which often entails destruction (where possible) of the 
relevant biological sample(s) along with any personal information relating 
thereto; in some cases, by a specific request of the participant data 
subject.592 Nevertheless, withdrawal is not always possible at all stages 
of the research process. “Consent to research may be withdrawn by the 
donor ‘unless such data are irretrievably unlinked to an identifiable 
person’ and that the data and biological samples should be dealt with in 
accordance with the wishes of the donor unless they are irretrievably 
unlinked.”593 In Switzerland, there is a standardised right to withdraw 
consent, which applies to pseudonymised samples and data and their 
future use. When consent is withdrawn, samples must be destroyed. The 
UK Biobank provides a sliding scale of withdrawal options reaching from 
                                                          
590 BM Knoppers and others, ‘‘Children and incompetent adults: consent and 
safeguards’ (2002) 3 Nature Reviews Genetics 223 
591 Ibid 
592 European Commission 42 
593 UNESCO International Declaration on Human Genetic Data 7 
209 
 
“no further contact”, “no further access” and “no further use”, whereas in 
Sweden researchers may still make use of the data even after the 
materials’ withdrawal. 
 
Withdrawal from research is a basic ethical requirement to be 
included in any consent form; the right to decide to withdraw participation 
from a research project without consequences for the participant.594 The 
‘right to withdraw with no consequences’ implies, in several cases, the 
destruction of biological samples. However, this option may no longer be 
feasible at all phases of the study; the sole destruction of the sample may 
not stop the use of the associated data analysis at advanced stages of 
the research.  
 
6.3.2 Tissue 
In order to reflect all the variables associated with the research 
type, biobanking guidelines should be developed for the type of tissue to 
be used depending on the project. As observed with regulations, such as 
those from the UK, determining the legal consequences depends on 
whether the tissue contains genetic information. Any potential further use 
of tissues must be established in advance; such as sample donation to a 
biobank for future research. “Prospective collection of samples for genetic 
research is an appropriate opportunity to deal with pertinent ethical and 
practical issues, rather than as and when the issues manifest as 
roadblocks for the research.”595  Potential unexpected situations and 
exceptions need to be covered, for example, retention periods of collected 
samples. If the consent forms do not allow retention after a certain number 
of years, collection of new samples would have to be collected “at the 
expense of time, funding and dissemination to the scientific community.596   
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Mexican biobanks use cerebral tissue, heart tissue, skin cells, 
blood plasma, brain spinal fluid, DNA, RNA, immortal lymphocytes, 
cellular lines and bone marrow fluid across several public biobanks in 
national health institutes, social security institutes, universities and 
technological institutes.597 Current guidelines set forth in related legal 
areas cannot be directly applied to biobanking. The General Health Law 
needs to differentiate between the different purposes of organs and 
tissues, and whether they will be used for transplantation or research 
purposes. As legal consequences vary considerably, each requires its 
own specific rules. The current minimum guidelines on transplantation 
cannot be directly applied to biobanking. 
 
The UK’s regulatory structure separates tissues and cells on the 
basis of their assumed biological ‘riskiness’.598 The relevant material 
described as: bile, blood, bone marrow, bones/skeletons, brain,  breast 
milk, buffy coat layer (interface layer between plasma and blood), cells 
when blood is separated), CSF (Cerebrospinal fluid), cystic fluid, faeces, 
foetal tissue, fluid from cystic lesions, hair (from deceased person), joint 
aspirates, mucus, nail (from deceased person), nasal and bronchial 
lavage, non-blood derived stem cells (i.e. derived from the body), non-
foetal products of conception (i.e. the amniotic fluid, umbilical cord, 
placenta and membranes), organs, pericardial fluid, platelets, pleural 
fluid, primary cell cultures (whole explant/biopsy present), pus, saliva, 
skin, sputum (or phlegm), stomach contents, teeth, tumour tissue 
samples, umbilical cord blood stem cells and urine. Non-relevant 
materials are: antibodies, sperm, RNA, lysed cells, gametes, artificially 
created stem cells, serum, nail (from living person), hair (from living 
person), embryos (outside the body), extracted material from cells, e.g. 
                                                          
597 Casabona and Simons 261 
598 S Weber, D Wilson-Kovacs and C Hauskeller, ‘The regulation of autologous stem 
cells in heart repair: comparing the UK and Germany ’ in C Lenk and others (eds), 
Human Tissue research A European Perspective on the Ethical and Legal Challenges 
(Oxford University Press 2011) 165  
211 
 
nucleic acids, cytoplasmic fractions, cell lysates, organelles, proteins, 
carbohydrates and lipids, cell lines, DNA, eggs, embryonic stem cells 
(cells derived from an embryo), cells that have divided in culture, breath 
condensates and exhaled gases. 
 
6.3.2.1 Post mortem samples 
According to the Irish human tissue bill, no hospital post-mortem 
examination should be carried out and no tissue retained for any purpose 
whatsoever without authorisation. The bill also covers consent 
procedures for the use of tissue from the deceased donors for the purpose 
of research. The bill contains several other provisions pertaining to 
research. When consent is given for organ and tissue removal and 
retention as part of the post-mortem examination process, consent for the 
purposes other than the diagnosis of the cause of death may not be 
presumed, but must be specifically obtained for research. Tissue from 
deceased persons may be used for research if the removal, retention and 
use for the purpose in question are authorised either by an advanced 
healthcare Directive, by next-of-kin or by a nominated proxy. In contrast, 
according to Swiss legislation, a small amount of material may be taken 
without consent from bodily substances removed during a post-mortem 
or transplantation and will be anonymised for research purposes, 
provided that there is no documented refusal of the deceased.599 In 
France, donations from deceased persons operates under the presumed 
consent system with opting-out possible through registration in a 
computerized national register. 
 
Macklin recognised that the main concern, regarding post-mortem 
material, is not regarding the dignity of the dead body, but respecting the 
relatives’ wishes and feelings towards that body.600 Macklin and Brazier 
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and McGuiness’ support the principle of autonomy of the living, which also 
involves the deceased and, in the case of biobanking, needs to at least 
not conflict with a decision made while the person was alive or a family 
decision.  
 
The General Health Law has stated that cadavers must be treated 
with respect and dignity. However, no specific ethical guidance has been 
provided on the fate of samples from deceased donors specifically in 
research areas. In some cases, the use of biological samples from 
deceased individuals is expressly regulated,601 which is desirable.  
 
6.3.3 The relevance of data protection and the 
European data protection directive  
Billie-Jo Hardy et al602 have suggested that, whereas data and 
sample sharing are a primary concern in many developed countries 
regarding consent in association with privacy and confidentiality, the 
priorities of developing countries should be centred on the sovereignty of 
the data and of samples.603 
 
6.3.3.1 Data and sample sharing 
“Internationally, issues that rapidly need to be addressed for 
productive and equitable collaborations include data and sample sharing, 
research capacity building in developing countries, and rules and 
guidelines for building and using international repositories containing 
long-term treatment outcomes in both developed and developing 
nations.”604 Clear limitations and specific safeguards should be applied in 
case biological samples are transferred abroad.605 
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In most European countries, personal data may be transferred 
outside the European Union or the European Economic Area only if the 
country in question guarantees an adequate level of data protection. A 
recent option to exchange tissue between countries with different 
regimes, respecting national regulations, is the coordinating “home-
country principle,”606 which consists of taking the country where the tissue 
and associated data were collected and which normally corresponds with 
the research subject’s nationality as the main point of legal and ethical 
reference. The latter principle does not affect the use of such tissue in the 
country where it is sent within a research project, “even if that other 
country has more strict regulations enforced for residual tissue 
research.”607 The home country principle has also been translated as a 
“home-biobank principle”; the biological material is able to be used 
following the rules and informed consent initially established by the first 
biobank. The regulatory regime in which the tissue was collected 
establishes the use of the tissue. 
 
6.3.3.2 Data protection in Mexico 
The concept of personal data is fundamental within data 
protection. In Mexico, the Law recently incorporated the concept of 
Sensitive Data. This concept includes sensitive information, such as 
genetic data. There are penalties in case of non-compliance, as a 
protective measure against potential discrimination caused by personal 
data processors, such as telecommunication companies (see Chapter 5).  
 
Legal requirements impact on the development of a common 
infrastructure for Mexican biobanks and the sharing of data and samples 
from across the borders. The Mexican General Health Law (article 317) 
establishes that organs, tissues and cells will not be able to be taken 
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outside of the national territory. Permission for tissues to be taken outside 
of the national territory will be granted only under specific requirements, 
except in emergency cases. (Article 317 Bis of the General Health Law).  
 
The original article presents conceptual deficiencies which lead to 
confusion. It is not clear what requirements need to be satisfied in order 
for tissues to be taken of outside the national territory and it is not 
explained what ‘urgent’ cases mean. This article, strictly applied would 
only cover blood, blood derivatives and stem cells, since the phrase 
saying that blood can be a source of genetic material is redundant for 
study populations. Hence, bone biopsies (and other tissues) for 
rheumatoid arthritis research and any other research unrelated to 
population studies can be freely taken outside the national territory. In 
Europe, this would be impossible. 
 
6.3.3.3 Data protection mechanisms 
In Van Veen’s opinion, “under certain conditions two-way coded 
data can be considered as anonymous data under the European data 
protection directive.”608 Coding is sufficient to avoid an individual patient 
being traced back, unless many variables are included, using databases 
in different locations.609  
 
Filter techniques seem to be a suitable choice, for example, privacy 
enhancing technologies (PET) provide coding techniques which allow 
donors to be anonymised and still uniquely discernible610 for tissue to be 
used in coded form.  
“Where it proves impossible to use anonymous or anonymised data or 
biological samples because of the specific features of the research, such 
data and samples may be used after being ‘coded’ (pseudonymised); ad-
hoc safeguards are envisaged in some cases to ensure that data and 
samples are pseudonymised under stringent confidentiality rules (e.g. 
                                                          
608 Veen 1438 
609 Schmidt 2380 
610 Veen 1438 
215 
 
double code) and the cases are specified in which it may prove 
necessary to de-code (de-crypt) the information in question.”611  
Data protection mechanisms need to be fit for both research and 
research participation purposes. “It is important for researchers to ensure 
that the informed consent captures all issues that are of concern to the 
participants and their communities.”612The main identified problem is the 
insufficient supervision by the Mexican authority to verify the compliance 
with these minimum ethical requirements. 
 
The transferral of biological material and associated data can be 
agreed whenever minimal general rules are part of the agreement, such 
as those provided by the EU directive and in the initial informed consent, 
providing the participant the choice to accept or deny authorisation for the 
transferral. The agreement may include: “Sending the samples in a coded 
form; the obligation, for the receiver of biological materials, to use them 
only according to the research protocol approved by the Ethics 
Committee, and return of all the remaining materials to the prior 
biobank.”613 The development and publication of tissue transfer 
agreements are relevant for matters such as “design issues, for example, 
the web site, access to the database, coding or labelling of the sample, 
etc.”614 These agreements “could have major implications for the 
conditions on how to work with and exchange tissue samples between 
the different European countries by law,”615 as long as they do not 
contradict local legislations. 
 
Confidentiality in Mexico is covered in the data protection federal 
laws (LFTAIPG) by the statement that the data subject will not be 
identified. However, the mechanisms to do this are not specified. In 
Germany, any transfers must take place in anonymised or coded form. In 
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Austria, the donor’s identity must not be known to the researchers using 
the specimens. Non-anonymised data may only be used for different 
purposes from those originally established under explicit and written 
consent. Spain and Greece show different postures. Informed consent in 
Spain is also required for anonymised samples, whereas in Greece 
anonymised data is non-personal and thus its protection is not within the 
scope of the Act. The Slovakian legislation follows the option of coding, in 
which a unique numerical code is allocated to the donor and to the 
donated tissues and cells. That ensures proper identification of the donor 
and the traceability of donated material protecting the identity of the 
research subject at the same time. 
 
Anonymisation would not be the best choice for Mexico due to its 
limited scientific value616 and the impossibility to truly anonymise data. 
Manasco argues that “due to the increasing amounts of clinical and 
genomic data, the ability to truly anonymise data and samples is 
impossible.”617 How the Mexican law will apply when data has not been 
anonymised or made unidentifiable is subject to interpretation. 
 
6.3.3.4 The European data protection directive 
The main data protection framework in the EU is the Data 
Protection Directive 95/46/EC.618 It has provided a framework for an 
international approach to protecting personal data privacy and appears to 
be gaining approval elsewhere.619 Data protection legal regimes in some 
countries, even outside of Europe, are based on specific data protection 
frameworks.  
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The European Directive 2004/23/EC620 provides general guidance 
on the exchange of tissues and cells between Member States to ensure 
the traceability of tissues and cells, subject to meeting the standards of 
quality and safety. Similar to other research ethics issues, more specific 
guidelines are needed to resolve ethical questions on data and sample 
sharing, for example, whether the authorisation to use tissue for research 
under flexible rules would have to be re-scrutinised if the material is then 
used in a country with strict rules.  
 
6.3.3.5 Re-contact issues 
Data associated with biological samples may involve various 
ethical implications under the current national guidelines; this is the case 
with discoveries of a personal informative value. However, genetic 
information is different from health information. If the research project 
does not involve individual clinical care and the research findings are not 
expected to have individual predictive value, the provision of feedback to 
the patient may not be necessary. These concerns are not unique to 
pharmacogenetics. Whilst the suitability of particular drug treatment may 
not be sensitive, the revelation of secondary information about disease 
predisposition or progression, which may follow test results, has potential 
adverse employment and insurance effects and implications for 
relatives.621 
 
There are similarities in the current national recommendations on 
biobanking in Switzerland, Austria and Germany. For example, the 
specifications regarding donors participating in biobank research consider 
who should be informed about findings with personal, diagnostic or 
therapeutic relevance (Switzerland) or findings which are essential to life 
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(Austria, Germany). Other frameworks are different. According to the first 
report of the Irish Council for Bioethics,622 in some situations it may be 
extremely difficult or impossible for investigators to re-contact individuals 
and obtain consent for the use of their archived biological material. This 
may be the case for large-scale studies involving the treatment of huge 
volumes of DNA sequence and/or expression data from large numbers of 
people.623 Material may have been stored for long periods of time, 
individuals may have died or become untraceable. In some cases, it might 
be prohibitively costly to re-contact large numbers of individuals to seek 
consent, especially for academic-led studies. Therefore, where it is not 
practical to obtain consent from individuals for use of their archived 
material, Research Ethics Committees may waive the requirement for 
consent. 
 
The best option should be decided in terms of research types. In 
general, the most important ethical aspect is the maintenance of “a strong 
link between the use of biological samples and the donor’s informed 
consent.”624 The informed consent form should give precise indications 
on the identifiability of the biological material and coding modalities. 
Within some types of research, the potential to know about an individual 
risk of disease from data associated to a sample is of statistical nature. 
No prevention is possible; therefore, re-contact is pointless. According to 
the European Commission, “in research projects there is no responsibility 
to return results to individuals.”625 Reciprocity would imply participants’ 
knowledge on how their contribution through sample donation is helping 
research.  
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In Mexico, although “there is a commitment to provide the research 
subject with updated information obtained during the study,”626 it has not 
been clearly established whether the research subject is entitled to the 
right to have any results obtained through research disclosed. In some 
informed consent forms, the person concerned is asked at the very 
beginning about his or her desire to be (or not to be) contacted again, 
while in some others the possibility of being re-contacted is excluded.627 
Even when both choices may be ethically opposed, the decision to be 
made on whether or not to provide feedback to the participant will depend 
on the nature of the research involved. “Whether such individual feedback 
is possible will very much depend on the nature and set-up of the 
research.”628  
 
6.4 Oversight 
International ethical oversight requires each country to be 
responsible to regulating “the nature of the control and bureaucratisation 
of processes.629” Not only has regional guidance been followed by 
Member States, but also national frameworks such as the Dutch Medical 
Contract Act, which is well known due to its clear structure. Eastern 
European countries, Lithuania and Estonia, have based their patient 
rights on the Dutch Medical Contract Act.630 Germany is regulated in 
terms of oversight under the auspices of one main authority and one main 
legal instrument, and clinical trials are subject to a more streamlined 
procedure.631 German governance team members talk about regulation 
in terms of the formalisation of procedures, while the UK team stressed 
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the emerging nature of regulatory practices and the process of bringing 
together different actors and agencies in the regulation of their trials.632  
 
Clinical trials are performed by Mexican public and private 
institutions.633 According to the General Health Law rules, health research 
through clinical trials can only be authorised by the Mexican health 
authority, that is, COFEPRIS. The institute aims to protect the population 
against sanitary risks through sanitary regulation, and administrative 
controls. In contrast to the CNB, COFEPRIS is responsible for monitoring. 
Due to provisions contained in European Directive 95/46/EC (which is 
currently under revision), Data Protection Authorities also have an 
important role in overseeing data, not only within biobanks, but also the 
use of data and samples by researchers. For example, Data Protection 
Authorities: have been empowered to identify the rules that can be 
relevant for biobank research in Italy, have given guidance to 
stakeholders in Germany, were responsible for monitoring the creation 
and operation of the Health Sector Database in Iceland, issued an 
authorisation to the legislators in Portugal on biobanks, were involved in 
public hearings in the national Parliament of Sweden, and, in some cases, 
have used their enforcement powers.634 
 
Regarding the oversight of the Mexican human genome, although 
the legislation describes the conduct to be sanctioned,635 no procedures 
exist to enforce them. The Mexican legislator has failed in involving the 
right authorities in the right issues. The Ministry of Health should not 
involve the National Institute of Genomic Medicine (INMEGEN) as a 
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government assessor and national reference centre to be responsible for 
the registration of ethical authorisations,636 since the INMEGEN itself 
needs to be regulated as it performs population studies.  
 
Examples of consistent European practices which could be 
effectively adopted by Mexico include:  
 “Biobanks’ accreditation should be sought with the competent 
national authorities, usually the Ministry for Health, the Ministry 
of Research or local pharmacology agencies.”637   
 “The creation of a biobank should be notified, and the 
competent national authorities, including the data protection 
authorities should accordingly set up registries of biobanks.”638 
  “Supervision should be carried out by the competent national 
authorities alongside the supervision of the national data 
protection authority.”639  
 “Management of biobanks should be committed to a specific 
individual or entity, usually from the medical (or biological) 
profession.”640  
 
6.4.1 Sanctions 
There are no explicit penalties for breaching EU guidelines, in the 
same way that Mexico does not have clear sanctions in terms of data 
protection. Even so, responsibility could be placed at the members’ local 
level. The situation is different at the local level, for example in the UK, 
where “serious violations of ethical conditions may prompt remedial 
action.”641 These include issuing cautions, disciplinary action, 
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professional misconduct, fitness to practiced procedures,642 suspension 
or termination of researcher’s or biobanks’ funding, fixed and variable 
monetary penalties, stop notices, compliance requirements, restoration 
requirements, civil sanctions, conduct audits and criminal prosecution.643 
Breaching of the Human Tissue Act or its codes of practice are legally 
founded reasons for suspension and withdrawing of licenses. “Inspect 
premises; and stop the use or transfer of human tissues for purposes; or 
in ways, that are not permitted.”644 In any case, the physical intervention 
itself requires the informed consent of the donor. This is the case in 
Germany, where extraction without informed consent constitutes an act 
of bodily injury according to 223 of the German Criminal Code.645  
 
The sanctions imposed by the Mexican law only consider direct 
threats to a subjects' personal welfare. The fact that Mexican ethics 
committees operate with ample discretion and little oversight continues to 
be problematic. Given that the only requirement for Mexican research 
ethics committees since 2012 is registration,646 no sanctions currently 
exist for noncompliance. Only a few aspects in relation to biobanking, 
such as population studies, have been considered for potentially serious 
sanctions.647 “The person who transports organ, tissues and components 
from living or dead donors outside the national territory (or performs 
related actions) will receive between four to fifteen years of imprisonment 
and a fine for 300 to 700 days of minimum wages.” The same sanction 
will apply to that person who performs actions related to the transportation 
of ADN tissue sources for genomic population studies. If the responsible 
person is a professional, technician or assistant within health areas, the 
penalty will additionally involve the suspension of professional activity for 
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a maximum of 7 years.648 Obtaining separate time-consuming 
authorisations may not be burdensome for researchers if the law, even 
when is not comprised in a single framework, is interconnected.  
 
6.4.2 Ethics committees 
RECs are the formal bodies that are common to European 
countries with the purpose of reviewing biobank protocols and the Data 
Protection Authorities responsible for the oversight of data processing. 
The ongoing reform on the ethical review process, both in the UK and 
Europe, focuses on the facilitation of good research; efficiency, 
effectiveness and proportionality are of key importance, but this has not 
always been the case.  
 
The UK, at some point, experienced “the failure to give statutory 
authority to all RECs”649 which led to a complex system at the time; 
“researchers felt stifled by bureaucracy.”650 Until recently, the REC 
system was voluntary and non-statutory. Today, however, “certain RECs 
– notably, those legally recognised under the Clinical Trials regulations – 
enjoy limited statutory status and formal authority to give ethical opinions 
on clinical trials involving investigational medicinal products.”651 The 
Mexican situation resembles some of the past experiences of the UK in 
terms of ethics committees.  The IMSS Mexican health department has a 
system of 335 local research ethics committees (LRECs). The UK 
Department of Health first recommended that district health authorities 
establish local research ethics committees (LRECs) in 1975. More 
detailed formal guidance was issued in 1991. Each local health authority 
was required to set up at least one, and there were over 200 LRECs in 
all. By 1997, due to limited guidance and coordination, the LRECs’ review 
process was often inconsistent; multi-centre researchers faced a diversity 
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of procedures and outcomes. However, RECs were acquiring 
independent statutory authority, which was later formally delegated by the 
UK Ethics Committee Authority (UKECA). Rather than giving all RECs 
statutory authority (as occurred in some countries), the Ethics Committee 
authority recognises certain RECs appointed by a range of authorities 
including: strategic health authorities, the National Research Ethics 
Service (NRES), universities and independent institutions.  
 
General oversight schemes at the national level are linked to ethics 
committees, for example the Human Tissue Authority in the UK, which 
does not have an easily identifiable Mexican equivalent. The Mexican 
Ministry of Health has been over-loaded with many responsibilities, 
including biobanking. This is concerning as the Mexican Ministry of Health 
is, in theory, responsible for the oversight of biobanking. Another level of 
oversight is undertaken by the institutions where the biobank is based or 
by the local health authorities which host the biobank.652 This could be 
equivalent to the National Institute of Genomic Medicine in Mexico. 
Generally, National Bioethics committees are also part of the oversight 
scheme for guidance purposes, for example, the Mexican National 
Commission of Bioethics.  
 
Coordination and authority will be key elements in the search for 
standard guidelines for Mexican biobanking research committees. 
Research ethics committees should assess the purposes to be achieved 
when setting up the given biobank. In some cases, ethics committees are 
required to assess each research project that is expected to rely on 
biological samples. However, it is rarely the case that the specific issues 
to be considered by ethics committees are examined in detail, and 
different approval procedures based on different arrangements are 
usually envisaged in the individual legal systems.653 Another choice is the 
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possibility of centralisation for ethics committees. At this point, Mexico 
only has LRECs. Participant M thinks that if each committee has different 
needs then it is fine that each institution has a committee.654 Although 
LRECs involve some advantages, at the same time, Participant M 
recognises that there can also be disadvantages: “we have multi-centric 
research and it is difficult to determine whose committee will scrutinise 
the project.”655 Experience in the UK has shown that the evolution from 
LRECs to centralised committees was part of a process which proved 
positive in the end. The same could be experienced by Mexico.  
 
6.4.3 Self-regulation and E-governance 
Regarding self-regulation, there is no clear evidence that its role 
has been determined for most primary European frameworks. The UK 
has experienced that “self-regulation is only likely to work effectively 
where it costs business more to breach the self-regulation policy than it 
does comply.”656 These types of agreements partly motivated the 1998 
UK Tissue Act. It was necessary to provide a legislative backstop for 
sectoral self-regulation with clear and effective penalties for non-
compliance with the law. “Public pressure for companies to operate in 
compliance with sectoral codes of conduct, while much touted as a 
valuable mechanism for facilitating effective sectoral self-regulation, is 
rarely sufficient by itself to ensure that this happens on a consistent 
basis.”657 Nevertheless, with legislation in place, self-regulatory practices 
can be acceptable if these do not contradict established rules. According 
to Kaye et al,658 “an inconsistent regulatory framework can also lead to 
innovation.” A good example is UK Biobank, which has set up its own 
governance systems to ensure accountability and transparency.” 
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Additionally, self-regulation has worked for some (although a small 
proportion) as a solution in Europe. New ideas for governance have 
recently gained traction from a collection of frozen specimens to virtual 
biobanks.659 New “e-governance” systems have emerged that allow 
consortia to function through self-regulation as the result of many 
initiatives marking the evolution of biobanking. The internet is now used 
to facilitate collaboration among medical researchers, gaining the consent 
of participants through web-based tools. One example is the EnCoRe660 
project, in which “dynamic consent,” was presented as a possible solution 
for the endless dilemmas of potential future re-consent; the consent of 
choice where participants are continually updated.  
 
Self-regulation in Mexico has resulted from attempts by those who 
participate actively and make decisions in biobanking activities and 
struggle to find uniform and consistent guidance. Normally, an ethics 
committee decides on the fate of biological samples after their first 
specified use. For instance, the committee has to resolve ethical 
controversy which could emerge from further uses, addressing the 
concerns involving privacy and data protection of participants who are still 
alive. The choice of re-contacting participants does not resolve the whole 
situation, it can become too difficult or unaffordable. If samples are 
anonymised and no privacy risks are involved, the ethics committee could 
determine that no further re-consent is necessary. Self-regulatory 
agreements are common instruments, agreed between the national 
representatives of the pharmaceutical industry in Mexico. However, the 
way self-regulation currently operates in Mexico has proved problematic, 
(See case study in Chapter 3) it has worked as a form of self-authorisation 
that can lead to exploitation.  
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6.5 Concluding remarks 
Analysing present legislation, which other countries have used to 
solve similar situations in Mexico, constitutes a way forward for a possible 
solution. There are still valuable lessons to learn from those countries 
which have already achieved the necessary frameworks for the use of 
archived samples, not only for genetic research, but other related 
biobanking aspects. International biobanking models with the potential for 
implementation in Mexico require a careful evaluation according to the 
needs of the national context. For this reason, the interpretation of ethical 
principles must be based on cultural sensitivities. The selected 
international governance models must also be sensitive to the needs of 
the different actors involved in biobanking.  
 
The main lesson to learn from Europe is the need to successfully 
harmonise external frameworks with local contingencies. Every issue is 
based on national realities and connected to cultural and ethical 
perceptions. No foreign regulation can “fit” the unique conditions currently 
faced by Mexico. That said, many real-world initiatives have inspired fresh 
thinking, including numerous examples from overseas biobanks. 
 
Mexico has the choice of learning from experiences or looking at 
processes that have proven effective among common circumstances. 
Past mistakes should assist future improvement. This chapter has 
identified some national frameworks to examine, based on contextual and 
circumstantial similarities. European biobanking frameworks vary 
significantly, depending on each country’s situation. The unification of 
biobanking standards in Europe currently remains unclear due to a future 
consensus that is difficult to envisage at present. European member 
states are aware of the difficulties  of adopting a European standardised 
legislation for biobanks, but recognise the need to “develop a consistent 
and coherent legal framework for biobanking that should protect 
participants’ fundamental rights, in particular in the areas of privacy, data 
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protection and the use of human tissue in research.”661 Several identified 
parameters can lead to effective standards for international sample and 
data sharing. Some identified actions can be avoided when designing 
biobanking legal policy, including genetic exceptionalism (especially at 
the population level) and excessive legal burdens.662 Specific, flexible and 
harmonised agreements are key elements to resolve the ethical and legal 
issues caused by divergent frameworks, such as those in Europe. 
International collaboration needs to take into account multidisciplinary 
aspects. The adoption of consensual guidelines may be an interim 
solution. There are important lessons to learn from the European 
experience, but more specifically about the European countries involved. 
The situation of each of them is different and each of them involves 
examples of similarities and disparities with the Mexican situation.  
 
Europe has developed a comprehensive framework due to the 
expansion of biobanks, ethical treatment of tissue, the necessity to share 
samples and related data, and ever increasing scientific and biomedical 
research. The current European Data Protection Directive could be 
relevant in the establishment of basic data protection, in terms of 
international research collaboration. Most studies in Mexico are multi-
centric these days.663 Consistent regulation is important if multi-centre 
trials are to cross national boundaries. Most European countries have 
effectively ratified data protection mechanisms, such as anonymisation or 
coding. However, in the case of more specific issues, such as informed 
consent, a more careful analysis is still required.  
 
Kaye has stated that biobanking improvement is part of a gradual 
process. In the UK’s case, “terminology and standards were in a state of 
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development and still emerging and there is considerable uncertainty 
within the research community.”664 Mexico is still in the early stages of a 
similar process, in which the coordination among stakeholders will play a 
fundamental role. Even when national collaborations involving research 
are intended to be equal and more independent, changes for the 
protection of citizens relate to: academics, judges, law makers, the 
government, human rights commissions and the wider society. The 
culture of transparency is essential where research takes place, and 
recent views relate closely to biobanking and public engagement.665 
Interviews presented in previous chapters emphasised the need to 
strengthen coordination among stakeholders. The independence of 
science and technology relies on the organisational level among Mexican 
groups, and helps to build the research subjects’ trust towards the 
decisions made by research teams and biobanks.  
 
Based on the European experience, the issues raised by Mexican 
biobanking require solutions that are sensitive to its own particular needs. 
Actions to implement include the development of appropriate ethical and 
legal attitudes towards the research participants and the value and nature 
of the research project, on a culturally sensitive basis. The same models 
used abroad for population studies could be used in Mexico, although 
Mexican populations participating in such studies are more vulnerable. 
Researchers have to find out the model or models that would be 
acceptable in the particular communities where research studies are to 
be conducted,666 which must include social experiences in defence of 
human rights.  
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7. Implementing change in Mexican biobanking 
 
7.1 Introduction 
 Previous chapters have made evident the absence of a consistent 
legal framework to govern the data and tissue necessary for research in 
Mexico, and significant legal inconsistencies have been discovered within 
Mexican biobanking. The aim of this chapter is to identify the best ways 
to implement change in Mexican biobanking, proposing ways in which 
those inconsistencies could be fulfilled. Governance, the conceptual basis 
of implementation, will also be discussed, in particular the model of 
reflexive governance will be analysed in order to determine the elements 
which could strengthen a suitable regulatory proposal.  
 
Priority areas, such as informed consent and data protection, will 
be focused in on as areas that require major changes in implementation. 
The role of key governing institutions will be explored in order to evaluate 
their effectiveness in both public and private institutions. Different degrees 
of external control and supervision will be highlighted as means to 
improve implementation. The role of trust will be explored. Finally, a brief 
analysis of emergent governance measures, as viable options while 
implementation takes place, will follow. 
 
7.1.1 The role of governance 
The etymology of the word ‘governance’ can be traced back to the 
Latin term gubernare, connoting rule making.667 Governance is a 
multifaceted concept. Robin Bunton and Alan Petersen668 suggest that 
the best governance focus should be inclusive. Gotweis and Lauss have 
proposed that the role of biobanking governance should be understood 
as “a strategy for patterning a network of interaction that unfolds within 
and across a number of different fields including a variety of activities that 
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go beyond regulatory activities.” These fields can be: science and 
technology, medicine and health, industry and economy, legal and 
ethical, and society and politics.”669 
 
7.1.2 The model of reflexive governance 
Gottweis and Lauss have highlighted the development of new 
modes of enquiry and models of ‘lay participation’ by policy makers based 
on public interests.670 Biobanking governance can be solely reflexive, 
through the assurance of long-term social commitment, by encouraging 
responsive participation from the diverse views of different 
stakeholders.671  
 
Models of reflexive governance involves “facilitating mechanisms 
of mutual learning in addressing genuine dilemmas.”672 When these 
emerge, it is about understanding them and addressing challenges, then 
working together to meet expectations. Reflexive governance 
acknowledges legitimate coordination and consequent mutual learning. 
However, coordination by itself is not sufficient; solidarity and trust also 
need to be reflected by governance in ethical features, such as informed 
consent. Reflexive governance, ultimately, signifies the need to 
encourage legal governance recognising legal boundaries and providing 
a firm basis for legal action. It also aims to encourage clarification on each 
stakeholder’s role in cooperative actions. The role of each stakeholder 
should be equal, following reflexive governance, otherwise it would not be 
legitimate.  
 
7.1.3 The legitimacy of governance actors 
 A substantial element of governance consists of the roles of 
involved actors and their legitimacy. It is about both the people and the 
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science.673 Dynamic and interactive research processes involve multiple 
actors: scientists, health professionals, policy makers, funders, industry 
and members of the public (including research participants). Bioethical 
researcher Mats Hansson674 argues that the data collected is not only 
linked to the patient but, in many cases, also to his relatives. This type of 
family link creates a legitimate interest in areas like efficiency and integrity 
of biobanks, i.e. governing the storage, use and sharing of samples. 
Biobanking is associated with those participating directly and with general 
public. This will be part of the process for long term biobanking 
legitimation. “The project’s long term viability could be threatened if 
biobank’s funders fail to adopt a more open approach and engage not 
only the project’s participants and stakeholders but the wider public.”675 
However, “there may also be third parties, such as insurance companies, 
employers or the police with an interest — which may or may not be 
legitimate — in gaining information about the diagnosed individual and his 
or her relatives.”676  
 
7.1.4 Public awareness and engagement 
According to Salter and Jones, the legitimation of biobanks’ ethics 
would not necessarily depend completely on the legal framework. 
“Traditionally, public support for new technologies has been assured 
through governmental regulatory arrangements that have relied heavily 
for their legitimacy on the authority of scientific advice.”677 Legitimising 
processes should consider public awareness as a sine qua non element 
for the materialisation of results in practice. Political will and leadership 
are expected to be the rationale of public engagement in terms of 
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organisation. In this sense, within the context of reflective governance, 
public engagement can work as “an effective means to address a 
concrete unmet need in biobanking practice.”678 Support from the media, 
along with other forms of knowledge dissemination, is essential and 
constitute a way to simplify the complexity of interaction processes.  
 
Public engagement by the biobanking community is essential,679 
as public interest is the main justification for the legal authority’s 
intervention in biobanking; “law might be called upon both to protect and 
to promote core interests engaged in biobank practices.”680 But in 
general, public support will be key in overcoming policy and legal 
obstacles. 
 
   7.1.4.1 Public forums, a way to materialise public 
engagement? 
Following O’Doherty and Burgess, when critical issues can be 
identified in the early stages of their evolution, more attempts can be 
made to create an appropriate dialogue with stakeholders and the public. 
This would enable the development of public awareness and public 
acceptance, favouring anticipatory arrangements such as regulation.681 
Public engagement involves exercises for the public to have a say 
regarding biobanking policy. The first step is selecting viable exercising 
options. Public consultation can be used to address criticisms and to 
enhance informed and more widely representative views of the public 
interest.682 
 
 It is necessary to achieve a reasonable consensus among 
citizens, and a suitable instrument for this purpose could be public 
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consultation. The implementation of consultation would require specific 
mechanisms such as identifying appropriate consultation types and 
incorporation of the results into policy making.683 Biobanks are expected 
to develop ways to maintain and attract participation. Knowledge 
dissemination of realistic health benefits associated with biobanking can 
be the main tool to incentivise active participation of the population.  
 
The participation of those involved in research biobanks should be 
acknowledged as equally valuable. From these recommended measures, 
educational sessions with stakeholders seem more suitable for Mexico at 
this point. Once participants and patients had proper knowledge, then 
there could be a more active participation in forums from research to 
medical expertise. As pointed out by Cambon-Thomsen et al., more 
biobank openness, balanced with an increasing use of dialogue and 
public-stakeholder consultation, can lead to the public demand of better 
controls.684  
 
Public forums may be viable for their representation and 
participation of scientists, industry, government and health and research 
representatives and the public in general. “To ensure that different 
perspectives are being considered, ethics and legal expert opinions are 
now used to complement the opinions of scientists to assess the risks of 
policies and practice.”685 The isolated example of INMEGEN’s open 
forums (Chapter 3), while it conducted the HapMap project, should be 
made compulsory to projects of this nature by law. The ‘Mexican HapMap’ 
showed an acceptable degree of public engagement, which is not a 
guarantee that every biobanking population project will follow the same 
self-regulatory steps. Hence, simultaneous encouragement of oversight 
will be critical for the legitimacy and operation of Mexican biobanks. 
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The Mexican legislative congress has also proposed forums,686 but 
these and other academic or medical and scientific areas of expertise, 
organise purely internal activities, unable to generate an impact on 
knowledge translation. Forums would be an open space of 
communication and interaction to discuss the benefits that could be 
achieved, whether these are aimed at the community, the Mexican 
population or even mankind, and whether the project could be linked to 
health programmes. More involvement is required from the scientific 
community; hence, the organisation of forums should be compulsory for 
these cases.  
 
 7.2 Priority areas 
7.2.1 Data protection 
Society needs to both recognise the vital importance of personal 
data and start demanding personal data protection. Data protection laws 
will only work effectively when data users are willing to be bound by them 
and there is meaningful enforcement against rogue companies and 
information pirates.687 Hansson has highlighted that the public, when 
participating in either biomedical or genetic research, consider the 
importance of privacy in relation to the study itself. Even when the degree 
of risk involved by biobanking research is minimal, “there is still reason 
for concern since insurance companies, employers, and other third 
parties may have a great interest in information acquired through human 
tissue sampling.”688  
 
Operative rules for disputed access would justify the involvement 
of the judiciary.689 An important and viable reference point for these issues 
would be to make sure that law and policy makers become aware of the 
                                                          
686 Science-and-Technology-Commission-Participant:K 
687 Charlesworth, ‘Implementing the European Data Protection Directive 1995 in UK 
Law: The Data Protection Act 1998 ’234 
688 Hansson417 
689 B Capps, ‘The public interest, public goods and third party access to UK biobank’ 
(2012) 5 Public Health Ethics 5 
236 
 
topic. The Mexican Congress requires greater expert support. Participant 
K, a member of the current parliamentary commission for Science and 
Technology, said that he was “not familiar with information about topics 
such as biobanks. Data protection has had a very strong impact recently 
and it has to do with biobanks. There are vulnerable groups to protect.”690 
Bioethics is not currently a priority in Mexico, which also means that, 
although biobanking is not the only issue within legislative works, it needs 
to be attributed to a specific commission.  
 
Participant J has highlighted the need for Mexicans to act sensibly 
as citizens by understanding the importance of personal data and then 
demanding personal data protection.691 If the Mexican population is not 
aware of the risks involved in the potential abuse of data when donating 
a sample, then the authorities will not be asked to provide protection.  
 
Law makers may, with careful attention, actually operate and 
protect participants. This is an argument picked up by leading policy 
makers, such as Participant K, who claimed not to be well informed 
regarding the topic but was interested in improving regulatory aspects. “I 
do not know about biobanks. I would have to have a look. I believe that 
persons who provide samples (freely or through a payment) need to know 
and authorise the extent of use of the sample and forthcoming data. 
Ultimately, it’s their identities.”692 
 
Gerardo Laveaga, IFAI’s commissioner president, has mentioned 
that “the dispersion of responsible subjects and the little awareness 
shown by those entitled to privacy and data protection are a couple of 
challenges to be faced by the IFAI and the legal Mexican community.” 
IFAI announced that, according to a survey organised by the institute, 
                                                          
690 Science-and-Technology-Commission-Participant:K 
691 Datap-protection-expert-at-a-public-research-institute-Participant:J 
692 Science-and-Technology-Commission-Participant:K 
237 
 
more than 50% of the participants are not concerned, or only a little 
concerned, regarding the fate of their personal data. “If we consider the 
amount of institutions dealing with personal data, this is highly 
worrying.”693  
 
7.2.2 Informed consent: the suitability of a specific 
model  
In terms of communication between participants and biobanks, two 
elements are needed to reinforce informed consent: specific consent 
procedures and a closer involvement from participants. “The inevitable 
decrease in reliance on informed consent and the increasingly obvious 
inability of researchers to guarantee protection of privacy should be 
countered by more attention on appropriate governance mechanisms.”694  
 
 Informed consent contributes to engage participants more fully in 
the research process. Bioethics literature has constantly emphasised the 
role of consent procedures preceding the act of donation as a device “that 
may contribute to instil trust,”695 and therefore legitimisation based on 
autonomy. If the donors’ trust is not obtained by consent and information 
procedures, such procedures are not necessarily sufficient to prevent 
irresponsible uses of data biobanks.696 Similarly, within medical areas, 
“several studies have revealed that health providers may not have the 
skills necessary to critically analyse and communicate genomic 
information and meaning, suggesting that some are not prepared for the 
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present flood of new consumers interested in genetic testing,”697 for 
instance. 
 
 The current Mexican rules remain inconsistent, fragmented and 
incomplete, if we take into account that most of the guidelines only cover 
‘the human genome’. The legality of some activities is not entirely clear 
yet, e.g. particular types of consent and the legal qualification of the 
sample source-person which “cannot be the same when samples are 
obtained within the healthcare context or within the research context.”698 
Chapter 5 showed that Mexican informed consent ethical guidelines are 
based on a predominantly medical focus and “more attention has been 
focused on health areas.” (5.1.2) 
 
 Designing a suitable consent model is not a simple task. The 
agreement on what model would suit the needs of Mexican citizens 
remains open to debate. A broad consent model would only be acceptable 
as long as a social need (such as health) is supported and autonomy 
respected. This is very difficult to achieve. The main role of informed 
consent is to determine more specific issues; such as when 
(re)consenting will be feasible and in what cases findings will be 
communicated to participants. More inclusive models are required to 
encourage better communication with research participants; e.g. by 
honouring their altruism, respecting their autonomy, and promoting trust 
in the biomedical research enterprise.699  
 
Mexican research participants would not yet be ready for a 
completely broad consent option, at least at present. For participant B, it 
would be difficult to design a general informed consent process suitable 
for Mexican biobanks, since “the idea has been to make general 
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recommendations and it would be good if we, researchers, knew the basic 
points to be covered.”700  
 
Participant H thinks it is worthwhile to design an informed consent 
proforma for collecting research samples that allows the researcher to do 
further research, “I have witnessed researchers complaining that they 
cannot re-contact participants; they may not see them again. It is very 
difficult and that involves the risk of wasting big efforts to collect the 
sample. We need to find mechanisms to resolve these situations and I 
think the best way is clarifying that the samples may be used in the future 
for other projects.”701 Participant K agrees with the idea that informed 
consent should be as specific as possible. “If the use is granted to only 
one institution, only that institution is entitled to use the samples, unless 
the person authorises further use. Samples cannot circulate freely. For 
me this is a new concept.”702  
 
 The sole change of informed consent forms will not make a 
significant difference. Informed consent processes should be enhanced 
by a strong legal rationale in order to ensure a more fair translation of 
biobanking benefits to society. Changes need to be substantial; informed 
consent can reinforce public engagement when it is demanded by social 
involvement. 
 
 Significant issues in Mexican biobanks could be resolved through 
the renewal of current informed consent processes. Participants within 
specific biomedical research projects need a different consent model from 
that established for clinical trials. A specific consent model would cover 
individual results, the right of everybody to know) or not to know their 
results) and non-discrimination measures. It needs to be preventive and 
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flexible but more preventive than flexible. “The scope of consent to future 
use of research samples should be considered with obtaining of initial, 
prospective consent to participate in a biobank.”703  
 
7.3 Main institutional issues 
According to Rial-Sebbag and Cambon-Thomsen, the inadequacy 
of traditional regulatory frameworks tends to result in a great governance 
challenge: the reluctance among lawmakers to define objects and 
structures, as well as their status, thus creating ambiguity and legal 
instability in all aspects.”704 Accordingly, a more active institutional 
collaboration in policy-making would avoid “policy conflicts, crises and 
social turbulences.”705  
 
Laurie argues that “failing to capture the notion of partnership”706 
will result in unworkable legislation in practice. Participatory governance, 
as it has been regarded by Murtagh and Harris, is a simple concept which, 
in a self-indicatory way, calls for cooperative views, optimising the 
translation of biobank science into societal benefit as a necessarily 
transdisciplinary project.707 As a result of analysing the context in Mexico, 
it can be stated that a significant amount of coordinated work is necessary 
to organise a legitimate agenda involving the public and the private sector. 
In principle, the most relevant approach is “a multidirectional exchange of 
knowledge and information among researchers, consumers, professional 
groups, industry, policy makers and public agencies.”708 Such a gradual 
involvement should eventually influence the translation of personalised 
medicine projects into practical results. Hence, participation needs to be 
boosted gradually.  
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7.3.1 Coordinating governance issues 
Coordination implies differentiating among different types of 
research. It is necessary to recognise that exceptional types of research 
require more protective measures, for example, those involving 
indigenous populations. This is part of a new sensitive paradigm within 
the social and political context of translational science; it should be able 
to include representatives from the main areas involved. It has been 
observed that a great number of biobanking projects in Mexico have been 
carried out in an isolated way, and the different biobanking networks are 
not coordinated. 
 
The 2004–2009 INMEGEN institutional programme709 covered 
nine strategic points for development, including alliances for the 
Nationwide Development of Genomic Medicine, the application of world-
class genomic technology to common health problems, compliance and 
investigation on ethical, social, and legal issues.  
 
Not all stakeholders may share the same interests, but all of them 
aim for knowledge translation. A broad perspective of knowledge 
translation is referred to as “a dynamic and iterative process that includes 
synthesis, dissemination, exchange and ethically sound application of 
knowledge.”710 As a result of combined actions, it is expected that 
stakeholders should develop a sense of interactive collaboration towards 
knowledge translation, including the public. As stated by participant I, “it 
is important to understand that we will never be exhaustive enough, that 
coordination is important and we will have some interrelated interests.”711  
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Hence the different public health institutions would use results 
obtained from different federal entities. The relationship between different 
biobanking stakeholders works as a chain, where the actions of a sector 
will affect or benefit a counterpart. This will be crucial for the creation of 
fit-for-purpose rules. For example, scientists need to explain the full range 
of possible choices that samples could be used for after collection; 
participants are normally interested in the fact that “the sample collection 
will be owned publicly.”712 This would in principle, be drawn to the 
attention of both public and private areas. Whether the institution is public 
or private affects the potential generation of profit or generation of 
information for public benefit, and this may be communicated at the initial 
point of collection. 
 
This proposal is meant to help the enforcement of fit-for-purpose 
rules beyond ineffective written laws, political discourse and non-
transcendent coordination, in which the public opinion tends to be 
excluded, partly due to collective disinformation on what could be gained 
socially and to what extent it is desirable. A possible starting point could 
be achieved by promoting cooperation and participation with biobankers 
in the design of the information and consent procedures, allowing new 
devices, possibly on the group or community level, for the debate of 
broad-scoped issues. Equal regulatory action taken by science, industry 
and policymakers is desirable without the involvement of excessive 
politics, which would create an imbalanced situation. 
 
7.3.1.1 Institutional coordination efforts 
A coordination effort in relation to the transportation of tissue 
outside Mexico, involving the health authority COFEPRIS and INMEGEN, 
was attempted through article 317 of the General Health Law. 
 
                                                          
712 Trust and Council 63 
243 
 
Article 317 bis The Ministry, in coordination with the National Institute of 
Genomic Medicine, as Federal adviser of the government and reference 
centre in the subject, will register the authorisations on transportation of 
human tissue outside the country.   
 
However, in the opinion of Participants D and E, this has not been 
achieved:  
“The amendments to article 317 bis have had no determinant impact 
whatsoever at INMEGEN’s operation. Article 317 bis is part of a block of 
more articles. The role of INMEGEN is not very clear; apparently it 
involves a governmental advisory role. Another article was enacted in 
2007 on genomic sovereignty, states that it is prohibited to take samples 
outside the country and then INMEGEN appears as a governance actor 
to authorise population studies and transport of samples overseas. If that 
was the case, we would have to have full offices revising applications. 
That has not happened. An agreement was reached with COFEPRIS, 
and it is still the only authority in this respect however, it is not specified 
in a written form. I hope this will be clarified one day.”713 
 
Participant G is aware that recently, it was established that 
INMEGEN would collaborate with the authority through a registry. 
However, so far, that has not happened. “At some point, the INMEGEN 
will have to play both a consultation and invigilating role. This will only 
work through coordination. It will not be possible with an obsolete law.”714  
 
Several attempts to enhance institutional coordination have proven 
unsuccessful, such as the plan to strengthening “the contact and 
exchange data among the national experts”715 included in the 2001 
legislative proposal for the General Health Law. The plan was intended to 
encourage the study and the development of new research projects, and 
so that information regarding social, ethical and legal aspects on human 
genetics would be better understood. However, there seems to be a gap 
between policy and institutional responses. The existing institutions either 
fail to deal adequately with the new regulatory issues raised by genomics 
or they still need to be created to respond to the new policy issues. In 
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Mexico, it is not only researchers who recognise this matter; the OECD716 
had previously emphasised the role of policy in fulfilling legal gaps, which 
could be closed by the government through policies integrated under the 
principles of justice that society has chosen to apply.717 
 
Beyond individuals, the establishment of governance relies on the 
institutional component. Gibbons suggested that “an institutional body is 
capable to take part in the resolution of any debates at different scales 
where oversight, regulation and transparency are too general” and, 
“where, characteristically, there is less internal and external oversight, 
regulatory accountability, or transparency.718”  
 
7.3.1.2 CNB: the key to govern biobanks? 
For the time being, it is clear that biobanks are not expressly 
covered by the commission. Clearly, the National Commission of 
Bioethics is not an authority. The benefits of the compulsory registration 
of ethics committees within the commission consist mainly of updates and 
academic diffusion. However, it could become a more active institution in 
Mexico. The CNB could provide the biobanking expertise needed to 
advise policymakers, lawmakers, biobanking professionals, the public 
and especially, ethics committees. Ingrid Brena pointed out, in this 
respect, that “it is imperative to implement regulations, national laws and 
international standards.”719  
 
Ethics committees could play a fundamental role in biobanking.”720 
If that was to happen, clearer and more specific advisory guidelines would 
be highly appreciated by stakeholders. Additionally, more advice and 
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oversight powers are urgently required. A specific biobanking organism is 
a possibility, but it would take time and great effort to materialise. 
Meanwhile, if the CNB can provide advice and the COFEPRIS has 
oversight, both institutions could work together. 
 
Both commissions (CNB and COFEPRIS) could join efforts with 
research institutions to protect biological samples; this is not far from the 
status quo. According to the recent reform regarding ethics committees, 
COFEPRIS will remain in charge of the committees’ registration. 
However, this will now have to include the authorisation of the CNB. The 
guidelines for the structure and operation of committees are being 
provided by the commission. Participant M,721 representative of the CNB, 
recognised the following: 
“We are related to the committees in terms of the registration and training 
of members; some of them lack knowledge on bioethics and they have 
started to work on that. The registration is helpful for the commission to 
identify where this training is necessary and to have records of 
established committees, especially now that they are mandatory.” 
 
The General Health Law was amended 2011 to state that the 
“…National Health Institutes Regulations basically consist of obligations 
to carry out clinical and experimental research into fundamental 
technology development within the area of genomic medicine; this should 
promote safety measures in its specialised area in order to further the 
links between national and international institutions.”722 This was 
allegedly planned in order to create a research network in the field of 
genomic medicine; to foster innovation and technological projects for 
creating means of diagnosis.723 According to the initial amending proposal 
(2001), the ‘National Reference Centre’ would be in charge of genomic 
medicine and genetic therapy, and deal with issues related to studies on 
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genomic medicine and its applications.724 The promotion of cooperation 
among public health institutions will contribute to human development. 
However, this will be achieved only by coordination encouraged through 
sound policies. 
 
7.3.2 Main issues within health institutional committees  
One of the main unresolved issues in Mexico is the absence of 
procedures for the enforcement of research ethics rules and, therefore, 
biobanking. It is necessary to determine the most effective binding level 
for new policies. Research Ethics Committees (RECs) or Institutional 
Review Boards (IRBs) are common to most jurisdictions. These bodies 
are the key decision makers in reviewing and allowing research protocols 
to proceed and therefore hold considerable power in the research 
governance and also enjoy wide social acceptance. Any research that is 
carried out using samples and information from a biobank will be required 
to seek REC approval. RECs have been responsible for approving the 
establishment of biobanks.725 
 
Even when LRECs are regulated, a study by Valdez et al726 on the 
performance of IMSS LRECs revealed that the IMSS handbook is not 
always followed. The foundation of the committees was not focused on a 
particular area. According to the study, the two main reasons that led to 
the foundation of an LREC were 1) Medical managers considered this 
necessary (11.9%) and 2) To follow established institutional rules 
(88.1%). Some practices among LRECs reflect that the committees are 
not specialised in particular topics, and it is common that requests are 
made for external support with decision making.  
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The IMSS study reported that only a few committees are 
specialised on issues such as the resolution of difficult cases, promotion 
of professional values, human rights vigilance and the promotion of good 
medical practice. These expectations reflect the nature of the committees, 
that IMSS committees and guidelines are more focused on health ethics, 
which can be partially applicable to biobanking. However, biobanking is 
more closely related to research ethics but the number of these cases is 
falling. In contrast, clinical cases have increased; i.e. complaints on 
medical attention and issues among health staff. 54.8% of the committees 
in the study reported such clinical issues.727 This has resulted in health 
committees with different guidance, different forms and different remits. 
 
7.3.2.1 Integration and diversity 
The IMSS study reported that 10% of LRECs had less than three 
Executive Directors and some of them had remained in the position for 
more than 6 years. Another factor which could negatively impact on the 
decisions of the committee is the reported absence of key members, e.g. 
the chair, “at most meetings.”728 Evidence of gender disparities were 
identified by the study as “professional bias”729 in the committees’ 
integration, as there were disproportionately more men than women.  In 
addition, less than half of the LRECs held meetings to issue a report of a 
project’s evaluation. According to Valdez et.al,730 this reflects a lack of 
interest and commitment within the IMSS LRECs system.  
 
7.3.2.2 Members’ background 
The IMSS handbook does not specifically state the academic 
background required for an ethics membership position.  Only 22% of 
committee members have PhDs. Most committee members hold a high 
administrative position within the institution in addition to their committee 
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membership. 50% of the committee members were doctors with a 
management position.731 This is not necessarily negative but could impact 
on the legal capabilities of the committees. IMSS LRECs tend to 
concentrate on rules, regulations and the law, and the resolution of a local 
committee is merely an administrative step which it has to fulfil. More 
attention should be paid to LRECs’ human resources. Valdez et al. 
suggested that “they may not be sensitive enough to the needs of 
vulnerable research participants…The sole presence of professionals in 
LRECs makes these committees less responsive to vulnerable 
populations when these populations are considered within the selection 
criteria for research proposals.”732 Most discussion of ethical challenges 
raised by the growth in the number of research biobanks focuses on the 
assumption that the only ethically relevant interests are those that 
concern risks to subjects’ welfare. Before the IMSS study, “no reliable 
follow-up studies about the structure and the functions executed by this 
system of LRECs had been completed,”733 for instance, only one out of 
1000 research projects was rejected, a figure which could reflect 
superficial assessment. 
 
7.3.2.3 Lack of bioethics expertise 
Although the IMSS handbook is intended to deal with health and 
research ethics, the composition of the IMSS committees is not balanced 
in terms of expertise. Participant N suggested that a problem is that they 
have “a few bioethicists.” Hence, this number cannot cover the demand 
for bioethics expertise. Additionally, Participant N raised concern about a 
lack of knowledge on bioethics. “They need training.”734 Other health 
institutions, including private institutions, follow different rules. The fact 
that the IMSS performs health care and research, having rules mainly for 
health care, reflects an imbalance in terms of expertise. 
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 7.4 Proposal 
Institutional coordination would be a good step in resolving 
problems on a national level. It is relevant to mention that these measures 
depend mainly on further changes to the regulation of research ethics 
committees. The particular actions to be taken to bring about the 
transformation of Mexican biobanking governance remain undefined. 
When social participation is not sufficiently incentivised, particular 
measures need to be implemented. “For lawyers, recourse to law is a first 
natural reaction to new social challenges.”735 So far, the legal experiences 
on biobanking cannot guarantee that the best choice will be formal 
governance. The two main choices, to be carried out by the public 
authority, are either encouraging self-governance through professional 
attitudes of the parties involved or regulating the activity by legal 
policies.736 A fundamental component of both choices will be information. 
The implementation of policy would need to incorporate sanctions and 
other consequences of legal noncompliance. 
 
In the end, powerful alliances of stakeholders, with government, 
industry and large scientific bodies, have achieved the most recent 
genomic advances. The regulation of biobanks depends on a firm basis 
of principles that require further explanation in practice, for example, 
access to human specimens and data for research purposes. INMEGEN 
has achieved a good reputation as a result of the organisation of studies 
currently developed, up to the point where it has been given the authority 
to approve population studies.737 Nevertheless, this implies potential 
disadvantages if one institution plays the double role of poacher and 
gamekeeper, something even more risky than self-regulation. 
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High-level policy decisions need to isolate, identify, and synthesise 
the key factors, characteristics, and attributes of biobanks across the 
board using simplified implementation schemas. A starting point consists 
of understanding the legal consequences of biobanks, which should be 
covered by generic simplified frameworks. Only this can provide the basis 
of any “practical, flexible, theoretically defensible, but readily adaptable 
instruments that might prove to be useful in shaping, managing, and 
implementing better biobanking regulatory systems in the future.”738  
 
There should be controls for each of the different types of 
collections. Some activities are common to biobanks in spite of their 
purpose, such as collection, storage and release of samples and 
associated data. Hence, it is vital to determine that the best 
conceptualisation choice will be inclusive, based on common standards, 
and, at the same time, specific where exceptions are required. 
Classification needs to be systematic, accessible, and functional in order 
to avoid governing guidelines being overtaken by practice. This is one of 
the first steps to avoid duplication and complexity. Each category needs 
to reflect “on why the categorical heading, and its sub-components, may 
be significant for regulatory purposes.”739 The idea that all kinds of 
biobanks, including forensic ones, should be regulated to protect donors 
and guarantee the correct working order of biobanks as research tools, is 
challenged by the idea that “no ‘taxonomic’ list can ever hope to be 
exhaustive.“740  
 
The main objective of a new policy is the provision of inclusive 
rules, and any potential policy object needs to be taken into consideration, 
although “certain kinds of biobanks should be ‘ring-fenced,’”741 or be 
treated as exceptional. Heterogeneity of biobank categorisation is 
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preferred for regulatory purposes “rather than the generation of a 
checklist.” Rial-Sebbag and Thomsen remark that the legal effects from a 
biological sample will differ depending on the context in which they are 
used,742 which will have significant implications. The multifactorial nature 
of the subject needs to be recognised when new regulations are enabled. 
Some specific types of collections will deserve more attention due to their 
nature.  
 
7.5 Ethical guidance or binding rules? 
Kaye and others743 have identified self-regulation as a typical 
failure in general biobanking policies. It has resulted from worrying 
legitimacy deficits and soft, regulatory techniques. Self-regulation is 
currently taking place due to the absence of oversight mechanisms to 
enforce the rules mentioned in the various partially applicable regulations. 
Self-regulatory practices can be detected in most current Mexican 
biobanking policies, affecting the execution of research projects. Self-
regulation and internal decisions have been the alternative for biobanks 
up to now as a result of the absence of specific ethical standards. 
 
From the evaluation of the relevant guidance, it is clear that the 
current framework of ethical guidelines presents weaknesses in the 
establishment of consistent rules for guiding authorities. Due to the 
absence of clear standards for research with samples and tissues, the 
decisions of more than one committee could present considerable 
variations regarding the same situation. A series of principles depends on 
interpretations and decisions attributed to ethics committees. The most 
evidently problematic areas are decision making, composition, operation, 
potential conflicts of interest and project assessment. Questions to 
participants on what choice would be suitable for Mexico obtained the 
following answers: (See Table 5 in annex p. 6) 
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Hence, self-regulatory attempts should be regarded by Mexican 
law makers as precedents for the creation of specific and stringent laws 
which respond to the needs of researchers and research participants. A 
degree of scepticism in this sense is preferable to an excessive reliance 
on those involved, in such a complex area as biobanking. The promotion 
of international guidelines, through optional adherence to international 
codes of ethics on health and scientific research, has taken place since 
2001744 with a partial response in practice. Mexican researchers would 
also prefer effective guidance which does not result in hampering 
administrative procedures. 
 
 In Participant A’s opinion, laws should not stifle research, and 
should be constrained to relevant parts of the research.745 Hence 
simplified procedures must be implemented as the alternative to an 
uncontrolled autonomy, which has not worked for Mexican biobanking. 
Ambiguity has been used opportunistically, and as a consequence, the 
organisers of numerous pharmaceutical trials aim to cover a number of 
requirements with no knowledge on scientific research, which are then 
evaluated and authorised by committees with the same ignorance on the 
topic. As a result, “a legal and ethical simulation is performed.”746 
 
Legitimacy is also based on specific forms of bioethical expertise. 
As Reich has pointed out,747 the current role of bioethics, within policy 
making and the governance of biobanks, should be based on such 
specific forms of the knowledge to be legitimated, rather than led by 
technocratic authoritarian or self-regulatory approaches. The regulatory 
aspects of biobanking are meant to be complemented by the expertise of 
ethics committees. Avoidance of exploitation depends on their decisions. 
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LRECs have the great responsibility of applying the current rules, self-
regulatory principles and international guidelines. This involves evaluating 
the scientific merit of a project corresponds to ethics committees. For this 
reason, members of LRECs need special training. They should be aware 
that these rules and regulations are not powerful enough which to 
determine whether a decision is right or wrong. Ethical issues will be 
resolved in a more centralised way if committees’ decisions are 
compulsory.  
 
Institutionalised ethics of this nature may include public concerns 
within the policy process, while they subordinate those concerns to an 
isolated defence of individual autonomy. However, “ethical issues 
concerned with public welfare do not have recourse to individual 
autonomy, yet a common theme is the legitimacy of decision makers and 
their policies in relation to the ‘public interest’.”748 
 
7.6 The need for oversight in biobanking 
An adequate attempt to start the discussion for what is required 
may be simpler if we know what should be avoided. In addition, it would 
be necessary to use ethical knowledge on biobanking to encourage legal 
enforcement. It is on the Mexican legislators’ agenda to become more 
supportive of medical science: “We will be vigilant of this great advance 
(the human genome),”749 a commitment which is still to materialise.  
 
 In the opinion of Gibbons, for biobanking governance, “a 
dedicated, independent statutory authority could reduce the risk of 
regulatory capture.”750 Gibbons recognises that “biobanks may be 
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governed or supervised effectively in many different ways, through 
structures put in place for overall project governance, day-to-day 
management, ethical oversight, compliance checking, and 
enforcement.”751 However, the required control will depend on the type of 
biobank. Different ‘types’ of biobanks warrant various forms, degrees of 
regulation and oversight. The proposed criteria would also take into 
account the nature of the institution, selecting principles for effective 
control, and inclusiveness matters. This means that small biobanks 
should be regulated too. Even though it is not written in law, fieldwork has 
shown that the current authority responsible for biobanks is COFEPRIS 
and not the National Bioethics Commission. Only one participant referred 
to the latter as the current authority, even though committees do not have 
binding power.  
 
If biobanks continue to come under the regulation of health laws, 
the oversight would come under the Ministry of Health. In case 
COFEPRIS retains the oversight of biobanking, it would need more 
experts and clinical data. Ideally, a new biobanking framework for Mexico 
would also cover data protection; data protection laws could be used to 
regulate the IFAI, the current institution in charge of the protection of 
public and private data, as long as data protection related to biological 
samples is regarded independently. In this case, the IFAI would have to 
be coordinated by the institution in charge of general biobanking 
oversight.   
 
Although COFEPRIS is currently the legal authority responsible for 
biobanking and establishes regulatory mechanisms for biological matters, 
many of the functions this institution has to perform have no connection 
to biobanking. It will be necessary to have a specific authority for 
biobanks, and one of the first steps would be to create an institution able 
to control and register biobanks. This has been the case in Spain and in 
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UK. (Chapter six compared Mexican and other countries’ laws). The 
creation of a National Registry of Protocols can be envisaged, making 
sure that rejected research protocols are not actually carried out, even if 
they find a supporting institution. The CNB cannot take on this role; its 
purpose has been designed to be purely advisory. Another possibility, 
though less suitable, is the creation of an organisation dependent on 
COFEPRIS.  
 
Fieldwork has shown (See Table 2 in annex p. 3) that the national 
supervision of biobanking can be attributed to COFEPRIS as it is 
responsible for the “sanitary control of organs, tissues, and human cell 
donation and transplant.”752 In contrast to the CNB, COFEPRIS has 
monitoring responsibilities. Research protocols are meant to be evaluated 
by the Internal Commission of Health Authorisation in Human Beings 
within COFEPRIS. Any committees must be registered at COFEPRIS 
using the “registry of commissions of research, ethics and bio security”753 
and applicants are assigned a registration code. COFEPRIS, as a 
supervisory and scrutinising authority, approved 538 research protocols 
in 2011.754 However, in practice, it has been detected that COFEPRIS 
has found it very difficult to deal efficiently with protocols involving 
increased biobanking activities. Participants A, D and E,755 agree that the 
numerous functions delegated to this commission have proven excessive. 
COFEPRIS’ extensive work has been directed to administrative controls 
to prevent health risks at the national level. The effective control of 
biobanks is still far away from being achieved; a situation that could justify 
                                                          
752 Comisión Federal para la Protección contra Riesgos Sanitarios (Federal 
Commission for the protection against health risks), Atribuciones, funciones y 
características de la COFEPRIS (COFEPRIS' atributions, functions and 
characteristics) 
 (Secretaría de Salud (The Mexican Ministry of Health, 2010) 
753 COFEPRIS 
754 Sánchez,  
755 Responsible-for-the-research-department-at-a-public-biobank-Participant:A, 
Responsible-of-the-ethics-department-and-researcher-at-a-public-biobank-
Participants:DandE 
256 
 
the creation of an alternative oversight organism or specific subdivision of 
COFEPRIS. 
 
7.6.1 The need for governance biobanking 
mechanisms 
Governance barriers might come from different perspectives and 
different interpretations of the main legal issues. Following Bunton and 
Peterson’s focus on governance, the law cannot advance separately from 
aspects such as policies.756 Once the legal background has been 
provided, the existence of legal issues is evident, such as the level of 
regulatory response, the role of decision makers, types of measures to be 
favoured, incentives and restrictions, and the distribution of 
responsibilities.  
 
A great problem within the Mexican experience has been finding 
suitable mechanisms in order to avoid contradictory operative rules on 
public goals. These need to “reflect both substantive and procedural 
aspects.”757 Many biobanks are purposefully designed as long term 
endeavours, ensuring the longevity of the biobank and the continuity of 
governance policies and mechanisms, fit-for-purpose over time, with 
respect to both private and public interests that are at stake.758  
 
Policy makers are committed to cover as many situations as 
possible, and scientists and academics need to be equally committed to 
provide constant feedback to their relevant sectors. The mechanisms 
need to cover the potential options for tissue samples when the research 
project has ended. Researchers are interested in avoiding “samples’ 
waste” of preserved tissue, and mechanisms should encourage 
maximising the use of valuable material for science. If the samples need 
to be disposed of on ethical grounds, this would also need justification 
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mechanisms. For benefit sharing and even the creation of a ‘Mexican 
biobank’ in the long term, agreements will not suffice. Mechanisms need 
to be imposed by the governance framework. 
 
Prainsack and Buyx propose the implementation of policy based 
on solidarity, an element to be analysed in depth in the next chapter, 
which includes actions and overarching goals of the research biobank, 
followed by specific requirements to provide: 
 Information about the research questions and contexts that the 
biobank supports at the time of recruitment. 
 Information on commercial strategies and interests.  
 Statement of future use: the participation agreement should include 
a statement that the biobank may be used to serve research that 
cannot yet be envisaged. 
 Re-contacting and feedback: participants should be informed what 
kind of data and information they will have access to. 
 A list of risks and benefits insofar as they can currently be 
foreseen.759 
 
Principles are required to reduce ambiguity; hence the publication 
of biobanking guidelines is essential. Despite significant legal gaps, the 
current biobanking rules need to start becoming effective through 
practical mechanisms. Implementation requires:  
 The need for a fully transparent process; 
 The need to articulate the values that inform decisions 
 The need for a scientific case to justify certain choices over others; 
 The need for procedures of accountability.760 
 
If any of these are absent, institutional coordination efforts are 
likely to be negatively affected; “it is almost certain that the sense of 
partnership would be damaged and that would attenuate ideas about the 
effectiveness of independent scrutiny and public accountability.761 
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 7.7 The role of trust 
The effectiveness of a governance framework to protect 
participants from abuses has an impact on public trust towards the law. 
The enhancement of socially ethical behaviour can be encouraged by a 
strong legal framework. Salter and Jones, based on the experience of UK 
Biobank, point out that scientific advances in genetics are dependent on 
the construction of novel forms of regulatory legitimacies,762 which need 
to be reliable. 
 
In biomedical research, the aim of creating public trust, of 
compliance and cooperation has been a primary strategy. The ethical, 
legal and social implications of prioritisation must not be set aside. It is a 
priority to find mechanisms for scientists and policy makers to approach 
research participants and patients more directly. This is one of the 
greatest challenges within the multi-cultural Mexican context. The lack of 
standardisation, scope and ethical significance of policies calls for uniform 
ethical biobanking guidelines. It makes it evident that oversight 
mechanisms and sanctions are preferred over voluntariness and hence, 
these should be adopted. 
 
 Biobanks are committed to sustain the trust of those who contribute 
samples.763 “When the pubic give their samples and information, they 
have to base their decision on trust; they need to have hope in the 
biobanks and faith in the biobankers, much in the same way that we have 
faith in our banker’s skills and honesty, and hope in the interest rate that 
the bank will be able to offer us.”764  
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 Public trust will help to overcome the challenge of upholding 
citizens’ willingness within biobanking.765 Reflexive governance can also 
encourage healthy scepticism as a means to promote trust.766 A degree 
of scepticism should be expected, which is preferable to not having any 
public response.  
 
  7.7.1 The impact of public trust in Mexican biobanking 
 If at the heart of the biobanking enterprise is the need to promote 
issues such as trust and the public interest, it is not clear that laws alone 
can deliver on this task.”767 Even when Mexico reaches a suitable legal 
biobanking framework, even the most detailed reforms present limitations 
beyond legislative technique.  
 
 The predominantly legal ambiguity and excessively trusted self-
regulation have been partly responsible for the Mexican public being 
either uninterested or sceptical. It could be observed from Chapter 4 that 
the legislative debate on genomic research did not receive any public 
pressure and remained stuck for more than a decade. This and other 
embarrassing situations have led national to regulators to lose a 
significant amount of credibility, and therefore trust.  
 
 Participant O768 emphasised that one of the greatest problems in 
Mexico is the lack of trust from citizens towards the legal system, an issue 
to which the media contributed. The participant shared anecdotical facts 
of the data bases available in a Mexico City flea market known as ‘Tepito’. 
This situation has made many citizens decline from readily disclosing 
data. Participant N has pointed out that even strict biobanking laws by 
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themselves may not work effectively if there is no trust in the law, 
especially researchers.769 
 
   7.7.1.1 Realistic promises or ‘genohype’ 
 In principle biobanks should be trusted as promoters of fair 
research contributing to public benefit. Normally, “patients have 
increasing opportunities to obtain information about health care products 
and services from sources outside the traditional healthcare setting, such 
as the printed press, television and the internet.”770 Breaching subjects’ 
trust does not necessarily mean allowance of exhaustive exploitation on 
the information; the difference could consist of previous explanation of the 
different uses and purposes of information. “The naturally trusting part of 
the public might not pay attention, not even if the irresponsibility of the 
goals is revealed in the information sheet.”771 Trust can be easily broken 
in a passive way. Omissions take place when the limits of accessibility 
are not explained.  
 “Concerns about privacy, intellectual property and possible uses of 
samples and data, as well as episodes of misadventure or inappropriate 
use of stored samples challenge biobank managers’ ability to maintain 
trust and regain it once is lost.”772  
 
 Mexican patients read in the newspaper that someone was saved 
from leukaemia. However they do not know that such achievement took 
perhaps years, several trials and that some failed.773 Topics such as 
personalised medicine involve numerous limitations, for instance, time. In 
a sense, Mexicans might have been given false expectations.  
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 Recently, novelty pieces of international literature have remarked 
the importance of public trust within biobank research,774 highlighting that 
people may participate in research in the hope to receive follow up 
examination or treatment.775 For a more integral relationship to be 
accomplished, the biobanking discourse needs to be more realistic; 
especially when promises are made, participants need to have increased 
expectations “as doctors come closer to making claims that a drug will 
work for them as advertised.”776 (Public understanding involves 
knowledge dissemination). Knowledge dissemination in Mexico requires 
strategically based techniques free of typical sensationalism. Media 
communications sensationalism has been termed “genohype,” and 
describes the exaggerated portrayal of the risks and benefits of genetic 
research and biotechnologies.777 Consequent public anxiety can be 
decreased by realistic and direct information. Similarly, if the limits set up 
in advance are breached, trust will be undermined. “To fail to use the 
resource for community benefit would be a betrayal of trust.”778  
 
 The principle of ‘integrity of purpose,’ aims to promote trust by 
strengthening the links between biobanks and society. Public trust can be 
restored through a policy of transparency covering the multiple interests 
of current and future patients. Biobanking governance needs to promote 
trust, but at the same time, regulate it. Any relationship based on trust 
needs coherence and consistency between biobanking promises and the 
results. Positive popular reactions can be expected only once those 
involved have true proper knowledge of what can be expected from 
biobanking and their rights; and once trust is generated. 
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   7.7.2 Natural trust: an element to enhance 
 Docornau and Strand have classed a sense of trust as ‘natural’: “a 
general trust in public medical research and the medical profession.”779 
The medical nature of some collections will encourage public trust and 
inspire a sense of responsibility by itself, “a priori.” Natural trust is highly 
desirable in order to achieve efficient enrolment of donors.780 The option 
of natural trust should be transposed from medical, towards the role of the 
doctor, to expertise grounds, towards ethics committees. However, this 
initially blind trust involves some risks. Researchers and doctors could act 
advantageously and the public could act irresponsibly, if a sense of 
responsibility is not maintained.  
 
 The establishment of limits would impact positively on the 
accessibility of samples, the subject and the group of subjects, by creating 
a sense of trust. Creating awareness among members of ethics 
committees from public institutions would also constitute a step in 
reinforcing the desired natural trust even among those who have 
developed scepticism. 
 
7.8 Emergent measures 
Following Hardy et al, the main question for countries that have not 
started genomics initiatives is, what are the potential entry points?781 
Even when the purpose of biobanks’ may not be completely certain, new 
governance needs to be as certain as possible, and preventive measures 
are required. In the short term, positive steps cannot be provided by 
instruments other than the law. Laurie782 has pointed out that the law is 
required when the systems have failed. Reflexive governance, through 
mutual learning, is a state in which the law is not even required; something 
unrealistic for the Mexican setting. Participant F has pointed out that 
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Mexico requires emergent measures based on governance, supported 
not only by the engagement of the public, but also all involved 
stakeholders.783  
 
The law will be helpful to alleviate systematic failure. Some of the 
measures evaluated could work in the long term and some of them are 
still emerging. The procedural legal field requires urgent attention, and the 
enforcement of principles of “independence, oversight and efficiency of 
control powers, including sanctions784” would be a good start. Following 
the reflexive governance approach, other measures to be taken consist 
of: 
 
 Designing-in interoperability with respect to scientific and 
governance approaches. 
 Designing-out approaches that are restrictive for sharing, 
cooperation, flexibility and mutuality, 
 Establishing policies and procedures for protection 
 Establishing policies and procedures to actively promote the use 
of the resource in keeping with its original purposes, 
 Ensuring the longevity of the biobank through carefully managed 
access policies and arrangements and stewardship of the 
resource, and 
 Ensuring that governance policies and mechanisms remain fit for 
purpose over time.785 
 
 Ethical review boards will play a key role in maintaining public 
trust,786 but can struggle to achieve it without an adequate legal policy, 
suitable training and expertise. They will be likely to be assigned the 
resolution of cases unforeseen by the law.  
 
 It is essential to raise awareness of participants’ rights in general 
regarding data protection. An urgent measure to be taken by the IFAI will 
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be to remain in contact with associations; proposed activities include the 
organisation of colloquiums,787 in connection with social campaigns to in 
order to build a sense of culture around the right of personal data 
protection. 
 
 7.9 Concluding remarks 
This chapter has identified relevant indicators used to measure 
consistency in terms of governance, through fieldwork showing insights 
from different biobanking areas. These indicators point to self-regulatory 
elements, which are detrimental to biobanking and should currently be 
avoided. The main detected inconsistencies are associated with 
deficiency and over-dependence on informal systems. The governance 
of biobanks in Mexico is ambiguous. According to the analysis, the current 
governance actors and institutions do not include a fully protective 
framework for patients and research subjects. This is partly due to the fact 
that the main motivation for the legal work has focused on national 
development and economic goals. 
 
Fieldwork has demonstrated that research governance is the main 
categorical element to enhance biobanking.  Research policies should be 
established for the acquisition of new samples, access to samples for 
research purposes, for destroying collections when samples have fulfilled 
their original purpose, if they are no longer suitable for their intended 
purpose, or if participants request the withdrawal of their specimens. 
These policies should be clearly described and openly available, where 
appropriate, to users and potential users of the specimen collections.788 
 
Fieldwork has revealed that a number of Mexican stakeholders still 
feel reliant on modifying the current biobanking structures, rather than 
creating new ones. However, the Mexican legal framework on biobanking 
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needs to be replaced in order “to protect and to promote core interests 
engaged in biobank practices and ensure that the science in question is 
responsible.”789 The view of encouraging a completely new biobanking 
framework prevails over the choice of reforms. 
 
The model of reflexive governance, an innovative approach relying 
on mutual stakeholders’ feedback, rather than solely on governance, 
requires trust schemes, which at the moment, Mexico needs to develop. 
The main legal deficiencies described through this chapter should initially 
be a target for legislators; law making is essential since “all biobanks 
require governance, at least to some extent.”790  
 
Even when currently, there are institutions associated with the 
governance of biobanks, these remain uncoordinated and their 
attributions disconnected from current biobanking rules. Public 
institutions, such as INMEGEN, should become a governmental priority 
in order to achieve common objectives through biobank research. 
Additionally, more engagement with the public would be highly beneficial. 
In the long term, formally enforced governance with a strong ethical 
background can be reinforced by public demands, the building of trust, 
acceptance and careful political negotiation.791 In response to socio-
cultural challenges, cooperation is essential; it needs to materialise in 
direct involvement with the public through participatory consultation 
forums.  
 
Provisional measures should be proposed as a starting point for 
substantial legal reform. The ever developing political debate around 
emerging human genome research and the collection of biological 
materials constitutes justification to reconsider not only regulatory 
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practices, but also strategies.792 Reflexive governance is the goal for 
Mexico in the long term, while specific general mechanisms for emerging 
initiatives are preferable in the short term. “The general point that 
governance was seen as the solution to concerns raised by biobanks 
should not be a surprise; rather, it reflects a widely held notion that 
governance mechanisms mediate relationships of trust in modern 
democratic societies.”793  
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8. Social solidarity and justice 
 
8.1 Introduction 
This chapter will investigate the role of social attitudes in 
legitimising Mexican biobanking regulations, focusing on social solidarity 
as a form of engagement through collective action. It argues that the latter 
is a relevant component for the emergence of effective biobanking 
policies, and it will address the main challenges of a social solidarity 
approach from a Mexican perspective. Finally, a discussion on the 
appropriateness of social solidarity as the rationale for biobanking policies 
will follow. 
 
The first section of this chapter will analyse social awareness and 
its impact on the current state of Mexican biobanking. The second section 
will analyse social alternatives to enhance the effectiveness of 
biobankling rules, exploring the role of solidarity. Literature on solidarity 
as an element contributing to the effectiveness of biobanks will be 
included.  
 
8.1.1 The importance of social attitudes 
Lumbreras and others support the idea that regulation cannot be 
understood in isolation, especially when biobanking research is closely 
linked to social benefit.794 Social attitudes have had a significant impact 
on the implementation of biobanking laws and ethical guidance around 
the world, including implementation in Mexico. However, Mexico’s 
reasons to regulate biobanks greatly differ from other countries.  
 
Recent discussions in international biobanking are centred on 
human rights (dignity and more specifically data protection and informed 
consent795). At the level of individual participation, well defined principles 
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of autonomy, beneficence and no harm should be upheld, and 
confidentiality and privacy of information is required to respect the 
participants and the dignity of human life. These principles have no 
geographical boundaries and have “common value” to all human beings 
in every part of the world. Nevertheless, substantive principles alone are 
not enough to determine policy frameworks. Universally accepted ethical 
principles of privacy, confidentiality and consent need special 
considerations in developing countries because their definition is also 
embedded in the cultural context alongside research ethics.796 For 
instance, Mexico’s predominant bioeconomic views have negatively 
affected the social side of biobanking.  
 
8.1.1.1 The role of cultural attitudes in biobanking 
A range of factors emerge from recognising the need for 
legislation, in which the most influential ones are historical, cultural and 
ethical. Historical circumstances have affected cultural contexts to a great 
extent. The values and culture that are implicit in a particular country may 
also influence the way that these various elements of governance are 
enacted.  
 
Christian churches, through the centuries, have asserted their right 
to express an opinion on medical matters of spiritual importance, while 
other major religions across the world similarly voice their opinion on 
matters of medical ethics, some not allowing any use of body tissue due 
to religious beliefs. In Mexico, small isolated groups of indigenous people 
may find that the use of data conflicts with religious or cultural 
understandings about their ethnic, legal or political claims relating to land 
or items of cultural patrimony.797 As stated by Simon et al, community 
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engagement implies recognising the cultural context surrounding 
biobanks.798 In the opinion of Gottweis and Zatloukal, the success or 
failure of biobanking projects depend on the ability of these to become 
part of the political and socio-cultural fabric.799  
 
Data obtained from interviews has revealed the need to explore 
socio-cultural elements, providing different insights, for example, 
Participants D and E have recognised that some people are still fearful of 
donating body parts for cultural reasons.800 Participant L801 remarked that 
currently, the most complicated part of biobanking are the cultural issues. 
Participant O802 referred to cultural boundaries regarding the treatment of 
tissue from the deceased; “in the case of organ donation, there is no 
social awareness because we have not encouraged it from elemental 
education. Then, suddenly trying to “force” a culture for organ donation 
would be discouraged.”803 Planned actions need to be based on 
awareness of people’s cultural views, for example, on tissue treatments, 
balanced with knowledge on the implications of sample donations.  
  
A major obstacle that biobanking actors frequently face is the 
Mexican public seemingly unaware of a number of ethical issues. The 
population need to be aware of ethical and practical issues in order to 
subject biobanking to proper scrutiny. The cultural diversity of Mexico 
means researchers need to be prepared if they are to produce knowledge, 
but also society needs to be able to respond if they are to use the 
generated knowledge adequately. 
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8.1.2 Public accountability and awareness 
Accountability to the public is a highly desirable element, which 
demands a degree of reciprocity. “In attempting to address these 
controversies in biobanks, it is of paramount importance to take into 
account public perception and trust of biobanks.”804 A biobank will be 
publicly accountable if it acts ethically by recognising and protecting the 
rights of those involved. Ethical research requires not only recognition of 
the benefits of personalised medicine, but also the moral issues involved. 
Biobanking can only be scrutinised publicly if the public are aware of the 
importance of the ethical aspects. Such recognition can foster public 
demands. The notion that payment or return of health information can 
outweigh a person’s privacy concerns may have implications for the 
ethical enrolment of subjects.805 In addition, health research can be 
seriously affected if fundamental research biobanking structures are not 
reliable. “If there is a perception that biobanks are not proceeding in a 
manner congruent with public interests, biobank research may be 
significantly hindered or prevented.”806 
 
Public awareness is necessary to support the accountability of a 
legal system through public scrutiny. It emerges when a significant 
number of citizens become interested in a topic, with well-founded 
political reasons. This interest, generally fostered by a need, starts at the 
individual level, for example, an individual need for protection against 
associated risks. Participants D and E agreed that a sense of trust is basic 
for biobanks to operate and that the legal rules play an essential role in 
this matter.  
 
Currently, there is a lack of awareness of the value of biobanking 
in Mexico and the consequences are costly to industry. In general, as 
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pointed out by Hewitt, “one additional obstacle to public-private 
partnerships is the lack of quality assurance in many public sector 
biobanks.”807 In terms of data protection, more overseas attention has 
been attracting foreign investment into the country,808 with regulation in 
place.  
 
Awareness of limits on prevailing biobanking rules is critical, as 
biobanking must always be viewed within a larger context. Public 
awareness may cause a contraposition of interests between industry and 
citizens. It would be concerning if the creation of rules instead of self-
regulation discouraged investment by industry. However, the opposite 
effect is more likely to happen. If the population is to be interested in the 
need for human rights protection, first, they need to be aware. The 
population need to understand the importance of topics such as personal 
data contained in biological samples. Public awareness can gradually be 
constructed through public scrutiny of the defence of individual and 
collective rights. In this particular case, awareness needs to be created 
on the rights which can be affected by the donation of a sample. Following 
this, the needs of those involved can then be clearly identified, demanded 
and be the subject of legal protection. 
 
8.1.2.1 Public awareness attitudes towards 
biobanking practices 
As pointed out by Vaught and Lockhart, in recent years public 
awareness of biobanking has grown significantly.809 However, there are 
still significant boundaries for the creation of specific biobanking 
regulations and the most important are the predominant cultural values. 
Most Mexicans are not aware of the risks when donating a sample; hence, 
no protection is demanded from the authorities. The public are not aware 
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of their rights, which slows down reform as it results in ambivalence. 
Paradoxically the public are unaware of the ethical issues and therefore 
quite happy with the situation. If they woke up to the potential rights 
infringements, then there would be more impetus for reform.  
 
Diverse opinions of stakeholders agree on the fact that public 
awareness in Mexico needs to be encouraged. In the view of Participant 
L,810 strengthening awareness on the potential benefits of research 
amongst the public is a key point for the resolution of too-passive social 
attitudes. Participant K811 believes that dissemination of information 
should be carried out at the same time as legal rules are encouraged, as 
a way to achieve legal compliance. If people are aware of their rights, they 
will also demand more protection of them. 
 
In the case of tissue sample donations in Mexico, there might not 
be significant social awareness because it would be unusual. For 
Participants D and E, Mexican social and political participation currently 
occurs to a low degree. A citizen’s donation of a sample happens because 
“Mexicans tend to have a ‘reverential respect’ towards the role of their 
doctor. Their donation could be encouraged only because “because their 
doctor told them to do so”,812 not because they are really interested in 
contributing to science. In the words of Participant N, “the population in 
general do not always understand the implications of donating a sample. 
Hence, the need for protection mechanisms is urgent in this respect.”813 
This helps to explain how the relationship between science and society 
tends to be split in Mexico. 
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Regarding awareness of indigenous communities, research in 
personalised medicine has been significantly helped by their samples, but 
they will always be a vulnerable group to protect. Reportedly, it is unlikely 
that a research team will come back to the community to inform donors of 
any results. “Researchers do not come back to the sample source to 
inform them of the publication.”814  Participants D and E have pointed out 
that indigenous people tend to ignore their need to be protected and what 
from.815 
  
Biobanking research depends on citizens’ willingness to act as 
donors and allow research on their donated biological samples and 
personal information.816 The core challenges of biobanks arise from their 
diversity, their longevity and the uncertainty that underpins their future 
direction.817 Under the principle known as proportionality of action, there 
can be exceptions to the principle of integrity of purpose if there are 
enough justified reasons. “Thus, risk to privacy can be seen as acceptable 
so long as the imperative to share is demonstrated, the benefits to the 
public interest are articulated, and the relative risks to privacy are 
minimised.”818  
 
8.1.2.2 Informed consent, an example of cultural 
influence 
The list of examples showing an absence of public awareness 
among the Mexican population is extensive; this is the case of informed 
consent. Although globally debated whether it is just a legal doctrine, the 
concept of informed consent is a significant ethical concern for developing 
countries because of the complications of social hierarchy at the level of 
the nuclear family, the community and the still prevalent paternal attitudes 
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to medicine where doctor is above the patient. This example also portrays 
the negative expected result from paternalistic ideologies in the practise 
of medicine used as coercion, where participants are ignorant about their 
rights.819 
 
Participants D and E820 believe that the cultural perceptions on the 
legal system also influence how people see the informed consent 
document.  In the US they have very long consent forms to avoid being 
sued. In Northern Europe they tend to be brief as people have more trust 
in their institutions. “Mexican people will not read a long informed consent 
document. It needs to be concrete.”821  
 
Participant N explained that the poor awareness among Mexicans 
means participants “just sign the informed consent form because they 
know it is part of the procedure, nothing else.” In the opinion of participant 
F, implementing a flexible consent model according to the needs of each 
biobanking type, “does not mean standardising the informed consent.”822 
 
If Mexican citizens are unlikely to read a long consent document, 
other choices need to be available for building awareness, especially in 
the case of vulnerable populations. It is the responsibility of researchers 
and health providers to ensure fair research and healthcare activities. The 
way information is presented has an impact on the public, who may not 
understand due to expertise or language barriers. An ideal informed 
consent process will ensure that participants understand all advantages 
and disadvantages from their participation.  
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Participants D and E believe that “informed consent in Mexican 
legislation needs to be very specific because of the trust level of people 
towards institutions.”823 The absence of social trust on institutions would 
make specific rules ineffective. Moreover, the Mexican population should 
be informed of potential scientific benefits that can be achieved through 
sample donation in a realistic way. In the end, biobanks entirely depend 
on citizens’ actions and the health of the greater population relies on 
biobanks. It was emphasised by participants D and E that, compared to 
other countries, there is much work to be done in Mexico on the area of 
trust. “Some Mexican researchers had the opportunity to ask Northern 
Europeans what should happen to their samples, and were surprised by 
the responses. The interviewees said that the ethics committee should 
decide on it. In Nordic countries, people are more open to sign an 
informed consent because they trust their institutions. In developing 
countries, the trust level of people was lower.”824 In the opinion of 
Participant O, regarding investment, the level of practical structure in 
comparison with other countries is significantly poor. “We have no means 
as databases, we are really behind.”825 
 
Consent must be inclusive and designed according to the needs of 
the ‘culturally sensitive’ target population. If an indigenous population 
demands data protection in the same way as other populations, it means 
that special measures will need to be taken; 1) to make that population 
aware of the involved risks and 2) to take the necessary measures to 
protect the group, given its character of vulnerability.   
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The following section will discuss whether Social Solidarity can 
work as the justification for biobanking activities in a country like Mexico, 
a country whose diversity is not only present in terms of ethnicity but also 
in the distribution of wealth among the population. 
 
8.2 The role of social solidarity 
Collective health depends greatly on social cooperation and 
interdependence.826 The role of solidarity is unifying in this respect, “a 
social force which contributes to the sustenance of the unity of a group of 
people.”827 Similarly to cooperation, solidarity is constructed on the basis 
of certain beliefs and has a cohesive effect, often considered necessary 
for the success of a social struggle.828  
 
It is precisely in a context of social struggle that elements of 
unification are needed. The majority of the Mexican population live under 
poverty conditions, which need to be helped by focusing on priority fields, 
such as health. Mexico has the second highest rate of obesity. One out 
of 11 Mexicans suffer from diabetes, the highest cause of death in Mexico. 
This percentage is 3 times higher than in Chile. 17% of public health funds 
are spent in the treatment of this disease. From 1960 to 2012, Mexican 
life expectancy had gained 2.8 years in men and 3.4 in women. Countries 
like Japan have gained 7 years in men and 10 in women. The average 
gain in OECD countries is 4.4 years in men and 5.6 years in women. 6.4% 
of the IPB is spent on health, in comparison with 9.6% from average 
OECD countries’ IPB. A Mexican spends 249 dollars per year on 
medicines, whereas an average OECD citizen spends 487 dollars 
annually. There are 1.7 hospital beds per 1000 habitants; whereas the 
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average for OECD countries is 3.1.829 These conditions are not shared by 
the whole of the population. Some sectors are wealthier than others. 
 
A more comprehensive approach could feed into discussions of 
compensatory and distributive social justice and, in this way, move 
towards resolving tensions that currently exist; such as social inequalities. 
Following Rawls, the role of justice, similar to solidarity, is also cohesive. 
There is justice when rational and reasonable individuals are constrained 
by the sense of fairness.830 This can be transposed to international 
grounds, taking into account that biobanking is an international reality 
where Mexico already participates.831 Whilst this concept of distributive 
justice holds particularly true in the relationship between the developed 
and developing world, “a more general principle of compensatory justice 
would also seem to underlie concepts of benefit sharing.”832 In this sense, 
the concept of solidarity can help society understand itself better.833 
Benefit sharing is still possible even within disparities. 
 
8.2.1 Criticism to solidarity in literature 
However, in the context of contemporary neoliberal societies, the 
influence of solidarity, by itself, in health and other social affairs, has been 
considered as weak.”834 Solidarity, being mediated by a commitment to 
an idea or a cause, is in that respect ideological.835 Solidarity can indeed 
become ideological when there are no realistic conditions that make 
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participants equal in practice. "A society which clearly perceives solidarity, 
interdependence, mutual risk and benefit, is preferred.836 Solidarity 
certainly needs to be strengthened by social cooperation and an 
appropriate sense of legality to fight economic inequalities. 
 
According to Samuel A. Butler, solidarity can be weak when 
attempting the provision universal healthcare. “Anything that might serve 
such a role (the provision of universal healthcare) is more properly 
understood as being grounded in concepts such as liberty, equality or 
justice than in solidarity.”837 Health affairs need the intervention of medical 
professionals, health policy analysts, and health policy makers. However, 
this does not only apply for solidarity, but also for justice and liberty. These 
could also become ideological without the coordination of stakeholders, 
social engagement and adequate legal rules. 
 
Health is a primary for everybody, despite their social condition. In 
this respect, the role of bioethics can be helpful. The benefits of medical 
research must be viewed as solidarity obligations to take social action 
over social interests.  Solidarity must become more widely active and 
explicit in bioethics analysis and argumentation as it endeavours to shape 
reasons for obeying norms and rules of common benefit in an open 
diverse society. 
 
8.2.2 Social solidarity and biobanking 
As emphasised previously, biobanking research involves priority 
areas and the use of diverse techniques, which involve the potential for 
discovering new therapies for diseases. In epidemiological terms, 
biobanking is socially oriented (stratified medicine) and individually 
oriented (personalised medicine). Accordingly, this link emerged from the 
                                                          
836 Jennings and Dawson 32 
837 SA Butler, ‘A dialectic of cooperation and competition: solidarity and universal 
health care provision’ (2012) 26 Bioethics 351 
279 
 
promise of personalised medicine to revolutionise health care by 
harnessing individual genetic information to improve drug safety and 
efficacy.838 One of the main targets of the diverse biobanking projects in 
Mexico has been for personalised medicine to benefit the whole 
population. The role of the public in biobanking is substantial due to the 
link between research and improvements in medicine for everybody. 
 
According to Wilson, “all research participants should receive 
information about general research outcomes and an indication of 
appreciation”839 Sadly, without adequate biobanking governance, the 
benefits of scientific research will never reach the poorest. Within 
biobanking, solidarity aims for the willingness of participants to donate 
time, samples and information with the only compensation being the 
knowledge of potentially having helped someone else’s health. 
“Researchers and patients should be seen as a team, each doing their 
share to promote the common good of improved health.”840 In terms of 
practicalities, it would appear that, where specific legislation relating to 
governance of the databases has been enacted, the matters of ethical 
concern are at least identified and an organisational response stated. This 
approach acknowledges the importance of the relevant ethical questions, 
and the relevance to the communities involved, assuming that they are 
equal. 
 
When participants are not equal, disparities need to be mitigated 
somehow. A socio-political discourse has been constructed from 
solidarity, which explains biobanking purposes as “a new process for 
agreeing to research participation in the form of a participation 
agreement, including a conceptual shift towards harm mitigation 
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strategies.”841 The guarantee that research would improve public health 
helps to legitimise solidarity in biobanking. “Sharing of our genetic 
constitution not only gives rise to opportunities to help others, but it also 
highlights our common interest in the fruits of medically-based genetic 
research.”842  
 
8.2.2.1 Social solidarity and ownership 
Innovative models of biobanking governance need to support 
collaborative approaches to improve health systems. Solidarity practices 
would manifest in biobank governance arrangements that envisage 
research participants “as partners in research to whom the biobank owes 
respect and veracity.”843 For this reason, it is relevant to inform 
participants of the type of research and anticipated findings that will be 
obtained.  
 
However, the principle of solidarity cannot be implemented in a 
completely free way. For example, the policy of not providing feedback to 
research participants may be based on solidarity reasons. This would be 
acceptable as long as the findings of the health consequences of the 
person are insignificant. Feedback on samples is not possible in some 
cases; samples are only used as a source of data, as medical registers 
are used in epidemiology. “Any benefit that can result from such research 
is a product not of the samples or registries themselves, but of the 
intellectual work done by the researchers.”844   
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Even when some databases involve free access, property rights 
are still a matter of ethical concern. Generally speaking, both researchers 
and participants envisage benefit to the public good, through a 
contribution to science. While participants agree to donate their samples, 
researchers have the choice of whether or not to share research 
materials. The ownership of knowledge or potential knowledge may 
become an individual or collective right, even in places where social 
inequalities are present. “The problem with genetic samples is that the 
research community has traditionally considered the DNA as a gift,”845 
which is an action of altruism and solidarity, not a ‘loan’ under a specific 
contract. Ownership issues have become a significant debate, which in 
the USA recently finished with the prohibitions of human genes patents.846 
The ethical focus present discussions are taking seems oriented towards 
the protection of citizens against extreme profit making interests. 
 
No references to intellectual property matters have been made in 
Mexico. It is very difficult to determine the individual ownership of such 
samples, and it could be assumed that they are the property of the 
biobank in which they are being stored. Gerardo Jiménez recognises this 
as a challenge to “the need for novel funding mechanisms and incentives 
to innovate and register intellectual property outside of the traditional 
format that conditions a significant proportion of scientists’ income, 
creating a legitimate urge to publish results.”847 
 
8.2.3 Solidarity as a means to help disparities 
Prainsack and Buyx ask whether it is necessary to offer any kind 
of benefit in exchange for a significant social contribution, for example in 
sample donation. This should not be misunderstood; this proposal does 
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not involve changing the sense of solidarity as a principle. Solidarity works 
as a principle of mutual advantage that Rawls portrayed as social ideal 
based on social cooperation, "in justice as fairness society is interpreted 
as a cooperative venture for mutual advantage."848 
 
Mexican biobanking requires agreements involving the sharing 
and exchange of materials between participants from diverse cultural 
backgrounds, still with interests in common. “Majority and minorities in a 
multicultural society share the same destiny in many respects, a fact that 
creates a sense of solidarity.”849  
 
According to solidarity as a principle, resultant inequalities should 
improve the least well off.850 Chadwick and Berg have suggested that 
underlying the concept of benefit sharing is the “ethically strong ideal of 
equal opportunities,” which results in the “duty of those who are well off 
to share with the poor.”851 Justice often implies solidarity when solidarity 
acts come from injustice towards an individual or oppressed class.852 
Thus, solidarity is manifest in the struggle of the working class against 
oppression, the flight of trade unions for the amelioration of working 
conditions, or the effort of liberation movements of minorities to achieve 
recognition.853 
 
Solidarity, reinforced by adequate legal controls and mutual 
engagement, provides protection against exaggeratedly unequal 
distribution.854 It offers a more careful analysis of benefits, costs and other 
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relevant factors that should be considered in the justification for a 
particular course of action or policy.855  
 
Legal governance, recognised as a multidisciplinary element, will 
face a series of challenges in practice. The main one is designing fit-for-
purpose binding rules which guarantee collective protection, for example, 
by ensuring autonomous participation and protecting the identities of 
underage and vulnerable participants. For instance, establishing the 
terms of disclosure of a propensity for illness (discovered through 
biobanking research) of a particular ethnic group.  
 
Solidarity can work as a transitional feature in order to strengthen 
the weakened trust of Mexican participants. Issues such as: insufficient 
public awareness (the prerequisite for public demands on human rights’ 
protection), poor dissemination of knowledge by ethics committees, a 
weak sense of trust by study participants and an economically focused 
knowledge translation, can all be alleviated through social solidarity 
approaches. “When it comes to large-scale biobanks consisting of 
altruistically donated materials, the purpose of the donation is to enhance 
scientific knowledge to promote people’s health.”856  
 
“In political terms, population–based genetic biobanks stand at the 
research frontier where the engagement between regulatory needs and 
ethical capacities are at their most acute, and where solutions are only 
just beginning to emerge.”857 The bioethical agenda must be considered 
in the same way as health priorities, such as campaigning against chronic 
diseases. Regulatory efforts in this area are worth the effort from a 
preventive approach. Genetic research is, in the end, a way to prevent 
these chronic diseases.  
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“Solidarity involves as deep understanding and interpretation of a 
lived experience perceived through a distinct cultural and personal 
lens.”858 According to Heyd, caring for others “constitutes a necessary 
condition for the operation of justice.”859 In this dimension of solidarity, it 
stands for a will to assist others, such as defending a particular “a cultural 
way of life” or better health conditions to those oppressed.860 This implies 
the recognition of differences among those involved within a multicultural 
society, in this case the differences that make indigenous communities 
vulnerable. A sense of identification, which also recognises differences 
amongst them is desirable.  
 
8.2.4 Is social solidarity the most 
appropriate? 
From the discussion above, solidarity has been considered a 
potential key factor to boost regulatory efforts, based on citizens’ 
willingness to cooperate voluntarily, because even the unequal share 
common interests. Solidarity also supports the idea that the wealthiest 
should, due their position, commit to help the poorest. However, the role 
of the law will be essential to help the disparities of a population where 
some are more vulnerable than others. 
 
8.2.1.5 Vulnerable populations, a separate 
subject 
The great diversity found within Mexican population is a challenge 
in terms of unification for public engagement. This is clearly depicted in 
the case of Mexican indigenous communities, who tend not to consider 
themselves as part of the society. They have historical claims to their own 
customs and laws. In contrast to the scepticism regarding data protection 
shown by citizens from the urbanised capital of Mexico, an apparently 
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greater indifference can be found amongst indigenous communities. 
Whitener and others explain how “the ‘genomic goldrush’, created by the 
fast advancement of knowledge in the area of genomics and the 
excitement for the possibility of new interventions for chronic disease, has 
resulted in conflict between indigenous communities and researchers.”861  
 
Regarding indigenous communities, for example, Sahota’s 
findings from a study in American Indian-Alaska Native Communities is 
an example showing coordination interests to involve not only scientists, 
but also involving tribal leaders and legal staff. This has helped to develop 
a research regulatory agency; as means to help to prepare the tribe to 
actively participate as research partners with academic research 
institutions and regulate research that is conducted within the 
community.862  
 
The case of American Indian-Alaska native communities has made 
evident the serious situations of vulnerable groups participating. 
Conflictive situations, such as that in Alaska, have attracted attention in 
the United States, and some actions have been implemented “in order to 
minimize the risks of conflict and community harm from genetic 
research.”863 The National Congress of American Indians has 
encouraged the participation of indigenous minorities through their 
representative “tribal governments,” for them “to play a more active role 
in the regulation of research occurring within the territory of their 
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sovereign control.”864 This example evidences an active proposal to 
minimise the vulnerability of the group.   
 
Such fundamental points support the rights for minorities to 
express their basic needs: health and cultural protection. This illustrates 
the many measures which should be implemented for the legal protection 
of indigenous communities, regarding their participation in Mexican 
biobanking research. 
 
Mexican indigenous people have historically suffered from 
stigmatisation and discrimination. In 2003, the Mexican government 
passed an anti-discrimination law which made any form of racial 
discrimination against indigenous people illegal, however Mexico’s 
indigenous communities still experience marginalization and continue to 
be disadvantaged and vulnerable.865 Even so, passive interest has been 
expressed towards a more protective legislation for indigenous 
communities participating in biobanking research. Mexican biobanking 
requires agreements involving the sharing and exchange of materials 
between participants from diverse cultural backgrounds.  
 
In this situation, “employment, treaty rights and cultural 
preservation” are top priorities,866 and also within the Mexican experience, 
cultural preservation is especially prioritised. This involves “access to 
traditional foods and income sources, and underscores the importance of 
community engagement when setting research agendas.”867 Avoiding 
legal failure in Mexican practice requires a cultural element to be 
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incorporated to the law. Vulnerable populations require special legal 
protection. 
 
8.2.1.4 Given the great inequalities in 
Mexico, can we expect solidarity? 
The idea that social solidarity can be used to justify biobanking in 
a society as unequal as Mexico’s is open to criticism. However, if the most 
vulnerable person can be afforded the same protection as the most 
privileged, then this criticism can be mitigated. 
 
The application of social solidarity in Mexico could be directed to 
society in general (as well as indigenous populations) as long as some 
boundaries are established. Under traditionally altruistic approaches, 
even indigenous donors are expected to donate samples with nothing in 
return. It is not acceptable to influence sample donation by benefits, such 
as access to knowledge on health conditions revealed through the 
sample, however, this is not explicitly guaranteed. Modern solidarity 
supports that researchers at least have to come back to the community 
and explain potential benefits and their extent. Ideally, as previously 
suggested, biobanking in indigenous communities should involve not only 
more participation of the scientific community, but specific benefits for the 
community under an exceptional protective approach.  
 
8.3 From research to health benefits 
In terms of social compensation, reciprocity should be expected 
from biobank databases. In health research, the transformation of 
bioscience into societal benefit is known as translation. Social 
expectations of science are significant, as science expects to benefit 
society in return for public investment. Biobanks are “the appropriate next 
step in translating recent advances, such as the mapping of the human 
genome, into knowledge of direct clinical and public health relevance.”868 
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Biobanks aim to provide a platform for generating new scientific 
knowledge to support the development of new policies, systems and 
interventions for enhancing the public’s health.  
 
The demand for studies confirming the usefulness of new genomic 
devices, with definitive and measurable clinical endpoints, such as sense 
of well-being and established medical outcomes, is constantly growing.  
 
8.3.1 Knowledge translation and social values 
The roles of medicine, science and the law are expected to be 
balancing elements in forthcoming regulatory processes between 
scientific and social values. “Translation of biobanking science demands 
the active involvement and intersection of perspectives of the full range 
of stakeholders: that is, co-evolution of translational research.”869 It has 
also been argued that bioethics has acquired a considerable political 
value and an ability to incorporate the different interests of citizens, 
science and industry within an apparently neutral discursive domain.870 
Benefits should be widely shared, since these databases were created 
from samples and data originating from public funds. According to 
Murtagh and others, innovative theories, tools and methods for analysing 
data in order to maintain privacy and confidentiality are examples of social 
demands. Their absence affects current models of translation, where 
biobanking research leads to potential benefits.871 
 
Whilst biobanking is thought to primarily develop healthcare, 
“particularly, translation into population level public health,”872 the 
development of science depends on the development of a social context 
where ethics and law really matter. New laws for the long term need to be 
directed specifically towards promises of health, since approaches which 
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are too diverse can create obstacles in practice. A common characteristic 
of the multifaceted ways of translation is that they express a sense of a 
complex, dynamic, but desirable social process beyond the science.873  
 
8.3.2 Knowledge translation and its regional 
boundaries 
The extent of benefit from knowledge translation depends on the 
development level of the country. Nyika has pointed out that “the 
development of the necessary frameworks for genetic research and use 
of archived samples is still in the infancy stages in most developing 
countries.”874 An example situation can be found in a study with patients 
from Mexico and Vietnam, in which whole exomes of 103 breast cancer 
abnormal growths and normal DNA tissue were sequenced. Furthermore, 
the entire genomes of 22 breast cancer abnormal growths and matched 
up normal tissue were also sequenced. However, the 2 types of samples 
examined875 are not yet subjected to specific ethical norms in either of the 
countries. In addition, it is highly problematic that the majority of 
developing countries’ populations may not benefit from new technologies 
due to prevailing socioeconomic factors. Hence, stakeholders should 
always make concerted efforts to ensure availability and affordability.876 
 
Practical expectations of biobanking are wider than the scarce 
legislation in Latin-America,877” as Mendoza and López have recognised. 
Mexico depends on the National Institute of Genomic Medicine to act as 
a hub for various human genomic medicine networks, which can be very 
beneficial as this will enable other Latin-American countries to understand 
their public health needs and develop genomic therapies without the need 
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to duplicate the initial investment already made by Mexico.878 As 
“bioscience reflects the disease priorities of contemporary societies,”879 in 
the case of Mexico, most of the current challenges relate to national 
health priorities.  
 
Despite recent advances, statistics from 2012 show that health 
conditions in Mexico are still relatively poor. One out of 11 children have 
low birth weight, compared with 1 out of 17 in Chile. Mortality in children 
under one is ten times that of Iceland and twice Chile’s. Despite obstacles, 
Mexico has recognised that “it is not justifiable to say that research is 
something luxurious that poor countries cannot afford because there are 
other priorities.”880 The social benefit from translation can take place 
through scientific benefits. These scientific benefits are beginning to 
develop with the potential for translation in the Mexican context. However, 
these are difficult to envisage at the present time. 
 
Limitations, if not seen in context, may prevail over ambitious 
intentions to reform biobanking regulations in parallel with the national 
health system. Presumably, large-scale databases are not the best 
choice for those developing, since risks of exploitation and not recovering 
great investments are high due to the current weak regulations. 881 Rather, 
direct investments for the provision of primary healthcare and preferential 
access to public databases would have a more immediate impact on 
population research of developing countries. Never the less, currently, 
great investments are taking place in Mexico. Carlos Slim Helú 
announced a $74 million dollar contribution into the Slim Initiative for 
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Genomic Medicine in the Americas (SIGMA)882, which aims to develop 
diagnostic tools and medicines for diseases, including breast cancer and 
type 2 diabetes, which are especially prevalent in the Mexican population. 
Genomics experts recognise the initial efforts but also their challenges, 
explaining that “translating genomics insights into useful tools and 
practices will take much longer than the program’s 3-year second phase, 
especially in an economy like Mexico’s, in which more than half the 
population lives in poverty.”883 The legal situation of Mexican current rules 
needs to improve for this kind of investments to be effective. 
 
Democratically led knowledge translation tends to have an impact 
on the official policies of countries, an impact which Mexican policies 
should aspire to. Another prerequisite for the development of public 
understanding is political will; obtaining funds for knowledge 
dissemination depends on political support. The next attempt for Mexican 
biobanking legislation will be critical in reinforcing social trust towards 
genomic institutions (such as INMEGEN). INMEGEN has accurately 
targeted diabetes, obesity and cancer as the main diseases affecting the 
health of the Mexican population.884 Therefore, Mexican bioscience must 
coherently prioritise research with these aims in mind. Institutions 
involved should demonstrate that the efforts made by public institutions 
to develop personalised medicine in the country can be fruitful both for 
economic development and public health. There is a co-dependence 
between biobanks and the public in terms of benefits, such as those 
promised to the Mexican population and which motivated the creation of 
INMEGEN. 
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Participants D and E885 have remarked that, in their experience, 
provision of feedback is impossible, not because they do not want to do 
it, but because of the particular statistical nature of biobanking projects. 
In some, genetic data becomes anonymised for a purely statistical 
treatment. This position is supported by Menasco.886 Population 
biobanking may not be so risky in general, since most of the time, even 
when anonymisation mechanisms have not yet been implemented in 
Mexico, population data becomes anonymised. 
 
In the case of INMEGEN, social solidarity can be strengthened by 
showing how the health system can rely on research. This argument may 
be contra-posed to the social interests of the citizens that may be hopeful 
of a potential treatment or a vulnerable population with basic health 
needs. Therefore, the legitimacy of solidarity is linked to a commitment 
directed to an undetermined group’s welfare, and does not mean that 
individual privacy and confidentiality will not be considered at the 
individual level. The solidarity approach for biobanks seems ideal but in 
practice it requires adjustments and exceptions, especially in the case of 
vulnerable populations. 
 
Health areas are considered key to reflecting the translation into 
benefits from biobanks towards the population. The main objective of this 
collaboration should be the integration of genome-based knowledge and 
technologies into the clinical and public health research agenda, thus 
forming the scientific basis for developing sound policies and effective 
interventions. This approach should become essential to fill the gaps in 
translating research results into population benefits.887 
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8.3.3 The desired impact of knowledge translation 
Practices of knowledge translation include: use of consensus 
conferences or expert panels, systematic reviews, narrative syntheses, 
meta-analyses, meta-syntheses and practice guidelines to contextualise 
and integrate research finding. It also includes dissemination via briefings 
and educational sessions with stakeholders (patients, practitioners and 
policy makers), engaging knowledge users in developing and executing 
dissemination/implementation plans, and media engagement. Knowledge 
exchange involves interaction between knowledge users and 
researchers. Consequently, results in mutual learning are expected from 
the process of planning, producing, disseminating and applying existing 
or new research in decision making. These need to be consistent with 
ethical principles and norms, and social values, as well as legal and other 
regulatory frameworks. Such networks demand the reshaping of some 
members’ normative cultures and beliefs.888  .  
 
Actions improving science of future health care are closely related 
and include “an explicit acknowledgment of the tools and methodologies 
that underpin translation of basic and applied research.”889 Ideally, 
knowledge could be converted into benefits for the population’s health, 
through the provision of more effective health services and products. 
Knowledge translation can happen in a number of ways and has historical 
links with “health promotion, health education and community 
development of engaging communities, health care providers and policy 
makers with health care issues, action and change.”890 These efforts 
could contribute to strengthen the Mexican health care system and 
society. 
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8.4 The international experience 
Current rules need to be updated as biobanking at the international 
level keeps expanding. Intense legislative work also needs to respond to 
international demands for standardisation. Community compensation is 
normally expected when participating in a research project. An 
international consensus is that, at a minimum, groups participating in 
research should receive some benefit.891 One way of such benefit to 
materialise could be that profit making institutions donate a percentage of 
their annual income to social healthcare. 
 
 The case of Sweden 
European examples, such as in Sweden, have shown that public 
awareness is linked to notions of benefit sharing, such as payment or 
return of health information. People from a Swedish study declared they 
were donating because it could help a relative with an illness in the future. 
According to Kettis Lindblad and others, there is a relevant component for 
this kind of social drive to happen: “the willingness is mainly driven by 
altruism, and depends on the public being well-informed and having trust 
in experts and institutions.”892 Solidarity has been the focus for social 
attitudes in countries such as Sweden. The solidarity approach is suitable 
for populations where people consider themselves similar to these others 
in a relevant aspect, or where shared practices take place in a given group 
or community. Welfare societies all share arrangements that are enacted 
and enforced by law, for example, solidaristic health insurance systems 
with compulsory contributions.893 
 
Even currently effective regulations, such as those from Sweden, 
faced challenges centred on ethical foundations. The Swedish biobank 
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893 Prainsack and Buyx, ‘A solidarity-based approach to the governance of research 
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company UmanGenomics failed to meet the IPR requirements of a 
successful market, despite its vaunted ethical foundations.894 However, 
these types of situations have triggered positive parliamentary attitudes; 
the Swedish Parliamentary Commission currently works on the basis that 
first, there should not be any legitimate area of application in the general 
field for genetic information, apart from the medical field, the judiciary and 
other areas and secondly, that these should be subject to a special 
regulation. 
   
 The case of the UK 
Interests over the future of samples and the possibility for them to 
end up being handled by legitimate or illegitimate third parties have 
caught the interests of a number of citizens who, at least in the UK, feel 
that “insurance companies are less likely to be sympathetic than 
employers in the event of illness.”895 However, the number of citizens 
aware of these concerns in Mexico is significantly low. A clear example of 
natural trust can be found in the operation of UK Biobank, which depends 
on the active co-operation of citizens.896 The approach followed by the UK 
in biobanking related pharmacogenetics research has encouraged trust 
by regulating it specifically through the National Health Service (NHS). 
  
British policies have sought to encourage awareness amongst staff 
by establishing binding rules and encouraging staff to familiarise 
themselves with them.  A primary need of health staff is evidently that of 
expertise. Two main positive results have been observed: 
1) The NHS’s capacity and public trust have been reinforced and 
2)  Its research benefits reassured.  
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The latter has built public confidence in the public regulation of 
pharmacogenetics research and development has been critical for the 
UK, where there has been “an improving understanding of the needs and 
benefits of translating research, and an engaged venture capital 
sector.”897 The international experience provides examples coming from 
medical areas, for example, the role of patient representatives in the UK 
is transcending to research representation areas and “trust can be 
immensely useful if one is to conduct public policy.”898 
 
A good example of the reciprocity relationship is the basis of UK 
Biobank’s functioning, in which two elements can be clearly identified for 
“an appropriate articulation of public good”:899 patients need to be 
informed in what terms accessibility will be granted and on the likelihood 
of those terms to be challenged, and established access limits according 
to the needs of the biobank. The main principle for biobanks to be 
accountable, and therefore trustworthy, is transparency. “Accountability 
makes it clear that the motivations of politicians and law-makers to open 
up the bank are informed by their own justificatory commitments to the 
public good.”900 In contrast, Icelanders are to be entitled to drug 
treatments developed as a result of the database, and such drug 
treatments are to be freely available to the entire Icelandic population.901 
 
Deliberative democracy, understood as a model in favour of actual 
interpersonal engagement902, has been one of the main aspirations of 
countries such as Britain and Germany.903 As a consequence, there have 
been attempts to attenuate the existing barriers between the technical 
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character of biobanking and the public. This can be achieved by 
acknowledging the role of trust in gaining transparency and control.904 
 
8.5 Education as means to avoid inequalities 
Docornau and Strand have remarked that when “donors are not 
familiar with the working of science they accordingly have to trust the 
experts.”905 In this context, donors are seen as “the public” and the 
biobankers as the “experts”. As reviewed in Chapter 6, the CNB has not 
achieved a full training scheme equivalent to that in the UK in terms of 
familiarising health staff with the current ethical and legal frameworks, 
which could be modified at the same time as trying to achieve this 
familiarisation. 
 
According to participant O, the main problem in Mexico is the poor 
dissemination of knowledge; it is not an absence of interest, but an 
absence of knowledge. Citizens’ demands can materialise if citizens are 
aware of the rights’ or benefits they are entitled. If the public reached an 
adequate level of knowledge, it would be necessary for biobanks or any 
biological sample repository to obtain and maintain the donors’ trust. The 
limited public knowledge of biobanks (particularly genetic and genomic-
oriented biobanks) points to “an ongoing need for public and community 
education and engagement on issues surrounding biobanking.”906  
 
The public seems to show a greater propensity to suffer the 
consequences of disinformation. It is not the only the public affected by 
poor dissemination of knowledge, “the biobankers may be unaware of 
ethical aspects that are contested in society in general or in academic 
discourse, aspects which in that case will be considered neither by 
biobankers nor by donors."907 
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Additionally, unintentional misconduct may occur when the sample 
collection managers do not fully understand the issues. Participant B 
mentioned she has felt the need for training and recognised, in her 
scientific position, her ignorance of what to do in many cases,908 for 
example, what to do with collections from projects whose initial purpose 
has been achieved. In this scenario, legal or ethical knowledge may be 
genuinely ignored by biobanking staff. Ideally, biobanks would never 
betray the trust of sample donors, intentionally or unintentionally.  
 
8.5.1 Educating the public 
Mexico has promoted an evidence based research agenda and 
any “research agenda with a population perspective should make public 
education about genomics a priority.909” However this has not yet 
happened. There have been significant investment efforts towards 
research, but not as much attention as is required towards educating the 
population. In the opinion of Participants D and E, for the public to become 
more involved and less dependent on rules in the long term, “wide 
changes on education and culture are necessary.”910  
 
A concerning issue within Mexican society is the population’s low 
level of access to internet. The average percentage of Mexican homes 
with internet access in 2012, was 25.9%, “an alarming” one in comparison 
with that of OECD’s average countries (71.6% in 2011).911 According to 
Lumbreras et al,912 despite the increased recognition of the importance of 
genetic and genomic education, the proportion of public funds devoted to 
research education, is too small compared with that devoted to basic 
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research. The OECD has accurately pointed out that “appropriate 
educational and reward structures are a necessary component for 
promoting data access and sharing practices. These considerations apply 
to those who fund, produce, manage, and use research data.”913 Hence, 
“it is crucial for biobank managers to understand and position the biobank 
in relation to macropolitical rationalities that are able to drive, facilitate, 
and fund biobanks and biobank networks in the decades to come.”914 
 
8.6 Concluding remarks 
This chapter investigated influential social attitudes towards 
biobanking in Mexico by analysing the concepts of solidarity and social 
justice and their application.  
Public awareness is the basis to legitimise biobanking research 
regulation. Social attitudes have been shown to have a great impact in 
the current state of biobanking in Mexico. The sustainability of biobanks 
in the long term depends on public scrutiny and trustworthy biobanking 
governance. A real ethical public debate will require broad participation. 
Repetitive situations are at risk of continuing to occur if consideration is 
not taken.  
 
The notion of long term participatory arrangements and understanding 
prevailing cultural views among stakeholders and public interaction, is 
crucial. Solidarity can work to legitimise social accountability as long as 
the intervention of the law establishes the extent of commitment among 
those participating. Hence, disadvantaged participants can help others 
and receive benefits as long as they are legally protected. 
 
In developing countries, such as Mexico, two of the main issues 
consist: firstly, the great differences among society, even when sharing 
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the same culture; such differences involve potential discrimination; 
vulnerable populations are exposed to the historic risk of being exploited 
in the name of research. Secondly, the improvement of biobanking legal 
rules. Even when scientists tend to expect that biobanks’ results will 
always be useful, it is a matter of concern whether the results will recover 
the cost of the biobank’s foundation. 
 
Ethical guidelines need to be implemented in a responsive way, 
following socioeconomic and cultural contexts. It is necessary for 
scientific work to be led coherently towards the real needs of the 
population.  The variety of stakeholders from diverse areas and different 
levels of participation, need to be equally regarded by the authority in 
terms of social, political involvement and knowledge provision. A lesson 
for Mexican government to learn is that the potential utility of population 
biobanking needs to be optimised through coordination policies initially 
focused on health benefits for the public. The establishment of legal 
thresholds required by scientists will make knowledge translation effective 
for the public and other stakeholders. Social commitment needs to be 
particularly emphasised in terms of public engagement and explicit 
acknowledgement of the required tools for research translation. 
Deliberative forums in connexion with social programmes thus offer a 
possible solution, as a way for the public to be prepared and accept 
personalised medicine. Political action can be exercised by programs 
encouraging public and private involvement towards planned results and 
promoting interaction with the public. All collaborations among 
stakeholders must be based on ethical principles of equality, benefit 
sharing and solidarity.   
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9. Conclusions 
 
The findings from chapters one to eight indicate that legal reform 
for biobanking in Mexico is necessary. National Biobanks are numerous 
and these are likely to increase. However, the cooperation between the 
private and public sector has been led by economical goals, leaving 
behind the ethical aspects of research. The ethics of clinical trials 
performed outside public health institutions are not only inconsistent, but 
optional to comply. The prevalence of economic interest has weakened 
the expansion of biobanks. In the absence of guidelines, each biobanking 
institution decides independently. Fragmented legislation tends to be only 
partially effective, promoting uncertain self-regulatory choices.  
 
 What are the best ways forward to alleviate legal weaknesses 
in Mexican biobanking governance?  
 Biobanks, currently seen as disperse health issues, are included 
in the General Health Law. The latter rules, far from being effective at 
covering biobanks, are the result of constant amending and legislative 
saturation. A complete legal reform is preferable to continually amending 
frameworks, which ‘somehow’ cover the topic. Even if biobanks were 
considered to be covered by the general health regulations, a special 
chapter would need to be created. This is still excessively complicated.  
 
 A new law on biobanking and personal data is the only suitable 
solution. The basis for biobanking regulation must be independent rules 
regarding samples for research are necessary. These could be contained 
in a statutory legal framework, starting by the definition of a biobank. The 
implementation of completely new rules will need to look at legal 
considerations, taking into account the legal actors and budget required. 
It will be also necessary to evaluate legal competence for responsibilities. 
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 Are biobanks effectively regulated in Mexico? 
The case studies presented in Chapter 3 ‘HapMap’ and the ‘Cohort 
profile study’ facilitated the assessment of important issues, which 
evidenced: tensions between academics and scientists, ambiguity 
regarding representatives and funding bodies and concerning failures in 
the protection of research participants. The analysis of biobanking 
regulation was approached not only through academic literature but also 
by data obtained through fieldwork. The responses of stakeholders also 
pointed out that existing rules on biobanks were limited, evidencing unfit 
for purpose regulations. 
 
 What risks, harms and values are involved? 
The general population deserve to have their rights protected, 
including the ethical treatment of their samples. Individual participation, 
far from being encouraged is being discouraged when participants 
discover that the scientists exaggerated the health benefits the participant 
would receive. Vulnerable groups are at even greater risk, so they will 
require even tighter legislation than the general public.  
 
The regulation of tissue should be based on exceptional cases. 
The scientific value of the research and the type of tissue to be used is 
the key to determine risk levels. Explanatory biobanking guidelines are 
essential. 
 
 What can we learn from the international experience? 
Even when various genomics projects are developed nationally, 
many of them are the result of international collaboration. Biobanking in 
Mexico does not always meet the basic ethical standards practiced 
internationally. The illustrative analysis of chapter six indicated that 
enforced strict national rules are essential. The law needs to be supported 
by academic expertise and the international experience  
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 What changes need to be implemented in Mexico? 
The administrative controlling procedures for biobanks should be 
constrained to specific areas, such as protection of participants’ rights, 
including informed consent and data protection. The first step is updating 
the law and the second, organising the official registration of samples 
taken outside of the country. This should be carried out by an 
administrative monitoring system in order to balance research 
participants’ protection and scientific progress. The centralisation of 
current LRECs in a single responsible institution is also recommended. 
This will simplify their operation and administration. Law makers need to 
be careful about creating an excess of bureaucracy. 
 
However, the current legal framework requires not only specificity, 
but also strong oversight. Provision for guidance through non-binding 
codes of ethics is not enough. It is necessary to create new authorities 
due to the degrees of expertise required. Governance institutions need to 
encourage ethical guidance free from subjectivity; there are human rights 
to be protected through compulsory rules. A good law protects people, 
includes sanctions for misconduct and encourages freedom of research. 
This is only being partially achieved in Mexico because of the absence of 
oversight procedures guaranteeing that biomedical research is ethical. 
Research ethics could be supported through the implementation of audit 
controls by legislative action led by ethics experts. Biobanking regulation 
needs to be based not only on legal principles such as transparency, 
clarity, independence and efficiency; effectiveness will depend on 
concrete rules and corresponding oversight procedures. It is fundamental 
to encourage a responsible regulatory body that can deal with the 
challenges of oversight as soon as possible.  
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 What are the main challenges when implementing change in 
Mexico? 
 The efficacy of new laws will also depend on coordination of all 
involved in biobanking. Academic work has not transcended to legislative 
forums as scientists continue working individually, apparently for the 
benefit of a vulnerable minority who are unaware of this. Most 
coordination activities which have been attempted in Mexico have not 
transcended dissemination of knowledge among experts. It is also the 
public who primarily need to be involved. The question on how the 
operation and development of biobanks can be combined with dignity and 
human rights’ protection of participants remains open. Several proposals, 
including the organisation of colloquiums has originated a purely 
academic discourse. No real demands from the public for better human 
rights’ protection in Mexico have emerged as a consequence.   
 
 The role of coordination is extremely important and needs to be 
encouraged. For example, institutional coordination can solve internal 
problems. Legal and medical experts must be listened to when laws are 
elaborated; otherwise lawyers can limit scientists’ valuable research. 
Stakeholders need more direct communication with policy makers. 
Incoherence and inconsistency within biobanking have led not only to the 
hampering of personalised medicine, but also failing coordination (among 
policymakers, regulators, and researchers). The development of scientific 
research depends on a structural framework adequate to the demands of 
public genomics, designed to promote its benefits. None of these actions 
can be guaranteed if no valid rules are implemented. However, the 
implementation of new biobanking governance and policy making is only 
a part of the solution. The rest relies on elements such as public 
awareness, solidarity and public trust. 
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 What is the role of social involvement in Mexican biobanking 
regulation? 
 Fieldwork encouraged social investigation on why even fit for 
purpose regulations involve the risk of being ineffective when social 
awareness is absent. Social issues such as public awareness can be 
resolved through education. The legal situation needs to be seen in 
context, and most importantly, based on the the culturally unique 
circumstances of Mexico. A fit for purpose regulation should combine 
legal and bioethical expertise and focus on limitations related to the 
special characteristics of Mexico.  
 
Legitimisation can be expressed by ethical behaviour motivated by 
the public recognition of the reliability of governmental institutions. Public 
trust is essential, since even the most adequate policy is useless if it does 
not become legitimised by the trust of citizens. The efficacy of 
implemented legal rules will rely on ethics, governance and the demands 
of a public who trust them. The way to achieve this is through solidarity 
involving access to the benefits produced by biobanking, social justice 
and education. 
 
 This thesis is aimed at inspiring further legislative works in Mexico 
and other Latin American countries, where situation regarding biobanks 
is quite similar. Participants in general were very interested in reading the 
completed work. Indeed, one participant, who has partial responsibility for 
legislating in the area of biobanking at the national level, said to be “keen 
organising a forum to discuss the outcomes of this study so a law project 
could be made and presented.”915 
 
 
 
 
                                                          
915 Interview with participant K 
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10. Annex 
Table 1 
A 
Biobanks are not regulated effectively. I don’t know whether there is really legislation to modify regarding confidentiality. I know 
that there were many gaps based on joint analysis on data confidentiality and privacy. There is much on privacy, but not on genetic 
privacy, which only a few times is included. The General Health Law provides with general articles, but if you do not have rules 
which detail due procedures, a general law is helpless. 
B 
In my opinion, biobanks are not regulated effectively. In my point of view, the legal side is fundamental and the main problem is 
the definition of questions to know the competence of the authorities in the institutes, the competence of the researcher, that of 
the sponsor or to determine if there is a limit of the pharmaceutical industry to support us. The law is not ambiguous but 
inexistent. In my view a legal framework, which could help us (researchers, in these areas of biomedicine), is being required; how 
to manage samples within biobanks. 
C 
 The regulation of biobanks in Mexico is inexistent. There is no rule whatsoever to regulate biobanks in general. We can find that 
each biobank has a ‘self regulation’. This can be elaborated by governance actors or even by individuals. For example, there are 
private blood banks and they are covered by general norms on the use of blood. Then, they have internal rules. There are 
minimum standards, but these do not apply to these concrete cases. We have no concrete security measures. 
D, E 
Biobanks are not regulated effectively in Mexico. There is a far way to go, this is a very easy question to answer. We have the 
general Health Law, obviously the rules on health research, the NOM regarding specific matters on blood banks. But, not 
something for established biobanks, to enable preservation and sharing of samples within research projects, there is nothing. 
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F 
Regarding biobanks, there is a health legislation that is applicable. Not in every aspect, but most of them. Instead, we need 
manuals or guidance so the user knows what laws are applicable for their biobanks. 
G  The legislation for biobanks in Mexico is not clear. 
H 
I consider that biobanks are not regulated effectively. This and other novelty health topics are outside the legislation. We may try 
to make the topic fit into the framework forcefully through general principles. But that is not the case; there is not an explicit ad-
hoc regulation for biobanks. It would be risky to give a determinant answer. I think it is necessary to analyse what parts of the 
legislation need to be reinforced. Some parts may be applicable. Initially I would say that it is necessary to enforce a new specific 
chapter on biobanks within the general Health Law, not outside this instrument. It could be also a NOM or another secondary 
instrument to explain additions to the General Health Law on biobanks. Mixing topics generates just confusion in applicability, we 
must avoid that. It has happened before, only because there is an article the topic we say it is regulated. We need a substantial 
proposal. 
I 
 I believe that the topic of biobanks, as many other bioethics topics, is included by a particular form, divided into various 
instruments of different types (civil, health, penal). They are unfocussed in the legal framework. My understanding is that there is 
no policy or specific section for the regulation of biobanks. I know that they are understood as sensitive data, such as health data 
contained in biological samples. 
J 
The current Mexican legislation allows that regulation through the Federal Law of Transparency and Access to Federal Public Data 
(LFTAIPF) on personal data. 
M 
Biobanks are not legally regulated as such specifically. They may be regulated somehow, but they are immersed in the Mexican 
legal framework. 
N I know there is legislation, but I do not know until what point they are effective. I also know work is being done in that respect. 
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O 
If effectiveness is understood in terms of complying with the legislation, biobank legislation is effective. If effectiveness is 
understood in terms of covering the main theoretical and practical biobanking topics, the answer is no. The law is very vague, 
ambiguous, lacks of clarity, no definitions, little consolidation, little study, little results from debate. We are very backwards in 
comparison with international advances. 
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Table 2 
A 
It is probably COFEPRIS, dependant on the Ministry of Health, which authorises many things. We have had authorisation from 
COFEPRIS for samples which have been transported outside the country, justifying the research project. COFEPRIS has a lot of 
legal force.  
D,E 
I believe that COFEPRIS has too much work. It is the authority on drugs, food and publicity. I do not think it will manage to do this 
other role. A lot of people has complained that applications for lab authorisations, for example, do not have a response after 
months.  I think that the commission will not have the time for the careful oversight of samples. 
G 
COFEPRIS must extend an authorisation in order to transport organs, tissue and blood outside the country. This is in the law. 
However, this is obsolete in terms of DNA. COFEPRIS is in charge of biobanks’ oversight. INMEGEN is granted licenses and 
authorisations by COFEPRIS, similarly to other health institutes. These authorisations include permissions for the operation of 
labs, correct handling of biological materials. A granted license involved that inspections can be carried out without notice to the 
institute.  
H 
I believe that the authority in charge is COFEPRIS. That is the sanitary and sanitary care authority in general.  
I In my opinion the maximum authority for biobanks is still the ethics committee.  
M 
My understanding is that COFEPRIS is the main authority. One of the ways the commission can collaborate with COFEPRIS is 
through the analysis of ethical implications. Joint collaboration is highly recommendable.  
 
 
5 
 
Table 3 
D 
I believe that the CNB could play an important role beyond the organisation of research ethics committees. The CNB should have a 
more active role in terms of regulation. The CNB is going across a new stage. On the 31st of October a new reform came up 
regarding the organisation of the ethics research and health committees. It is about an authorisation for those committees to keep 
operating, once the authorisation from COFEPRIS has been obtained.  They are at a very early stage and I hope this more active role 
involves protocol revision.  
F 
The CNB is not an authority, but it has officially been established that the commission will be consulted for bioethical matters. The 
commission can recommend following specific national instruments.  
H 
The CNB organises studies for consultancy purposes and provides training for ethics committee members (so members understand 
their role within the committee).  The recent changes on compulsory committees for health and research within the General Health 
Law give more faculties to the commission. It is on the way to be more like a governance institution. I think we are in a transition 
period. In terms of biobanks we have nothing but the organisation of academic seminars. The ethics committees are internal. We 
anticipate a mechanism to register and follow these committees. This registry originally used to belong to COFEPRIS. Now the CNB 
is collaborating with them in this registry. COFEPRIS is still the authority. I do not think the CNB will intervene as an authority 
because it was created with a different nature. The creation decree does not allow the commission to go further than help with the 
registration of committees. The main points are to strengthen the committees, to make sure that any research project in Mexico is 
done by an institution, that the institution has an ethics committee to authorise the research project and protect the dignity of the 
participants.  
I 
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The role of the CNB is to be an adviser. It will not say whether something is legal or illegal but can say if it is correct or incorrect. 
The nature of the commission is not to be an authority of any kind. It would be good that it had more legal strength. However the 
commission’s role is to provide guidance on public policies from a bioethical point of view. The commission will never become a 
public prosecutor on bioethics, it is an administrative organ. The commission, after the amendments, was involved in the 
formalisation of ethics committees in health institutions. The commission is elaborating guidelines for the operation and structure 
of such committees; number of members, resolutions, general requirements. 
L 
The commission has the challenge of training. It organises plenty of courses. We are looking for strategies to cover the training 
demands. The commission has records of the committees. They know that at least those registered must comply with the CNB 
guidance. The intention is to unify the operation of the committees and avoid that some are less strict than others, that they are 
multi-disciplinary and plural. The commission follows some issues closely and gives an opinion. We have guidance for the 
integration of the ethics committees at hospitals and research institutions. They are mandatory. The commission sometimes 
provides opinions on law projects that are sent to us. 
M 
The CNB is a non centralised institution of the Ministry of Health. It is dedicated to study and disseminate bioethics questions and 
knowledge.  
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Table 4 
C 
A year ago it was established that these committees are compulsory. More progress is necessary and it must be determined in what 
cases advisory committees are required and when they should be stringent. In my opinion, biomedical research deserves to be 
looked at by an authority. A way of taking control is authorisation at the project’s beginning; no project can be done without 
approval. Afterwards, projects must be followed up by an ethics committee.  
O 
The ethics committees are completely unstructured and passive. I perceive that the CNB has a few lawyers (who are very young by 
the way, just starting), it is not plural. They have understood the commission as a group of medical doctors which will apply purely 
medical ethics. This is not bioethics. There are no philosophers, no jurists in the committees. It is sad that “The Bioethics College,” 
Mexican NGO, is more organised than the CNB.  
L 
Committee members are not experts i.e. on data protection. They are intended to protect the research subject by making sure that 
the research protocol is well founded.  There is a tendency, I notice, towards making the committees stronger by training committee 
members.  
I It is difficult to standardise the committees, it is not the same a committee in Mexico City and a committee in a remote community.  
H 
The 2011 reform to the General Health Law introduced the committees. Now, the addition to the article 41 bis will be governed by 
criteria from the CNB. Our guidelines are becoming compulsory in the integration and operation of the committees, so they are 
plural, multidisciplinary, have clear objectives, clear boundaries and extents. This will impact positively on the protection of the 
research subject.  
M 
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In my opinion, ethics committees should definitely be stronger. I see committees as the instruments to make bioethics practical. The 
idea is to train committee members that can also be trainers in the future. One of the limits of the commission is a reduced number 
of staff for a great number of committees to train in the country. Ethical guidelines are as important as legal rules. The key point is 
educating the population so they also consider ethical criteria. However, some stakeholders are over defensive on what will happen 
to them if they do not comply with some requirements. Research committees have to be registered in both COFEPRIS and the CNB. I 
attended a health related event in which a bi-national committee was discussed. The two involved countries were participating in the 
project. According to Mexican legislation, the committee scrutiniser has to be that one from the place where the research takes 
place. The rules of the place apply in that case. 
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Table 5 
C 
I believe both the ethics and the law are complementary. We need to act ethically and generate these principles from inside the 
community. This can be developed within the community of stakeholders. However the social impact of the topic requires legal 
rules as well. For example establishing a biobank, the fact of collecting biological samples involves risks regarding the use of the 
samples.  
G 
In my opinion, we do not have the culture. I believe that law and ethics must complement each other. The ethics will not always be 
coherent with the law in practice, especially on subjects where genetics is related. It goes beyond individual rights. Relatives are 
also involved. 
A 
Ethical guidance is fine, but you also need sanctions when things are not well done. Not everybody is ethical. Perhaps, both are 
necessary. 
D,E 
I think both the law and the ethics are necessary. The legal side is necessary to establish the rules of the game and make people 
respect those rules. It is also about essential controls, not bureaucratisation.  It involves a lot of work. I believe on the ethics as the 
cultural side of doing science, sharing and collaborating. I believe it is the two pillars, the ethical and the legal one. If people’s 
mentality and culture do not change, we have to be dependent on the stringency of law. If things change, researchers will be 
familiar with the idea that it is not their samples, but with the idea that there is a lot to gain from sharing.  It will take time though.  
O 
A bioethics code cannot be stringent because that is not its nature; I understand codes of ethics as codes of principles. I do not 
think that creating new codes is the answer. I think education on bioethics is central at universities. The bioethical principles are not 
being taught. That does not depend on whether rules should be mandatory or not.  
I 
I believe there is always a tendency, perhaps due to lack of trust, to believe that there is a separation between law and ethics. They 
are closely related but not all the ethical principles have to be legal. 
F We are full of ethical guidelines. People feel that ethical codes are not mandatory, so they are not respected.  
10 
 
H 
I believe that topics such as biobanks start with ethical guidelines and then these become part of the legal framework. However, 
first the topics need to be deeply studied, starting by the law makers.  
L Not all of us are ethical. So we need to encourage protective measures beyond just goodwill. 
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Table 6 
 
C 
The role of international principles is to orientate countries, so they can select guidelines and then develop and adapt 
them to their own legislations.  Legislators many times copy other countries’ legislations that they believe are more 
advanced. Approximately 8 years ago, it was being planned to implement a Spanish act by copying it to the Mexican 
framework. Such an act had been derogated in Spain as it was contradicting European Union principles. Mexico was 
aiming to copy it identically. In the case of biobanks, the advantage is that there are numerous instruments which can be 
adapted.  Comparative law is always helpful. It allows you to investigate how your country is positioned. The problem is 
when you try to apply frameworks incoherently with the reality of the country. Comparative law presents advantages, 
the problem is the implementation. Every topic is related to specific problems of the country. It is also related to cultural 
and ethical levels. 
D,E  Mexico is very different from other countries, yet there is nothing (in terms of biobanking).  
I 
We do have a human genome law, but we have a chapter on the human genome and we have some sanctions in the 
penal code. However, we are not like France, for example, they have a bioethics law.    
K 
Before making the law, we need information on pioneer countries’ public policies, authorities. We need to determine 
the frequency of abuse and recurrence on this topic.  
O 
I have seen that the academia becomes desperate to participate in the encouragement of new laws without serious 
analysis. They do not look at comparative law. I do not mean that we need to implement other countries’ legislation, but 
we can reference the experiences and failures from other countries. It may work.  
 
 
 
 
 
 
 
 
 
12 
 
Table 7 
 
C 
I believe that the informed consent depends on each biobank’s purpose and extent. The utility of the sample must be defined in 
advance, which involves the destruction of samples once such a purpose is reached.  
D,E  
Informed consent varies to a great extent. If it is for individuals, we aim to protect their autonomy, if it is for indigenous 
communities; we aim to protect the group.  
F 
I am against general informed consents and general explanations on benefits, benefits have to be clear as well as the damage 
caused. That is another important point I have seen in informed consent. I believe that there must be a general regulation of 
informed consent, but each case needs a specific consent according to the participant’s age.  However, I consider that there needs 
to be a general context for informed consent. This would provide the rationale (unknown by many) of any informed consent. 
Something very important is the determination of benefits for the individual and the group, how it will impact on the group 
permanently. In genomic population studies it is not clear how the community is benefited, how the individual and the group are 
protected. We need to define specific informed consents for each situation. Some can include extension of periods to study the 
samples and some of them are project limited or time limited. 
G 
Informed consent within the INMEGEN is a form sent by our labs. Our area revises them to verify they comply with the General 
Health Law requirements. This informed is general as it aims to cover the majority of consent points by different areas.  
L 
Sometimes researchers do not understand what is being protected through some administrative measures that seem just 
bureaucratic. I learned that in my Masters degree. At some point in the past I was doing research in child obesity. One day I became 
very frustrated that a mother refused to participate in the project. I thought it was a waste, since the benefits were for her children, 
who suffered obesity, because she was obese. I could not understand that she had the right to refuse to participate and I only saw 
the researcher’s perspective and thought it as for their benefit. Now I see the value of respecting persons’ decision on their 
participation, beyond research benefits. 
M 
Our main concern regarding informed consent is that autonomy is respected at all times, depending on the participant’s 
understanding of the consent. We look for clearness on the implications for the participant and concise language and that the 
informed consent is seen as a process, not a document. I think it would be risky if the commission elaborated a consent form as 
each situation requiring IC is different. The commission disseminates the importance of informed consent. We have worked on 
informed but not exhaustively, there is still a lot to do. 
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O 
The problem about informed consent is that it is known only by some lawyers and the health institutions. However, other public 
servants do not know it. 
N I believe that informed consent presents gaps to really be considered effective. 
H 
The commission has aimed to promote the informed consent not as a document, but as a process so the patient understands the 
procedures in which he is participating freely, within a clinical treatment. We aim that people stop looking at the IC as a document 
who protects the doctor. The main problem with IC in my opinion is that it has been strongly encouraged as a legal document, not 
as a process. 
L 
I think that IC is one of the greatest challenges will be understanding informed consent for research. The role of the IC in Mexico 
has been misunderstood. It started in health areas. The research consent does exist in Mexico and so do the research committees. 
They will not approve a protocol without consent. It is recent and unfortunately a signed IC does not guarantee that the person 
understood the IC. Legally the hospitals use informed consent to protect themselves. This should not happen within research. I 
understand informed consent for research in more general sense. I have participated in a research project from the National 
Institute of Nutrition. It was about women’s’ hormonal cycles. It consisted of the donation of a samples and a hormonal profile in 
exchange. I remember signing something but never knew what use was given to my sample. I think that is a serious institution so 
they might have used it for a single purpose and destroyed it afterwards. 
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 PARTICIPATION  OBJECT CHRONOLOGY SAMPLE COLLECTION SAMPLE LOCATION  DATA PROTECTION  RESULTS  
RESULT 
AVAILABILITY RESPONSIBILITY 
INTERVENING 
INSTITUTIONS  
‘Cohort 
Profile’: 
The Mexico 
City 
Prospective 
Study 150 000 adults 
To assess 
reliably the 
association
s of 
established 
risk factors 
and 
possible 
new ones, 
with 
common 
causes of 
death in 
Mexico. To 
seek 
informatio
n on the 
incidence 
of cancer, 
non-fatal 
vascular 
events, and 
diseases.  
1995 – 1997 
Sample 
collection: 
1995-1997 
Lasting: 
undefined 
Future: 
Undefined, 
depending on 
participants' 
mortality rates  
10 ml venous blood 
samples into a single 
EDTA tube labelled 
with a barcode unique 
to the participant. 
Mexico City, The 
Mexican Ministry of 
Health “Secretaría de 
Salud”, Oxford United 
Kingdom. CTSU Lab.  
Participants followed 
up indefinitely for 
cause-specific 
mortality through 
Mexican death 
registries. At 5 year 
intervals, a reasonably 
representative sample 
of at least a few 
thousand surviving 
participants will be 
invited for re-
assessment, including 
initial questions, 
measurements, and 
blood collection 
procedures. The 
underlying and 
contributing causes of 
death were coded 
according to the 10th 
International 
Classification of 
Diseases. This 
information, together 
with personal 
identifying information 
was recorded in a 
Ministry of Health 
database that was 
established as a 
consequence of this 
study  and in other 
official databases. 
Chronic diseases 
often associated 
with affluence 
tend to be most 
prevalent in the 
north of the 
country; whereas 
chronic diseases 
normally 
associated with 
poverty tend to 
be most prevalent 
in the south.  
Publishing in the 
International 
Journal of 
Epidemiology 
Language: 
English  
The study has 
been funded by 
the Mexican 
Ministry of 
Health, the 
National Council 
for Science and 
Technology  and 
the UK Wellcome 
Trust. Indirect 
funds came from 
the Medical 
Research Council, 
the British Heart 
Foundation and 
Cancer Research 
UK, and additional 
support for 
international 
studies of 
smoking from the 
US NIH Fogarty 
International 
Centre. 
Ministry of Health 
General ministry 
of epidemiology, 
Mexico 
Ministry of 
health’s 
promotion and 
prevention.  
Clinical Trial 
Service Unit, 
University of 
Oxford, UK. 
Conacyt 
authorised the 
study 
Genomic 
diversity of 
the 
Mexican 
Population: 
The 
‘HapMap’ 
Project 
300 people, 
including adults 
and children. 
Population 
study.  
Ancestry 
analysis by 
the 
inclusion of 
one 
Mexican 
Amerindian 
group and 
data from 
the 
HapMap. 
Providing 
evidence of 
genetic 
differences 
between 
Mexican 
subpopulat
ions that 
2005 - 2009 
Lasting: 4 years. 
Future: No re-
contact 
purposes 
Anonymous blood 
samples from 300 
nonrelated and self-
defined Mestizos and 
30 Amerindian 
Zapotecos were 
collected in 7 states in 
Mexico: Guanajuato, 
Guerrero, Sonora, 
Veracruz, Yucatan, 
Zacatecas, and 
Oaxaca. Samples were 
labelled to know 
where they came from 
and the sex of the 
donor.  
National Institute of 
Genomic Medicine 
INMEGEN, Mexico 
City 
Open forums organised 
in the participating 
communities, which 
were approached 3 
weeks before the study  
to explain its purposes 
and implications. 
Translators came from 
the participating 
communities. 
Anonymisation with no 
withdraw possibilities 
was initially intended 
and further exceptional 
recontact was not 
discarded. Two 
witnesses intervened 
to ensure that 
participation (including 
that of children) was 
self willing.  
Genetic 
differences 
among Mexican 
Mestizos from 
different regions 
in Mexico are 
mainly because of 
differences in 
Amerindian and 
European 
contributions. 
Outliers with an 
African proportion 
15% and 
intraregional 
variability in this 
component were 
observed in 
Veracruz and 
Guerrero. When 
Mexican 
INMEGEN 
webpage 
Languages: 
English/Spanish  
INMEGEN 
This work was 
supported by 
funds from the 
Federal 
Government of 
Mexico to the 
National Institute 
of Genomic 
Medicine and by 
infrastructure 
donated by the 
Mexican Health 
Foundation 
(FUNSALUD) and 
the Gonzalo Río 
Arronte 
Foundation. 
The study was 
approved by the 
Ethics, research 
The study was 
approved by both 
the scientific and 
ethics committees 
of the National 
Council of 
Technology 
‘Conacyt’ and the 
Ministry of 
Health. The study 
was conducted 
following the 
current legal 
framework by the 
General 
Legislation of 
Health.  
Experts from the 
National 
Commission of 
Bioethics and the 
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should be 
considered 
for 
association 
studies of 
complex 
diseases. 
The first 
genome 
wide 
genotyping 
efforts of a 
recently 
admixed 
population 
in Latin 
America.  
Contributio
ns to the 
developme
nt of 
genomic 
medicine in 
Mexico and 
Latin 
America. 
subpopulations 
were compared to 
Hap- Map 
populations, most 
showed 
decreased 
diversity, and only 
Sonora had a 
similar pattern to 
that of Asians. 
and biosecurity 
internal 
Commissions of 
the Institute.  
President of the 
Human Genome 
World 
Organisation 
participated and 
CIOMS guidelines 
were followed.  
Institutional local 
agreements were 
signed.  
1 
 
 
